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Introduction and overview of thesis 
Following implantation of the first coronary stent in 1986 by Jacques Puel in Toulouse, 
coronary stenting has, from a sequence of pioneering registries in the late 1980's to an era 
of randomized trials in the 1990's, come to adopt a prominent role in today's practice of 
interventional cardiology. In its conventional naked metallic form, coronary stenting 
represents a mechanical approach to a biological problem. When appropriately deployed, 
the coronary stent can tack back dissections and restore normal flow in vessels with 
threatened or acute closure and provides a means to optimize elective angioplasty of 
primary and recurrent stenoses in both native coronary arteries and aorto-coronary vein 
grafts by enforced remodelling. 
Much of our current understanding and expectations from coronary stenting has been 
derived from extensive experience with three primary stent prototypes, namely the Palmaz-
Schatz (a balloon-expandable mesh stentL the Gianturco-Roubin (an unsheathed balloon-
expandable coil stentL and the Wal/stent (a sheathed self-expanding mesh stent with coil-
like flexibility). The last few years has witnessed in addition to modifications of the above 
prototypes, the introduction of a new generation of stent designs with variable emphasis 
on low metallic surface area, low balloon-mounted profile, flexibility, and radiopacity. With 
such a variety of structural designs and such a spectrum of coronary lesions amenable to 
stenting, it is likely that each new stent will have to prove its own indications and niche. 
Instead of comparing the efficacy of each stent design with conventional balloon 
angioplasty, new stents will soon have to demonstrate their efficacy relative to previously 
established stents. 
OUf evaluation of coronary stenting has been primarily through the recording of hard clinical 
endpoints (reintervention, bypass surgery, myocardial infarction, and death) and through 
the technique of quantitative coronary angiography (OCA). QCA provides, at the time of 
the interventional procedure, guidance of optimal stent deployment and allows 
quantification of acute luminal gain and acute recoil following stent implantation. At 
angiographic follow-up, OCA provides a measurement of intrastent restenosis in addition 
to changes in vessel calibre proximal and distal to the stent. 
The decision on whether or not to stent during an interventional procedure is frequently 
based upon the angiographic findings alone in the absence of (and to prevent) any clinical 
deterioration of the patient. The documentation by OCA of a residual stenosis post 
intervention (the SUboptimal result) or the progressive deterioration in the minimal luminal 
diameter of a threatened vessel closure may provide an indication to stent. Once 
committed to stenting, QCA facilitates precise sizing of both the diameter and length of 
the selected stent. OCA of both the inflated intrastent balloon and the resultant stented 
lumen allows the sensitive detection of points of residual luminal narrowing and guidance 
of additional high pressure intrastent balloon inflations. 
The recent introduction of on-line QCA to nearly all interventional suites, has contributed 
significantly to the transformation of the previous art of coronary stenting of the 1980's 
associated with an unfavourable rate of subacute stent thrombosis and restenosis to the 
current practice and science of OCA-optimized stenting characterised by a large acute 
luminal gain often with a negative residual diameter stenosis and consequent low rate of 
subacute stent thrombosis and ability to accommodate intimal hyperplasia over the ensuing 
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six month period. In addition to complementing clinical observation, OCA has in multicenter 
stent trials served as a surrogate for clinical endpoints. Such a surrogacy is of increasing 
importance as the incidence of hard clinical events post stenting continues to fall and the 
era of randomized trials for the comparison of stents of different design is dawning. The 
reliability and validation of QCA thus becomes of fundamental importance for both the 
optimal practice and scientific evaluation of coronary stenting. 
Part I of this thesis addresses the reliability of the methodology we currently use to 
evaluate coronary stenting, namely OCA. The reliability and validation of quantitative 
angiographic measurements and the validity of clinical surrogacy by QCA for coronary 
interventional trials are examined, while Part /I of this thesis reports the results of 
quantitative angiographic and clinical evaluation of the acute and long-term outcome of 
both elective and bailout stenting of native coronary arteries and the primary stenting of 
aorta-coronary vein grafts. 
In chapter II, we report for the first time our results of three studies ( (i) on the discordance 
and surrogacy of clinical events and QCA, (ii) catheter calibration for OCA measurements, 
and (iii) the application of the technique of signal-averaging for the analysis of analogue 
video data) conducted over the last two years to evaluate quantitative coronary 
angiography. The validity of utilising QCA as a surrogate for clinical endpoints is analyzed 
with cumulative frequency curves by the comparison of the minimal luminal diameter at 
angiographic follow-up in patients with and patients without clinical end-points who have 
participated in multicenter interventional trials of balloon angioplasty and coronary stenting. 
On the basis of the relationship between clinical and QCA endpoints and the recent insights 
provided by our matching studies and by intracoronary ultrasound, a strategy for the design 
of sequential restenosis prevention studies is proposed. In chapter II we also report the 
results of a study on catheter calibration adding more data to the ongoing controversy on 
whether catheter calibration of QCA measurements should be performed on the catheter 
in the contrast-free or contrast-filled state. Furthermore in chapter II, the value of 
conventional statistical parameters for the reporting of validation studies is critically 
appraised, the current shortcomings are expounded with the aid of hypothetical validation 
results, and a new approach for the reporting and interpretation of QCA validation studies 
is proposed and applied to the results of one of our most recent comparative validation 
studies. Finally in chapter II, we report the results of our application of the technique of 
signal averaging in an attempt to increase the signal to noise ratio of analogue angiographic 
images recorded on videotape for QCA analysis. In-vitro stenoses of known diameter were 
recorded at reduced speed in edge-enhanced and in unfiltered modes on videotape at four 
different catheterization laboratories. With the use of a multiple frame grabber and 
customized digital signal averaging software, the potential applicability of the technique 
was evaluated. 
In chapter III, the results of a comparative study evaluating the performance of 10 QCA 
systems at major core laboratories in North America and Europe are reported. A 
standardized set of cineangiograms of intra coronary phantom stenoses were analyzed at 
each laboratory in an objective and user independent manner. No system was found to be 
perfect and all systems demonstrated both random as well as systematic errors. A global 
tendency to underestimate large luminal diameters and to overestimate small luminal 
diameters by all QCA systems was revealed. 
In chapter IV, we report the results of an attempt to overcome the overestimation of small 
luminal diameters by the introduction of a dynamic edge detection algorithm with variable 
weighting of the first and second derivative and variable kernel size of the derivative 
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operator. The experimental algorithm was evaluated on a set of in-vivo phantom stenoses 
with a range of 0.5mm to 1.9mm. On the basis of the promising results it is conceivable, 
that the conventional approach of a fixed weighting of the first and second derivatives for 
all QCA measurements may be inappropriate, and that overestimation of small diameters 
may be solved by increasing the weighting of the first derivative and reducing the kernel 
size of the derivative operator and similarly underestimation of large diameters might be 
addressed in the future by increasing the relative weighting of the second derivative. 
With the advent of coronary stents and the "bigger is better policy", larger minimal luminal 
diameters are now being achieved by coronary interventional procedures compared to the 
results previously achieved by balloon angioplasty alone. To date no in-vivo model has 
allowed the evaluation of QCA performance in the range of lumen diameters encountered 
by stenting. In chapter V, we report a new technique for the delivery of coronary "stent 
stenoses" for the evaluation of QCA measurements of large luminal diameters in pigs. 
While our previous technique of intra coronary insertion of phantom stenoses required the 
permanent attachment of double lumen plexiglass channels to the tip of a Fogarty catheter, 
we devised a new technique based on the principles of coronary stent delivery. Single 
channel stenoses were mounted on a compliant balloon catheter. Prior to the introduction 
of the balloon-mounted piexiglass stenoses through the carotid sheaths of anaesthetized 
pigs, the balloons were inflated at low pressure within the stenoses to produce a firm 
dumbell fixture with subsequent secure and effective delivery of the stent stenoses to the 
coronary arteries. Deflation and subsequent withdrawal of the mounted balloons allowed 
the acquisition of angiographic stenoses of up to 2.9 mm for the evaluation of QCA 
performance. 
Quantitative coronary angiography can be performed by two basic techniques, geometric 
(the edges of the vessel are detected in two dimensions) and densitometric (the relative 
brightness intensity of the vessel is quantified to provide a three-dimensional estimation 
of cross-sectional area from a single view). In chapter VI, we compare the measurements 
provided by these two QCA techniques with the measurements provided by intracoronary 
ultrasound in patients undergoing coronary interventional procedures. 
Having validated our primary methodological technique for the evaluation of coronary 
stenting, Part II of this thesis proceeds with the sequential evaluation of the stents 
currently available for clinical evaluation. In chapters VII - IX, the Wallstent is evaluated, 
in chapter X the Palmaz-Schatz stent, in chapter XI and XII the Gianturco Roubin stent, in 
chapter XIII the bailout stent, in chapter XIV the AVE Micro stent, in chapter XV the Wiktor 
stent and Wallstent, and in chapter XVI the Cordis stent. In chapter XVII the mechanical, 
radiographic, and angiographic characteristics of all currently available stents including the 
ACS Multilink stent are quantitatively compared and finally in the concluding chapter, 
(chapter XVII" a potential clinical niche for each stent design is proposed. 
The European registry of coronary Wallstent implantation in the 1980's reported a high rate 
of subacute thrombosis which was felt to relate in part to the high requirement for multiple 
stents and thus result in the delivery of a higher metallic (and thus potentially 
thrombogenic) burden. This arose from a major degree of longitudinal shortening upon 
expansion of the WaUstent. To address this limitation, the design of the Wallstent was 
changed to produce the new Less Shortening Wallstent (LSS). These changes in structural 
design and insights gleaned from the previous European multicenter registry data are 
presented in detail in chapter VII. 
Concerns over the potentiallongterm sequelae of a foreign body in the coronary vessel wall 
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have been expressed over stenting throughout the last decade and restraint in elective 
stenting urged until such data becomes available. In collaboration with Jacques Puel and 
his team in Toulouse, the long-term quantitative angiographic outcome of patients who 
received a Wallstent in the mid 1980's including the first patient ever stented is presented 
in Chapter VIII. The quantitative angiographic results are compared with those of the acute 
procedural and 6 month angiographic follow-up and are found to be most encouraging. 
The results indicate that, as with balloon angioplasty the restenosis process following stent 
implantation appears to be a time limited phenomenon, that progression of intrastent 
atherosclerosis is not accelerated, and that the ostia of side branches "jailed" by the mesh 
of the WaUstent remain patent. Such reassuring data suggests that the development of 
biodegradable stents may not offer many long-term mechanical advantages over coated 
metallic stents beyond the advantage of providing a greater reservoir for prolonged elution 
of pharmacological agents. 
In chapter IX the results of the first evaluation of the new' Less Shortening Wallstent are 
presented from a multicenter safety and feasibility study in coronary vein grafts taki.ng the 
new Wallstent design off from the bench top and into the clinical arena. 
In the BENESTENT trial, elective implantation of the Palmaz-Schatz stent was shown to 
convey an improvement of both clinical and angiographic outcome compared to 
conventional balloon angioplasty. In chapter X, the impact of vessel size on clinical 
outcome is examined for the stent and balloon populations of BENESTENT. Using both a 
logistic regression (continuous) as well as a categorical approach, it is determined that 
stenting in vessels below 3.0mm conveys an increased risk of subacute stent thrombosis 
and an increased number of clinical events in the 12 month follow-up period. Furthermore, 
the interaction of vessel size and stent : vessel ratio on outcome is analyzed using a 
multivariate approach. The study provides clinical guidelines on the range of vessels 
suitable for stenting as well as directions for stent sizing under the guidance of on-line 
QCA. 
The Gianturco-Roubin stent is a flexible coil stent with transversely oriented struts. In 
chapter XI the expansion and distribution of recoil following Gianturco-Roubin stent 
deployment are examined in a detailed quantitative angiographic analysis. A policy of stent 
Qversizing and use of an additional high pressure intrastent inflation with a non-compliant 
balloon are recommended to compensate for recoil and improve the acute angiographic 
result. 
In chapter XII, the GRACE trial (Gianturco-Roubin stent in Acute Closure EvaluationL in 
which the author of the thesis has been integrally involved over the last two and half years, 
is reviewed. The substrate of the trial - acute and threatened closure following angioplasty 
is reviewed and the relative efficacy of bailout stenting versus repeated prolonged balloon 
inflation are compared by a review of the literature. The concept of the "pre-study" for the 
screening and learning curve of investigators with the Gianturco-Roubin stent deployment 
technique and the concept of the "rolling protocol" design with periodic updates in an 
attempt to ensure that, when reported, the results of the randomized trial have implications 
for current clinical practice with optimal stent sizing and evolving approaches to 
anticoagulation and antiplatelet therapy. In chapter XIII, the current concepts and 
challenges of bailout stenting are addressed and the inherent difficulties of hard and soft 
criteria are discussed with implications for future clinical trials. 
The AVE· Micro stent represents a new direction in stent design. Its short size and 
radiopacity render it ideal for exquisite positioning under radiographic guidance in ostial 
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lesions as a single device, and for improving the inflow and outflow of longer stents as a 
complementary device in multiple stenting. In chapter XIV, we report our experience with 
this new stent primarily in the domain of multiple stenting of long and complex coronary 
dissections. 
In chapter XV, the gain loss relationship and luminal renarrowing process following Wiktor 
stent and following Wallstent implantation are studied and compared with results obtained 
with balloon angioplasty and directional coronary atherectomy by the technique of linear 
regression analysis after normalization for vessel size. 
In chapter XVI, the problem of rest enos is assessment within the new radiopaque tantalum 
Cordis stent is assessed by intracoronary ultrasound and by quantitative coronary 
angiography using both geometric and densitometric techniques. 
In chapter XVII the quantitative mechanical, radiographic, and angiographic characteristics 
of each of the currently available coronary stents are compared. To determine in a 
standardized and uniform manner the relative compliance and radial force provided by each 
stent design, we designed a customized bench"top stent compliance measurement device. 
Pressure-compliance curves were created for each of the stent designs. While the AVE 
Micro stent was found to provide the greatest radial force, the Wal/stent was found to be 
the most compliant. To determine the relative radiopacity of each stent we performed 
densitometric analysis on an alignment of all stent designs and found the ACS stent to be 
the most radiolucent and the Cordis stent to be the most radiopaque. We subsequently 
compared the influence of each of the stents on the reliability of automated quantitative 
angiographic measurements. These characteristics are of relevance for QCA as well as for 
ease of precise positioning of each stent under radiographic guidance. 
In the concluding chapter, (chapter XVIII) the char/lcteristics and substrate of each of the 
current clinical indications and coronary lesions for stent implantation are evaluated with 
specific reference to their stent requirements. The suitability of each stent design to match 
these interventional requirements are reviewed on the basis of the findings of this thesis, 
on the basis of clinical experience, and on the basis of published studies. Finally the 
advantages and disadvantages of each stent are discussed a potential clinical niche for 
different stent designs is proposed. 
Coronary stenting has in ten years come a long way. As coated and drug delivery stents 
now undergo clinical evaluation and the era of randomized trials comparing stents of 
different design for each clinical indication is dawning, it is becoming clear that coronary 
stenting is here to stay. 
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Chapter II 
Quantitative coronary angiography: 
An integral component of interventional cardiology. 
David Keane, Patrick W Serruys. 
In: Topol EJ, Serruys PW (eds), 
Current Review of Interventional Cardiology, 2nd edition. Current Medicine, Philadelphia USA. 
1995;205-233. 
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QUANTITATIVE CORONARY 
ANGIOGRAPHY 
Since the development of semiautomated quan-
titative ventriculography by the use of the first 
and second derivatives of the brightness proi1le 
by Slager and coworkers [1-3] in the mid 19705, 
the application of these principles and the COll-
version from analogue to digital processing for 
the development of semiautomated quantitative 
coronary angiography (QCA) by Reiber and 
coworkers [4] in the late 1970s, and the clinical 
application of QCA to intcrvcntional cardiology 
in the early 19805 by Serruys and coworkers [5], 
QCA has undergone a series of refinements. 
These include reduction in processing time; 
more user-friendly hardware and software; more 
versatile handling capabilities-not only for 
cineangiograms but also for angiographic 
images stored on analogue videotape and on a 
variety of digital storage and media formats; 
techniques for isocentric calibration [6]; three-
dimensional reconstruction of biplane 
angiograms [7]; and more sophisticated edge 
detection algorithms 18J. Perhaps the most excit-
ing refinement over the past decade has been 
the provision of on-line QCA. 
The development of QCA has paralleled our 
advances in interventional cardiology and has 
contributed significantly to our current under-
standing of coronary artery disease. The replace-
ment of visual assessment by semiautomated 
QCA for the conduction of scientific studies was 
both timely and welcome [9,1O,11-J. By provid-
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ing computerized, objective, and reproducible 
measurements of coronary luminal dimensions, 
QCA offered a scientific medium for the study of 
acute procedural results and serial changes over 
medium-term (6 months) and long-term foHow-
up. In particular, changes in the absolute mini-
mal luminal diameter (l"ILD) have been utilized 
for the study of acute luminal gain and subse-
quent restenosis following coronary interven-
tional procedures and changes in the mean 
luminal diameter have been utilized for the 
study of progression-regression of coronary 
artery disease [12J. Following the establishment 
of off-line QCA as a reliable research tool, on-
line QCA was adopted in routine clinical prac-
tice to guide coronary interventiona} proce-
dures. Its virtually ubiquitous availability in 
modern interventional suites has allowed the 
application of interventional principles, such as 
"the bigger, the better," learned from off-line 
QCA analyses and device sizing using on-line 
QCA has now become an accurate science 
rather than subjective art. 
\,Vith the advent of complementary or com-
petitive imaging modalities (intracoronary ultra-
sound, angioscopy, intracoronary Doppler, mag-
netic resonance imaging. ultrafast computerized 
tomography and three-dimensional echocardio-
graphy) for coronary luminal quantification, 
defense by QCA of its title, the gold standard for 
scientil1c research and subsequent growth of its 
role in clinical practice will become critically 
dependent upon the demonstration of superior 
reliability of QCA measurements. Given that QCA 
TABLE 12-1. NEGATIVE QUANTITATIVE CORONARY ANGIOGRAPHY RESULTS FOR THREE 
PHARMACOLOGIC TRIALS ON RESTENOSIS PREVENTION AFTER BALLOON ANGIOPLASTY' 
MlO follow-up MlD follow-up loss loss 
placebo active Rx placebo active Rx 
Study Patients, IJ mean± SO (range) mean± SO (range) mean± so (range) mean± SD (range) 
CARPORT 522 1.46±O.S9 mm 1,49±O.S8 mm 0.31±O.S4 mOl 0.31 ±O.5S mOl 
(0.00-2.95) (0.00-3.15) (-1.09-2.89) (-0.71-2.54) 
MERCATOR 595 1.48±O.S4 mm 1.S4±O,,54 mm O.29±0.49 mOl O.27±0.Sl mOl 
(0.00-3.15) (0.00-3.15) (-1.04-2.29) (-0.99-2.26) 
PARK 592 1.44±0.S8 mill 1,43±O.62 mm O.24±O.S2 mOl 0.27±0.49 mOl 
(0.00--3.41) (0.00-3.57) (-0.81-2.29) (-1.16-2.211 
"Note the relatively high standard deviation of the measurements which incorporates the variability of quantitative coronary 
angiography (QCA) measurements (±O.20 mm) as well as the clinical range of outmme following intervention (ranging 
from total occlusions to an increase in minimalluminal diameter IMLDJ at follow-up 1>.1.5 mmJ). 
20 
QUANTITATIVE COnONAUY ANGIOGRAPHY: AI'i 1t\'TEGRAL COMPONENT OF- IN"TERVENTIONAL CAIIDiOLOGY 
necessitates the performance of repeated inva-
sive procedures, and yet docs not provide direct 
data on the vesscl wall, it is unlikely that the cur-
rent dominant role of QCA will survive into the 
next decade. Given that 1) 18 years following the 
introduction of interventional cardiology, its 
overwhelming limitation continues to be the 
bane of restenosis, and 2) that angiographic pre-
dictors of primary procedural success and com-
plications are primarily derived from the art of 
qualitative angiography U3-21] rather than the 
science of scmiautomated quantitative angiogra-
phy, this chapter reviews the insights provided 
by, the current limitations of, and the challenges 
ahead, for QCA in interventional research and 
practice. 
QUANTITATIVE CORONARY 
ANGIOGRAPHY IN CLINICAL 
RESEARCH 
QCA AS A SURROGATE FOR CLINICAL EVENTS 
IN THE STUDY OF RESTENOSIS FOlLOWING 
CORONARY INTERVENTION 
STUDIES OF PHAR!vlACOLOGIC AGENTS FOR 
THE PREVENTION Or HES'fENOSIS 
Over the past 5 years, a significant number of 
scientifically conducted trials on the prevention 
of restenosis following coronary intervention 
w,ing QCA endpoints as a surrogate for clinical 
events have been entirely negative [22-28]. The 
failure of the tested phamacologic agents to 
exert any detectable effect on luminal loss at fol-
low-up as assessed by QCA (Table 12-1) has 
been disheartening in view of the promising 
results of preclinical in vitro and in vivo studies. 
The disappointing angiographic results of these 
trials threw into question the ability of QCA to 
detect minor differences in study populations 
(because of the random and systematic errors of 
QCA measurements). Of some restoration of 
faith in QCA, in addition to being angiographi-
cally negative, these trials also failed to detect a 
difference in clinical outcome between the 
actively treated and control patients. Although it 
should be acknowledged that the power calcula-
tions of these trials were based on QCA-derived 
primary endpoints and not clinical event rates. 
In support of the tenet that QCA presents a 
reliable surrogate for coronary events, a sub-
analysis of the MERCATOR study population 
demonstrated an association or coupling 
between the QCA-derived parameter, minimal 
luminal diameter ([vILD) at follow-up and the 
clinical event rate [23]. MLD at follow-up was 
divided into quintiles and a pattern of decreas-
ing MLD with increasing coronary events and 
decreasing exercise test performance was 
demonstrated Cfable 12-2) [23]. 
To further test the validity of lIsing QCA as a 
surrogate for clinical events in restenosis preven-
tion studies following coronary intervention, we 
can compare the QCA results of those patients in 
whom a major clinical event (reinterventioll, 
b}11<ISS surgery, myocardial infarction, or death) 
ocurred with QCA results of those patients in 
TABLE 12-2. PROGNOSTIC VALUE OF THE MLD AT FOLLOW-UP IN 595 PATIENTS 
IN THE MERCATOR TRIAL DIVIDED INTO FIVE EQUAL GROUPS' 
Exercise test, IJ (%) Clinical events, n (%) 
MLD <1 mm ST ~1 mm Sf 
follow-UI), change and change and 
mm 110 chest pain chest pain MI Reintervention Angina None 
<1.10 70 (75) 24 (26) 5 (4) 49 (41) 24 (20) 41 (35) 
1.10-1.39 88 (88) 12 (12) 1 (I) 18 (IS) 25 (21) 74 (63) 
1.40-1.63 103 (90) 11 (TO) 2 (2) TO (8) 31 (26) 77 (64) 
1.64--1.91 99 (93) 8 (7) I (I) 7 (6) 21 (15) 89 (75) 
~1.91 111 (98) 2 (2) 1 (1) 7 (6) 18 (15) 94 (78) 
Total 
patients 471 57 10 91 119 375 
'A relationship between the quantitative coronary angiography-derived variable, r .... \lD at follow-up and both functiol1<l1 perfor-
mance and clinical events is apparant. ,,"'I!-myoc,l((lial infarction; MlD-minim<lllumin,ll di<lmeter. From {231; with permission. 
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whom a clinical event did not OCCUI' (Figure 12-1). 
Despite failure of QCA to detect an effect of the 
pharmacologic agents on luminal narrowing, it is 
clear in Figure 12-1 that QCA is effective in the 
separation of c1inical-event-positive and clinical-
event-negative patient groups. In three drug stud-
ies the difference in meanl'vlLD between the dini-
cal-event-positive and the clinical-evcnt- negative 
patients was 0.37 nllll for CARPORT (p;::::; 3.E13); 
OA2mll1 for ]'vfERCATOH (P::: 6.E17); and 0.51 mm 
for PARK (P::: 3.En). for patients who received a 
Palmaz-Schatz (Johnson & Johnson, USA) stent in 
thc BENESTENT study, the diffcrence in i'vILD 
between the clinical-event-positive and the clini-
cal-event-negative patients was cven lllore strik-
ing, 0.86 mm (p;::::; 2.E.JR). These differences offer 
further support to the validity of including QCA 
A 
c 
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25 
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./// 
-_/ 
1.191n= 170) 
1.57 In= 505) 
.1=O.J7mm 
P=3.E-13 
o~----._----._----._--~ 
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MLO F-UP, mm 
100-r------------==~~~~-----, 
B£NE$TENT /,/-"'-
75 
Event + /~:~nt-
/ 1.12 (n" 111) 1.98(n=366) ,\ = 0.66 mm P= 2.E--46 
O~----~----._----._--~ 
o 3 4 
MLD F-UP, mm 
FJgure 12-1. QUelntitative ("own,,!), angiography (QCA) in 
the differentiation of event positive and event neg<ltive 
patient groups in CARPORT, MERCATOR, PARK, ,1nd 
BENESTENT. To test the validity of using QCA itS a surro-
gate (or dinical events in (('stenosis prevention studies, we 
compared the QCi\ results o( those patients in whom el 
melior dinic,11 event (reint('rvl'ntion, bypass surge!)', 
myocardi'll infarction, or death) occurred with the QCA 
results of those patients in whom a clinical cvent did nol 
occur. The patients were t,lken from three neutral pharma-
CLJRREl\'T REVIEW OF INTERVENTIONAL CARDIOLOGY 
endpoints as either primary or secondary end-
points in the study ofmediulll-term outcome fol-
lowing coronary interventional procedures. 
SHOULD QCA BE E.,XPEr::TED TO DETECT A 
PIIARfvIACOLOGIC REDUCTION OF RESTENO-
SIS FOLLOWING BALLOON ANGIOPLASTY? 
To address this important question the following 
points should be considered. 
1. The reproducibility of analyses of serial angio-
graphic studies in a given static patient popu-
lation for a QCA system (which is currently in 
use at a (;ore laboratory for the analysis of 
multicenter restenosi.s trials) has been 
assessed in two recent studies [11 ,29J. In both 
studies this clinical reproducibility has been 
shown to he ± 0.20 mm. This figure would be 
B 
o 
100',-----------------"0,'0', ~------, 
MERCATOR 
75 
Elient + 
50 
25 
o 
PARK 
75 
25 
o 
Elicnl-
MLDF-UP, mm 
Event-
2 
MtOF-UP, mm 
1.16(n",147) 
1.59 (n= 631) 
,\ "'0.42: mm 
p= 6.E-17 
1.08{n=232) 
1.59 (n = 503) 
.1=0.51 mm 
p= 3.E-27 
3 
4 
4 
cologie ~tl!dies (CARPORT, tvlERCATOR, and PARK and 
from the patients who had rereiwel a stent in a positive 
device randomized tria! (BENESTENT). QCA was highly 
e((ediw in the separation of tlw dinical event-positive 
and clinical event-negative patient groups. These differ-
ences (up to 0.86 mm in BENESTENT) lend support (or tIlt' 
policy of including QCA endpoints as either primary or 
seCOnd,1!)' endpoints in the slud~' of medium-term ou\-
COI)lP following coronary interventional procedures. 
F-up-foJ!ow-up; f\·ILD-rninimal lumen diameter. 
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expected to be significantly higher in the 
absence of the controlled angiographic condi-
tions of a prospective clinical trial coordinated 
by a core angiographic laborator}~ 
2. The average loss in luminal diameter at 6-
month angiographic follow-up of patients 
treated by balloon angioplasty is approxi-
mately 0.30 nUll [22-25]. 
3. If clinically effective, a pharmacologic agent 
that blocks one or more steps of the biologic 
cascade that leads to intimal hyperplasia 
might be expected to result in a 25% reduction 
of luminal loss at 6-month angiographic fol-
low-up. The l1gure for estimated reduction of 
25% is based on the probability that a drug, if 
highly effective, would reduce intimal hyper-
plasia by 50%. Given the recent evidence from 
intracoronary ultrasound (ICUS) studies by 
i\'Iintz and coworkers [30] and ongoing work 
at the Thoraxcenter, indicating that intimal 
hyperplasia composes only 40% to 56% of the 
luminal renarrowing following coronary bal-
loon angioplasty while the remainder of the 
renarrowing consists of late constriction of the 
vessel, a 25% reduction in luminal renarrow-
ing is at least reasonable if not optimistic. 
'1. The natural variation in a patient population 
with 6-mollth angiographic results is large, 
ranging from a total occlusion at follow-up 
(MLD = 0 mm) to an increase in MLD during 
follow-up by remodelling (ivlLD > 3.5 mm). 
This has resulted in a standard deviation of 
MLD at follow-up for treated and control 
patients of more than ± 0.5 mm. 
5. Thus, in the conduction of restenosis trials we 
arc expecting QCA with, at very best, a clinical 
reproducibility of ± 0.20 mm, to be able to 
detect a difference of 0.06 mm (equivalent to 
the size of one pLxel on QCA systems offering 
a high resolution and less than one pixel in 
other QCA systems) between the widely rang-
ing (0 111m > 3.5 111m) treated and control 
patient groups. 
It could therefore be proposed that we possi-
bly are expecting too much by relying on QCA to 
detect a pharmacologic effect on restenosis fol-
lowing balloon angioplasty. Can we continue to 
justify the execution of further trials testing sin-
gle pharmacologic agents on the prevention of 
restenosis following balloon angioplasty, know-
ing that it is highly unlikely that such drugs will 
reduce late vessel wall constriction? 
In view of the above concerns, we should 
reconsider the application of QCA in studies on 
restenosis prevention. "Vhat measures can we 
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take to increase our ability to detect a phanna-
cologie effect on restenosis? 
Can we improve on the reproducibility of seri-
al QCA analyses? A series of practical measures 
can be demanded by the core laboratory in the 
conduction of randomized angiographic trials to 
reduce the variability of radiographic acquisition 
and subsequent analysis. An outline of these mea-
sures is provided later in this chapter. Radiograph 
technology and image quality are continuously 
improving with each new generation of equip-
ment. The resolution of digitally stored images has 
now greatly increased and in most systems the 
focal spot size can now be reduced to 0.4 1111ll. 
Although the tube would expire mare quickly due 
to overheating if the focal spot was always set at 
the smallest setting, it might be reasonable to 
request that all angiograms for QCA trials be 
recorded using the smallest focal spot. This mea-
sure should reduce the point spread function and 
should thus reduce the tendency to overestimate 
small luminal diameters by QCl\. All QCA systems 
undergo a continuous process of validation at core 
laboratories and subsequent refinement of algo-
rithms and recalibration. The contribution ofhoth 
the hardware components as well as the software 
algorithms should be considered as potential 
points for technical improvement in QCA perfor-
lllance. QCA validation is discussed later in this 
chapter. Can we improve on our pharmacologic 
strategies? Given the lllultiple pathways and phas-
es of biologic cascade of restenosis, it is likely that 
only a combination of several drugs targeted for 
and administered during the different stages of 
the restenosis process will prove to he finally e11ec-
tive. Can we increase the substrate of our clinical 
model for the testing of potential restenosis pre-
ventative therapies? To determine whether bal-
loon angioplasty provides the optimal substrate, 
we need to review the insights provided by QCA 
011 luminal renarrowing following the application 
of different coronary interventional devices. 
THE IDEAL CLINICAL MODEL FOR TESTING 
RESTENOSIS PREVENTATIVE THERAPIES: 
INSIGHTS PROVIDED BY QCA AND 
MATCHING 
Analysis of QC:A data from interventional studies 
llsing matching [31-35J as a surrogate for ran-
domized trials has provided us with an accurate 
predictor of outcome of subsequent randomized 
trials and offers an effective mechanism for 
power calculations of prospective trials. For the 
testing of a specific hypothesis, the process of 
matching can at times provide a more pure and 
effective model than a prospective clinical trial, 
as confounding variables can be removed pro-
vided that the pool of patients from which the 
ideal matches are selected is sufficiently large. 
fvlatching can overcome some of the inherent 
limitations of prospective randomized trials. For 
instance, in a prospective randomized trial it is 
difficult to decipher whether the greater resteno-
sis after atherectomy or other device compared 
with balloon angioplasty is a result of the greater 
acute luminal gain or due to the mechanism of 
gain. In oLir most recent matching study we have 
demonstrated that not only does luminal loss 
increase with increasing extent of luminal gain 
[34,36] but also that luminal loss varies accord-
ing to the mechanism of luminal gain [35]. Using 
the same QCA system that measured an average 
loss following balloon angioplasty of 0.30 mm as 
described above, we had previously found that 
the luminal loss following atherectomy is 0.68 
mm [3'1]. \Vhen we subsequently matched for 1) 
vessel size, 2) acute procedural gain, and :-3) rvILD 
postprocedure in a second study [35], the mech-
anism of atherectomy (cutting) was found to 
induce a greater subsequent loss of 0.53111111 
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25 
20 NS W'\-A 
/'.;0,02 
15 PL-A 
" E /'<0.0001 P.;0,05 E 
10 
1'<0.05 LUM-A 5 
P<O.OOOI 
0 
Pre-DCA Post-DCA F-UP 
Mechanisms of PTCA 
25 
20 EU,I-A 1'.;0.02 
P.;0.002 
15 
"E P.;O,OI NS 
PL-A 
E 10 
5 ~ LUM-A P.;O.OOOI 
0 
Pre-PTCA Post-PTCA F-UP 
24 
CUUlUlNT RF.VlF.WOF INl'EHVENTIONAL CAIUJIOLOGY 
compared with the loss of 0.26 mm at (-) months 
following the stretching action in the matched 
balloon angioplasty patients. When the .MLD 
postathercctomy was divided at the median into 
optimal atherectomy (l\'ILD post> 2.47 nun) and 
suboptimal atherectomy (MLD post < 2.'17 mIll), 
the MLD at 6 months follow-up was 1.92 nUll for 
optimal atherectorny and 1.67 mm for subopti-
mal atherectomy (P < 0.05) [351. Of greater 
importance for our quest of the ideal clinical 
model for testing restenosis preventative thera-
pies, we found that the loss at () months follow-
ing optimal atherectomy was 0.86 ± 0.64 mm 
compared with 0.42 ± 0.59 rum for suboptimal 
atherectomy. 
Clearly, evpn with a standard deviation of 
QCA measurements of ± 0_64 mm (which incor-
porates the reproducibility of ± 0.20 mm of serial 
clinical QCA measurements in a static popula-
tion as well as the natural variability of the study 
population in angiographic outcome at 6 
months), the likelihood of QCA detecting a 20% 
reduction in resten(lsis following atherer.tomy 
(0.17 mm) compared with a 20% reduction in 
restenosis following balloon angioplasty (0.09 
mm) will be greater. 
Figure 12-2. Merh,mislii of luminal rerwrowing following 
perlllt;1neous translumindl corona!)' angiogr,lphy (PTCA) 
and directional alher('ctomy (DCA)_ Jnlracoron,1!)' ultra-
sound studies at the Thoraxcenter have (ompared the 
mechanism of luminal renarrowing following P"ICA and 
following DCA. Luminal rl'narrowing (UJf\'I-A) is due to a 
higher proportion 0( intinlal hYJ.lerplasia (p),HjUl' are'], PL-A) 
and a lower proportion of late vessel constriction (external 
elastic membrane area !fEM-A]) following DCA (2B'X, late 
vessel wall constriction) compared with balloon angiopl.:tsty 
(44'1" late vessel wall constiction). These re~ults h,we signif-
icant implications for pharmacologic attempts ilt restenosis 
prevention following different devices, given that ,1 drug 
would be unlikely 10 effcct lilte vessel wall constriction. 
F-Ulr-fo!low-up; NS--not significant. 
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Additionally we have found, in an ongoing 
program of comparison by rcus of the mecha-
nism of restenosis following different coronary 
interventional devices, a higher proportion of 
intimal hyperplasia and a lower proportion of 
late vessel wall constriction (external elastic lam-
ina area) in restenosis following atherectomy 
(28% late vessel wall constriction) compared with 
balloon angioplasty (44% late vessel wall con-
striction) (Fig. 12-2). Thus, if a drug was highly 
effective clinically and reduced intimal hyperpla-
sia by 50%, this would result in an approximately 
3()% reduction in luminal renarrowing following 
atherectomy compared with an approximately 
2B% reduction following balloon angioplasty. 
On the basis of the above findings we have 
adopted the optimal atherectomy model for the 
study of a pharmacologic agent for the prevention 
of restenosis in European Carvedilol Atherectomy 
Restenosis Evaluation (EUROCARE). This is a 
multicenter trial that will compare the et11cacy of 
a polypharmacodynamic agent (the actions of 
which include strong antioxidant properties) in 
the prevention of restenosis using a QCA-derived 
variable as a primary endpoint (MLD at follow-
up). Our adoption of the optimal atherectomy 
model has allowed us to reduce the number of 
patients required for recruitment in a randomized 
trial to 350 patients as well as increase the statisti-
cal power of ollr study compared with previous 
balloon angioplasty trials. 
In the first study of QCA and matching of 
baseline stenosis characteristics, de Jaegcre and 
coworkers [31J demonstrated that luminal loss 
following coronary stenting i::> greater (0.48 mm 
after \'Vallstent implantation) compared with a 
matched balloon angioplasty population (0.20 
mm) [31]. This increased luminal loss following 
stenting was subsequently confirmed in two 
prospective randomized trials [37-39]. 
Furthermore, by the provision of a chronic radial 
force, early recoil and subsequent late vessel wall 
constriction following stenting is reduced to less 
than 20% (with likely greater reduction in vessel 
wall constriction from the more rigid mesh stents 
compared with the more flexible coil stents 
[39,40], and the restenosis substrate is thus likely 
to be a more pure form of intimal hyperplasia-
the substrate against which most pharmacologic 
agents have heen shown to be effective in pre-
clinical trials. 
In view of our somewhat shaken confidence 
in the sensitivity of QCA (Iumenography) to 
detect a pharmacologic reduction in restenosis 
and given that a significant portion of the 
increase in plaque volume may be accommodat-
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cd by olltward expansion of the vessel wall [41], 
we have in EUROCARE also incorporated reus 
(nmrelography) imaging to compare plaque vol-
ume in the actively treated and placebo patient::>. 
Thus EUHOCAHE promises to be a showdown 
between the two imaging modalities. Should 
ICUS detect a reduction in plaque volume at 6 
months plus or minus a greater luminal cross-
sectional area at G months, and should QCA fail 
to detect a reduction inluminal renarrowing, our 
reliance on QCA to provide the primary endpoint 
(as the gold standard) of future clinical trials test-
ing a single potential agent for restenosis preven-
tion is likely to change. 
PHASES AND DESIGN OF RESTENOSIS TRiAlS 
Following an initial experience of successively 
negative trials characterized by variable trial 
design, power calculations, patient selection, 
and endpoints, a rational standardized three-
phase approach to the prospective clinical 
assessment of potential pharmacologic agents 
for restenosis prevention was proposed [42]. 
Phase 1 comprised a small noncomparative 
pilot study (approximately 100 patients) using 
clinical endpoints only to demonstrate the safety 
of the drug in the setting of percutaneolls coro-
nary intervention and possibly to detect an effi-
cacy trend that might be taken into considera-
tion in the power calculations of phase 2. 
In phase 2, providing the drug was shown to 
be safe in phase I, a medium-sized controlled 
trial (approximately 600 patients) would be 
undertaken that was statistically powered to 
detect differences in QCA-derived variables as the 
primary endpoint. Clinical variables would also 
he studied as secondary endpoints although the 
trial would not be powered to detect a statistically 
significant reduction in major clinical event rate. 
In phase 3, providing a significant improve-
men~ in angiographic outcome was demonstrat-
ed in Phase 2, a large clinical trial (approximately 
2000 patients) would be undertaken without 
QCA to put the clinical eftlcacy of the drug to the 
test (as well as serendipitously putting the pre-
dictive value ofQCA to the test). 
Such screening of potential pharmacologic 
agents by mediulll-sized QCA trials, has yet to he 
demonstrated to be scientifically justified. Of 
interest was the approach taken in the design of 
the EPrc trial [43,44]. Rather than performing a 
QCA trial, the second phase of the above 
approach was bypassed and a large (2099-
patient) clinical trial was directly undertaken. 
This approach has, in retrospect, at least for this 
pharmacologic agent (c7E3-a platelet llb/ll1a 
integrin antibody fragment), proven to be effec-
tive, A drug has been shown to be clinically efiica-
dow; without the expense (both temporal as well 
as fiscal) of incorporating follow-up angiography 
and QCA. However, in order to determine how 
this drug exerted a reduction in clinical event 
rates, rather than to determine whether this drug 
will be clinically effective, a QCA trial with c7E3 
has now been undertaken (EPILOG), In addition 
to the luxurious position of testing the angio-
graphic mechanism of action of c7E3 (ie, reduc-
tion in total occlusions (thrombosis) or reduction 
in global renarrowing), EPILOG will also serve to 
put QCA, the surrogate, to the test retrospectively, 
A common path between these two alterntive 
approaches for the assessment of a potential 
pharmacologic agent for the prevention of 
restenosis, of phases 1, 2, 3 as proposed above and 
the 1, 3, 2 approach taken in the EPIC and EPILOG 
trials, might be the merging of phases 2 and 3, 
whereby the second (final) phase would consist of 
a clinical trial of 2000 patients and would include 
the performance of follow-up angiography with 
QCA in GOO of the 2000 patients, This strategy 
would be more economical in the long term and 
would lead morc quickly and directly to a defini-
tive result. Such economy and expedience in the 
execution of clinical trials could also he proposed 
for the merging of restenosis and prob'Tession tri-
als, whereby the patients participating in a 
restenosis trial testing a pharmacologic agent that 
would be likely to reduce both restenosis and pro-
gression (eg, the antioxidant, carvedilol [EURO-
CAREJ or the Hl'vIGCoA reductase inhibitor, fluvfls-
tatin [fLAREJ [45]) or a calcium antagonist 
[46-------48J would be ll1f1intained on active treatment 
find undergo follow-up angiography at G months 
and at 3 years \\~th QCA of all coronary segments, 
IMPLICATIONS FOR INTERVENTIONAl TRIALS 
DERIVED FROM THE STUDY OF QCA IN ' 
PROGRESSION AND REGRESSION TRIALS 
Further evidence in support of the use of quanti-
tative coronary angiography as a surrogate end-
point for clinical coronmy events, arises from 
studies on progression and regression, where 
initially isolated angiographic evidence of pro-
gression has been subsequently followed during 
longer-term follow-up by higher clinical event 
rates, This positive predictive value of angio-
graphic endpoints has been demonstrated for 
both visual assessment [49J as well as for semi-
automflted quantitative coronary angiography 
[11-,48J. Is the coupling of QCA and subsequent 
clinical events due to the observation of a para-
CURRENT HEVIE\V OF INTEnVEi\TTIONAL CAR[)JOIJ1{;Y 
phenomenon, or docs the measurement of a 
severe coronary stenosis by QCA directly predict 
an increased risk of occurrence of a coronary 
event in this tmget vessel at the point of the min-
imallUlllinfll diameter? Little and colleagues and 
other investigators have revealed that coronary 
occlusions that produce a myocardial infarction 
frequently occur at sites that previously con-
tained minor, insignificant luminal nalTO\vings 
and that the lesions with the severest stenosis 
me often found to be patent in such patients 
[50-5<lJ. It has been proposed that angiographic 
evidence of progression or regression in one seg-
ment may be a marker of disease activity that 
mfly involve other coronary segments but not be 
flpparent on the coronary angiogram [50"]. 
Whether this holds true for the demonstration 
by QCA of severely restenotic lesions (large lumi-
nalloss over 6 months) following intervention 
has yet to be clearly demonstrated. It hfls been 
proposed that the endoillminal cap of fI 
restenotic lesion is more stable and less suscep-
tible to fissuring than a primmy atherosclerotic 
plaque of equivalent luminal diameter. Thus, it 
might be expected that the detection of resteno-
sis following intervention by QCA might be more 
predictive of functional reversible ischemia, 
recurrence of angina and subsequent sympto-
matic need for revascuiarization, rather than 
predicting myocardial infarction and death. 
QCA IN RANDOMIZED TRIALS COMPARING 
INTERVENTIONAl DEVICES: DISSOCIATION 
BETWEEN QCA AND CLINICAL ENDPOINTS 
Our trust in QCA to detect statistically significant 
differences in outcome in patients undergoing 
coronary interventional procedures has been par-
tially restored by the simultaneous and mutually 
supportive positive QCA results of BENESTENT 
and STRESS, which used different QCA systems to 
compare angiographic outcome at () months in 
patients receiving a Palmaz-Schatz stent and 
patients undergoing balloon angioplasty alone 
[37-38J. The value of QCA was further strength-
ened by both of these studies as the reduction in 
QCA-determined restenosis was associated \\~th a 
reduction in the number of clinical events in those 
patients randomly selected to receive a stent. 
CAVEAT and CCAT also used different QCA 
systems (single worst view reported) to compare 
outcome following directional coronary atherec-
tomy and following balloon allgioplasty [55,5G-J, 
CAVEAT included all coronary vessels while CCAT 
only included left anterior descending vessels, 
Assessment of acute angiographic outcome by 
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off-line QCA in the core laboratories resulted in 
an angiographic success rate « 50% diameter 
stenosis) for atherectomy and for balloon angio-
plasty in CAVEAT of 89% and 80%, respectively 
and in CCAT of 98% and 91 % respectively, \'Vhile 
the pattern of relatively larger acute luminal gain 
following atherectomy was revealed by the off-
line QCA analyses at the core laboratories of both 
trials, the difference between 89% and 98% for 
acute angiographic success rates for atherectomy 
between the two trials is more than would be 
expected given that the procedural policies of 
both trials were so similar, Although many expla-
llations for this difference may exist, one possibil-
ity that should be considered is a systematic dif-
ference in the QCA systems used to analyze the 
trials in the core laboratories, It is of interest that 
in CAVEAT the lllean residual diameter stenosis 
postatherectomy as assessed by the off-line QCA 
system at the core laboratory was 29% in compar-
ison with 15% when assessed by the investigators, 
CAVEAT reported an isolated Significantly 
larger MLD in the proximal left anterior 
descending artery at G months in patients treat-
ed by atherectomy (1vlLD = 1.32 mm for atherec-
tomy and 1.12 111m for balloon angioplasty (P< 
0,01), however, a reduction in clinical events 
over the 6-month follow-up period was llot con-
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ferred in these patients [55]. This uncoupling of 
angiographic and clinical outcome was found to 
persist when follow-up was extended to 1 year 
[571, Such dissociation of angiographic and clini-
cal results behests caution in the excessive 
reliance on QCA as a surrogate endpoint for clin-
ical coronary events. Further caution on the reli-
ability of QCA arises from a discordance 
between the angiographic results of CAVEAT 
with the angiographic re:-mlts of CCAT, which 
reported no difference in either angiographic or 
clinical outcome at 6 months between the 
atherectomy (l'vlLD at follow-up::: 1.55 mm) and 
balloon angioplasty Uv[LD at follow-up::: 1.61 
mm) patients, 
A paradoxical trend between QCA and clini-
cal outcome was also seen in the PARK trial 
where despite a trend for reduced clinical events 
in the treated (ketanserin) patients compared 
with the control (placebo) patients, a trend in thp. 
opposite direction was seen in the QCA results 
whereby the luminal loss was greater in the treat-
ed patients (fig, 12-3), Although the reasons for 
such a paradox betweell QCA and clinical out-
come in a pharmacologic study may be complex, 
they again undermine the policy of exclusive 
reliance on QCA as the sale primary endpoint of 
interventional trials, 
Figure 12-3, PiHadox of quantitative coronary angiogra-
phy (QCA) and clinical (('suits in the PARK trizt!. A and B, 
Dissociation between QCA and clinical outcome was 
seen in the PARK trial where despite i1 trend for reduced 
clinical events in the treated (ketanserin) patients COI)1-
pared to the control (placebo) patients, a trend in the 
opposite direction was s('(~n in the QCA results whereby 
the luminal loss was greater in the trt'ateel patients . 
1\lthough the reasons for such a paradox between QCA 
and clinical outcome in a pharmacologic study may be 
multifactorial, they behest caution in the exclusive 
relianCl' on QCA as the sole primary endpoint of interven-
tionaltrials. MLD-minirni11 luminal diameter. 
A common finding in the QCA analysis of 
the four randomized device trials, CAVEAT, 
CCA1; BENESTENT, and STRESS was the rela-
tively small vessel size reported. Although the 
inclusion criteria of the trials requested a vessel 
size of more than 3.0 mIn (or;:::.: 3.0 mm) as 
assessed on site by the investigator, the mean 
preprocedural reference vessel diameter as 
assessed by off-line QCA at the core angio-
graphic laboratory was on average approxi-
mately 3.0 nun with an average standard devia-
tion of approximately 0.47 nUll for the four 
trials. Tn addition to possibly reflecting poten-
tial errors in the estimation of vessel size by the 
investigators on site, these results would also 
be consistent with a tendency of off-line QCA 
systems when calibrated by the catheter to 
underestimate measurements of large luminal 
diameter as suggested by .several QCA valida-
tion studies. Appropriately, in none of these 
four device trials were patients excluded from 
Figure 12-4. Cn-line quantitative corclnar), angiography 
(QCA) to guide interventional procedures. A, ;\n osti<'ll 
lesion of <'l saphenous vein jump gr,lft was found to have a 
minimal luminal diameter (MLD) of 1.29 mm with <'l per-
cent diameter stenosis of 68% and d length of 17 rnm. A 
self·expanding less shortening coromry \'Vallstent of 4.5-
mm nominal diameter and 29-mm nominal impldnted 
length was selected to provide a stent to vessel difference 
of OA-mm diameter and a margin of 6 mm at the proximal 
and distal ends of the stenl (10 reduce the risk of misplace-
ment by shortening of the Willistent upon expansion). Bf 
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the per protocol analysis by virtue of the mea-
surement of a vessel size of less than 3.0 mm at 
the core angiographic laboratory. 
APPLICATION OF ON-LINE QCA IN 
INTERVENTIONAL PRACTICE 
The emergence of digital (subtraction) angiogra-
phy has allowed the on-line performance of QCA 
measurements in the catheterization laboratory, 
so that a technique previously confined to 
research applications has been transformed into 
a practical technique, directly influencing clini-
cal decision making in real time (Fig. 12-4). 
In October 1993 we undertook a survey of 
interventional practitioners in Europe who had 
an experience of greater than 40 directional 
coronary atherectomy cases. At that time, 34 of 
the 36 interventionalists surveyed used on-line 
QCA, while only 24 of the 36 had experience with 
intracoronary ultrasound. 
Following release of the radiolucent Wallstent a residual 
MLO of 1.67 mm was nWilsured, C, A noncompliant b<'ll-
Joon of 4-mm diameter WilS selected and inflated within 
the VValistent to a peak pressure of II atmospheres during 
which the inflated balloon was found to have a uniform 
in(Jation with a MLO of 3.91 mm and a percent diameter 
stenosis relative 10 till' mean bal/oon diameter of 11%. D, 
Final postprocedural measurement confirmed a rcsidual 
,\ollD of> 3,00 mm and a percent di<'lmeter stenosis of < 
20'Yo, both of which have been shown to be associated 
with a reduced risk of subacute thrombosis. 
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During an interventional procedure on-line 
QCA can be used to provide an interpolated ref-
erence diameter to guide balloon-artery ratios 
[58,59J and the sizing of other devices. Recent 
studies using off-line QCA would indicate that 
appropriate stent sizing (oversizing) and infla-
tion is of significant value and should effect 
long-term outcome [37,60J. 
The use of on-line QCA to confirm that an 
optimal result has been achieved has now 
become an integral component of interventional 
practice, particularly since the adoption of the 
bigger the better policy. The definition of angio-
graphic (procedural) success is becoming more 
stringent (a moving target), and in EUROCARE, 
OARS, and BOAT this definition has changed 
from the traditional residual diameter stenosis 
of less than 50% to the new definition of less 
than 20% or 15% [35]. 
Other than to determine the diameter and 
length of a stent, the role of on-line QCA in the 
quantification of a threatened closure or dissec-
tion is limited. Clearly in the case of acute clo~ 
sure, on-line QCA can only provide the reference 
diameter of the proximal segment. In the case of 
a threatened closure, 1110st information can be 
gleaned by serial visual assessment of dynamic 
parameters such as TIM I flow over time (by 
examining a sequence of images) [61~63). The 
serial quantification of a static pararneter such 
as the documentation of a reduction in rvrLD 
over 15 minutes by repeated on-line QCA can he 
of some help but is usually superfluous. The 
presence of a radiopaque guidewire in a dissect-
ed vessel further confounds QCA analysis as 
demonstrated in figure 12-5. Edge-detection 
algorithms typically perform poorly and unpre-
dictably in the case of extravasation of contrast, 
however, the recent development by van der 
29 
Zwet and colleagues [8) of a gradient field trans-
form algorithm that is capable of tracking dis-
sections with extraluminal contrast and complex 
lesionalmorphology more accurately than mini-
mal cost criteria algorithms may improve the 
value of on-line QCA in the assessment of 
threatened vessel closure. 
Although it would be expected that the elimi-
nation of some steps in image acquisition and 
processing and the elimination of nonisocentric 
calibration should result in improved reliability of 
on-line QCA measurements, a recent study using 
phantom stenoses in porcine coronary arteries 
found that the accuracy and precision of one off-
line QCA syslem was comparable with those 
obtained by an on-line QCA system using a differ-
ent edge detection algorithm [64~GG1. It seems, 
therefore, that basic concepts derived from the 
study of cinefilm images by reliable off-line QCA 
systems can be applied to on-line analysis to 
guide the operator during diagnostic and inter-
ventional procedures accepting a degree of dis-
crepancy in absolute values according to the par-
ticular on-line and off-line QCA systems deployed 
[(-)6J. \'\,ith the recent introduction of intervention-
al policies sllch as the bigger the better for bal-
loon angioplasty and directional atherectomy and 
the change in policy from matching of stents to 
reference vessel size to a policy of oversizing. it 
could be considered that on-line QCA has 
become an essential requirement for optimal 
coronary interventional practice. 
Although QCA can provide a measure of cur-
vature, roughness, symmetry, and plaque vol-
ume, and indirect calculations of the hemody-
namic significance of lesions [(-)7-,68), these 
quantitative measurements have been inadc~ 
quately validated and their current reliability 
appears to he no better than that provided by 
Figure 12-5. Tracking of it radiopaque guidewire hy 
quantitative coronary angiography (qc/\j. Tracking of a 
radiopaque guidewire by QCA during catheter calibration 
in the contrast-empty state. The presence of a radiopaque 
guidewire in a catheter or coronary vessel may interfere 
with automated edge detection, in the absence of sliffi-
cil'nt contrast medium. 
visual qualitative assessments of lesion charac-
teristics. \·Ve are currently assessing the agree-
ment of semiautomated quantitative coronary 
measurements with traditionally derived visual 
assessments of ABC classifications. Agreement 
and correlation appear to be very poor for 
almost all parameters. Thus, despite the known 
poor interobserver agreement of visually 
assessed qualitative parameters, further 
improvements and research will be required 
before the use of computer-derived quantitative 
measurements of lesion and vessel morphologi-
cal characteristics can be recommended. 
WHICH QCA VARIABLE CONVEYS THE 
MOST INFORMATION? 
Prior to the introduction of QCA, the severity of 
coronary lesions used to be expressed in terms 
of percent diameter stenosis. Following the 
report that the restenosis process involves the 
normal reference segments immediately proxi-
mal and distal to the treated lesion [69], expres-
sion of restenosis rates in terms of percent diam-
eter stenosis was subsequently found to be 
uninformative, at times deceptive (eg, pseudo 
regression {70]), and insensitive to the detection 
of a therapeutic effect in restenosis trials and 
imparted a reduction in statistical power of stud-
ies. The absolute minimal luminal diameter at 
follow-up is a static measurement providing an 
objective, reproducible and unambiguous para-
meter for the expression of the final angiograph-
ic outcome and conveys information of func-
tional significance, while change in minimal 
luminal diameter provides a dynamic parameter 
to describe the process of luminal gain and loss. 
Determination of the reference vessel diameter, 
however, continues to be of value for the selec-
tion of device and stent size during on-line 
analysis and for obtaining direct comparisons 
between study groups in view of the known 
effect of vessel size on absolute luminal loss fol-
lowing intervention. 
The conventional method of determination 
of the reference vessel diameter requires the 
user to select a reference position at a normal 
proximal point. In arteries with a focal obstruc-
tive lesion and clearly normal proximal and dis-
tal luminal diameters, selection of the reference 
point should be fairly reliable. However, in cases 
where the proximal part of the arterial segment 
contains both stenotic and ectatic areas, the 
selection may be difficult and unreliable. To 
overcome this subjectivity, an interpolated tech-
nique was developed to determine the reference 
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diameter at the actual site of the stenosis with-
out operator interference. The basic principle 
behind the technique is the computer estinla-
tion of the original diameter values over the 
obstructive region (assuming there was no coro-
nary disease present) based on the diameter 
fUllction. Following this approach the reference 
diameter is taken as the value of the polynomial 
at the position of the minimal luminal diameter. 
This objective and reproducible technique of 
reference vessel diameter determination is not 
yet available in all QCA systems hut its value is 
becoming increasingly more recognized. 
PRACTICAL MEASURES IN 
ANGlO GRAPHIC ACQUISITION 
AND QCAANALYSIS FOR 
THE IMPROVEMENT IN 
REPRODUCIBILITY OF SERIAL 
QCA MEASUREMENTS 
PINCUSHION DISTORTION 
Pincushion distortion introduces a selective 
magnification of objects in the periphelT of an 
image compared with those at the center. This 
can be overcome by the recording of a centime-
ter grid from each angiographic system to be 
analyzed off line. Some QCA systems can then 
memorize the degree of distortion by each sys-
tem and make adjustments accordingly during 
each subsequent analysis. Furthermore, regions 
of interest should be filmed at the center of the 
image whenever possible. Fortunately the newer 
image intensifiers introduce significantly less 
pincushion distortion than previous ones. 
S-DISTORTION 
S-distortion, which results from geomagnetism 
and additional local magnetic field forces, 
varies considerably according to the angulation 
of the X-ray gantry. Corrective functions for 
such S-distortion are complex and have the 
potential to introduce more error than they 
promise to resolve. 
ASPECT RATIO 
\'Vith the use of video as a storage medium for 
coronary angiograms, a new source of distortion 
and challenge arises for QCA-the aspect ratio. 
Non-CCD cameras (eg, vidicon or plumbicon) 
have an independent horizontal and vertical 
adjustment for magnetic beam deflection. This 
can give up to 10% differences between horizon-
tal and vertical adjustment for magnetic beam 
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deflection. This results in up to a 10% difference 
between horizontal and vertical dimensions and 
thus the spatial orientation of the coronary seg-
ment becomes critically important. In addition 
to the horizontal and vertical gain in the X-ray 
camera, aspect ratio errors may also be intro-
duced if the dock speed of the digitization board 
in the radiograph system is not adjusted for 
square pixel size. Furthermore, aspect ratio 
errors will occur if the aspect ratio of the frame 
grabber or the video digitizer in the QCA system 
is different than 1:1 (eg. in some systems it is 
4:3). r..·Iost QCA systems offering pincushion dis-
tortion correction can now also correct for error 
in the aspect ratio (fig. 12-6). 
DIFFERENCES IN ANGLES AND HEIGHT 
LEVELS OF THE X-RAY GANTRY 
To improve the sensitivity of angiographic stud-
ies to detect change in luminal diameter over 
time, it is important that paired angiograms are 
acquired in the same views. This can be 
achieved by the automatic on-line recording of 
gantry settings and table height and selected X-
~ ~ ~ ~ 'I t t t 
>- ~ ~ 'I t t + t ~ 
+ + + + + + + t , 
+ + + + + + + -" -" 
>( + + + + + + -" -" 
>( + + + + + + + -" 
J + + + + + + + -" 
J + + + + + + + -" 
J J + + + + + + + 
J J + + + + .. .. + 
Pol. order'" 3 Pitch", 10.0 mm 
Pixel size"" 0.1934 mm sdX=3.311pixel$ 
Aspect ratio = 1.0162 sd y '" 3.201 pIxels 
Centerc-1.1,-S.1 mm set D = 4.606 pixels 
Orientation angle = -3,4 degrees Distortion vector· 1 
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ray exposure factors (kV, rvIa) or written docu-
mentation on a technician's worksheet of the 
settings when on-line recording is unavailable. 
Attention to the table height and to the focal 
spot isocenter distance and the focal spot image 
intensifier distance will become increasingly 
more important if a drive toward isocentric cali-
bration is to he effective. 
MULTIPLE MATCHED VIEWS 
\,\'hen the method of QCA is geometric (edge 
detection) rather than videodensitometric, it is 
important that multiple orthogonal views (three 
for the left coronary artery and two for the right) 
be analyzed rather than a single worst view to pro-
vide a reliahle analysis of eccentric lesions [71], 
DIFFERENCES IN VASOMOTOR TONE 
Because vasomotor tone may vary widely during 
consecutive coronary angiographic studies, it 
should be controlled at all times. Intracoronary 
nitrates should be administered immediately 
before pre- and post-procedural angiograms 
and at follow-up. Calcium antagonists are also 
Figure 12-6. Aspect r.lllo and pincushion distortion. In 
addition to correcting for pincushion distortion, some 
Qllillllil<1tive coron.1ry ,lflgiography (QCA) systems C,1I1 also 
corrl'c1 for the aspect ratio (difference in horizont.ll and 
vertical dimensions associated with videotape recordings 
of coronary angiograms). This is achieved by the rt'cord-
ing of a centimeter grid at the beginning of a procedure. 
The d('[cc(ed and subsequently corre{:\t'd or rectified 
points of intersection of tht' centimeter grid can be seen in 
the figure. The pincllshion distortion from this rMliograph 
system (Philips Del) is relatively mild and typical for the 
CUrrent generation of radiograph hardw,lf{o. It can be 
appreci.lteci that the recording of the ,lngiographic 
catheter in the center of till' illlage and then the curonary 
stenosis in the center of tht' illlage will (('sult in minimal 
distortion even v",hen subsequently analyzed by a QCA 
systemtlMt does not corrt·( t (or distortion. 
given at some centers; however, their action may 
be of slower onset. 
INFLUENCE OF CONTRAST AGENTS ON 
VASOMOTOR TONE 
The vasodilatory effects of contrast agents on 
epicardial coronary artery tone appear to be 
smaller with non ionic compared to ionic agents, 
\"'e therefore recommend the use of nonionic 
iso-osmolar contrast media for angiographic tri-
als, Contrast concentration is also known to exert 
a marked effect on QCA measurements, and thus 
adequate vessel filling is essential for the reliabili-
ty of serial QCA, This point is demonstrated in 
Pigure 12-7 where the elTect of [)O% contrast and 
100% contrast concentrations were compared in 
vitro in a multicenter study [72J of 10 QCA sys-
tems in North America and Europe, 
CATHETER AS A SCALING DEVICE 
For off-line analysis, the guiding catheter is typi-
cally used as a scaling device for calibration of 
angiographic measurements, As the manufac-
turer's nominal size of catheters is unreliable, the 
external diameter of the catheter is measured by 
a precision micrometer. The image quality of the 
recorded catheter is dependent on the catheter 
material, the kilovoltage of the X-ray source and 
the concentration of the contrast agent, Nylon 
catheters have the largest effect on the angio-
graphically measured size and are therefore not 
recommended for quantitative angiographic tri-
als, The effect of the contrast-filling versus con-
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trast-empty states are discussed later in this 
chapter, It is hoped that by the introduction of 
isocentric calibration techniques over the next 
few years (also discussed later in this chapter) 
many of the errors associated with catheter cali-
bration will be avoided, 
LENGTH OF THE ANALYZED SEGMENT 
Anatomic landmarks as bifurcations are used for 
the manual definition of start and endpoints of 
arterial segments to be analyzed to minimize the 
problem of nonidentical analyses. 
MANUAL CORRECTIONS 
Only very rarely is it necessary to enter either 
soft or hard corrections to the edge detection 
procedure, Corrections should be discouraged 
(particularly of the l'vrLD) even in the presence 
of a dissection with extraluminal contrast, 
where the edge detection algorithm will typi-
cally include the extravasation in the presence 
of a continuous large channel connecting the 
true and false lumens and will typical1y 
exclude the extravasation in the presence of a 
discontinuous small connection between the 
true and false lumens, The computer registers 
for both the right and left hand contours, the 
length of the arterial segments that were man-
ually corrected, 
FRAME SElECTION 
An end-diastolic cine-frame is selected for 
quantitative analysis to avoid motion and blur-
ring effects. 
Figure 12-7, Effect of contrilst concentration on quantita-
tive coronary angjogriJphy (QCA) performance. As patt of 
a multicenter QCA villidiltion study, a series of phantom 
stenoses were recorded in vitro (plexiglass blocks). The 
stenosis channels were serially filled with 50'/'" and 1 (}O% 
contrast and recorded on cinefilm. The cinefilm was then 
analyzed by off-line QCA at 10 care angiographk labor,1-
taries in North Anll'rici'l and Europe. It can be seen that 
QCA measurements were most accurate wl1etltlle 
stenoses w('re filled with J OO'X, concentration of ronlrdSt. 
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CALIBRATION OF QCA 
MEASUREMENTS 
CATHETER CALIBRATION 
''''hether calibration of QCA measurements 
should be based on contrast-empty or contrast-
filled catheters has not yet-been universally 
agreed upon [73-79]. 1\vo studies, that have rec-
ommended the use of the contrast-empty state 
have adopted a similar methodologic approach 
and have been performed on the same QCA sys-
tem that uses a fixed weighting of the first and 
second derivative [73,79]. After calibration by 
using a centimeter grid as a scaling device, QCA 
measurements of contrast-filled and contrast-
empty catheters in vitro have been compared 
with the true external diameters of guiding 
catheters that have been measured by a preci-
sion micrometer (tolerancl <0.001 nUll). Such 
direct micrometer measurements of the external 
diameter of guiding catheters in a dry state at 
room temperature (20°C less than the tempera-
ture at which catheters are recorded in vivo) 
result in a measurement of on average 0.025 mm 
smaller than the normal manufacturers' stated 
size [79]. Allowing for individual variations relat-
ing to the trilaminar composition of different 
catheters Cfable 12-3), QCA measurements in 
the contrast-empty state have been found over-
all to provide the best agreement with the true 
external diameter of the catheters. 
The methodologic approach of the above 
two studies [73,79}, however, does not directly 
examine the reliability of QCA measurements 
when calibrated by a catheter, but rather 
addresses QCA measurements of catheters when 
calibrated by a centimeter grid. furthermore, it 
should be remembered that ultimately QCA 
measurements are performed on contrast-filled 
vessels and not on the atherosclerotic walls of 
contrast-empty vessels. Although agreement of 
measurements of catheters by QCA and by 
micrometer were better when in the contrast-
empty than in the contrast-filled state, they 
resulted in a smaller calibration factor (mm/pix-
ell) [73,76,79]. Thus QCA measurements of coro-
nary segments will be smaller when calibrated 
by contrast -empty catheters. We know that QCA 
systems underestimate measurements of coro-
nary luminal diameters of >0.7 mm when cali-
brated by contrast empty catheters (64,72J. 
Although the reasons for this underestimation 
by QCA measurements probably relate to several 
technical factors! we have shown that when QCA 
TABLE 12-3_ TRILAMINAR COMPOSITION OF CORONARY 
GUIDING CATHETERS' 
Manufaclurert Series Trilaminar composition 
Bard lIlumen Teflon, Kevlar braid, Pebax 
Cordis Diaventional Trilon, Steel braid, Nylon 
DVI Brite Tip Teflon, Polyurethane, Ultrax 
Atherectomy 
Medtronic Sherpa Polyurethane, Steel braid, Teflon 
Schneider Soft Touch Teflon, Steel braid, 
Polyurethane 
Sclmed Triguide Teflon, Steel braid, Trilon 
"All of the above guiding catheters were found to be tmderestimated by quanti-
tative coronary angiography (QCA) measurements. Underestimation was less 
when the catheters were analyzed in the contrast-empty 5tate (_3 % ) compared 
with the contrast-filled 51ate (-7%). The DVI atherectomy guiding catheter, 
which does not contain steel braiding, was found to be underestim,1ted the 
most by QCA measurements (-7% in the contrast-empty state and -14% in the 
contrast-filled slate). Use of angiographic guiding catheters as a scaling device 
for calibration of QCA measurements will thus resufl in smaller measurements 
of ('Oronary stenoses when a contrast-filled catheter is used (ie, smaller cali-
bration factor (mm/pixel). 
tCordis, Miami, Fl; Medtronic, Minneapolis, MN; Schneider, Buelock, 
Switzerland; Sdmed, Minneapolis, f..lN. 
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measurements of the same coronary luminal 
diameters are calibrated at the isocenter, this 
underestimation is significantly improved [72J. 
Thus until QCA systems no longer underesti-
mate measurements of coronary luminal diame-
ters, there are few compelling reasons to select 
the contrast-empty state during catheter calibra-
tion. This is perhaps particularly important dur-
ing the conduction of an atherectomy trial, 
where luminal diameters will inherently be larg-
er than those encountered in an exclusively bal-
loon angioplasty triaL 
In a study (perviously unpublished) to test 
whether such caution is warranted we compared 
QCA measurements of in vivo contrast filled 
phantom stenoses of known 'diameter in porcine 
coronary arteries when calibrated by three differ-
ent techniques: 1) calibration on a contrast-filled 
guiding catheter, 2) calibration on the same guid-
ing catheter in the contrast -empty state, and 3) 
calibration at the isocenter. The QCA system was 
an experimental edge detection algorithm [80J 
with variable weighting of the first and second 
derivative, which was designed to overcome the 
problem of overestimation of small diameters. The 
guiding catheter used was an 8-v Schneider 
(Buelach, Switzerland) guiding catheter that had 
previously been found in one of the above studies 
[79J to be most accurately measured by QCA in the 
contrast-empty state. The accuracy and precision 
for the three calibraton techniques arc given in 
Table 12-4. Accuracy of QCA measurements of the 
coronary stenoses was poorest when calibrated by 
the contrast-empty catheter, improved slightly, 
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when calibrated by the contrast filled catheter 
(less underestimation of coronary luminal diame-
ters), and was best when calibrated at the isocen-
ter. The precision and standard eITor of QCA mea-
surements was best during calibration by the 
contrast-filled catheter. vVhile these results only 
have direct implications for one catheter and one 
QCA algorithm, they indicate a point in the 
process of QCA analysis that requires further 
research and clarification, and most importantly 
they indicate a potential point with significant 
scope for improvement in the reliability of QCA 
measurements. A comprehensive study on QCA 
calibration should be undertaken on. several QCA 
systems to directly determine the accuracy and 
precision of QCA measurements of contrast-filled 
vessels when calibrated by contrast-empty 
catheters in vivo and when calibrated by contrast-
filled catheters in vivo. 
ISOCENTRIC CALIBRATION 
An improvement in the reliability of QCA mea-
surements might be achieved hy abandoning the 
use of the angiographic catheter as a scaling 
device entirely and aiming for isocentric calibra-
tion. In essence, the pixel size (nulls) for each 
image intensifier field size is known (from the 
recording of a centimeter grid) and docs not 
change throughout a procedure (nor indeed 
from day to day). By using a biplane radiograph 
system a coronary stenosis can be filmed at the 
isocenter by positioning the stenosis at the cen-
ter of the image in hoth planes. \'Vhen a coronary 
stenosis is filmed at the isocenter the errors 
TABLE 12-4_ CALIBRATION TECHNIQUES FOR QUANTITATIVE CORONARY ANGIOGRAPHY' 
Absolute mean Precision (SO of Standard error 
Calibration Accuracy {signed error {unsigned signed (standard error of 
technique differences), mOl differences), mOl differences), mm the estimate), mm 
Contrast-empty 
guiding catheter -0.21 0.24 ±O.23 ±O.19 
Contrast-filled 
guiding catheter -0.18 0.22 ±O.20 ±O.17 
At the isocenter 
(centimeter grid) -0.08 0.20 ±O.24 ±0.24 
'Comparison of three calibration techniques for quantitative coronary angiography. In vivo phantom stenoses of known 
diameter in porcine coronary arteries were used to compare the three techniques. A Schneider B-F quiding cathetf'r and 
all experimental edge detection algorithm with variable weighting of the first and second derivative were used for this 
comparison. 
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introduced by catheter calibration can be avoid-
ed. VVhen an investigator fails to film the stenosis 
precisely at the center of the image in one of the 
planes (and thus inherently not at the isocenter 
of both planes), a complex mathematical formu-
la can be applied to COlTect for the displacement 
from the isocenter {7j. If one accepts a deviation 
of approximately 1 cm from ·the center of the 
image in either plane this may still provide supe-
rior reliability of QCA measurements than that 
provided by catheter calihration, which current-
ly does not correct for the out of plane distortion 
of the angiographic catheter, which is located in 
the coronary ostium. The coronary ostium will 
invariably be either further or nearer to the 
image intensifier than the coronary segment 
containing the stenosis. This source of absolute 
error will particularly effe\;t the QCA measure-
ment of stenoses located in the mid and distal 
segments in each of the th :ee major coronary 
arteries, while QCA analysis of stenoses in the 
proximal segments (ie, American Heart 
Association classification segments 1,5,6,11 {81]) 
will be less susceptible to the calibration error 
introduced by out-of-plane distortion. 
During application of a laserwire for the 
treatment of chronic total occlusions, biplane 
imaging is required to guide the direction of 
advancement of the lasenvire to reduce the risk 
of perforation. In Total Occlusion Trial with 
Angioplasty assisted by Laser guide-wire 
(TOTAL) isocentric calibration will he used at the 
core angiographic laboratory, and should pro-
vide an indication of the relative merits and fea-
sibility of noncatheter calibration for future 
interventional trials.-
QCA BY GEOMETRIC AND 
VIDEO DENSITOMETRIC 
TECHNIQUES 
The two principle techniques for quantitative 
angiographic measurement are edge detection 
and videodensitometry. Only the edge-detection 
results of QCA mcasurements have been utilized 
in multicenter intervention trials to date. Edge 
detection involves the detection of luminal bor-
ders by weighting of the 1st and 2nd derivatives 
of the digitized brightness profile, which are 
converted into absolute values after calibration 
with an object of known diameter, such as the 
shaft of a guiding catheter. Because the observed 
morphology in a single-view angiographic image 
is critically dependent on the projection, the use 
of edge detection necessitates the incorporation 
of multiple matched orthogonal views to provide 
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a three-dimensional approximation of the dis-
eased segment. 
More information can be extracted from a 
single view angiographic image by considering 
not only the relative changes in pixel brightness 
values upon which the edge detection technique 
is based, but also be integrating the absolute 
pixel brightness values. The intensity of the X-
rays entering the image intensifier is in principle 
related to the absorption path length of the inter-
vening medium by the Lambert-Beer law. The 
brightness intensity assimilated between two 
corresponding contour positions may thus pro-
vide a measure of the arterial cross-sectional area 
and is independent of the projection (in the 
transverse plane of the coronary segment). This 
method (videodensitometry) can he practically 
applied when the pixel brightness values are cali-
brated, ie, when the relationship between the 
pixel brightness values and the absorption path 
length (mm) of the contrast-filled artery is con-
stituted. Videodensitometry assesses the relative 
area stenosis by comparing the density of con-
trast in the diseased and normal segments. The 
major limitation to videodensitometry is the 
strict requirement of an angiographic projection 
perpendicular to the long axis of the vessel (to 
prevent oblique cuts that would lead to overesti-
mation of the luminal area) and the absence of 
overlapping, or closely parallel side branches or 
other vessels in the segment to be analyzed 
(which would interfere with the density of the 
lesion due to background subtraction). 
Densitometry is also more sensitive than edge 
detection to densitometric nonlinearities (X-ray 
scatter and veiling glare) and to inconsistent con-
trast filling of vessels. New techniques for the 
correction of background density irregularities 
have been recently developed {821; however, their 
superior efficacy in improving the reliability of 
QCA measurements by videodensitometry has 
yet to be demonstrated by comparative studies, 
Comparison of, edge detection and video-
densitometry in validation studies using phan-
tom stenoses in vivo have shown promising 
results for videodensitometry, although random 
error (noise) rather than inaccuracy continues to 
be its primary limitation [83,841. In a recent 
comparison by Escaned and coworkcrs [85J of 
the variability in QCA measurements by edge 
detection and videodensitometry of a single pro-
jection of clinical angiograms, the variability of 
videodensitometry measurements postangio-
plasty compared favorably with edge detection 
and indicated that by virtue of its independence 
of complex luminal morphology videodensitom-
etry might be of potential value in the clinical 
assessment of dissections [85,86]. 
The clinical application of video densitometry 
in interventional research and practice has to 
date been limited. Videodensitometry may be 
used to detect intracoronary thrombus by a mis-
match in cross-sectional area measurements 
from video densitometry and edge detection in 
two planes. Detection of intracoronary thrombus 
may also be achieved by the use of pixel variance, 
A potential application of QCA by videodensito-
metry may be the derivation of volumetric mea-
surements of coronary segments for the study of 
serial changes in diffusely diseased vessels [87J, 
This application, however, may prove to be of 
greater value for the study of progression-regres-
sion in coronary segments of small diameter 
(where Ieus catheters would wedge) rather than 
for the study ofinterventional cardiology [871. 
Thus, although the option to perform mea-
surements by videodensitometry is an added 
advantage for scientific research particularly for 
small lesions where accuracy of videodensitom-
etry may be superior to edge detection and 
where reus catheters will wedge, videodensito-
me try could not be considered as an essential 
featuIB,for a functional QCA laborator)~ 
Given the resolution and silver grain size in 
cinefilm, edge detection is unlikely to benefit sig-
nificantly from the introduction of on-line QCA 
(typical pixel size with 5-inch image intensifier 
setting::: 0.14 mm) whereby,the process of cine-
film exposure and development is bypassed, 
Videodensitometry on the other hand, has been 
vulnerable to the nonlinearities between X-ray 
exposure and the densitometric characteristics of 
cinefilm that are only partly and crudely correct-
ed by accepting a logarithmic rather than a linear 
relationship in densitometric analysis of cinean-
giograms. Given the 256 grey levels of digital 
imaging and the linear relationship between 
radiograph exposure and the pixel brightness 
value, it is likely that we can expect some 
improv~ment in the performance and reliability 
of videodensitometry with the advent of digital 
transfer of angiographic images to core laborato-
ries and by the lise of videodensitometry on-line 
in the catheterization laborat0l1~ 
VALIDATION 
Although, today there arc approximately ten 
commercially available QCA systems, there is as 
yet no standardized or universally agreed valida-
tion procedures to enable direct comparisons 
among QCA systems and the subsequent 
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exchange and integration of data of angiographic 
studies from different core laboratories. QCA 
analysis involves the processing of an image 
through a series of technical steps involving both 
hardware and software components, Each step 
including the projector, magnification, camera, 
digital resolution as well as the edge detection 
algorithm effects the reliability of measurements, 
Importance should therefore be placed on the 
selection of the hardware as well as the software 
components when acquiring a QCA system, and 
the system should be calibrated after completion 
of the entire image processing chain, A compre-
hensive review of the hard"ware and software 
components for established QCA systems has 
been previously described by Johan Reiber [88J. It 
appears that most QCA systems are calibrated 
according to the results of in vitro validation 
studies. However it is only by the performance of 
in vivo validation studies that the conditions of 
heterogenous scatter and veiling glare encoun-
tered in the human thorax can be reproduced, 
Thus, development of QCA systems upon in vitro 
results may partly explain the overall poor results 
of QCA validation revealed by in vivo studies [72], 
Qualitative coronary angiography validation 
studies can be stratified into those attempting to 
determine the accuracy and systematic errors of 
QCA measurements and those attempting to 
determine the reproducibility of repeated mea-
surements in clinical practice. Both are of value 
and are mutually complementary; To determine 
the accuracy and the range over which overesti-
mation and underestimation of QCA measure-
ments occur, a series of stenoses of known diam-
eter are required, These stenoses, which are 
usually made of plexiglass may be recorded in 
vivo or in vitro, The primary limitation of in vitro 
studies is their underestimation of the errors 
likely to be encountered in vivo or in clinical 
practice, The primary limitation of studies 
assessing reproducibility of QCA measurements 
of clinical angiograms is their inability to provide 
any measure of reliability. Thus a QCA system 
that is found to have excellent reproducibility of 
clinical angiograms might be perceived by the 
unwary as being reliable, even though if the 
same QCA system was submitted to in vivo vali-
dation studies using phantom plexiglas stenoses 
of known diameter the system might be found to 
be reproducibly unreliable, eg, underestimation 
of large diameters by 0.30 HUll and overestima-
tion of small diameters by 0.05 mm, Thus both 
forms of validation tests should be encouraged 
and are necessary if we are to eradicate the sys-
tematic and random errors currently encoun-
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tered in hoth on-line as well as off-line QCA. 
\".'hen reading the report of clinical trials, it is 
common to encounter a brief sentence stating 
that the QCA system deployed has been validat-
ed or that the QCA system has a reproducibility 
of 0. OX mm, "What does this mean? \-Vere the val-
idation studies performed with in vitro or in vivo 
models? How were the validated measurements 
calibrated? \"'as it the reproducibility for interob~ 
server or intraobserver measurements? \-Vas a 
preselected stop frame used and analyzed 
repeatedly at the same sitting or did the operator 
of the QCA system have to select the frame on 
each sitting in a blinded manner at 5 minutes, 2 
hours, 30 days and 90 days apart [89,90-}? Given 
the magnitude of the clinical implications of 
QCA trials for interventio'laI practice, reports of 
QCA trials should include an adequate descrip-
tion in the methods sectiOlJ of the likely overesti-
mation and underestimation and reproducibility 
of the reported QCA results on the basis of in 
vivo QCA validation studies, Only then will the 
reader be able to determine the true angio-
graphic outcome in the study population, This 
description of QCA was partly provided in the 
report of the CCAT trial, where in addition to 
detailed descriptions of the angiographic acqui-
sition and angiographic analysis and calibration, 
was the inclusion in the manuscript of the 
results of the intraobserver reproducibility by 
the trial personnel for immediate reanalysis 
(0.07 mm) and for 25 paired angiograms ana-
lyzed 6 months apart (0.20 mm) [56-1. The 
demand for such measures and publication of 
quality control in the execution and reporting of 
multicenter angiographic trials is likely to 
increase over coming years, 
Another problem contributing to the confu-
sion over validation studies is the absence of a 
standardized set of cinefilms that could be used 
to test all QCA systems. In light of this problem, 
a cooperative validation study of QCA systems 
w,ing the same set of in vitro and in vivo cine-
films calibrated by both the isocenter and with a 
catheter as a scaling device, was recently under-
taken at ten centers in North America and 
Europe [72J. I\'larked variation in performance, 
among commercially available QCA systems as 
well as those that have been developed in house, 
was revealed, No system was found to be perfect 
and all systems either underestimated or overes-
timated measurements to varying degrees. The 
results of the study would suggest that it would 
be difficult for core laboratories using different 
software or hardware QCA components to 
directly share or merge data without the intro-
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duction of mathematical corrective functions for 
the results of each system, 
A difficulty encountered in making direct 
comparisons between the performance of differ-
ent QCA systems, even when validated by the 
same series of phantom stenoses, is deciding 
which statistical parameter is most discerning 
and informative, Traditionally, validation of QCA 
systems has been based on the statistical parame~ 
ters of accuraC)~ precision, correlation coefficient, 
standard error of the estimate, and the equation 
of linear regression given by the intercept and 
slope. Although each parameter provides a 
unique index of a QCA system's performance, 
direct comparisons between QCA systems is con-
founded by the interdependence of all parame-
ters and the application of one parameter in iso-
lation can be misleading, Would it be possible to 
generate a single derived parameter to incorpo-
rate the essence of all the above parameters? 
Accepting that some parameters reflect minor 
problems that could be corrected by recalibration 
of the system and others reflect l110re serious 
problems of noise, it might be possible to convey 
the most essential information about a QCA sys-
tem's performance by only one or two parame-
ters, such as the correlation coefficient and the 
corrected standard error of the estimate after nor-
malization of the measurements for an intercept 
of zero and a slope of one [66J. Applying this pro-
posal of normalization for a y intercept of zero 
and a slope of 1 to the results of a recent multi-
center QCA validation study (72J of the in vivo 
series of measurements calibrated by the 
catheter, a simplified model for the comparison 
of various quantitative coronary analysis systems 
is presented, based on the exclusive use of the 
corrected standard error of the estimate (SEEc) 
and correlation coefficient (1') (Table 12-5). 
CLINICAL ApPLICATION OF QCA 
VALIDATION RESULTS 
By modification of the principle of normaliza-
tion of QCA measurements for an intercept of 
zero and a slope of one, the angiographic 
results of trials such as BENESTENT and 
STRESS could be merged and the angiographic 
results of CAVEAT and CCAT merged by the cor-
rection of their respective QCA results (by their 
known systematic errors from in vivo validation 
studies of the QCA systems used in each trial) 
for an intercept of zero and a slope of one, Thus 
if a hypothetical QCA system was found during 
an in vivo validation study with catheter cali-
bration to overestimate small diameters and 
underestimate large diameters and thus have a 
regression analysis of y :::: 0.20 nlIn + O.BOx then 
all angiographic results produced by that sys-
tem would be normalized as true MLD :::: (mea-
sured MLD-O.20 mm}/0.80. 
Following the application of this normaliza-
tion for their respective QCA systems, the results 
of the two stent trials could be merged and the 
results of the two atherectomy trials merged. 
Clearly such normalization will not improve the 
reproducibility (random error) associated with 
each QCA system; however, the desensitizing 
effect on the trials exerted by the noise of each 
QCA system (high standard deviation of mea-
surements) should be partially overcome by the 
increase in the total number of observations 
provided by the merging of the respective data-
bases (thus reducing the standard error of the 
mean and increasing the sensitivity of the 
merged analyses). 
FAILURE OF THE PARAMETER ACCURACY 
TO CONVEY THE SYSTEMATIC ERROR 
OF A QCA SYSTEM 
The statistical parameter of accuracy can at 
times be misleading, Given that most QCA sys-
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tems tend to overestimate small diameters and 
underestimate large diameters, the regression 
line of most QCA systems intersects the line of 
identity at a point above 0.5 mm on the X axis. 
An example of how the reliance on one or simple 
statistical parameters to convey an impression 
of the performance of a QCA system can be mis-
leading is the use of accuracy. If in the conduc-
tion of a validation study the number of obser-
vations (phantom stenoses) ablwe and the 
number of observations below the point of inter-
section of the regression and identity lines are 
equal, the reported accuracy for the QCA system 
may be close to zero. This would occur for exam-
ple if the difference between QCA measure-
ments and the true values above the point of 
intersection is -0.2 mm (underestimation) and 
the difference between QCA memmrements and 
, the true values below the point of intersection is 
+ 0.2 mm (overestimation). This deception arises 
from cancellation of the signed differences of all 
measurements for the entire validated range. 
This inability of the parameter of accuracy to 
cOllvey the systematic error of QCA measure-
ments can be overcome by the reporting of the 
absolute mean error of QCA measurements. By 
TABLE 12-5. NORMALIZATION OF THE STANDARD ERROR OF THE ESTIMATE 
FOR AN INTERCEPT OF ZERO AND A SLOPE OF ONE-
Normalized 
QCA system Intercept, mm Slope Correlation SEE, mm SEEe, mm 
0.19 0.74 0.89 ±0.19 ±O.27 
2 0.14 0.76 0.96 ±0.12 ±O.16 
3 0.15 0.69 0.89 ±O.19 ±0.27 
4 0.04 0.66 0.91 ±O.16 ±O.24 
5 0.00 0.83 0.98 ±O.O9 ±0.11 
6 0.34 0.58 0.91 ±O.14 ±0,23 
7 0.12 0.63 0.90 ±O.16 ±0.25 
8 0.05 0.71 0.87 ±O.22 ±0.31 
9 0.17 0.57 0.91 ±O.14 ±O.24 
10 0.20 0.60 0.83 ±O,22 ±O.36 
Average 0.14 0.68 0.91 ±Q,16 ±O.24 
*Given the inlerdcpence of all conventional statistical parameters fur the description of quantitative coronary angiography 
(QCA) validation results, it becomes difficult to select which statistical parameters should be utilitzed for direct comparisons 
of different QCA systems. One approach would be to normalize the validation results of each QCA system under compari-
son for an intercept of zero and a slope of one. The normalized (corrected) standard error of the estimate (5[[c) (ur each 
QCA system would then be directly comparable between svstems and provide an index of the noise or random errur to be 
expected from each system after recalibration and eliminatiun of systematic errors. The LOrretaliofl coefficient will not alter 
during the normatiz,ltion process and thus could be directly used (or comparisons between QCA systems. \Ve have ,1pplied 
this statistical proposal to the results of a recent multicenter QCA validation stud~' whereby the results of ten different QCA 
systems are presented. The results are (or an in vivo (porcinE' coronary <Htefies) series of phantom stenoses of known diame-
ter and \"'ere calibrated using a guiding catheter positiuned in the coronalY ostium. 
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taking the unsigned differences, the deviation or 
error of each measurement from the true value 
is taken into account and conveys to the reader 
the systematic error to he expected from QCA 
measurements within the validated range. This 
point is illustrated in Figure 12-8, }vhere for a 
hypothetical series of QCA measurements, the 
accuracy is 0.00 mm and the absolute lllean 
error is 0.15 mm. 
Many previous QCA validation studies have 
used the statistical approach proposed by 
Bland and Altman [891. however, this approach 
provides little additional information over lin-
ear regression analysis. Bland and Altman [91] 
designed their statistical method to display the 
agreement between two measurement systems 
in the absence of a golden standard and thus 
their approach is of limited value to a study 
when the true value of th~ measured objects is 
known. One method of aci"iressing the problem 
of comparative validation would be to express 
accuracy and precision at any given true value 
of a phantom stenosis in a categorical manner. 
If a consensus was reached on the most rele-
vant absolute value of diameter at which accu-
racy and precision of QCA systems should be 
compared (eg, 1.5 mm) then one value for 
accuracy and precision could be given for each 
QCA system. If, however, the regression line for 
a QCA system crossed the line of identity in the 
vicinity of this point (or ncar the midpoint of a 
validated range) then the derived accuracy 
value would appear deceptively favorable. 
Alternatively, a series of three accuracy and 
precision values could be given for each sys-
tem for three true values of lumen dimension, 
eg, 1.0, 1,8, and 2,7 mm roughly corresponding 
to likely measurements of minimal luminal 
Accuracy vs absolute mean error 
~ :::.----------'-.--.--.--.--.--.--.--.--.--:.-01' 
f 1.20 --
~ 0.80 
g 0.40 
0.00 0.40 0.80 1.20 1.60 2.00 
True value of stenoses, mm 
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diameter pre- and postcoronary intervention 
and of reference vessel diameter. 
QCA AND ANALOGUE VIDEOTAPE 
'''Tith the increasing availability of digital (sub-
traction) angiography, many interventional 
suites have already entered the era of the film-
less cath lab, While some radiograph systems 
have digital export facilities, most currently use 
analogue videotape for export and long-term 
storage of dneangiograms. Videotape offers the 
advantages of easy handling, instant replay, 
and low cost [92-95] and thus in many institu-
tions videotape has been welcomed as a more 
convenient recording medium than 35 mm 
cinefiIm, Despite the hasty replacement of 
cinefilm at many interventional suites, the suit-
ability of video recordings for QCA has not yet 
been established, The limited shelf life of 7 
years for videotape may render it unsuitable for 
important c1incial trials on the results of which 
Food and Drug Administration approval for a 
device or pharmacologic agent may subse-
quently be sought. 
Videotape may introduce additional noise 
and potentially worsen the reproductibility of 
QCA measurements by virtue of the introduction 
of the following additional steps in the data pro-
cessing of angiographic images: 
1. Video camera in X-ray image intensifier, 
2. Analogue to digital conversion to provide digi-
tal angiographic images on hard disk (parallel 
\'Vinchester disks for real time processing). 
These digital images may be compressed to 
increase the number of stored frames in an 
error-free or lossless compression format 
without resultant deterioration in precision of 
figure 12·8, ACCUf,lCY of quantitative coronary angiogra-
phy (QCA) meaSUrl'ments. Linear regression of a hypothe-
tical QCA valiclfltion study where the accuracy reported 
for the QCA system is 0.00 mm even though 1) nut a sin-
gle individual measurement had an accuracy of 0.00 mrn, 
and 2) the systematic tendency to overestimate small 
luminal diflmeters flnd underestimate large luminal diame-
ters. This highlights the irwlequacy 0( the term accuracy 
to portray the cumplete picture of a qCt\ system's perfor-
mance and systematic errors, and supports the use uf the 
parameter, absolute medn error, which is independent of 
the sign (±J uf the individual QCA measurements. 
QCA measurements, or filtered to provide 
edge enhancement (contrast). 
3. Digital to analogue conversion for export to 
videotape with conservation of the edge 
enhancement if applied. The video-recorder 
itself may introduce additional high frequency 
noise. 
4. Analogue to digital transfer (CCD camera in 
QCA hardware). 
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The imminent replacement of video cameras by 
CCD cameras in image intensifiers will provide 
more geometrically accurate images (thereby 
reducing pincushion distortion and avoiding the 
primary on-line analogue to digital conversion). 
To determine the potential application and 
reliability of videotape recording for off-line QCA 
for clinical studies we recently carried out two 
studies. In the first we compared QCA measure-
TABLE 12-6. IN VITRO COMPARISON OF 
QUANTITATIVE CORONARY ANGIOGRAPHY 
MEASUREMENTS OF CINEFILM AND VIDEOTAPE RECORDINGS 
WITH AND WITHOUT EDGE ENHANCEMENT' 
Recording Accuracy, Precision, 
medium 111m 111m Correlation Regression SEE, mOl 
Cinefilm -O.ID ±O.O8 0.997 y=O.OI ±O.OS 
mm + 93x 
Video-N -0.11 ±O. J8 0.987 Y = 0.13 ±O.12 
mOl +85x 
Video-E -0.10 ±0.11 0.992 y = -0.06 ±0.11 
mnl + 9Bx 
~Results of off-line quantitative coronary angiograph}' (QCM validation (CAAS II) of cine-
film and videot.lpe recordings of in vitro stenoses_ The videotape recordings tested were 
of normal images and of images that had undergone a process of on-line filtering-edge 
ennancementl}s.ing a Philips DCI system. The random error (noise) of QCA analyses was 
lea,t for dnefilm analyses <lnd greater for videotape. The process of on-line edge 
enhancement was found to convey a reduction in random error (improvement in preci-
sion and st.lndard error of the estimate ISEE) in subsequent off-line QCA analysis. Video~ 
E-videotape recordings of edge enhanced angiographic images; Video-N-videotape 
recordings of normal (unfiltered) .lngiograpi0 images. From Ozaki and Coworkers 1951; 
with permission. 
TABLE 12-7. AGREEMENT OF QUANTITATIVE CORONARY 
ANGIOGRAPHY MEASUREMENTS OF CLINICAL STENOSES 
BETWEEN CINEFILM AND VIDEOTAPE' 
Comparison 
Video-N-Cinefilm 
Video-E-Cinefilm 
Mean of differences 
(Agreement), mm 
0.14 
0.04 
SD of differences, 
mm 
±O.20 
±O.13 
'Results of off-line quantitative coronar~' angiograph~' (QCA) validation studies where 
the results of QCA analyses of dnefilm were used as a reference for the assessment of 
QCA measurements of videotape recordings. The terms accuracy and precision, how-
ever, are not used as the true values of the coronar~' stenoses pre- and post-percuta-
neous tr.lnsluminal coronary angiograph~' are unknown. Video-E-videotape record-
ings of edge enhanced angiographic images; Video-N-videotape rewrdings of normal 
(unfiltered) angiogr.lphic images. 
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lllents of cinefilm and videotape recordings of 
experimental stenoses of known diameter in vitro 
as well as comparing QCA measurements of the 
two recording media of clinical coronary artery 
stenoses pre or postballoon angioplasty [95]. All in 
vitro and clinical angiograms were recorded on a 
DCI X-ray system (Philips, Best, The Netherlands) 
in the Thoraxccnter catheterization laboratory and 
all off-line QCA analyses were performed on the 
CAAS II QCA system (Pie Medical, Maastricht, The 
Netherlands). The results of this study are present-
ed in Tables 12-6 and 12-7. Videotape recording 
,vas associated ,vith a deterioration in both accura-
cy and precision although edge enhancement of 
the images (filtering of the digitized images on the 
DCI system in the cath lab prior to their export (A 
to D transfer) on videotape, was seen to convey 
some improvement in the QCA measurements. 
In our second study (previously unpublished) 
we undertook a multicenter trial of videotape 
recordings for QCA analysis. \·Ve compared the 
accuracy and precision of video recordings of in 
vitro stenoses from four different e}.'ternal cardiac 
catheterization laboratories and examined the 
effect of the application of edge enhancement 
(compared with normal processing) from each x-
ray system. In this second study we also assessed 
the potential application of a signal averaging 
techniquc to reduce the additional noise of video 
recordings (ie, to raise the signal to noise ratio). 
The signal averaging technique consisted of the 
digitizing by the QCA system of multiple video 
frames of the same image (by using a custom-
designed frame grabber) and averaging of their 
data (frozen images were recorded on videotape at 
a speed of one angiographic image per 25 frames 
of videotape). All in vitro stenoses (on a back-
ground of plexiglass blocks and copper plates) 
were filmed at the isocenter in the 7-inch image 
intensifier field size with the smallest focal spot 
size setting for each X-ray system (0.4 to 0,5 mm). 
Again the QCA system used for all off-line analyses 
\"as CAAS II. All QCA measurements ,,,ere calibrat-
ed by the recording of a centimeter grid in each lab-
oratory. The average pixel size during QCA a.nalysis 
after optical magnification (x 2) and digitization of 
the video images was 0.19 mm (this is considerably 
larger than the typical pixel size of cinefilm record-
ings of 0.06 mm). Correction for pincushion distor-
tion was applied to all video images prior to analy-
sis. The results of this study are presented in Tables 
12-8 and 12-H and Figure 12-9. 
rVfarked variability was seen from one 
catheterization lab to the next. In the X-ray sys-
tem of catheterization lab I, in addition to excrt-
ing a marked effect on accuracy (from 0.07 mm 
TABLE 12-8. EFFECT OF ON-LINE EDGE ENHANCEMENT 
OF DIGITAL IMAGES EXERTS WIDElY VARIABLE AND 
UNPREDICTABLE EFFECTS ON SUBSEQUENT OFF-LINE 
QUANTITAIVE CORONARY ANGIOGRAPY ANALYSIS 
Catheter lab I 
Catheter lab 2 
Catheter lab 3 
Catheter lab 4 
OF VIDEOTAPE RECORDINGS' 
Normal processing. mm 
Accuracy Precision 
-0.08 ±O.O9 
0.07 ±O.40 
0.07 ±O.32 
-0.05 ±O.lO 
Edge-enhanced, mm 
Accuracy Precision 
-0.12 ±O.10 
-0.05 ±O.39 
-0.03 ±O,lO 
-0.05 ±Q,19 
'Results of off-linequan!itative coronary angiography (QCA) measurements of in 
vitro stenoses on videotape recorded in four different catheterization lahs, 
M,uked v':lfiabifitywas ~een from one c.lthett'rtzalion lab to the ne.\t. In the X-ray 
sy~tem of catheterization lab 3, in addition to exerting a mJrked effell on aCUlra-
qo {(10m 0.07 mOl to -0.03 mm) edge enhancement improved precision of off-
line QCA measurements. In ,ontrast, edge enhancement of the images in 
,.1theteriz<ltion labs I and 2 had no effect on off-tine QCA measurements and in 
c<ltheteriz.ltion lab 4 edge enhan<-ement was vsso<-iated with a deterioration in 
precision of off-line QCA measurements. On-line edge enhanct:'ment of digital 
images in catheterization lahoratories may exert a significant died on subse-
quent off-line QCA an,1I}'sis of .1nalogue videotape recordings of the enhanced 
ima,l',es. The effect varies LOnsider.lhly from one X-fa}' system (and the filtering 
level se!ect<->d) to another. 
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to -0.03 Bun) edge enhancement improved preci-
sion of off-line QCA measurements. In contrast, 
edge enhancement of the images in catheteriza-
tion labs 2 and 3 had no effect on off-line QCA 
measurements and in catheterization lab 4 edge 
enhancement was associated with a deteriora-
tion in precision of off-line QCA measurements. 
Thus, it appears that on-line edge enhancement 
of digital images in catheterization laboratories, 
exerts a significant effect on subsequent off-line 
QCA analysis of analogue videotape recordings of 
the enhanced images. This effect varies consider-
ably from one X-ray system (and the filtering 
level selected) to another. 
Signal averaging (by multiple frame grab-
bing) was found to convey no detectable 
improvement in the reliability of QCA measure-
ments. The reliability of QCA measurements of 
videotape recordings var~' significantly from one 
X-ray acquisition system to another. These 
results indicate that analogue videotape record-
ings of angiographic images are generally 
unsuitable for the conduction of interventional 
trials using off-line QCA at a core laboratory. 
Occasionally individual X-ray systems with par-
ticular edge enhancement filter settings may 
provide images of sufficient quality for off-line 
QCA of videotape recordings presumably due to 
faithful tracking by the off-line QCA edge detec-
tion algorithm of the enhanced edge previously 
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inscribed by a reliable on-line edge-enhance-
ment algorithm. Thus, centers with filmless cath 
labs with only analogue videotape export for-
mats that wish to participate in multicenter 
interventional trials should be individually 
screened by appropriate QCA validation tests to 
determine the reliability of their angiographic 
images for off-line QCA. 
FUTURE DIRECTIONS 
AND CONSENSUS 
European and North American working groups 
are currently assessing potential digital and ana-
logue storage media for the nImless catheteriza-
tion laboratory. Storage media currently under 
consideration currently include hard disks, com-
pact discs, optical disks, digital tape, and stan-
dard analogue tape. On the basis of availability, 
freedom of data compression and decompres-
sion requirements, videotape initially appeared 
attractive; however, the resolution and reliability 
of video formats with or without edge enhance-
ment for off-line core lab quantitative angio-
graphic analysis appears to be inadequate for 
research purposes, and compact disks will soon 
be widely available in catherization laboratories. 
VVhile a degree of loss may be acceptable for 
routine clinical purposes, the compression and 
decompression of angiographic images hy a Jossy 
TABLE 12-9. RESULTS OF OFF-LINE QUANTITATIVE CORONARY ANGIOGRAPHY OF 
SIGNAL-AVERAGED IMAGES OF IN VITRO STENOSES RECORDED ON VIDEOTAPE' 
Number of frames averaged 
1 field 
Filtration 16 frames 8 frames 4 frames 2 frames 1 frame (0.5 frame) 
Catheter lab 1 ±O.09 mm ±O.13 mm ±O.12 mm ±0.11 mm ±0.11 mm ±0.t3 mill 
normal processing 
Catheter lab 1 ±O.IO mm ±0.08 mm ±0.07 mm ±O.12 mm ± 0.10 mOl ±0.12 mm 
edge enhanced 
Catheter lab 2 ±OAO mill ±0.48 mill ±0.49 mm ±0.41 mm ± 0.44 mm ±0.47 mm 
normal processing 
Catheter lab 2 ±O.39 mm ±O.IS mill ±O.16 mm ±O.17 mm ± 0.22 mm ±0.33 mm 
edge enhanced 
'In vitro validation study of off-line quantitative coronary angiograph).' {QCAI analysis {(,\AS H) of videotape recordings from 
two cdtheter labs with normal video recordings and with !he application of edge enhancement Despite a subjective 
improvement in images (visual assessnlE'nO, signJI Jver,lging of the video images by the use of a multiple frame grabber 
was not found to convey an improvement in the precision of off· line QCA measurements. 
42 
QUANTITATIVE CORONARY ANGIOGRAPHY: AN INTEGRAL CO~IP()NENT 01' INTEHVENTIONAL CARDIOLOGY 
technique (which can achieve compression 
ratios from 10 to 1 to 80 to 1 (for monochrome 
images)) would be unacceptable for QCA pur-
poses. Thus only error-free compression algo-
rithms (which normally achieve a compression 
ratio from 2 to 1 to 10 to 1) should be used for 
angiographic images, which will subsequently be 
used for QCA analysis. Each compression algo-
rithm offers different compression-decompres-
sion processing times as weU as range of com-
pression ratios. Fractal compression appears to 
be one of the most promising techniques for 
angiographic images. Further advances will be 
made when the manufacturers of radiograph sys-
tems agree on a common storage medium and 
software language (eg, Diacom) for digital 
exchange of angiographic images for QCA 
Over the past 2 years a group of international 
investigators have held meetings to address the 
current lack of standardization of data acquisi-
tion, analysis and validation for the conduction 
of progression-regression and restenosis trials. It 
is envisaged that the imminent report of this 
international QCA consensus group will provide 
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Figure 12-9, Iv\ulticenter validation study of quantitatiVe 
coronary angiography (qCi\) measurements of videotape 
images recorded at different catheterization laboratories. 
5 
A and H, t\ series of phantom stenoses were recorded in 
vitro (plexiglass blocks) at different catheteriz<ltion labs. 
The images were then recorded at each site onto <Inalogue 
videotape and brought 10 a core angiogr<lphic laboratory 
where they underwent QCi\ analysis (CAAS H). QCA 
results of the videotape imLiges varied markedly from one 
catheterization lab to Llnother. In the figure, it c<ln be seen 
that in catheterization lab 1 (A) (QCA measurements have 
been plotted against the true values on the graph) the 
results were of high qULllity where the process of analogue 
videotape recording subtended a minimal degree of ran-
dom error (precision:=: ± 0.09 mOl, standard error of the 
estimate [SEE] :=: ± 0.090101). In contrast, in catheteriz<ltion 
lab 2 (B) the process of analogue videotape recording 
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guidelines for the design of future quantitative 
angiographic studies. 
Until sources of systematic and random 
error in QCA measurements can be greatly 
reduced, we should consider an integrated 
approach for the assessment of coronary artery 
disease. QCA (static picture) should be com-
bined with ICUS (murelography) as well as 
dynamic data such as Doppler or other flow 
measuring techniques (pressure wire). 
Vlhile QCA offers objectivity and superior 
reproducibility compared with visual assessment, 
extensive improvements are reqUired before QCA 
can be accepted as a reliable tool for the predic-
tion of cardiac events. \'Vide differences exist in 
the performance of currently available QCA sys-
tems, highlighting the difficulties in attcmpting to 
make direct comparisons between absolute mea-
surements of one angiographic study with those 
derived from a different QCA systcm or with on-
line analysis in clinical practice. 
Qualitative coronary angiography validation 
studies should be performed in a uniform and 
standardized manner to provide meaningful 
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introduced an Urlan ('ptable degree of random error (noise 
prl'Cision :=: ± OAOmnl, stamlLird error of the estimate :=: 
0,42mm). A~ 10 be expected in the absence of edge 
enhancement, video recording only introduced noisl' ,md 
did not r('sult in a shift or systematic error of QCA med-
surl'nwnts. Of particular interest are the vailies of accura-
cy rl'ported for these two series of validation results, 
wfwrd)y the accuracy of QCA measurements of vidl'olclpe 
imflges frolll catheterization lab 2 (0.07mm) is at leas! as 
good ,1S for catheterization lab 1 (-0.080101) ,lnd highlights 
the importance of understanding fhe relevance and nll'ar1-
ing of the different ~Iati~tical parameters used to describe 
me<1SUrl'nwnt sysl('IllS. !"llD-minimalluminal diametl'r; 
video-N-vidcotdlw recordings of normal (unfiltered) 
angiogr'lphic images. 
data that can be used to compare the perfor-
mance of QCA systems, to guide the recalibra-
tion of QCA algorithms and to facilitate the 
maintenance of high standards of QCA for scien-
tific studies and clinical practice, 
Power calculations and study design of 
angiographic trials should he adjusted for the 
precision of the QCA system utilized to avoid the 
risk of failing to detect smail differences in 
patient populations, 
Hesults of validation studies should he given 
both as the normalized (corrected) values in addi-
tion to the absolute values of the statistical para-
meters, In the reporting of clinical angiographic 
studies, absolute values of luminal diameter and 
CUHUliNT REVIEW OF INTERVl!NTIONAL CARDIOLOGY 
values of statistical significance fOf differences 
between study populations should be accompa-
nied by the results of the appropriate validation 
parameters of the QCA system deployed to facili-
tate the interpretation of the study's findings, 
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Background Computerized quantitative coronary angiogra-
phy (QCA) has fundamentally altered our approach to the 
assessment of coronar), interventional techniques and strate· 
gies aimed at the prevention of reeurrence and progression of 
stenosis. It is essential, therefore, that the performance of QCA 
systems, upon which much of our scientific understanding has 
become integrally dependent, is evaluated in an objective and 
uniform manner. 
Methods and Reslilts We validated 10 QCA systems at core 
laboratories In North America 'and Europe. Cine films were 
made of phantom stenoses of known diameter (0.5 to 1.9 mm) 
under four experimental conditions: in vjvo (coronary arteries 
of pigs) calibrated at the isocenter or by use of the catheter as 
a scaling device and in vitro with 50% contrast and 100% 
contrast. The cine films were analyzed by each automated QCA 
system without observer interaction. Accuracy and precision 
were taken as the mean and SD of the signed differences 
between the phantom stenoses, and the measured minimal 
luminal diameters and the correlation coefficient (r), the SEE, 
the y intercept, and the slope were derived by their linear 
C linical trials incorporating quantitative coronat)' angiography (QCA) have made a significant impact on the practice of interventional cardi-
ology. They have reported the results of vessel size, 
lesion severity, and short- and long·term angiographic 
outcome of patients undergoing interventional proce-
dures. On the basis of the BENES TENT, STRESS, 
CAVEAT, and CCAT trials, angiographic guidelines 
have been proposed for the application of interventional 
devices.!·4 Furthennore, on the basis of restenosis pre· 
vention studies such as MARCATOR, PARK, and the 
US Angiopeptin trial and of progression·regression 
studies, pharmacological agents ha\'e been deemed to 
be ineffective because by the QCA approach a difference 
in minimal luminal diameter at follow-up has not been 
detected.5 .6 
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regression. Performance of the 10 QCA systems ranged widely: 
accuracy, +0.07 to +0.31 mm; precision, :!::0.14 10 :!::0.24 mm; 
correlalion (r),.96 to .89; SEE, :!::0.11 to :!::0.16 tnm; intercept, 
+0.08 to +0.31 mm; and slope, 0.86 to O.M. 
Conclusions There is a marked variability in performance 
between systems when assessed over the range of 0.5 to 1.9 mm. 
The range of accuracy, intercept, and slope values of this feport 
indicates that absolute measurements of luminal diameter from 
different multicenter angiographic trials rna)' not be directly 
comparnble and additionally suggests that such absolute mea-
surements may not be directly appJ[cable to clinical practice 
using an on·line QCA system with a different edge detection 
algorithm. Power calculations and study design of angiographic 
trials should be adjusted for the precision of the QCA system 
used to avoid the risk of failing to detect small differences in 
patient populalions. This study may guide the fine·tuning of 
algorithms incorporated within each system and facilitate the 
maintenance of high standards of QCA for scientific studies. 
(CirCII/afiolJ, 1995;91:2174·2183.) 
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The results of these trials, however, have been gener-
ated by different off·line QCA systems. It is not known 
whether their results are all of equal reliability and to 
what extent each system overestimates or underesti-
mates the true coronary dimensions. To determine the 
reliability of the angiographic results of interventionai, 
restenosis, and progression·regression trials, a validation 
of 10 QCA systems at major core angiographie labora-
tories in North America and Europe (including the core 
laboratories that performed the QCA for all of the 
above-mentioned trials) was undertaken, 
QCA systems with poor precision may fail to detect 
small but significant differences in study populations, 
whereas QCA systems with poor accuracy may provide 
misleading results of absolute measurements of minimal 
luminal diameter. TIle results of studies based on unre· 
liable QCA systems may not be directly comparable to 
those of more reliable systems. To render the results of 
angiographic studies meaningful and universally appli· 
cable, it is important that QCA systems be validated in a 
systematic and standardized fashion. Results of single-
center validation studies will vary according to the 
individual characteristics of the models of the phantom 
stenoses used and their radiographic acquisition. 7•1() 
Without a standardized approach to validation, it be-
comes difficult to assess to what degree individual an-
giographic studies arc reliable, the significance of their 
failure to detect relative changes in minimal luminal 
diameter, and how much weight should be attributed to 
absolute values of minimal luminal diameter derived 
flom individual QCA systems. Furthermore, it is only by 
detailed validation studies that errors in QCA measure· 
ments can be identified and thereby provide guidance 
for the refinement of QCA systems. 
To assess the QCA systems under radiographic can· 
ditions reflecting clinical practice in addition to those of 
optimal radiographic acquisition, phantom stenoses of 
known diameter were used as a reference both in vivo 
(after insertion in the coronary arteries of pigs) and in 
vitro (Plexiglas blocks), TIle QCA systems were assessed 
by their measurement of the absolute value (in millime· 
ters) of the minimal luminal diameter within the artifi· 
cial stenoses, which has previously been shown to be 
more reliable than relative measures (percent diameter 
stenosis) of coronary artery dimensions based on the 
definition of a reference contour,n.D 
Methods 
Phantom Stenoses 
The phantom stenoses used in vivo as well as in vitro 
consisted of radiolucent acrylate and polyamide cylinders 
with precision·drilled circular lumens 0,5, 0.7, 1.0, 1.4, and 
1.9 mm in diameter. Optical calibration of the stenosis 
channels using 40·fold magnification gav{j a tolerance of 
0.003 mm. Parallel to the stenosis lumen, a second lumen 1.3 
mm in diameter was drilled in the cylinders to enable their 
attachment to the tip of 4F Fogarty catheters (Vermcd). The 
lumens of the Fogarty catheters contained a removable 
metallic stylet, which aided the intracoronary insertion of 
the phantoms as well as their positioning in the radiographic 
isocenter, Details of our experimental approach to QCA 
validotion have been described. 14•16 
In Vim Studies 
The procedures followed were in accordance with institu· 
tional guidelines for animal studies. The phantom stenoses 
were inserted into the coronary arteries of anesthetized York· 
shire pigs (45 to 50 kg), Twelve·French introducer sheaths were 
surgically placed in both carotid arteries to allow the sequential 
insertion of the phantom stenoses on 4F Fogarty catheters and 
the insertion of the angiographic guiding catheter. To minimize 
the effect of respiration on angiographic acquisition, mechan· 
ical ventilation was temporarily discontinued immedi(Jtely be· 
fore each contrast injection. With two methods of calibration, 
two series of measurements were obtained for the in vivo 
series, providing an assessment of the variability of nonisocen· 
trk calibration, 
In Vitro Studies 
The phantom stenoses were serially lnserted into a Plexiglas 
acrylate model to approximate the attenuation and beam 
hardening (peak kilovolt IkVpJ level, 75 kV) produced by the 
human thorax. L1,L8 The Plexiglas channel, including the artifi· 
cial stenosis, was then filled with contrast medium (iopamldol 
370, Bracco; 370 mg iodine/mL) at concentrations of 50% and 
then 100%. Each phantom stenosis filled with contrast medium 
was recorded on cine film. By use of h .... o concentrations of 
contrast medium, tv.'o series of measurements were obtained 
for the in vitro series, allowing an assessment of the variability 
introduced by contrast concentration, 
Calibration 
All the in vitro cine frames were calibrated off·line by scaling 
from a steel object of 3·mm diameter recorded at the radio· 
graphic isocenter as previously described,!H6 Both the 3·mm 
scaling object and subsequently the in vitro phantom stenoses 
were filmed precisely at the isocenter of the x·ray system. L9 The 
calibration procedures available in each off·line QCA system 
were applied to the images obtained by automatcd edgeS1 
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detection to produce the corre~ponding calibration factors 
(millimeters per pixel), 
All in vivo frames were calibrated by scaling from the 
isocentric 3·mm steel object; subsequently, the analysis was 
repeated and frames were calibrated by scaling from the 
angiographic catheter, which was achieved by the nonisocen· 
tric radiographic acquisition of the unfilled tip of the 
contrast catheter (positioned at the coronary ostium as in 
routine clinical practice), A recent study using a centimeter 
grid showed that QCA measurements correspond to the 
outer diameter of the catheter and that the use of contrast· 
empty catheters (-2,9%) yields more accurate results than 
contrast·filled catheters (_7.1%).2002L The diameter of the 
nontapering part of each SF polyurethane catheter was 
measured (diameters of the individual catheters ranging 
from 2.49 to 2.54 mm) with a preciSion micrometer (No. 
293·501, Mituto),oj accuracy, 0.001 mm), resulting in the 
respective calibration factors (millimetcrs per pixel). In the 
in vivo series, after the intracoronary insertion of each 
phantom stenosis and before angiographic recording, the 
radiopaque tip of the guide wire of the Fogarty catheter thai 
was located in the side channel of each phantom was used as 
a marker in two planes to ensure that the phantom stenosis 
lay at the radiographic isocenier. The guide wire was then 
removed before coronary angiography. 
Image Acquisition and Processing 
A monoplane Philips Poly Diagnost C2 machine equipped 
with an MRC x·ray tube and powered by an Optimus CP 
generator (Philips Medical Systems International BV) was 
used for all radiographic imaging. The 5·in (12.5·cm) field 
mode of the image intensifier (focal spot, O.S mm) was 
selected, and the radiographic system settings were kept 
constant (kVp, rnA, ms) in each projection. All phantoms 
were imagcd in two projections sequentially and acquired On 
35·rnrn cine film (CFE type 2711, Kodak) at a frame rate of 
25 images per second with an Arritechno 90 cine camera 
(Arnold & Richter) with an 85·mm lens. The cine films were 
processed by a Refinal developer (Agfa·Gavaert) for 4 
minutes at 28°C, The film gradient was measured in all cases 
to ensure thai the optical densities of interest were on the 
linear portion of the sensitometric curve. From each angio. 
gram that fulfilled the requirements of quantitative analysis 
(no superimposition of surrounding structures, no major 
vessel branching at the site of the phantom), rl homoge. 
neousl}' filled end· diastolic coronary image was selected. Ten 
in vitro and 19 in vjvo frames were suitable for quantitative 
analysis of the artificial stenoses, 
Quanlitalhoc Angiographic Analysis 
The cine films of the phantom stenoses were analyzed 
off·line by 10 QCA systems in nine participating centers, 
Each center had a unique combination of QCA ~oftware and 
hardware. The default settings of optical magnification, 
Iight·emitting diode settings, etc, at each core laboratory 
were used without a\ter:l.Iion, It is assumed in this study that 
each core laboratory (through continuous Internal quality 
control assessments) has established for itself the optimal 
settings and operations for its individual QCA system, The 
resultant pixel size after digitizalion depended on the video 
camera pixet matrix (Table 1) of each system and ranged 
from 0.07 to 0,20 mmfpl·xel. The list of participating centers 
and details of their QCA systems are given in alphabetical 
order in Table 1 (it should be noted that the subsequent 
results for the 10 systems are given in a different order 
anonymously), None of the QCA systems tested had been 
previously c:.librated at prior validation testing with the type 
of phantom used, One of the investigators (EJ\'l.v.S.) visited 
all the centers, bringing the same set of films for (Jnalysis to 
each center consecutivcly. The same set of preselected cine 
frames was analyzed at each center to avoid the introduction 
of any variability between QCA systems associatcd with 
frame selection by each operator. l2 A technician working at 
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TAOLE 1, Details of aCA Systems 
Opllcal Magn1llcatlon Video Camere 
SUe Clna Projector of Clna Film Images Camara (VIdeo Converter) Pixel Matrix aCA Syatem 
A Vanguard XR35 Yo. Vidicon tube Analogue Artrek version 1.6: 1992 
B ~ Tagarno 35.A.X y" Vanguard W-6 Analogue 525 line Arlrek version 1.6; 1992 
e Tagarno 35.A.X Yo. Newvlcon Analogue Mrek. ve/slon 1.36: 1991 
0 CAP 358 y" Vidicon Analogue Arlrek. version 1.6; 1991 
E Amplo 35 Yo. CCO chip 756 AWOS 
581 
f Ta9a1Oo 35CX y" CCO array 1710 CMS I 
1330 
G Tagarno 35CX Yo. CCO array 1710 CMS II 
1330 
H CAP 3SE Yo. CCD chip 512 eMS 
48' 
Tagarno Yo. CGO chip 512 In house 
48' 
J Tagarno 35CX No CCD chip 1320 8M15S 
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aCA Indicates quantitative coronlll)' al'l9iography: CAP, cine al'l9iography projector; CGD, charged coupled de~ice: AWOS, artery work stalion; 
CMS, coronary ang:ography analysis system; CMS, cardiovascular measurement system; artd SMlSS, 51 Michael·s/Sunnybrook. system. 
each cenler who was unaware of the true diamelers of the 
phantom stenoses performed the automated QCA analysis 
of all cine frames in the presence of the investigator. To 
maintain scientific objectivity and to ensure that the direct 
comparisons between the 10 QCA systems were valid, 
operator intervention or editing of the automated edge 
detection was not permitted. An example of a contrast-filled 
phantom stenosis in vivo and its subsequent contours out· 
lined by one of the QCA systems is given in Fig 1. 
OIH mm 
: .. ···"---I--·L· f-~- .. \.. .... f .. \ ........ . 
.. .. ~_l· .. 
Statistical Analysis 
The individual geometric measurements of minimal luminal 
diameter were compared with the true phantom diameters 
by simple subtraction and by linear regression analysis. The 
mean of the signed differences between measured values and 
IIle known diameter of the phantom stenoses was considered 
an index of accuracy and the SO of the differences an index 
of precision. 
0" 
000 
FIG 1. The borders of a coronary segment containing a phantom stenosis are outlined by the automated edge-detection algorithm of 
one of the validated quantitative coronary angiography systems. Diameter function Is plotted al bottom of figure. 
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TABLE 1. (Continued) 
Correction for DIgital Magnification Final Pixel 
Mo.nulocturor of eCA Pincushion D)slortlon 10 Imog& for Analysis Matrix of eGA Algorithm Principle 
lmageComm, USA No 
ImageComm, USA No 
ImageComm, USA No 
ImageComm, USA No 
Siemens, Germany No 
Pie Medical, the N&therlands y" 
Pie Medical, the Netherlands y" 
MOOis, the Netherlands No 
Harvard University y" 
Universlty of Toronto No 
Results 
The individual indexes of accuracy and precision are 
given for all four validation series (in vivo with two 
calibration techniques and in vitro with two contrast 
concentrations) along with the average of their unsigned 
(absOlute) values for all 10 QCA systems validated in 
Table 2, The averages for accuracy and precision, for 
correlation coefficient and SEE, and for intercept and 
slope for all 10 QCA systems are given in Table 3, 
Indexes of Agreement 
Accuracy of the 10 QCA systems ranged from 0,07 to 
0,31 mm, and the correlation coefficient ranged from ,96 
to ,89, The intercept of the regression line was positive 
for all 10 QCA systems and ranged from +0,08 to +0,31 
mm, whereas the slope of the regression line for all 10 
QCA systems was <1.0 and ranged from 0,86 to 0,64, 
Application of these regression lines indicates percent-
age accuracies for the 10 QCA systems ranging from 
+26% to -1% (mean, +7,2%) for measurements of 
lumen diameters of 0,5 mm, percentage accuracies from 
TABLE 2, Accuracy and Precision 
In Vivo In VIvo 
y" 512 lsI and 2nd derivative 48' 
y" 512 lsI and 2nd derivative 
480 
y" 512 lsi end 2nd derivative 
480 
y" 512 lsi and 2nd derivative 
480 
y" 512 OpUmal convolution 
512 
No 512 lst and 2nd derivative 
512 
y" 1770 lst and 2nd derivative 
1330 
y" 512 1st and 2nd derivative 
512 
y" 512 1st and 2nd derivative 
512 
No 1320 Density profile of tr6cker boxes 
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-7% to -24% (mean, -14,9%) for lumen diameters of 
1.5 mm, and percentage accuracies from -11% to 
-29% (mean, -20,5%) for lumen diameters of 3,0 mm, 
Indexes of Noise and Consistency 
Precision of the 10 QCA systems ranged from ±0,14 
to ::'::0.24 mm, and the SEE ranged from :to,l! to 
±0,16 mm, 
An indication of the variability of performance among 
the 10 QCA systems can be visualized by comparing the 
results of the in vivo lest calibrated by the catheter for 
two of the systems depicted in Fig 2. 
Influence of the Validation Model 
As expected, it can be seen in Table 2 that the 
performance of each individual system varied from one 
validation test to another, In the in vivo series, accuracy 
was better when calibrated at the isocenter than on 
catheter calibration in all 10 systems validated (see Fig 
3), The method of calibration did not influence the 
precision or SEE of QCA, In the in vitro series, both 
Cathetor Isoconter In Vrtro 50% In Vitro 100% Averego 
A p A P A P A P A P 
-0.09 0.23 0.07 0.21 -0.12 0,10 -0.01 0,16 0.07 0.16 
-0.14 0,\7 -0.01 0,18 0.01 0,16 -0.14 0.D7 0.08 0,15 
-0.20 0.24 -0,14 0.31 -0.16 0,\7 -0.17 0,14 0,17 0.22 
-0.35 0,23 -0.11 0.15 -0.26 0.06 -0.13 0,14 0,31 0.15 
5 -0.19 0,13 -0.09 0.16 -0.25 0.13 -0.15 0.13 0,17 0.14 
6 -0,13 0,26 -om 0.22 -0.12 0.14 -0.07 0,24 0,08 0.22 
-0.30 0.25 -0.Q7 0.22 -0,29 0,13 -0,23 0.13 0,22 0.18 
8 -0.28 0.26 -0.25 0.20 -0.41 0.16 -0.13 0,17 0,27 0,20 
9 -0.33 0.26 -0,26 0.22 -0.29 0.20 -0.Q9 0.28 0.24 0.24 
10 -0.24 0.30 -0.15 0.24 -0.31 0,17 -0.2t 0.19 0.23 0.23 
Accuracy {A) and procision (P) are the mean and SD of tho dilferonces (mm) betwoen the 
measurement of lum;nal diameter derived by quantitative coronary angiography (OCA) and 
the true diameter of the phantom stenoses. 
In vivo c6theter Indicates In vi~'o series of measurements calibrated by the catheter, In vivo 
Isocenter, In vivo serles of measurements calibrated at the Isocenter; In vitro 50%, In vitro 
series of measurements with 50% contrast calibrated at the Isocenter; In vitro 100%, In vitro 
series of measurements with 100% contrast calibrated althe Jsocenter; and everage, average 
of the unsigned results. 
Results for the OCA systems (I through 10) are presented In Tables 2 and 31n the same 
order anonymously and are In a d,lferent order than the systems detailed In Table 1. 
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TABLE 3, Summary of Validation Rosults 
Accur.cy Preel.lon Correlation SEE Intercept Slope 
0.07 0.16 ," O.It) 0.20 0.77 
2 0.06 0.15 .96 0.12 0.17 0.82 
3 0.17 0.22 .90 0,16 0.17 0.70 
4 0.31 O.lt) .96 0.11 0.11 0.79 
5 0.17 0.14 .96 0.12 0.08 0.86 
6 0,08 0.22 .94 0.12 0.31 0.64 
7 0.22 0.16 .93 0.15 0.16 0.76 
, 0.27 0.20 .92 0.16 0.11 0.73 
9 0.24 0.24 .89 0.16 0.17 0.65 
10 0.23 0,23 .91 0.16 0.18 0.67 
Accuracy, protlslon. and parameters of linear regression (correlation, SEE. Intercept. and 
slope) fOr the 10 quantitative coronary angiography (OCA) syslems. The values given are tha 
IIvefllges of tha unsigned results from the four valida lion series (the In viy" serles calibrated 
by the catheter, the In vivo serlos calibrated al the Isocenler; the In vilto series with 50% 
contrast calibrated at the Isocenter; and the In vitro series with 100% contrast calibraloo at 
the Isocentelj. 
Resulls for the OCA systems (1 through 10) are presented In Tables 2 and 3 In the same 
order anonymously and afe In a different order than Iha Systems detailed In Table I. 
accuracy and the SEE were found to improve when the 
concentration of the injected contrast was 100% com-
pared with 50% during validation of 8 of the 10 systems. 
Discussion 
This study demonstrates the wide range of perfor-
mance provided by 10 QCA systems currently in use in 
North America and Europe. The clinical implications 
of such widely different results are considerable and 
can be divided into the clinical implications of inac-
curacy and the clinical implications of imprecision of 
QCA measurements. 
3 
0.5 -
+-OCA System 5 
+ OCA System 9 
- . Une of Identity ~"';"""/ "" t ~~/~// + 
+ 
O~ ____ L-__ ~~ __ ~ ____ ~ ____ _ 
o 0.' 
" " Phantom Diameters (mm) 
FIG 2. Graph showing in vivo data for two of the quantitative 
coronary angiography (OCA) systems va!ldated. An Indication of 
the variability of performance of the QGA systems validated Is 
demonstrated by linear regression of the results for OGA sys-
tems 5 and 9. The raw data for the In vivo OCA analysis 
calibrated by the catheter as a scaHng device has been plotted 
on the y axis with the true phantom stenosis diameters on the x 
axis. Each data point represents a single analysis of a cine frame 
from each anglographlc sequence. The accuracy was -0.19 mm 
for system 5 and -0.33 mm for system 9; the precision was 
±0.13 mm for system 5 and ±0.26 mm for system 9; the 
correlation was .98 for system 5 and .91 for system 9; and the 
SEE was ±O.09 mm for system 5 and ±O.14 mm for system 9. 
Clinical Implications of QCA Inaccuracy 
All systems were found to have a positive intercept 
(>0) and a slope of <1, indicating that many clinical 
studies to date using QCA may have overestimated the 
baseline minimal luminal diameter of their study popu-
lations and underestimated the acute gain in minimal 
luminal diameter after coronary intervention. For exam-
ple, with QCA system 9, the linear regression analysis of 
which is displayed in Fig 2, a vessel of 2-mm diameter 
will be reported as 1.31 mm, and a procedural improve-
ment in minimal luminal diameter from 0.5 to 1.9 mm 
will be reported as a luminal gain of only 0.77 mm. This 
may result in the establishment of angiographic guide-
lines that, when directly adopted in clinical practice 
using on-line QCA,7.14.23.24 may lead to device-vessel 
mismatching and inappropriately aggressive luminal 
gains and when adopted in subsequent clinical trials may 
lead to inappropriate inclusion criteria. By underestima-
tion in the range of typical reference vessel diameters (in 
addition to overestimation in the range of typical mini-
mal luminal diameters). clinical studies reporting their 
QCA results exclusively in terms of percent diameter 
stenosis will be less instructive than studies disclosing the 
absolute values of the minimal luminal diameter. These 
findings contrast with visual assessments of luminal 
diameter, which tend to overestimate acute luminal gain 
Pelred results for each OCA system 
FIG 3. Bar graph showing effect of calibration on accuracy of 
the In vivo series. The accuracy of quantitative coronary ang\og-
raphy (OGA) Is seen to Improve during calibration at tha Iso-
canter compared with tha use of the anglographlc catheter as a 
scaling davlce. Solid bars Indicate catheter; shaded bars, Iso-
center. 
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(it should be noted, however, that the variability between 
visual measurements has previously been shown to be 
many times higher than between QCA measurementsu ,U ). 
Measurements by some QCA systems were so differ-
ent from the true phantom diameters and so different 
from other QCA systems that the direct pooling of 
absolute angiographic data from different core labora-
tories may be rendered invalid. Although little could 
be done to correct for the random error in QCA 
results before the sharing of data between core angio-
graphic laboratories, application of a corrective func-
tion could be applied to compensate (recalibrate) for 
the known systematic errors of each QCA system. 
Specifically, the regression formula {y=a+b(x)J de-
rived from standardized validation studies of each 
QCA system could be applied to the results of angio-
graphic trials, thereby normalizing to an intercept of 0 
and a slope of 1 for each core laboratory [corrected 
result=(measurement result -intercept)/slope J. Such 
a step might facilitate the meta-analysis of comple-
mentary intervention studies such as STRESS and 
BENESTENT or such as CAVEAT and CCAT. 
Clinical.JmpJications of QCA Imprecision 
It could be proposed that poor accuracy or consistent 
overestimation or underestimation of absolute luminal 
diameters does not inherently abrogate the value of 
QCA in the detection of changes in serial angiographic 
studies, and perhaps the inherent noise (random error) 
of the system is more important for clinical trials. The 
high absolute values for precision (up to :to.30 mm) and 
SEE (up to :to.22 mm) provided by some systems 
indicate that calculation of study power and sample size 
for clinical studies should differ from one angiographic 
core laboratory to another. For example, for a nvo-Iimb 
angiographic restenosis study, a population size of 1022 
patients would be required if QCA system 5 (precision, 
:to,!3 mm) were used, whereas a population size of 1356 
patients would be required if QCA system 10 (precision, 
:to.30 mm) were used to detect a difference in loss of 
minimal luminal diameter at follow-up of ~0,1O mm 
(providing a value of 0:=.05 and a power of 90% and 
allowing for a patient dropout rate of 15%).6,29,30 How-
ever, it should be acknowledged that the value of 
precision reflects not only the random error of measure-
ments but also the systematic errors of a measurement 
system.31 It may therefore be more appropriate to use 
the known SEE of a QCA system for th.e power calcu-
lations of clinical trials rather than the value of precision 
of the QCA system. In the absence of such adjustments 
in study design, differences between study groups may go 
undetected or fail to reach statistical significance if a 
QCA with a large random error is used. 
The effect of the precision of a QCA systcm on the 
ability to clearly detect a difference among study popu-
lations can be seen graphically in Fig 4, in which a 
hypothetical study population has been analyzed by two 
different QCA systems, one with a poor precision and 
one with a good precision (the mathematical analysis 
used Lotus 1-2-3, Release 2.0 for Windows, Lotus 1993): 
The patient populations in graphs A and D are identical 
and represent a hypothetical study population in a 
restenosis trial 6 months after coronary intervention; 
one group of patients (treated with placebo) has "reste-
nos is" (mean change in minimal luminal diameter at 
follow-up of 1.0 mm), and the other group does not have 
"rest enos is" (mean change in minimal luminal diameter 
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at follow-up of 0.0 mm) after successful treatment with a 
drug. Graphs Band E display the precision (0.08 and 
0.30 mm) of two hypothetJeal QCA systems used to 
analyze the above study populations. Graphs C and F 
show the resultant measurements of the same study 
population by the two different QCA systems. In graph 
C, the significant difference between the two treatment 
groups (placebo and active drug) has been clearly de-
tected by the highly precise QCA system. In graph F, the 
difference between the treatment groups has been lost 
(or the difference does not reach statistical significance) 
when analyzed by the imprecise QCA system, Similarly, 
a bimodal distribution of luminal renarrowing within a 
population may appear as unimodal when assessed by an 
imprecise QCA system.J2 
In Vivo Versus In VHro Dahl 
The tables of results provided in this report contain an 
average of the four validation tests for each QCA 
system. It is debatable, however, whether the results of 
in vivo tests (in which veiling glare and scatter are 
heterogeneous because of overlying structures) and in 
vitro tests (in which veiling glare and scatter are homo-
geneous) calibrated by different methods should be 
grouped together and thus attributed equal importance 
in view of their unique characteristics and implica-
tions. 17,18 Correlation behveen the different validation 
series was poor; however, this was to be expected, given 
the different combinations of hardware and sofnvare 
components of the 10 QCA systems (eg, different 
weightings of the first and second derivative would be 
expected to respond differently to the sharper change in 
brightness profile associated with 100% contrast or using 
a steel object for calibration). Although the contrast of 
the steel objcct was sharp, it was on the linear portion of 
the sensitometric curve, and, indeed, rather than result· 
ing in a greater underestimation of stenosis measure-
ments, QCA measurements calibrated by the steel object 
were associated (to a major or minor degree) with less 
underestimation of true diameters compared with cath· 
eter calibration, as shown in Table 2 and Fig 3. TIlis 
finding of improved accuracy most likely results from the 
isocentric location of the steel calibration device rather 
than the catheter, which Jay in the coronary ostium 
proximal to the coronary segment containing the steno· 
sis as in clinical practice (with subsequent out-of-plane 
magnification). The results of the in vivo validation test 
calibrated by the catheter most closely reflect the prac-
tice of off-line analysis as performed in multicenter 
angiographie trials by a core laboratory, and in most of 
the 10 systems these results were poorer than those of 
the other three validation tests. 
Influence of Hardware and Software Components of 
Each QCA System 
The influence of the camera and cine-video converter 
on the final result of QCA analysis is highlighted by this 
study, which showed that although three centers had the 
same software package, remarkably different results 
were obtained because of their unique combinations of 
hardware components. AJthough our study was not 
designed to determine which components of the QCA 
chain were responsible for introducing the most noise, it 
is clear from our results that a core laboratory conduct· 
ing follow-up studies should revalidate its QCA system 
whenever a hardware or software component is ex-
changed or upgraded.33,34 This is of particular relevance 
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FIG 4. Graphs showing the effect of the precisIon of quantitati\le coronary angIography (QCA) systems on the ability to clearly detect 
a difference among study populallons when a hypothetical study populallon (graphs A and 0) has been analyzed by two different QCA 
systems: one with good preciSion (graph B) and one with poor precision (graph E). The difference between the treated and placebo 
patients has been detected (graph C) by the precise QCA system, whereas analysIs by the Imprecise QCA system (graph F) falls to 
detect the difference or fails to reach statistical sIgnificance (the mathematical analysiS used lotus 123, Release 2.0 for Windows, lotus 
1993). MLD Indicates minimal luminal diameter. 
to progression·regression trials, in which a QCA system 
4 years old is likely to have been upgraded at the core 
laboratory by more modem versions of the software. 
Posili\'e Directions and the Future of QCA 
The results of this study have already been used by the 
producers of some of the QCA systems to refine the 
algorithms incorporated within each system. Many of 
the systematic errors detected can be corrected by 
recalibration of the QCA software or tuning of the 
weighting of the first to the second derivative in the 
edge·detection algorithm,3s,36 whereas it would be 
expected to be more difficult to clear a system of 
noise, which usually reflects hardware impediments. 
Experimental algorithms currently under develop· 
ment include an adaptive dynamic weighting of the 
first and second derivatives to overcome the problem 
of overestimating measurements of small vessels and 
underestimating measurements of large diameters37.37a 
and a gradient field transform incorporating a "short· 
est-path" algorithm rather than a traditional smooth-
ing "minimal· cost" algorithm to cope with the abrupt 
changes in luminal contour encountered after coro-
nary angioplasty.38 
Given the considerable time, effort, and cost of con-
ducting restenosis and progression-regression trials, it 
seems reasonable to aim for a precision of clinical QCA 
measurements of .:50.20 mm for the analysis of current 
multicenter angiographic studies. 11 is hoped that such 
an arbitrary threshold could be reduced over coming 
years when high-resolution digital x·ray cameras and 
hiuh-resolution digital export formats (with lossless com-
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pression) are widely available at all investigating centers. 
An additional proposal that could be considered for 
clinical studies to reduce the variability of QCA mea-
surements would be for the investigators to reduce the 
setting of the focal spot size of the x-ray source to its 
smallest value (currently 0.4 mm in most x-ray systems) 
for the recording of the individual angiograms of pa-
tients participating in angiographic trials. Other steps for 
the reduction of variability of QCA measurements and 
the standardization of angiographic acquisition have 
been described in detai1.37,39-43 
Despite the variabilities in QCA measurements high-
lighted by this study, we should remain appreciative of 
the increased understanding of coronary artery disease 
afforded to us by the widespread application of QCA 
to scientific research and clinical practice. QCA has 
alleviated the subjectivity and high variability of visual 
assessments,26.1I!AH~ the errors and invalidity of the 
percent diameter stenosis for the assessment of pro-
gression/regression (pseudoprogression),12.2s.43 and 
the limitations of the dichotomous approach for the 
evaluation of restenosis,I3.31.4M6 The provision by 
QCA of objective and absolute measurements of 
coronary luminal diameter has significantly enhanced 
our approach to the assessment of noninvasive and 
invasive coronary interventions. It is hoped that the 
findings of our study will serve as a stimulus for the 
further improvement of QCA so that it may remain 
the gold standard and complementary technique to 
the new intracoronary imaging modalities for the 
acute and serial assessment of coronary artery 
dimensions. 
Study Limitations 
Although this study assessed the variability of mea-
surements provided by automated QCA of a standard-
ized set of cine films, it does not quantify the additional 
variability that might be introduced by variation in 
patient position and x-ray gantry settings during serial 
angiographic studies40.57 (although this is now minimized 
by the design of most current trial protocols), the 
recording and developing of cine films at different 
institutions, frame selection (although this is now stan-
dardized by selection of end-diastolic frames22.41), and 
the occasional manual correction of detected contours 
(although this should be kept to an absolute minimum in 
angiographie core laboratories). TIle cumulative impre-
cision, including these factors, has been quantified in two 
clinical studies using one of the QCA systems validated 
and has been found in both studies to be ±0.20 mm (SD 
of measurements of serial angiograms).ts.5S 
It can be seen in Fig 1 that although the contours of 
our phantom stenoses possessed an abrupt (90°) onset 
and termination, they were smooth over their 8-mm 
length. In clinical practice, many lesions are irregular, 
with rapidly changing arterial boundaries after coronary 
intervention. Given the use of a smoothing minimal-cost 
algorithm along scan lines perpendicular to the axis of 
the vessel) currently available QCA systems might be 
expected to fare less favorably if challenged with dissec-
tions and complex lesions compared with the angio-
graphic stenoses presented in our study, Initial results 
with an experimental gradient-field transform algorithm 
provide hope that future QCA systems might be able to 
cope with more complex lesions.38 This could perhaps be 
best tested in future validation studies by postmortem 
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casts of diseased human coronary arteries with ulcerated 
plaques, dissections, and complex morphology. 
The diameters of the phantom stenoses in Ihis study 
(0.5 to 1.9 mm) were in the range of obstruction 
diameters of human coronary stenoses rather than typ-
ical reference vessel size. It is noteworthy that the 
average minimal luminal diameters before, immediately 
after, and at 6-month follow-up arc 1.03, 1.78, and 1.48 
mm for balloon angiopiasty,29 0.98, 2.03, and 1.47 mm 
for directional coronary atherectomy,3 and 1.07,2.5, and 
1.83 mm for stent implantation. I The positive intercept 
values of the regression line for all the systems in this 
study indicate that most QCA systems tend to overesti· 
mate in the lower range of luminal diameters «1 mm). 
llw slope (b), however, was <1 for a1l systems, indicat-
ing that for larger reference vessels, the QCA systems 
tested would underestimate the true lumen diameter. A 
standardized set of phantoms of large diameter should 
be produced for future multicenter studies to compre-
hensively examine the performance of QCA systems 
over the complete range of vessel size. The inlracoro-
nary insertion of phantom stenoses of Jarge diameter 
may, however, prove to be difficult in the porcine model 
in view of the limited size of the coronary artery lumen. 
Conclusions 
This study has revealed wide differences in the per-
formance of currently available QCA systems, high-
lighting the difficulties in attempting to make direct 
comparisons between absolute measurements of one 
angiographlc study and those derived from a different 
QCA system or with on-line analysis in clinical practice. 
Power calculations and study design of angiographic 
trials should be adjusted for the precision of the QCA 
system used to avoid the risk of failing to detect small 
differences in patient populations. 
QCA validation studies should be performed in a 
uniform and standardized manner to provide meaning-
ful data that can be used to compare the performance of 
QCA systems, to guide the recalibration of QCA algo-
rithms, and to facilitate the maintenance of high stan-
dards of QCA for clinical practice and scientific studies. 
The entire chain of a QCA system should be revalidated 
each time the version of QCA software is upgraded or a 
hardware component is exchanged. 
In the reporting of angiographic studies, absolute 
values of luminal diameter and values of statistical 
significance for differences between study populations 
should be accompanied by the results of the appropriate 
validation parameters of the QCA system used so as to 
facilitate the interpretation of clinical studies, 
Appendix 
The foJlowing centers and investigators participated in this 
study (both the centers and investigators are given in alphabet-
ical order). 
Beth Israel Hospilal, Bos\ol\, Mass: Donald Baim. Brigham 
and Women's Hospital, Boston, Mass: C. Michael Gibson. 
Cleveland Clinic, Cleveland, Ohio: Stephen Ellis, Eric J. Topol. 
George Washington University, Washington, DC: John Reiner, 
Allan Ross. H6pital Universilaire Saint Jacques, Besan~on, 
France: Jean Pierre Bassand. Mount Sinai Hospital, Toronto, 
Ontario: Allan Adelman. St Michaels Hospital and Sunny-
brook Health Science Center, Toronto, Ontario: Paul W. 
Armstrong, Anatoly Langer, Normand Robert, Bradley 
Strauss, Martin Yaffe. Thomas Jefferson Hospital, Philadel-
phia, Pa: David Fischman, Sheldon Goldberg. Thoraxcenter, 
Rotterdam, the Netherlands: Carlo di h-iario, JOrgen Haase, 
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David Keane, Eline Montauban van Swijndregt, Patrick W, 
Serruys, Corne lis Slager, Washington Cardiology Center, 
Washington, DC: Martin D. Leon, Jeffrey Popma, 
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In Vivo Validation of an Experimental Adaptive 
Quantitative Coronary Angiography Algorithm to 
Circumvent Overestimation of Small Luminal Diameters 
David Keane, MB, MRCPI, Ed Gronenschlld, PhD, Cornells Slager, MSe, Yukio Ozaki MO, phD, 
Jurgen Haase, MO, phD, and Patrick W, Serruys MO, phD 
INTRODUCTION 
The reliability 01 quantltatlve coronary angIography (OCA) measurements Is of funda· 
mental Importence for the study and practice of Interventlonal cardIology. In vivo vall· 
dation resulla have consIstently reported a tendency for QCA systems to overestimate 
amallluminal dIameters. Such a systemallc error may result In the underestlmat!on 01 
luminal gain durIng Inlracoronary procedures and In the underestlmallon 01 progressIon 
of coronary artery dIsease dUrIng longlludlnal studies. 
We report the In vivo validatIon results of an experimental adapllve edge·detectlon 
algorithm that was developed to reduce overestimation of small luminal diameters by 
Incorporating a dynamIc function of variable kernel size of the derlval1ve operator and 
varIable weighting of the first and second derlvallves 01 the brightness prollle. The reo 
suits of the experimental algorithm were compared to those of the conventional parent 
edge detection algorHhm with fixed parameters. 
Dynamic adjustment of the edge·detecllon algorithm parameters was round to Im-
prove measurements of small «o.a·mm) lumInal diameters as evIdenced by an Intercept 
of +.07 mm for the algorlthm with variable welghl1ng compared to +0.21 mOl lor the 
parent algorllhm wIth IIxed weighting, A slope of < 1 was found for both the par~nl and 
experimental algorithms with subsequent underestimation of large lumInal dIameters. 
SystematIc errors In a QCA system can be fdenillied and correcled by the execution 
of objective In vIvo validation studies and the consequent refInement of edge·detectlon 
algorithms, The overestImation of small luminal diameters may be overcome by the 
lncorporal1on 01 a dynamIc edge·detectlon algorithm. Further refinements In edge·detec· 
lion algorithms wltl be required to address the Issue of undoreslfmallon of large luminal 
dIameters bofore the absolute values derived from OCA measuremenls can be consld· 
ered accurate over the full rango of clinIcally encountered rumina I diameters. 
"1995 Wil~y,l(5S. 1"'0. 
Key words: coronary arteriography, quanUtallve coronary angiography, vaHdallon 
computerized quantitative coronary angiography 
COCA) has fundamenlally altered our approach to the 
assessment of interventional techniques and strategies 
aimed at the prevention of restenosis and progression of 
coronary artery disease. The reliability of QCA measure-
ments is therefore of central importance for the validity 
of angiographic trials and the application of their results 
to clinical practice. 
ies according to the individual QCA system as well (IS the 
validation model (e.g., in vitro or in vivo, focal spot size 
of X-ray system). In a rcccnt multicenter validation study 
of QCA systems at core angiographic laboratories in 
From the Department of InterventionaJ Cardiology. Thoraxcenler. 
Erasmus University Rotterdam, and Department of MediCi'll Informal, 
ics. University of limburg. l.1ai'lslrich1. the Netherlnnds. 
RCCviv,'d Ortobcr P), !1)yt r<:vi_,i()11 .ICL'CrICd F~hru<Jr}' 2, 1"95. Overestimation of small luminal diameters by auto-
mated QCA systems has been consistently reported for 
both edge detection, IlS welllls videodensitometric algo· 
rithms [1-6J, The degree of reported overestimation va[-
'£} 1995 Wifay-Llss, Inc. 
Address rcprint rcquests 10 PJtrick W. ScrfUYS ~I.D., O.:r~Ir!ll1ellt M 
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shy, PO Box t73~, ROHcrd,lm JOOO DR, the NcthcrlJnds. 
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North America and Europe, we found that 011 lO QCA 
systems validated, overestimated measurements of small 
luminal diameters [1). The clinical implications of such 
overestimation include the reporting in clinical trials of 
smaller luminal gains than actunlly nchievcd at interven-
tion, the underestimation of progression [8,9] of coro-
nary artery disease in longitudinal studies, and the un-
derestimation of the vasospastic response to ergonovine 
provocation tests [10). Furthermore, in the una lysis and 
interpretation of QCA validation studies, the overestima-
tion of smull luminal diameters by a given QCA system 
may partially compensate f6'l the underestimation of 
large luminal diameters by QCA systems, resulting in the 
reporting of a highly favorable accuracy value for the 
QCA system, for the total range of diameters validated 
[7}. 
While one approach to overcome this phenomenon 
would be to provide a look-lip-table for the results of 
small luminal diameter measurements based on regres· 
sian analysis of in vivo validation studies, given the un· 
predictable degree of X-ray scalier in the thowx and 
possible motion blur of the heart, a dynamic modifica-
tion of the edge·detection algorithm to address this issue 
would be scientifically preferable. We report in vivo val-
idation results for an experimental QCA edge tktection 
algorithm which was developed (University of Lim· 
burg), in an attempt to overcome the problem of overes-
timation of small luminal diameters by incorporating an 
adaptive correction function. The experimental algo-
rithm was based on a conventional parent edge detection 
algorithm, with fixed weighting (50:50) of the first and 
second derivatives. A comparable approach to algorithm 
modification has been reported by Sonka et al. [13J, who 
also used an edge operator that was dependent on the 
approximate diameter. 
To determine the efficacy of the dynamic adaptive 
algorithm, we compared the quantitative measurements 
of this experimental algorithm with those obtained from 
the parent algorithm with fixed weighting for the same 
series of in vivo angiographic stenoses. Angiographic 
"phantom" stenoses of known diameter, mimicking hu-
man coronary artery obstructions, were serially inserted 
in the coronary arteries of nnesthetized pigs and the QCA 
measurements of the cineangiograms obtained were 
compared with the known dimensions of the phantoms, 
to determine the reliability of the two QCA algorithms. 
METHODS 
Stenosis Phantoms 
The stenosis phnnloms consisted of radiolucent acry-
late or polyimide cylinders with precision-drilled eccen-
tric circular lumens of 0.5, 0.7, 1.0, lA, and 1.9 mm in 
diilmeter, as previously described (2,3). The OUier diam-
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elers of the cylinders were 3.0 or 3.5 rnm <lnd all were 
8.4 mOl in length. Acrylate was used to produce the 
phantoms with small stenosis diilmeters ((l.5 ilnd 0_7 
mm), whereas the less frngile polyimidc was better 
sllited to the drilling of 1,1fgc stenosis diameter.', (1.0, 
lA, and 1.9 mm). Purnllelto the stenosis lumen:1 second 
channel of 1.3 mm in diameter was drilled ill the cylin-
ders to attach them to the tip of 4 Fr Fogarty catheters 
(Venned, Neuilly en Theile, FrHllce). The central lumens 
of these catheters contuined a removable metal stilette, 
which was used for intrucoronary insertion of the phan-
toms, as well as for their positioning in the radiographic 
isoccnter during the in vivo experimenl$. 
Animal Preparation 
Following an overnight fasl, four cross· bred 
Landrace-Yorkshire pigs of 45-50 kg in weight were 
sedated with intramuscular ke\:lIuine (20 mg/kg) Hild in-
travenous melOmidatc (5 mglkg). The animals were in-
tubated and connected to a respirator for intermillo.;ll\ pos-
itive-pressure ventilation with a mixture of o,xygcn Hud 
nitrous oxide. Ventilator settings werl' adjusteu during 
the experiments 10 maintain the arterial pH a\ 7.35 -7 .45, 
pCO~ ,It 35-45 mm fig, :111d the p02 :1\ > 150 mrnHg. 
Anesthesia WilS nlldtllained with a cOl1tinuou~ intrave· 
nous infusion of pcntobarbitul (5-20 mg/kg/hr). 
Vnlved introducer sheaths (12 Fr: Vygon, Ecouen, 
France) were surgically placed in both carotid arteries to 
allow sequential insertion of the angiographic guiding 
catheter nnd the stenosis phantoms. An 8 Fr introducer 
sheath WilS placed in a femoral artery for the introduction 
of a 7 Fr high-fidelity micromanomeler (disposable mi-
crotip catheter, type 811/160, Cordis·Senlron, Roden, 
Netherlands). JugUlar venous access was secured for the 
administration of medications and fluid. Each ilnimal 
received an intravenous bolus of acetylsalicylic acid (500 
mg) and heparin (lO,nOa IU), und a continuous infusion 
ofhepnrin (IO,OUO IUJhr) \VilS mainl<lined throughout the 
procedure, to prevent the furmalion of illl intracuronary 
thrombus. 
Calibration of Quantitative 
Coronary Measurements 
Two different calibration methods were ilpplied to 
each series of quantitative coronary ill1<1lysis measure· 
ments: ' 
CUflFelltionai catheter calihration: The nlllltapl.:ring 
part of the tip of each gF polyurethane guiding cathetc~ 
(EI Gamal, type 4, Schneider, MN) was mcusured (di-
ameters of the individual cntheters ranged (Will 2,49 to 
1.54 mm) with ,\ prcci:-;ioll microllleter (\'0. 293-)01. 
MiwlOYO, Tokyo, Jilpan: accuracy 0.001 mm). The c;lth-
eter WilS then introduced into the ascending aorta via the 
left carotid <Jrtery and engaged in the ostium of the left 
QuantitatIve Coronary Angiography Atgorllhm lor Small LumInal Diameters 
coronary artery. Before injecting contrast medium the 
catheter tip was flushed with saline and recorded on cin-
efilm for subsequent off-line QCA. 
Calibration at the isoccnler: A cylindrical metallic 
object (drill~bit) of known diameter (3.0 mm) was placed 
at the isocenler of the X·rny system and recorded on 
cinefilm. For the two QCA systems, the avail:lble cali-
bration procedure using automated edge detection was 
Hpplied to the images obtuined, yielding the correspond-
ing calibration factors (mm/pixel). 
Coronary Angiography and Placement of 
Stenosis Phantoms In Vivo 
After engaging the guiding catheter in the left main 
coronary artery, intracoronary isosorbide-dinitrate (1 
mg) was administered to control coronary vasomotor 
tone before the insertion of the phantoms. The stenosis 
phantoms were serially wedged in the left anterior de-
scending or left circumflex artery and positioned in the 
radiographic isocenter using the tip of the metal wire as 
a marker, which was removed prior to angiography. Cor-
onary angiography was performed by ECG (R-wave)-
triggered injection of 10 ml iopamidol 370 at 37"C with 
a programmed injection rate of 10 ml/sec (rise time = 0) 
through the 8 Fr guiding catheter, using a pressure in-
jector. To minimize the effect of ventilation on angio-
graphic acquisition, the respirator was disconnected dur· 
ing contrast injection. 
Image Acquisition and Processing 
Cineangiography was performed at 25 frames/sec on a 
monoplane Philips Poly Diagnost C2 machine equipped 
with an MRC X-ray tube and powered by an Optimus ep 
generator (Philips Medical Systems International BV, 
Besl, Netherlands). The 5-inch (12.5-cm) field mode of 
the image intensifier (focal spot 0.8 mOl) was selected, 
and the radiographic system settings were kept constant 
(kVp, rnA, msec) in each projection. All phantoms were 
imaged at the isocenter sequentially in two projections, 
with particular cure taken to minimize foreshortening of 
the segment of interest and acquired on 35'0101 cinefilm 
(CFE type 2711, Kodak, Paris, France), using an Ar~ 
ritcchno 90 cinecllmera (Arnold & Richter, Munich, 
Germany) with an 85-mm lens. The cinefilms were pro-
cessed by a Refinal developer (Agfa-Gavaert, Le-
verkusen, Germany) for 4 min at 28°C. The film gradient 
WllS measured in all cases to ensure that the optical den-
sities of interest were on the linear portion of the sensi-
tometric curve. 
From each angiogr<lnl that fulfilled the requirements of 
image quality for automated quantification (no superim-
position of surrounding structures, no major vessel 
branching at the site of the phantom position), a homo-
geneously filled end·diastolic coronary image wus se-
Icctcd for off-line QCA. Twenty end-diastolic frames of 
the phantom stenoses were sujtabk for edge-dctcctinn 
anulysis. A sufficiently long luminal Cl)fOnary segment 
was sekcled for quantitative analysis Ull all images. 
Automated Edge Detection Algorithms 
The software for Dl)th th~ experimental and the con-
ventional pHrent edge detection ulgorithms were loaded 
on the same QCA hardware components f~, 11, [5J. On 
both the conventional ilnu expnimental QCr\ ."yst~'m, it 
6.9 x 6.9mm region of interesl within [he It-: x 24-mm 
cineframe is oigitized into a 512 x S12-pixel matri.'.; 
using a CCD-camcra (8 bits = 256 density kvels) rc-
suiting in a final resolution of 1,329 x 1,772 pixels. A 
correction for pincushion distortion (14] was applied for 
both series of analyses. For both systems, the user de-
fines a number of centerline points within the arteria! 
segment which are subsequently connected hy stf<light 
lines, serving <1S tt first approxim<'ltion of the vessel cen-
terline. The edge-detection algorithm is carried out in 
two iterations, First, the moue I is the initially defined 
centerline; second, the model k, a recomputed centerline, 
determined automatically as the midline of the contour 
positions, which were detected in the first iteration. 
The basic automated edge-detection algorithms for 
both the experimental and conventional parent algo-
rithms nrc similar and arc based on the first <md second 
derivative functions applied to the brightness profiks 
along scan lines perpendicular to a model, IIsing minimal 
cost critcrla. For the conventional system, the weighting 
of the first and second derivatives is fixed at 50:50 for 
analysis of ull luminal diameters. For tht! experimt!ntal 
algorithm, the following approach was adnptcd. A nllm-
ber of computer simulations were performed to gain in-
sight into the pnrameters responsible for the overestima-
tion <It small vessel sizes. Theoretical density profiles of 
circular lumens werc convolved with a gllllssian function 
to reflect the X·my system's blurring function. On lht'se 
profiles, the edge detection algorithm wus applkd. It wus 
observed thut the computt!d diameters art! Jurger than the 
true diameters below 1.5 mOl. The overestimation in-
creased with pixel size, the width of the blurring fUllc-
tion, and the weight faclOr of the second derivative 
(16,171. Also, the smaller the diameter, the I,II-ger the 
overestimation. On the other hand, <l small kernel size of 
the derivativc operator has a favornble effect on the re-
sults because it compensates for the limited number of 
pixels defining the extent of small diameters [L"iJ. Note, 
however, that small kernel size makes the edge-detection 
algorithm more sensitive to noise in the image, as fewer 
pixcls are involved in the computation. On lhe basis of 
these simulutions, an algorithm W,IS gcneralcd which 
adapliwly varies the weighting or the lirst :lnd ~ccond 
derivative and adjusts the kernel size as n function of the 
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Fig, 1. aCA measurements calibrated by the anglographlc 
oatheter of the experlmentel and convenllonal edge.deteollon 
algorithms were plotted agalnsttha true values of the stenosIs 
channels by linear regression. The results of the experimental 
algorithm are given as light squares and a light continuous 
regressIon line; the results of the conventional algorHhm €Ire 
approximate diameter measured in the first iteration. For 
small diameters, the ratio of the first to the second de· 
rivative was proportionally greater. Moreover, the kernel 
size of the derivative operator was adjusted to campen· 
sate for the limited number of pixels defining the extent 
of small diameters [15,16]. The experimental algorithm 
was udaptive only up to (and attenuated toward) a first 
iteration diameter measurement of 1.7 mm. 
Measurement of the Obstruction Diameter 
Once the contours of the stenosis phantoms were de· 
fined, the diameters of the artificial obstruction were 
automatically derived from the diameter function on each 
coronary antilysis system. For the purpose of compara-
tive validation, user interaction on the computerized re-
construction of phantom contours was e:-:cluded. 
Statistical Analysis 
Using both calibration methods (calibration ,11 the iso-
center and catheter calibration), the individual measure-
ments for obstruction diameter obtained by the two QCA 
algorithms were compared with the true phantom diam-
eters. The mean of the signed differences between the 
measurement values ("obstruction diameter") and the 
tnw diameters of the phantom stenoses was considered 
an index of accuracy and the standard deviation of the 
differences an index of precision. The mean absolute 
error was derived from the mean of Ihe absolute (un· 
signed) differences between the measured values and tht: 
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gIven as dark diamonds and a dark continuous regression line; 
end the IIno of Identity Is represonled by the Interrupted line. 
OVerestImation of small luminal diameters as seen wIth the con· 
venl10nal algorithm [y <= 0.21 mm + 0.75 (xll was avoided by 
the experImental algorithm by Ihe Incorporation of adaptive dy· 
namlc functions [y == 0,07 mm + 0.76 (xll. 
true diameters.The measured vulues were plotted against 
the true phantom diameters by linear regression. Mea-
surements with the same algorithm of the samt: stenoses 
derived from calibration by the catheter and calibration.1I 
the isocenler were comp,lTcd by Student's [-les1 for 
paired data. 
RESULTS 
The experimental algorithm with variable kernel size 
and variable weighting of the firsl and second uerivativc 
was found 10 be effective in the reductioll uf uwrcslima-
tiun of QCA measurements of sl11all luminal diameters. 
This improvemcnt in the pcrfonnanl't: of OC\ m\."lsur,,;-
meots of sm,tli luminul diameter is evidenced in Figures 
1 and 2, where thc results for the e,,",perimental ulgurithm 
UTe compared to those of the parcnt algorithm both when 
the mC<lsurements were calibr<l!cd by using the catheter 
as a scaling device (Fig. 1) ilnd when olt'u')urements wen; 
calibrated at the isocenler (Fig. 2). The values uf the 
linear regression analysis are presentcd in Table I. 
When QCA meusuremenls were calibr:..!ted by the 
catheter, the conventional cdge-detection .:llgorilhm 
yieldeu an intneept of +0.21 111m and u slupe of 
O.75(x), This overestimation of small diameters was re-
duced by the experimental algorilhm, which had an in-
tercept of 0.07 mm and a slope of D.76(x), 
Calibration of QCA rneasuremenls ,ll Ihe isocenlcr for 
the conventional edge· detection :JJgorilhm, resulted in 
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QCA (mm) 
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Fig. 2. QCA measurements calibrated at Ihe Isocantor of tho 
experImental and conventional edge-detection algorithms were 
plotted agaInst tho true values of tho stenosis chflnnels by lin-
ear regression. The results of the experImental algorllhm ate 
given 88 I/ght squares and a IIghl continuous regreSSion line; 
tho results of the conventlonsl algorithm are gIven as dark dl· 
amands and a dark continuous regression line; and the line 01 
IdenlJly Is represented by the Interrupled line. Overestimation 
of small luminal diameters as seen with the convenUonel algo-
rithm (y = 0.30 mm + 0.80 (x)1 was avoided by the experimental 
algorithm by the Incorporallon of adaptIve dynamIc functlons 
Iy = 0.05 mm + 0.68 (x)). 
TABLE I. Luminal DIameter QCA Measurements Calibrated by Catheter or by Isocenter for ExperImental and Conventional 
QCA Algorithms' 
A,;curacy (mm) Pr..:ci~ion (mm) Meal! crror (mill) Corrcl~tion SE (mm) R~glc,,;ion (mnl) 
CorlVcntiunJI OCA cJtheter calibrJlion -(WO :to.23 0.17 (I.St) .:!:(J.20 (J.21 + 0.75(;.;) 
Experimental QCA '.ltheter calibrntion -0.21 .:!:0.22 0.2.1 O.l}t :to.1') 0.07 + O.76(x) 
Ct.lnven!iOrlJi QCA iSoCcn\,r calibration O.Q7 ±O.21 0.15 0.91 :tU.tlJ OJU + (J.,~(J(x) 
Experimental QCA iso,cnter calibration -O.!!S :!:O.24 0.2U O.li!) :!:U.2..J i).US + I).HoS(\) 
• Note the luwer intercept values for the regression linc uf the c"{pcrimCnlJI ~Igorithm which inC<.lrpUfJtC5 vJriJhlc kernel sile uf II!e dcrivJ!i\'~ ur~r.ltor 
and valiJblc weighting of the first and second derivJtive of the brightness profile 
both a greater positive shift (intercept) and a higher slope 
of +0.30 mm and 0.80(x), respectively. This overesti-
mation of smull diameters was reduced by the experi-
mental algorithm, which had an intercept of 0.05 mm 
und u slope of 0.88(x). 
Given the degree of overestimation of small diameters 
by the conventional system (particularly during calibra· 
tion at the isocenter) in conjunction with the underesti-
mation of larger diameters, it is not surprising that the 
overall accufilcy (mean of the signed tlifferenccs) fOf the 
validated range of 0.5-1.9 mm was more favorable for 
the conventional algorithm on account of the compensa-
tion [7J of the positive (small-diameter) <Jntl negative 
(large-diameter) signed values. Furthermore, despite (he 
low slope of the conventional algorithm (U.75(x) <lnd 
O.BU{x) for the catheter and isocentcr calibration, respec-
tively), the mean error [mean of the absolute (unsigned) 
differences between the measured values and the true 
phantom valuesJ for the conventional algorithm (0.17 
and 0.15 mm) was lower than for the experimental HI· 
gorithm (0.23 and 0.20 mm), un .:lccount of the greater 
positive shift ussociated with the convention,d Hlgorithm 
and associated superior p~'rformance in hlrger lumin:d 
diameters. 
DISCUSSION 
The key findings of this study were (I) v,didatinn by 
the analysis of in vivo stenosl.!s of a st:lIHJard convcn· 
tional QCA algorithm reveals a well·rccognised problem 
of overestimation of small luminal diameters as well :is 
underestimation of larger luminnl diameters: (1) applica· 
tion of an experimental dynamic algorithm with adaptive 
weighting of the first <Ind second derivative and ;1Il ;Id-
justive kernel size to circumvent the prohlem or ()VI.!rI.!S· 
timution of smlllliuminal diameters results in a reduction 
in such overl;stimnlion of small «O.H-mm) luminal di-
ameters; (3) application of this experimental adaptive 
66 
Keane et al. 
algorithm to lurger luminal dimensions (>O.H. mm) re-
sults in greater underestimation of meusurcmcnts, partic-
ularly when caUbmted by the catheter; and (4) although 
the reduction in mensured diameter achieved by applica-
tion of the adaptive algorithm is greatest for smalliumi-
nal diameters and attenuated for larger diameters, the 
experimental algorithm in its current form (the algorithm 
is currently programmed to exert some activity up to 
diameters of 1.7 mm) confers no overall benefit for the 
whole range of 0.5-1.9 mm diameters validated on ac-
count of a greater underestimation of vessels >0.8 mm. 
Overestimation of Small Luminal Diameters 
Overestimation of small luminal diameters is a fre-
quent finding of in vivo validation studies [1J and effec-
tive measures ntlempting to increase our understanding 
and to overcome such overestimation are required. The 
clinical implications of such overestimation of small lu-
minal dimensions arc significant. If in n clinical trial 
using the conventional algorithm, un improvement in 
coronary luminal diameter is achieved by balloon angio-
plasty or rolablator from 0.4 mm preprocedure to 1.8 
mm postprocedure, a gain of 1.05 or 1.12 mm for cath-
eter or isocentric calibration, respectively, will be allrib· 
uted to the device, instead of a true luminal gain of 1.40 
mm. Similarly, progression of a lesion in a longitudinal 
study from ,\ minimal luminal diameter of 1.0-0.4 mm 
would be underestimated by the conventional algorithm 
(progression would be estimated to be 0,45 or 0,48 mm 
for catheter or isocenlric calibration, respectively). In the 
current form of the experimental adaptive ulgorithm with 
variable weighting programmed up to a diameter of 1.7 
mm, no significant benefit would be conveyed over the 
conventional algorithm - the luminal gain as above 
would be reported as 1.06 or 1.23 mm for catheter or 
isocentric calibration, respectively, and the progression 
3S above would be reported as 0.46 or 0.53 for catheter 
or isocentric calibration, respectively. 
The reasons for the overestimation of small luminal 
diameters by QCA systems remain unclear; potential fac-
tors include a point spread function relating to the focal 
spot size and limited resolution of the entire X-ray im-
aging chain [16] and too large a pixel size relative to the 
vessel diameter, as well as too great a kernel size of the 
derivative operator. While corrective numerical func-
tions, based on the known pallern of underestimation or 
overestimation of QCA measurements, could be applied 
to the results of angiographic trials, it may be more ef-
fective ami reliable to correct the systematic inaccuracies 
of a QCA system by the development and fine-tuning of 
dynamic adnptive algorithms, 
We have demonstrated that the overestimation of lu-
minal diameters of <O.S mm cao be effectively reduced 
by the incorporation of a dynumic function of variable 
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kernel size of til\? ikrivativ~ operator anti variable 
weighting of the first ,lIld second derivative in the edge 
detection algorithm. The experimenuJ! edge detection al-
gorithm, however, will require further modification to 
address the low slope of the system; i.e., the underesti-
mation of larger luminal diameters before it could be 
udopted in clinical practice. 
Calibration 
The use of angiographic catheters for the calibration of 
quantitative coronary .\Oalysis systems may influence the 
outcome of luminal diameter measurements. Variations 
in catheter composition may result in v<ITying X-ray Ilt-
tenuation [18-20] and therefore in differences in thc au-
tomated detection of the contour points. In our study, 
only one type of catheter was used for calibration; there-
fore, the influence of different mnleriais on calibration 
was excluded. The results of the present study show that 
the vulues using catheter calibration arc smaller than 
those using calibration at the isocenter (P < 0,(l01). 
Theoretically, a greater distance between image intensi· 
(jer and catheter tip than between im,lge intensifier and 
isocenter would result in oUl-of-plane mngnification pro-
ducing smaller calibrntion fuc\ors (mm/pixel). This error 
can be circumvented by out-of-plane correction <IS pro-
posed by Wollschltigeret at. [21J or by calibration at the 
isocenter of the X-ray system. 
QCA Validation Studies 
Given the increOlsing role of QCA in thc evaluation of 
interventional curdiology [7], it has become i.:ssentiulthat 
the performance of QCA itself should undergo objective 
and scientific evaluation. While in vitro te'it series are 
more eusily standardized, their results arc not :!lways 
representative of QCA measurements of clinical angio-
grams, as heterogeneous beam scattering and variable 
bacground density within the thorax and thc potential 
influence of motion blur are unpredictable. In vivo val-
idation studies on the other hand arc of clinical relevance 
<lnd provide an indication of the reliu\Jility of clinicHI 
angiogmphic trials, the Significance of their failure to 
detect relative changes in luminnl dimneter and how 
much importance should be ,lttributcd to absolute values 
of luminal diameter derived from individu<ll QCA sys-
tems. Furthermore, it is only by detailed validation stud-
ies that systematic errors in QCA systems can bt: iden-
tified and thereby provide guidnnce for the refinement of 
algorithms incorporated within QCA software. 
Statistical Parameters for QCA StudIes 
Investigators reporting and readers illtcljm.:tillg QCA 
dnta should be fnmiliar with the limitations of the con-
ventional statistical pMameters used to described QCA 
validation sl\ldies [7J. As recenlly described in detail [71, 
Quantitative Coronary Angiography Algorllhm for Small Luminal Diameters 
the reporting of the "accuracy" of QCA measurements 
over a validated rnnge may fail to convey Ihe error to be 
expected from a given QCA measurement on account of 
cancellation of the signed differences of overestimated 
(below the intersection of the regression and identity 
lines) and underestimated (above the intersection of the 
regression and identity lines) measuremenls, This point 
may be revealed by the reporting of the absolute mean 
error, which is independent of the sign (+ /-) of the 
differences between the true and measured values-it 
can be seen in the results of our study that the absolute 
mean error was consistently grea:er in value than the 
value of the accuracy for both the conventional and ex~ 
peri mental algorithms (Table I), Alternatively, the reader 
might be well served by the provision of the accuracy of 
measurements at a number of different dimensions, 
rather than for the entire validated range as reported con-
ventionally; review of Figure 2 clearly shows that the 
accuracy of measurements for dimensions of 0.4-0.8 
mm is superior with the experimental algorithm, that the 
accuracy for dimensions of 1.0-1.2 mm is eqllivalent for 
the experimental and conventional algorithms, and for 
dimensions of 1.4-1.9 mm that the accuracy of measurc-
ments with the conventional algorithm is superior to 
those of the experimental algorithm in its current form. 
For the same reason, precision of QCA measurements 
will be dependent on the range of validated diameters, 
while the standard error of the estimate (SEE) will more 
closely reflect the random error or noise to be expected 
from the QCA system particularly after correction for an 
intercept of 0 and a slope of 1 (SEEc) [4,7,22J. 
CONCLUSION 
Systematic errors in a QCA system can be identified 
und corrected by the execution of objective in vivo val-
idation studies and the consequent refinement of cdge-
detection algorithms, The overestimation of smalliumi-
nul diameters by QCA measurements muy be overcome 
by the incorporation of an iterative algorithm with dy-
namic adjustment of the kernel sizc of the derivative 
operator and adaptive weighting of the first and second 
derivative of the brightness profile of the vessel in rela-
tion to the dinmeter to be detected. Further refinements 
in edge-detection algorithms will be required to address 
the issue of underestimation of large luminal diameters 
before the absolute values derived from QCA measure-
ments can be considered to be accurate over the full 
range of clinically encountered luminal diameters. 
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Chapter V 
Insertion of balloon-mounted "stent" stenoses of up to 2.9mm 
in porcine coronary arteries for the in-vivo validation of 
quantitative coronary angiography. 
David Keane, Wim van der Giessen, Yukio Ozaki, Ad den Boer, Patrick W Serruys. 
(in review) 
71 
2.9mm "stent" stenoses in porcine coronary arteries 
ABSTRACT: 
Background. With the advent of "the bigger the better" policy and the increasing use of 
new alternative interventional devices associated with large luminal gains, the need arises 
for in-vivo phantom stenoses of large diameter for validation of quantitative coronary 
angiography measurements lOCAl. 
Objectives. To address this challenge and increase the direct clinical applicability of QCA 
validation results, we developed a new technique of in-vivo phantom stenosis deployment, 
permitting a range of stenoses of up to 2.89mm to be inserted in porcine coronary arteries. 
Methods. Balloon-mounted single channel "stent stenoses" were introduced through the 
carotid arteries and positioned in proximal coronary segments under fluoroscopic guidance. 
Cineangiograms of the stenoses were recorded for QCA validation of an edge detection 
algorithm currently used for the analysis of interventional trials. 
Results. For the QCA system validated, the accuracy over the entire range of 0.5 to 
2.89mm stenoses was -.20mm compared to the previously reported accuracy of -.09mm 
for the same edge detection algorithm when validated over a smaller range of stenoses of 
0.5 to 1.9mm. 
Conclusions. The underestimation of OCA measurements (-.20mml revealed by these new 
large diameter in~vivo stenoses, indicates that the development and fine tuning of QCA 
algorithms should no longer be based upon cinefilms of conventional in-vitro stenoses 
which fail to convey the heterogenous X-ray scatter and veiling glare encountered in-vivo 
and indicate that clinical angiographic trials to date (particularly those with stenting and 
atherectomyl may have underestimated the true luminal gain achieved by coronary 
interventional devices and underestimated the absolute luminal loss reported at 6 month 
follow·up. 
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INTRODUCTION: 
Quantitative analysis of coronary arteriograms plays a major role in interventional 
cardiology and clinical research (1 ~1 0]. Validation of the accuracy and precision of 
quantitative coronary angiography (OCA) has traditionally been based upon the use of in~ 
vitro models, whereby plexiglass blocks or water are used to approximate the beam 
hardening and attenuation of the X-ray beam in the human thorax {11]. In order to increase 
the quality and direct clinical applicability of QCA validation results, we have more recently 
reported the insertion of plastic stenoses in porcine coronary arteries to simulate the 
heterogenous scatter and veiling glare of the human thorax {12, 13}. The range of phantom 
stenoses using this approach (from 0.5mm up to 1.9mm) has, however, been limited by 
both the technique used to deploy the stenoses as well as by the size of porcine coronary 
vessels. 
Given that most QCA systems have been found to underestimate measurements of large 
diameter, the reported accuracy from validation studies using stenoses of 0.5 to 1.9mm 
diameter will be more favorable than those using a larger range of diameters. The 0.5 to 
1.9mm range has, however, been in the range of human coronary stenoses undergoing 
conventional balloon angioplasty. The average minimal luminal diameter of coronary lesions 
pre- and post- balloon angioplasty and at six month follow-up as observed in multicenter 
trials are 1.03, 1.78 and 1.48mm respectively [14]. With the advent of coronary stenting 
and atherectomy and the recently introduced interventional policy of "the bigger the 
better" the minimal luminal diameter of lesions currently undergoing interventional 
treatment have become significantly larger: 1.07,2.5 and 1.83 mm for stent implantation 
[15), and 1.29, 2.78 and 1.92mm for "optimal atherectomy" [16J for luminal diameters 
pre-procedure, post-procedure and at 6 month follow-up respectively. 
This new direction in interventional practice demands that QCA systems also perform 
accurately in vessels with such large diameters. 
In order to cover this new range of clinically encountered minimal luminal diameters, we 
expanded our QCA validation methodology by using a new technique of in-vivo "stent 
stenosis" deployment, allowing a range of stenoses of up to 2.89mm to be evaluated. The 
cinefilms obtained were used to validate QCA by edge detection and to determine the 
optimal image intensifier field size for angiographic studies. 
METHODS: 
Phantom stenoses. Seven phantom stenoses with diameters ranging from 0.5 to 2.9mm 
were studied. All phantom stenoses were constructed of radiolucent polyimide cylinders 
with precision-drilled circular lumens (tolerance of .003mm). The absolute internal 
diameters of the stenosis channels were measured to the nearest 0.001 mm by a light 
profile projector (Mitutoyo PJ300, Tokyo, Japan). The stenosis channels were of 0.50, 
0.69, 1.00, 1.41, 1.95, 2.49 and 2.89 mm diameter. 
The construction of the 0.5 to 1.95mm series of phantom stenoses was of the same 
principle as previously reported [12,13]. These were designed for both ease of removal 
from the coronary artery as well as ease of insertion. Parallel to the stenosis lumen, a 
second channel of 1.3 mm in diameter was drilled in the cylinders to enable their 
attachment to the tip of 4 F Fogarty catheters IVermed, Neuilly en Theile, Francel. The 
l!Jmens of the Fogarty catheters contained a removable metallic stilette, which aided the 
intracoronary insertion of the phantoms as well as their positioning in the radiographic 
isocenter. 
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We designed our new larger "stent stenoses" with the primary aim of keeping the outer 
diameter of the cylinders to a minimum usable size despite increasing the inner lumen of 
the stent stenosis. A single channel cylinder was constructed for deployment on an inflated 
angioplasty balloon. Once positioned in the coronary artery, the balloon was deflated and 
withdrawn and the facility to remove these larger phantom stenoses was thus forfeited. 
The length of all stenosis channels was B.4mm. The outer diameter of the cylinders for 
intracoronary insertion for the dual channel series of phantom stenoses, was 3.0mm for 
the 0.5 stenosis phantom, and 3.5mm for the 0.7 to 1.95mm phantom stenoses. For the 
single channel stent stenoses the outer diameter of the cylinders for intracoronary insertion 
was 3.0mm for the 2.49mm phantom stenosis and 3.5mm for the 2.B9mm phantom 
stenosis. 
Experimental Procedures. The procedures followed were in accordance with the 
institutional guidelines for animal studies and compiied with the Guide for the Care and Use 
of Laboratory Animals [17]. All stenoses were inserted in the coronary arteries of two 
anaesthetized Yorkshire pigs (26 and 33kg). The animals were premedicated with ketamine 
hydrochloride. General anaesthesia was induced by enflurane and sodium pentobarbital. 
Sodium pentobarbital was also used to maintain general anaesthesia and finally at the end 
of each study to sacrifice the animal by overdose. Arterial blood gases, acid base balance, 
electrolytes and haemoglobin were serially monitored throughout the studies. 
The animals were given aspirin 900mg intravenously at the beginning of the procedure. 
Heparin, 5,0001u, was given intravenously every hour. The phantom stenoses were bathed 
in heparin prior to intracoronary insertion and the operators gloves and angioplasty balloon 
were washed with heparin prior to handling of the phantom stenoses. Intracoronary 
isosorbide dinitrate (1 mg) was administered prior to angiography of each phantom stenosis. 
Non-ionic contrast medium, iopamidol 755mg/ml (lopamiro 370, BRACCO, Italy) was 
heated to 37°C prior to intracoronary administration. 
A 12 F and a 9F introducer sheath was surgically placed in the right and left carotid 
arteries respectively to allow the sequential insertion of the phantom stenoses mounted on 
Fogarty and balloon catheters and the insertion of the angiographic guiding catheter. An 
BF soft tip guiding catheter (ELG4 S, Schneider, USA) was used for intra coronary contrast 
administration. 
First the 0.5 to 1.95mm series of dual channel phantom stenoses were serially inserted 
and located at the radiographic isocenter (as previously described {12,13)). After 
arteriography (see below) they were removed from the coronary arteries. Then the larger 
series of single channel stent stenoses were inserted in the coronary arteries as follows: 
A guidewire (0.01B", 270cm, Road Runner™, Cook Inc, Bloomington, IN) was first 
introduced into the coronary artery through the guiding catheter. The guiding catheter was 
then withdrawn and the tip of the guidewire was left in the distal segment of one of the 
three main coronary arteries. A single channel polyimide cylinder was then mounted on a 
noncompliant 3.5mm angioplasty balloon which was inflated to a pressure of 2 
atmospheres prior to insertion through the 1 2 F carotid introducer, thereby providing a 
secure dumbell attachment of the stent stenosis as illustrated in figure 1. The balloon 
mounted stent stenosis was then advanced over the guidewire to be positioned in the 
proximal segment of the left anterior descending, circumflex or right coronary artery. After 
adjustment of the X-ray gantry to ensure that the stent stenosis lay at the radiographic 
isocenter, the balloon was deflated and withdrawn with the guidewire to allow coronary 
angiography. The latter single channel cylinders were retrieved post mortem by either 
reinsertion and reinflation of the balloon or by thoracotomy. 
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Figure 1. A single channel polyimide cylinder with an inner diameter of 2. 49mm can be seen 
to be firmly mounted on a balloon inflated to 2 atmospheres. 
Figure 2. Coronary angiographic image of the luminal stenosis induced by a single channel 
2.49mm polyimide cylinder which has been positioned in the proximal segment of a porcine 
left anterior descending artery. QCA (edge detection) measurement of the segment 
containing the stenosis reveals an obstruction diameter of 2.41 mm 
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Radiographic acquisition. 
The cineangiograms were recorded on a Coroskop T.O.P. X-ray unit which incorporated 
a Polydoros ISIC generator and a Megalix 30/82 X-ray tube with a focal spot size of 
0.4mm (Siemens A.G., Munich Germany, - 1994 release). Each intra coronary phantom 
stenosis was placed at the isocenter of the X-ray system and recorded in two orthogonal 
views in three image intensifier (II) field sizes 5" (13cm), 7" (17cm) and 9" (23cm) thus 
generating a total of 84 angiographic sequences for quantitative analysis. 
The radiographic system settings were kept constant (kVp, rnA, ms) in each projection. All 
stenoses were imaged in two projections sequentially and acquired on 35-mm cinefilm (CFE 
Type 2711, Kodak, Paris, France) at a frame rate of 25 images/s, using an Arritechno 90 
cine camera (Arnold & Richter, Munich, Germany) with an 100 mm optical lens (over 
framing). The cinefHms were processed by a Refinal developer (Agfa-Gevaert, Leverkusen, 
Germany) for 4 minutes at 28°C. The film gradient was measured in all cases to ensure 
that the optical densities of interest were on the linear portion of the sensitometric curve. 
Quantitative Angiographic Analysis. 
Frame selection. The optimal angiographic frame from each of the 84 sequences was 
selected for QCA analysis. Frame selection was based on being end-diastolic, the absence 
of overlapping vessels, minimal foreshortening and homogenous filling of contrast - an 
example of a frame selected with automated contour detection is shown in figure 2. 
Correction of pincushion distortion. Prior to the performance of the calibration and 
quantitative analyses of the stenoses, computerized correction for pincushion distortion 
was applied by the recording and subsequent off-line digitization of a centimeter grid. 
Calibration. The QCA measurements were calibrated by the use of the guiding catheters 
as a scaling device as performed during the conduction of clinical interventional trials 
[8,9,15J. The nontapering catheter tips were measured with a precision-micrometer 
(Mitutoyo No.293-501, Tokyo, Japan; accuracy 0.001 mm) taking the average of repeated 
readings. 
Automated Edge Detection. Cinefilms were quantitatively analyzed off-line in a core 
angiographic laboratory using the standard edge detection algorithm of the Cardiovascular 
Angiographic Analysis System (CAAS II; Pie Medical, Maastricht, The Netherlands) [18], 
The entire 18 x 24 mm cineframe is digitized after optical magnification at a resolution of 
1329 x 1772 pixels on a CCO camera. The edge detection algorithm is based on the first 
and second derivative functions applied to the digitized brightness profile along scanlines 
perpendicular to a model using minimal cost criteria. The contour definition is carried out 
in two iterations. First, the user defines a number of centerline points within the arterial 
segment which are interconnected by a straight line, serving as the first model. 
Subsequently, the program recomputes the centerline, determined automatically as the 
midline of the contour positions which were detected in the first iteration. Manual 
correction of the automatically detected contours was neither necessary nor performed in 
this study {in routine practice at angiographic core laboratories, subjective manual 
correction of the detected contours at the minimal luminal diameter is kept to an absolute 
minimum e.g. in the case of complex dissections with contrast extravasation, which was 
not present in any of our porcine coronary angiogramsj. 
"Minimal" versus "obstruction" diameter measurements. On the CAAS I, the parameter of 
"minimal luminal diameter" is taken as the shortest distance between the two luminal 
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Figure 3. The "minimal luminal diameter" (min diam) and the "obstruction luminal diameter" 
(obs diam! in the CAAS /I system. The "minimal luminal diameter" is taken as the shortest 
distance between the two luminal contours i.e. the absolute minimum of the diameter 
function curve, The "obstruction diameter" is determined as the diameter of the vessel at 
the midpoint between the closest diameter positions on both sides of the minimum luminal 
diameter that exceed the minimum value by 5%. 
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contours [19J, Thereby, the absolute minimum of the diameter function curve is provided. 
In addition to measuring the minimal luminal diameter, the CAAS II also calculates a so-
called "obstruction diameter" [20]. The derivation of the "obstruction diameter" is 
illustrated in figure 3 and is determined as the diameter of the vessel at the midpoint 
between the closest diameter positions on both sides of the minimum luminal diameter 
which exceed the minimum value by 5%. This additional variable has been created in an 
attempt to circumvent possible underestimations of the true value caused by quantum 
noise - its efficacy and reliability relative to the more conventional "minimal luminal 
diameter" measurement has not been previously validated. 
Statistics. The QCA measurements for the minimal luminal diameter and the obstruction 
diameter were compared with the true phantom diameters to generate values for accuracy 
(mean of the signed differences) and precision (standard deviation of the signed 
differences) and by linear regression (true phantom diameter as the independent variable) 
to generate the indices of correlation, standard error of the estimate, intercept and slope. 
RESULTS: 
Accuracy and range of stenoses. The results of all analyses are presented in detail in table 
1. Measurements for the entire range of phantom sizes (0.5 - 2.89mm) by OCA, using the 
conventional 5" and 7" image intensifier field sizes, revealed an accuracy of -.20mm. In 
contrast, analysis of only the 0.5 to 1.9mm range of phantom stenoses of our current 
study (i.e. excluding the 2.49 and 2.89mm cineframes) yielded an accuracy of -.16mm. 
Regression analysis. Regression analysis of the results for the entire range of phantom 
stenoses yielded an intercept and slope of y = .01 + .87(x) - see figure 4. The precision 
and standard error of the estimate, were ± .15mm and ± .12mm respectively. 
Image intensifier field size. The results for the 5", 7" and 9" image intensifier field sizes 
are presented in table 1. As to be expected, no systematic deterioration in accuracy 
occurred with increasing pixel size from .063mm (7" image intensifier) to 0.082mm (9" 
image intensifier) while precision and standard error of the estimate (which are indices of 
random error and noise), both deteriorated with the 9" image intensifier setting. No 
improvement in precision or standard error of the estimate, however, was found when the 
image intensifer field size was reduced from 7" to 5" (when the pixel size decreased to 
.050mm). 
"Minimal" versus "obstruction" diameter measurements. The validation results for the 
"minimal" and the "obstruction" diameter are given in table 1. A slight improvement in 
accuracy of edge detection of .02mm was found when measurement of the "obstruction" 
diameter (-.20mm) was compared to measurement of the "minimal" luminal diameter (-
.22mm). 
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Figure 4. The true diameters of the phantom stenoses on the X-axis have been plotted 
against their DCA measurements (obstruction diameter) on the Y-axis for the 5" and 7" 
image intensifier field sizes. The accuracy was -.20mm for the entire range validated (0,5 
to 2.89mmJ and the regression line has a slope of less than 1 (-.03 + .89(x)) indicating 
underestimation of large luminal diameters. 
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accUlacy pr(!cision cO/relation std error r(!gression pixel size 
5" image intenslfier -.21mm ±.15mm .99 ± 12mm -.03mm + .SS{x) .050 ± .002mm 
7" Image Intensifier -.18mm ± 15mm .99 ± 12mm -.02mm +.90/xl .063 ± .003mm 
9" image intensifier -.18mm ± 21mm .98 ± .15mm .09mm + .83/xl .082 ± .003mm 
"obstruction" luminal diameter -.20mm ±.15mm .99 ±.12mm -.03mm + .89(xl .057 ±.007mm 
"minimal" luminal diameter -.22mm ±.16mm .99 ±.12mm -.02mm + .871xl .057 ±.007mm 
0.5 to 1.9mm phantom range -.16mm ±.14mm .98 ±.08mm .07mm + .7a/x) .057 ±.007mm 
Table 1 
Luminal diameter measurements for 5", 7 '. & 9" linage intensifier settings. 
'Obstruction" versus "minimal" luminal diameter measurements for 5" and 7" image intensifier settings combined. 
Results of DCA meas(Jrements for file 0,5 to 1.9mm range of phantom stenoses onlv for 5" and 7" linage lil/ellsifier settings combined. 
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DISCUSSION: 
Experimental Technique. In this study, we report a solution to technically overcome the 
limitations of earlier QCA validation studies by successfully inserting phantom stenoses of 
2.5 and 2.9mm diameter on an inflated angioplasty balloon in vivo. Given that these large 
"stent" stenoses cannot be removed in-vivo, the maximum number of such single channel 
stent stenoses which could be deployed in a single animal is three (one in the proximal 
segment of the left anterior descending, the circumflex and the right coronary arteries). 
This limitation can be overcome by the prior insertion and withdrawal of dual channel 
phantom stenoses of smaller internal diameter using a fixed attachment to Fogarty 
catheters. 
QCA. results. Over a series of in-vivo stenoses from 0.5 to 2.9 mm in diameter, QCA 
measurements were associated with an accuracy of -.20mm and a precision of ± .15mm. 
Such a degree of underestimation of large luminal diameters (slope = .89(x)), is greater 
than previously detected by in-vivo validation studies using a smaller range of phantom 
stenoses and has significant implications for the interpretation of multicenter interventional 
trials. 
Effect of increasing range of phantom stenoses on QCA measurements. By increasing the 
range of in-vivo phantom stenoses (0.5 - 2.89mm) we have revealed a greater 
underestimation (-.20mm) of measurements by QCA than demonstrated by our previous 
in-vivo validation studies (-.09mm) using a smaller phantom stenosis range of 0.5 to 
1.9mm [12]. This finding results from two methodological differences. Firstly the 
cineangiograms in our previous studies were recorded on an older generation (1991) X-ray 
system with a larger focal spot size of O.8mm (instead of the O.4mm focal spot size used 
in our current study). This resulted in our previous studies in greater point spread function 
and a positive shift (intercept) with overestimation of very small diameters which partially 
compensated for the underestimation of larger values by bringing the overall accuracy (for 
the 0.5 to 1.9mm range) closer to zero (i.e. by cancellation of the signed differences). 
Secondly the absolute underestimation by edge detection increases with larger values and 
thus inclusion of stenoses of > 2.0mm in our current study resulted in a greater 
underestimation for the entire range (0.5 to 2.89mm). This concept can be elaborated by 
considering a number of sample values: For a given QCA system with an intercept of 
.01 mm and a slope of .87(x) it can be seen that measurement of a phantom stenosis of 
1.00mm (typical pre-intervention minimal luminal diameter) will result in a reported QCA 
measurement of 0.88mm (accuracy of -.12mm) while measurement of a phantom stenosis 
of 2.8mm (typical post-optimal atherectomy minimal luminal diameter) will result in a 
reported measurement of 2.47mm (accuracy of -.33mml. It is thus clear that extension of 
the range of in-vivo phantom stenoses can result in the reporting of greater absolute 
inaccuracy for a QCA system. Furthermore our study confirms the degree of 
underestimation of larger diameters predicted from extrapolation of the regression line 
beyond the previously validated range (ie beyond 1.9mm). 
Implications for clinical trials. While the degree of inaccuracy of QCA measurements of 
large luminal diameters revealed by our study has not been detected by previous validation 
studies using a smaller range of in-vivo stenoses, the tendency to underestimate luminal 
diameters of > 1.0mm is not unique to the particular edge detection algorithm studied. In 
a recent validation study of 10 QCA systems at core angiographic laboratories in North 
America and Europe all were found to underestimate luminal diameters to some degree 
[211. The clinical implications of the underestimation of large luminal diameters include the 
reporting in multicenter interventional trials of an underestimation of the true luminal gain 
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achieved at intervention and underestimation of the % diameter stenosis of all lesions. 
Furthermore, the degree of subsequent luminal loss at 6 month angiographic follow-up will 
also be underestimated, Such underestimation of luminal gain and subsequent loss and % 
diameter stenosis measurements will be particularly marked in interventional trials of 
devices associated with large luminal gains (e.g. the optimal atherectomy trials ; 
EUROCARE, BOAT, OARS [1 6]). 
Until such time as OCA algorithms are developed and calibrated for images of in-vivo 
stenoses, rather than in-vitro images which fail to convey the heterogenous X-ray scatter 
and veiling glare of the thorax, it might be proposed that results of OCA measurements in 
angiographic trials should be transformed by a look-up-table based on the linear regression 
results of in-vivo validation studies (eg for CAAS II this would be y ~ -.03mm + .89(x)). 
Thus an angiographic trial using CAAS " reporting a mean luminal diameter of 2. 5mm post 
intervention might be more appropriately reported as indicating a true luminal diameter of 
2.81 mm {Le. (2.5mm + .03mm) / .89). Furthermore, the results of angiographic trials 
analyzed at different core laboratories with different OCA systems could be merged by 
correcting for the systematic error of each system as determined by in-vivo validation 
studies preferably using the same standardized set of in-vivo phantom cineangiograms. 
Application of such a normalization or corrective function to the results of each core 
angiographic laboratory might reveal that differences in luminal gain previously reported 
by different clinical studies for the same device may be greatly reduced. The inaccuracy 
in OCA measurements of large luminal diameters revealed by our study indicate that 
caution should be applied before directly applying the absolute results of multicenter 
angiographic trials to routine interventional practice in the catheterization laboratory, 
particularly in this new era of "the bigger the better" and widespread use of devices 
associated with large luminal gains in large vessels (eg stenting and atherectomy). 
Image intensifier field size. We have shown that the use of either 5" or 7" image intensifier 
field sizes provide a resolution of adequate quality for quantitative coronary angiography 
and both should be permitted in the protocol of multicenter angiographic trials. The g" field 
size was found to incur a minor loss in precision an·d standard error of OCA measurements 
without any change in accuracy or systematic shift. Therefore the occasional selection at 
an angiographic core laboratory of a g" frame (when available) for quantitative analysis 
would be acceptable when the 5" or 7" angiographic sequences are found to be unsuitable 
for OCA analysis (eg due to poor contrast filling or vessel overlap), albeit accepting a 
slightly poorer precision for the individual analysis. 
"Minimal" versus "obstruction" diameter measurements. We have demonstrated that for 
OCA measurements by the CAAS /I system, the selection of the obstruction diameter 
rather than the minimal luminal diameter conveys an improvement in accuracy of .02mm. 
Even though this improvement is clearly small, we have now adopted the obstruction 
diameter rather than the minimal luminal diameter as the primary endpoint in on-going 
clinical trials. 
Conclusion. To increase the direct clinical applicability of OCA validation studies for 
recently completed and ongoing interventional trials, the range of in-vivo phantom stenoses 
can be increased up to 2.9mm in porcine coronary arteries using a single channel "stent 
stenosis" technique in combination with our previously reported technique of insertion of 
dual channel phantom stenoses of smaller diameter. Extension of the range of phantom 
stenoses significantly affects the reported accuracy for a given OCA system and directly 
supports the implications from previous studies using smaller in-vivo stenoses that 
automated OCA algorithms underestimate large diameters in-vivo and thus underestimate 
acute luminal gain and subsequent chronic luminal loss following interventional procedures. 
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The results of this study are of particular relevance to the interventional policy of "the 
bigger the better" and widespread use of devices associated with large luminal gains in 
large vessels (eg stenting and atherectomy). 
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ABSTRACT: 
Objectives. The aim of this study was to determine whether coronary luminal area obtained 
from intracoronary ultrasound (lCUS) agree with measurement obtained by edge-detection (ED) 
or videodensitometric {V D) quantitative angiography pre and post coronary intervention, and 
which factors playa role in the discordance between ICUS and quantitative angiographic 
measurement. 
Background. While the primary role of intra coronary ultrasound (lCUS) may be the imaging of 
coronary mural pathology, precise quantification of luminal cross sectional area (MCSA) would 
offer a significant advantage. 
Method. One hundred thirty patients who underwent successful balloon angioplasty (SA, 
n ~ 100) or directional atherectomy (DCA, n ~ 30) were examined pre and post intervention. 
Minimal cross sectional area (MCSA) obtained from the three quantitative techniques were 
compared by the mean afld standard deviation of their signed differences. 
Results. Vessel size and lumen obtained after intervention was significantly larger in DCA than 
BA. MCSA obtained by ICUS was significantly larger than MCSA measured by ED and VD 
both pre and post BA or DCA. Correlation of MCSA measurements by ICUS and ED was 0.59 
pre BA and 0.57 pre DCA, which deteriorated to a correlation of 0.48 post BA and 0.41 post 
DCA. The correlation between ICUS and VD was 0.50 pre BA and 0.48 pre DCA, the 
correlation between ICUS and VO was 0.63 post ,SA and 0.58 post DCA. Post intervention 
better correlation was shown between ICUS and VD than that between ICUS and ED. 
One hundred lesions were classified according to the degree of vessel damage post BA. 'While 
the correlation between measurements obtained from ICUS and ED was 0.13 in lesions with 
angiographic dissection, 0.40 in the presence of angiographic haziness and 0.71 in the 
absence of dissection and haziness, the correlation between measurements obtained from 
ICUS and VO was 0.31 in lesions with angiographic dissection, 0.60 in the presence of 
haziness and to 0.76 in· smooth lumen. The agreement both between ICUS and ED, and 
between ICUS and VO deteriorated in lesions with dissection. 
Conclusions. MCSA obtained by ICUS is significantly larger than MCSA obtained from both 
ED and VD. Agreement between ICUS and ED considerably deteriorated after intervention. The 
complex morphological changes induced by angioplasty may augment the discordance of 
MCSA measurements by ICUS and quantitative angiography. VO may provide an acceptable 
alternative for ED in lesions with complex morphological changes induced by intervention. The 
absolute values of lumen dimensions obtained from ICUS, ED and VO after angioplasty should 
be interpreted with care, especially when used to decide on the necessity for further 
intervention. 
86 
ICUS vs. Edge Detection QCA vs. Videodensitometry QCA 
INTRODUCTION: 
While quantitative coronary angiography is still the golden standard in interventional 
cardiology, many pathologic studies indicate that angiography may underestimate the extent 
and severity of atherosclerotic disease (1 *4). Intracoronary ultrasound is felt to be more 
sensitive than angiography in the qualitative assessment of vessel wall morphology including 
the detection of calcium 'deposits and plaque rupture (5* 15J. Intracoronary ultrasound may 
provide useful information in the guidance of coronary intervention procedure (16* 18). Precise 
quantitative analysis of luminal cross sectional area by intracoronary ultrasound would offer 
a significant advantage. Previous studies have provided conflicting evidence on whether 
quantitative measurement derived from ICUS agree with the measurement obtained from 
quantitative coronary angiography (5,6,10,19-221. 
To clarify whether intracoronary ultrasonographic measurement agrees with quantitative 
coronary angiography, and which factors may play a role in the discordance between 
ultrasound and quantitative angiographic measurement, we compared minimal cross sectional 
luminal area obtained from intracoronary ultrasound and both edge*detection and 
videodensitometric quantitative angiography. 
METHODS: 
Patients. One hundred sixty*eight patients who had intracoronary ultrasound IICUS) 
examination pre balloon angioplasty (BA) or pre directional coronary atherectomy (DCA) at the 
Thoraxcenter were candidates for this study. Twenty*three of these patients were excluded 
because intracoronary ultrasound (lCUS) examination post intervention was not performed. 
Fifteen patients were excluded from the study because either their angiographic or ultrasound 
recordings were of inadequate quality for quantitative analysis. The remaining 130 patients 
were selected for the study. Of these 130 patients, 100 patients were treated with BA and 
the remaining 30 patients underwent DCA. Pre intervention, total occlusion of the target lesion 
was observed in 7 patients and the ultrasound catheter completely occluded the coronary 
lesion (cross sectional area of less than 1.61mm2 with a 4.3Fr ultrasound catheter or cross 
sectional area of less than 0.73mm2 with a 2.9Fr ultrasound catheter) in 87 patients. Pre 
intervention intra coronary ultrasOl:md images were analyzed in the remaining 36 patients. Post 
intervention ICUS measurements were carried out in all 130 patients. 
Balloon angioplasty (BA) or directional coronary atherectomy (DCA). All patients received full 
anticoagulant therapy including intravenous aspirin and heparin before intracoronary ultrasound 
examination and intervention. Coronary angiograms were recorded on cinetilm after the 
intra coronary administration of isosorbide dinitrate (1 * 2mg). A 0.014 inch high torque floppy 
guide wire (Advanced Cardiovascular Systems, Santa Clara) was inserted to guide the 
ultrasound catheter and the balloon or atherectomy catheter. The size of balloon or 
atherectomy device was determined to match the vessel reference diameter obtained from on* 
line quantitative angiographic measurement. 
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Table 1. Baseline clinical characteristics 
Patients 
Malelfemale 
Age (years) 
Stable I Unstable angina 
Coronary vessel 
RCA 
LAD 
LCX 
SVG .. 
SA 
100 
81/19 
60 ± 10 
53/47 
100 
31(31 %) 
47(47%) 
18(18%) 
4 (4%) 
Lumen measurement by edge-detection (mm) 
MLD pre 1.14 ± 0.41 
RD pre 2.88 ± 0.65 
MLD post 2.11 ± 0.54 
RD post 2.99 ± 0.71 
Lumen area measured ICUS (mm 2) 
MCSA pre 3.36 ± 0.99 
MCSA post 5.19 ± 1.90 
ICUS vs. Edge Detection DCA vs. Videodensitometry DCA 
DCA 
30 
27/3 
57 ± 9 
16/14 
30 
7(23%) 
19(64%) 
4(13%) 
0(0%) 
1.23±0.44 
3.06 ±0.75 
2.87 ±0.65 
3.66 ±0.59 
2.77 ± 1.00 
7.67 ±2.25 
p value 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
.001 
.001 
.001 
ns 
.001 
SA; balloon angioplasty, DCA; directional coronary atherectomy, LAD; left anterior coronary atery, RCA; 
right coronary artery, LeX; left circumflex coronary artery, MLD; minimal luminal diameter, RD;reference 
diameter, MCSA; minimal cross sectional area. 
Quantitative coronary angiography (OCA). The new version of the computer-based Coronary 
Angiography Analysis System (CAAS 111123,24) was used to perform the edge-detection (ED) 
and videodensitometric (VOl quantitative analysis. In the CAAS analysis which has previously 
been described elsewhere (24-28), the entire cineframe of size 18 x 24 mm is digitized at a 
resolution of 1329 x 1772 pixels. Correction for pincushion distortion is performed before 
analysis. To standardize the method of analysis pre and post intervention, all study frames 
selected for analysis were end-diastolic to minimize motion artifact, and arterial segments 
were measured between the same identifiable branch points in fDultiple matched views after 
the administration of isosorbide dinitrate (29-30). 
Edge-detection (ED) QCA Analysis. Boundaries of a selected coronary segment are detected 
using a weighted sum of the first and second derivative functions on the brightness profile of 
each vessel scan line automatically (22,23). The absolute diameter of the stenosis (in mm) is 
determined using a contrast free guiding catheter as a scaling device (32). Using the diameter 
function, the luminal diameter at the site of lesion (minimal luminal diameter; MLD) and a 
computer-derived estimation of an interpolated reference vessel diameter (RD) at the site of 
the lesion was determined. Minimal cross sectional area (MCSA) was calculated from the 
value of minimal luminal diameter (m2) obtained from the edge-detection analysis in multiple 
matched views pre and post intervention. 
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Videodensitometric (VD) QCA Analysis. Videodensitometric measurement is based on the 
relationship between the attenuating power of the lumen filled with contrast medium and the 
X-ray image intensity (23,33). Using this relationship, a videodensitometric profile which is 
proportional to the cross-sectional area of the lumen was obtained. Subtraction of patient 
structure noise was applied after computing the linear regression line through the background 
pixels located on both sides of the detected luminal contours. Consecutive densitometric 
profiles of the analyzed segment were acquired in all scan lines perpendicular to the vessel 
including lesion, reference and non-diseased area. Conversion of the individual 
videodensitometric profiles to absolute values was performed after a transformation of the 
videodensitometric profile found in a cross-sectional area of non-diseased segment, assuming 
a cross-sectional area at any point is proportional to the densitometric profiles at the point. 
Minimal cross sectional area (MCSA) was calculated from the average value obtained from the 
videodensitometric system in multiple matched views. 
Qualitative angiographic assessment. Qualitative coronary angiographic assessment was 
performed by the consensus of at least two experienced angiographers. Angiographic 
dissection was defined as a dissection classification type 8, C, D, E and F (34). 
Image Acquisition of Intra coronary Ultrasound (lCUS). Following selective coronary 
angiography, a mechanical intracoronary ultrasound imaging catheter (30-MHz, 4.3Fr or 2.9Fr, 
CardioVascular Imaging Systems, Sunnyvale, CAl was introduced over a 0.014 inch 
guidewire. After the imaging catheter was passed into and beyond the lesion, a slow manual 
continuous pull-back was started to obtain an initial assessment of the target lesion. A second 
pull-back was performed using a motorized pull-back device with a constant speed of 1.0 
mm/second. A simultaneous fluoroscopic image of the position of the ICUS catheter-tip was 
continuously displayed using a split screen format. Side branches visible on both the 
ultrasound and angiographic images served as reference points to ensure that the coronary 
sites of ultrasound and quantitative angiographic analysis were identical. ICUS images were 
stored on super VHS videotape for subsequent analysis. 
Quantitative assessment of Intracoronary ultrasound (lCUS). Luminal area was defined as the 
integrated area central to the intimal leading edge echo. Images with minimal cross sectional 
area (MCSA) were selected from the pull-back sequence by reviewing the position of the ICUS 
catheter on the angiographic image using the split screen format and by review of the time 
log and audio recording of the procedure. 
Qualitative assessment of Intra coronary ultrasound (lCUS). Presence of calcium was graded 
into three categories - calcium free, focal deposit « 90 degrees of the vessel circumference), 
and moderate or diffuse (> 90 degrees). Lumen morphology after intervention was graded into 
three categories; a smooth lumen was defined as a regular and even shape of the lumen; an 
irregular lumen was defined as an uneven or rough border of the lumen or partial tear and 
crack of the plaque toward the media; and a dissection was defined as a split or tear behind 
the plaque 17,8), 
Interobserver variability. To determine the interobserver variability of ICUS measurements, 30 
lesions were independently measured by two observers. The mean signed difference and 
correlation of the measurements of cross sectional area was 0.02 ±0.37mm2 and 0.97 
respectively. 
89 
ICUS VS, Edge Detection DCA vs, Videodensitometry DCA 
Statistical analysis. While previous studies (5,6,10,19-22) applied linear regression analysis 
in comparison between ICUS and angiographic measurements, Bland and Altman (35) have 
recommended the use of the mean and standard deviation of the signed differences between 
two measurement systems as an index of agreement between two systems in the absence 
of the known true values. Thus, we took the mean and standard deviation of the signed 
differences between ICUS and OCA measurements as an index of agreement between ICUS 
and OCA measurements instead of linear regression analysis. The individual measurements 
obtained from ICUS and OCA were compared using the paired Student's t-test and correlation 
coefficient. 
RESULTS: 
Part 1 - results for aI/lesion types: 
Baseline characteristics comparison between BA and DCA. The clinical characteristics of the 
patients are provided in Table 1. While no difference was found in age, gender, anginal 
symptoms (36) and distribution of diseased vessel between the BA group and the DCA group, 
reference diameter (RD) pre and post intervention and minimal luminal diameter (MLD) post 
intervention obtained from edge-detection quantitative angiography was significantly larger 
in the DCA than in the SA patients. While pre intervention MCSA obtained from ED, VD and 
ICUS was not different between the SA and DCA groups, post intervention MCSA was 
significantly larger in the DCA than in the SA patients as determined by all three measurement 
systems. 
Comparison between ICUS and ED pre and post BA. While pre SA (26 lesions) the mean value 
of MCSA was 3.36 ±0.99mm' derived by ICUS and 1.12 ±0.96mm' obtained by edge-
detection (ED) measurements, post SA (100 lesions) mean MCSA was 5.19 ± 1.90mm' 
derived by ICUS and 3.48 ± 1. 76mm' by ED. The figures 1 a and 1 b display the agreement 
between measurements obtained from ICUS and ED according to the statistical approach 
proposed by Bland and Altman (35). Pre SA the mean difference between the two 
measurements was 1.43 ± 1.12mm2. Post SA (Fig 1 aJ the mean difference was 1.71 
± 1.87mm2. Post SA the agreement between the two measurement systems deteriorated in 
comparison with pre SA. MCSA obtained by ICUS was significantly larger than MCSA 
measured by ED both pre and post BA (p<.001 and p<.0001 respectively). The correlation 
coefficient of measurements by the two techniques was 0.59 pre SA and 0.47 post SA 
respectively. 
Comparison between ICUS and ED pre and post DCA. While pre DCA (10 lesions) mean MCSA 
was 2.77 ± 1.00mm' derived by ICUS and 1.19 ±0.81 mm' by ED, post DCA (30 lesions) 
mean MCSA was 7.67 ± 2.25mm' derived by ICUS and 6.49 ± 2.56mm' by ED. Pre DCA the 
mean difference between the two measurements was 1.33 ± 1.02mm2. Post DCA (Fig 1 b) 
the mean difference was 1.18 ± 2.62mm2. The correlation coefficient was 0.59 pre DCA and 
0.41 post DCA. MCSA derived from ICUS was significantly larger than MCSA measured by 
ED both pre (p < .01) and post (p < .05) DCA. The correlation between the two measurement 
systems deteriorated after DCA in comparison to pre DCA. 
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Comparison between ICUS and VD pre and post BA and DCA. Mean MCSA determined by 
videodensitometry (VD) was 1.32 ± 1.02mm' pre BA (26 lesions) and 1.16 ± O. 72mm' pre 
DCA (10 lesions) ; and 3.92 ± 1.82mm' post SA (100 lesions) and 4.44 ±2.35mm' post 
DCA (30 lesions). MCSA obtained by ICUS was significantly larger than MCSA measured by 
VD both pre and post SA and DCA. The correlation coefficient of the ICUS and VD 
measurements was 0.50 pre SA and 0.48 pre DCA, and 0.63 post SA and 0.58 post DCA. 
The mean difference and standard deviation between the two measurements was 1.1 5 
±1.12mm' pre SA and 1.32 ±1.00mm' pre DCA, and 1.27 ±1.61mm'post SA and 0.83 
± 2.0Bmm2 post DCA. Fig 2 displays the comparison of measurements between ICUS and VD. 
Post intervention the agreement between ICUS and VD was better than the agreement 
between ICUS and ED (Fig 1). An example of ICUS, ED and VO measurements post 
intervention can be seen in Figure 3. 
Part 2 ~ results according to qualitative lesion characteristics,' 
Role of angiographic dissection in the agreement between ICUS and ED after BA (Table 2). 
One hundred lesions post BA were classified according to the following angiographic features 
(Table 2); a) presence of angiographic haziness, b) presence of dissection, and c) absence of 
haziness and dissection. The correlation coefficient of ICUS and ED quantitative measurements 
was 0.71 in lesions without haziness or dissection, 0.40 in lesions with haziness, and 0.12 
in lesions with angiographic evidence of dissection. 
Table 2. Comparison of agreement between measurements of ICUS and edge detction QCA 
according to lesion characteristics in 100 patients undergoing Balloon Angioplasty 
Lesion characteristics on angiography 
Absence of dissection and haziness (n = 47) 
Presnce of haziness (n = 26) 
Presence of dissection (n = 27) 
Lesion characteristics on ultrasound 
Smooth lumen (n = 32) 
Irregular lumen (n = 38) 
Presence of dissection (n = 30) 
Calcium free lesion (n = 26) 
Focal calcium lesion (n = 42) 
Moderate to diffuse calcium lesion (n = 32) 
Mean 
difference 
(mm 2) 
1.16 
2.44 
1.96 
1.28 
1.53 
2.39 
1.75 
1.71 
1.67 
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Standard 
deviation 
(±mm2) 
1.48 
2.00 
2.14 
1.64 
2.00 
1.81 
1.83 
1.38 
2.44 
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Figure 1. The agreement between !CUS and edge detection QCA (ED) post SA fA) and post DCA 
fB) according to the statistical approach proposed by Bland and Altman (35). 
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Figure 2. The agreement between ICUS and videodensitometry QCA (VDl post BA fA) and post 
DCA (BJ according to the statistical approach proposed by Bland and Altman (35). 
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One hundred lesions post BA were graded according to their morphological pattern as 
assessed by intracoronary ultrasound examination. The correlation of leus and ED quantitative 
measurements was 0.63 in lesions with a smooth lumen as determined by ultrasound, 0.49 
in lesions with an irregular lumen, and 0.24 in lesions with ultrasound evidence of dissection. 
Lesions post BA were classified according to the degree of calcium deposits on ultrasound 
examination. The correlation of ICUS and ED measurements was 0.71 in calcium free lesions, 
0.37 in the presence of focal calcium deposits, and 0.15 in the presence moderate to diffuse 
calcification. Thus the presence of dissection or calcium was associated with a deterioration 
of agreement between ICUS and ED measurements. 
Comparison of the agreement between ICUS and VD in dissected lesion post BA ITable 3). 
The relationship of ICUS and ED measurements was examined in one hundred lesions post BA 
according to their angiographic features (Table 3); The correlation of ICUS and ED 
measurements was 0.76 in lesions without dissection or haziness, 0.60 in lesions with 
haziness and 0.31 in lesions with angiographic evidence of dissection. 
Table 3. Comparison of agreement between measurements of ICUS and Videodensitoetry QCA 
in 100 patients undergoing Balloon Angioplasty 
Lesion characteristics on angiography 
Mean 
difference 
(mm 2) 
Absence of dissection and haziness (n = 47) 1.02 
Presence of haziness (n = 26) 
Presence of dissection (n = 27) 
Lesion characteristics on ultrasound 
Smooth lumen (n = 32) 
Irregular lumen (n = 38) 
Presence of dissection (n = 30) 
Calcium free lesion (n = 26) 
Focal calcium lesion (n=42) 
Moderate to diffuse calcium lesion (n = 32) 
1.54 
1.48 
0.98 
1.14 
1.76 
1.25 
1.24 
1.33 
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Standard 
deviation 
(±mm2) 
1.40 
1.76 
1.79 
1.53 
1.72 
1.47 
1.53 
1.49 
1.85 
0Watix1 
cceffidEnt 
(r) 
.76 
.60 
.31 
.73 
.63 
.43 
.81 
.43 
.42 
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The relationship of ICUS and EO measurements were also examined in lesions post BA 
according to their morphological pattern as assessed by ultrasound. The correlation of ICUS 
and EO measurements was 0.73 in lesions with a smooth lumen, 0.63 in lesions with an 
irregular lumen, and 0.43 in the presence of ultrasound evidence of dissection. especially in 
the presence of angiographic or ultrasound evidence of dissection. The correlation of ICUS and 
VO measurements was 0.81 in calcium free lesions, 0.44 in the presence of focal calcium 
deposits, and 0.42 in the presence moderate to diffuse calcification. 
The agreement and correlation of VD and ICUS measurements was higher than the agreement 
and correlation of EO and ICUS measurements especially in lesions with moderate to diffuse 
calcium (Table 2). A similar pattern was seen when lesions treated by DCA were categorised 
according to their morphological characteristics (see Table 4). 
Table 4. Comparison of agreement between measurements by ICUS, edge detection QCA (EO) 
and videodensitoemtry QCA (VD) in 30 patients undergoing Directional Coronary Atherectomy 
Mean Standard 0rnJati:<l 
difference deviation ooefIidfflt 
(mm2) (±mm2) (r) 
ICUS versus ED 
Lesion characteristics on ultrasound 
Absence of haziness and dissection (n = 19) 1,15 2,52 0,52 
Presence of haziness or dissection (n = 11) 1.24 2,92 0,12 
Lesion characteristics on ultrasound 
Smooth lumen (n = 8) 0,68 1,99 0,74 
Luminal Irregularity or dissection (n = 22) 1.37 2,84 0,25 
Calcium free lesion (n = 12) 0,67 1,99 0,68 
Focal to diffuse calcium lesion (n = 18) 1.53 2,97 0,24 
ICUS versus VD 
Lesion characteristics on ultrasound 
Absence of haziness and dissection (n = 19) 0,92 1.81 0,71 
Presence of haziness or dissection (n = 11) 0,68 2,57 0,27 
Lesion characterisUcs on ultrasound 
Smooth lumen (n=8) 0,52 1.77 0,80 
Luminal Irregularity or dissection (n = 22) 0,95 2,21 0.44 
Calcium free lesion (n = 12) 0,33 1.40 0,84 
Focal to diffuse calcium lesion (n = 18) 1.16 2.42 0.40 
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Figure 3. Quan(;tative angiographic analysis by edge detection (ED) and videodensitometry (VO) 
and ICUS analysis post balloon angiop/asty BA in the middle segment of the left circumflex coronary 
artery. The leus image (right side) shows an irregular lUmen with partial rupture of a soft eccentric 
plaque. The elliptical and irregular shape of the lumen may explain the discordance between 
measurements of the minima/lumen cross sectional area (MeSA) obtained from ICUS (4. 1 mm2) and 
edge-detection DCA (minima/luminal diameter of 1.92mm (MeSA 2.99 mm2)} and videodensitometric 
QCA measurement (3.20 mm2J. To overcome the limitation of single view quantitative angiography the 
average of multiple matched views was utilized. 
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DISCUSSION : 
The unique features of our study design were as follows: 1) This is the first study to compare 
both edge-detection and videodensitometric quantitative angiographic measurements with 
ICUS measurements. 2) The agreement of measurements in the absence of the known true 
luminal dimensions was compared using the method proposed by Bland and Altman (35). 3) 
The influence of both luminal and vessel wall morphology on the relationship of ICUS and 
quantitative angiographic measurements was examined 4) An attempt at intracoronary 
ultrasound examination as well as quantitative angiography was made in all lesions both pre 
and post intervention. 5) The study population was the largest ever performed for the purpose 
of comparison of ICUS and quantitative angiographlc measurements. 
The principle findings of our study were as follows: 1) MCSA obtained by ICUS was 
significantly larger than MCSA measured by either edge-detection or videodensitometric 
quantitative coronary angiography both pre and post BA and DCA. 2) The agreement between 
ICUS and ED deteriorated considerably after both BA and DCA. 3) The complex morphological 
changes induced by anoiopiasty contributed to the discordance of the agreement of two 
measurement systems. 4 \ ICUS measurements were foun~ to provide a better agreement with 
videodensitometry than with edge detection, particularly in lesions with complex morphological 
changes post intervention. 
Agreement between ICUS and ED-OCA in previous studies. Previous studies have provided 
conflicting evidence on whether luminal measurements obtained from intracoronary ultrasound 
agree with edge detection quantitative angiographic (ED-OCA) measurements in human 
coronary arteries. In general, previous studies which examined the relationship of the ICUS 
and ED-OCA measurements in normal coronary segments reported a favourable correlation 
between the two quantitative imaging modalities (5,10), while those studies which included 
lesions post angioplasty reported a poor correlation of the two measurement techniques 
(6,21,22). 
Role of vessel wall disruption post intervention and calcification on the agreement between 
(CUS and QCA measurements. Our study clearly demonstrates that luminal area obtained by 
ICUS was significantly larger than both ED and VD with considerable deterioration of the 
agreement after BA and DCA. The agreement deteriorated in proportion to the grade of 
damage induced by intervention in both ED and VD compared with ICUS. A progressive 
deterioration in the relationship of ICUS and QCA 'measurements was seen in accordance to 
the presence of an irregular lumen, luminal haziness, or dissection. Thus exclusive reliance 
upon either QCA or ICUS measurements for the guidance of coronary interventional 
techniques and the determination of post intervention results may be unreliable. A similar 
progressive fall in the relationship between ICUS and QCA measurements was seen in 
accordance with the degree of vessel wall calcification. Of interest, Fitzgerald et al. (7) 
indicated that calcium has a direct role in promoting dissection by increasing shear stress 
within the plaque during coronary angioplasty, and thus the deterioration of agreement 
between ICUS and QCA in calcified lesions may indirectly relate to the predisposition to the 
occurrence of dissection or haziness induced by intervention. In our study population, 31 % 
of lesions with moderate to diffuse calcification developed angiographic evidence of 
intraluminal haziness and 41 % developed a dissection post intervention. 
97 
ICUS vs, Edge Detection QCA vs, VideodensitometryQCA 
Contributing factors to the discordance of ICUS and QCA measurements. A number of factors 
may have contributed to the observed discordance of ICUS and QCA measurements. The 
dissected lumen which may not be completely filled by contrast medium on account of a 
poorly communicating channel between the true and the false lumen or on account of nearly 
stagnated blood in the false lumen which may contribute to the relative underestimation by 
contrast angiography measurements. Ultrasound fall-out due to guide wire artifact and 
elliptical angulation of the ultrasound catheter within the longitudinal axis of the vessel may 
augment the discordance of ICUS cross sections with QCA measurements. Additionally, 
introduction of the ultrasound catheter may itself result in tacking back of dissections and 
stretching or dilatation of the vessel (Dotter effect) and thereby result in a larger lumen during 
ICUS examinations post intervention compared to the less invasive technique of contrast 
angiography. 
QCA by videodensitometry provided a better agreement and less relative underestimation in 
relation to ICUS measurements than QCA by edge-detection. The underestimation by edge 
dete,ction relative to ICUS measurements may reflect the propensity of the contour detection 
algorithm to trace the change in brightness profile in the contrast-weak channel between the 
true and false lumens (37) while ICUS measurements and measurements by videodensitometry 
in multiple views may have included the contribution of the false lumen. Such a phenomena, 
however, would not account for the relative underestimation be edge detection in the pre-
intervention phase. It may also be possible that the interventional cardiologist tends to select 
angiographic projections which best demonstrate both the stenosis pre intervention and the 
residual stenosis post intervention, - "worst view" angiography. ICUS and videodensitometry 
are not projection-dependent and both would provide a measure of the "depth" as well as the 
"width" of the lumen cross section. Edge-detection, however, only provides a measure of one 
diameter (the "width") of the lumen and assumes a elliptical cross section. Even after 
averaging of multiple matched views as performed in our study, the assumed average cross 
section may have been based upon multiple !tworst views" which although they were per~ 
protocol > 30° apart, they were not necessarily truly orthogonal views, and thus the "worst 
view" was not necessarily balanced by the "best view". Such 'a limitation to quantitative 
angiography by edge-detection has been an inherent limitation to all coronary interventional 
trials and attempts to address this limitation by three-dimensional imaging in truly orthogonal 
views (with catheter- independent isocen,tric calibration) are currently under evaluation (38-
40). Of interest, in a recent study evaluating the performance of ten edge-detection QCA 
systems at core laboratories in North America and Europe, all ten edge detection QCA systems 
were found to underestimate the known true dimension of symmetrical phantom stenoses in 
porcine coronary arteries in-vivo (28). 
Conclusion. Minimal lumen cross sectional area measurements obtained by intra coronary 
ultrasound are significantly larger than measurements provided by both geometric and 
videodensitometric quantitative coronary angiography both before and after intervention. 
Agreement between intra coronary ultrasound and geometric quantitative angiographic 
measurements deteriorate considerably after intervention. Complex morphological changes 
induced by intervention may playa role in such a discordance between the two quantitative 
imaging techniques. Videodensitometry may provide an acceptable alternative for edge-
detection quantitative coronary angiography in lesions with complex morphology. Exclusive 
reliance upon the absolute values of coronary lumen dimensions derived from intra coronary 
ultrasound alone or from geometric or videodensitometric quantitative angiography alone to 
guide coronary interventional procedures or to determine post interventional results may be 
unreliable. 
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Chapter VII 
Structural design, clinical experience, and current indications of the 
Coronary Wallstent. 
David Keane, Peter de Jaegere, Patrick W Serruys. 
Cardiology Clinics 1994; 12:689-97. 
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STRUCTURAL DESIGN, CLINICAL 
EXPERIENCE, AND CURRENT 
INDICATIONS OF THE CORONARY 
WALLSTENT 
STRUCTURAL DESIGN 
TIle Walls tent (Schneider, Biilach, Switzer-
land) has a stainless steel tubular mesh design 
with longitudinal flexibility. A total of 18 to 
20 monofilaments 0.07- to O.IO-mm thick are 
used to fabricate each coronary Walls tent, re-
sulting in a metallic surface area in the ex-
panded state of approximately 20%" and a 
metallic cross-sectional area 0.062 mm<.15 This 
relatively high metallic surface area (com-
pared with 8% for the new advanced cardio-
vascular system {ACS] stent) may be of theo-
retical importance as it appears likely that 
stents of lower metallic surface area are less 
thrombogenic and cause less inflammatory re-
sponse in the vessel wall. The intersections of 
the filaments of the mesh structure are not 
fixed or soldered together, thereby affording 
greater longitudinal flexibility in comparison 
with that of the Palmaz-Schatz mesh design. 
Vessel splinting is, thus, not prominent in 
either native or vein gmft coronary vessels 
following Wallstent implantation. Early con-
cerns of friction from metal surfaces rubbing 
together at points of filament intersection ap-
pear to be unwarranted, and signs of such 
complications have not emerged from clinical 
studies. 
Dr. D.wid Keane, MRCPJ, is a a>cipimt of a travel grant 
from TIle Peel :-'ledical Research Trust, J,ondon, England 
David Keane, MB, Peter de Jaegere, MD, 
and Patrick W. Serruys, MD 
TIle stainless steel alloy is cobalt-based, and 
energy dispersion spectrometric studies have 
identified elements of chromium, iron, nickel, 
and molybdenum in addition to cobalt,l~ thus 
indicating that the Walls tent consists of a 
more heterogenous alloy than many other 
metallic coronary stents. TIle radiopacity of 
the Wallstent during conventional cineangi-
ography is relatively low (compared with that 
of the tantalum Wiktor and Strecker stents); 
however, with advances in digital pulsed 
fluoroscopy, the Wallstent mesh can usually 
be identified (at 50 kV) even after removal of 
the radiopaque markers of the delivery sys-
temY Unlike some other stainless steel stents 
(e.g., Palmaz stent) but similar to tantalum 
stents (e.g. Strecker stent), the vVallstent has 
been found not to move or deflect during MR 
imaging, even under high magnetic field 
strengths. I '. lY However, as stents become in-
corporated into the vessel wall after several 
weeks, ~vfR imaging of patients with ferro-
magnetic stents is probably safe after a suita-
ble period has elapsed to ensure stable posi-
tioning of the device. n 
The Wallstent is self-expanding and, there-
fore, does not require a balloon for deploy-
ment. This may be particularly advantageous 
in friable, diffusely diseased bypass grafts at 
high risk for embolization with balloon angio-
plasty. Jnstead, the Wallstent is mounted on a 
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lO'N-profile catheter and is maintained in a 
collapsed state until it is progressively re-
leased by the retraction of its rolling mem-
brane (Fig. 1). 11le doubled-over restraining 
membrane and delivery mechanism prevent 
accidental release of the stent, and a partially 
deployed Wallstent can often be ·withdrawn 
proximally or removed entirely.6 
Dilatation of a balloon within the Wallstent 
is normally performed after its release to ac-
celerate early expansion, to ensure symmetri-
cal and adequate apposition of the stent 
against the vessel wall, and to dissipate 
thrombus within the stent (Fig. 2). The Wal-
Istent is thought to continue to expand until 
an equilibrium is reached between the elastic 
recoil of the vessel wall and the radial force 
of the sten1. l 
TIle low profile of the Wallstent compares 
ws<:; 6<:; MM 
favorably with that of stents which require 
balloon mounting. The outer diameter of the 
coronary stent-mounted delivery catheter of 
the Wallstent is 1.57 mm (Schneider, Bulach, 
Switzerland) in comparison with 1.65 mm for 
the preballoon-motmted Palmaz-Schatz mesh 
stent Uohnson & Jolmson, Paris, France) and 
2.13 mm for the balloon-mounted Gianturco-
Roubin coil stent (Cook, Bloomington, IN). 
This feature increases the versatility of the 
Wallstent and, coupled with its longitudinal 
flexibility, results in its aptitude to negotiate 
proximal vessel tortuosities and points of 
small luminal diameter. Furthermore, its low 
profile permits introduction of the Wallstent 
through an 8-F guiding catheter (O.077-inch 
internal diameter), and, thus, exchange of the 
femoral sheath and guiding catheter during 
the bailout management of an acute occlusive 
Figure 1. Deployment of the Wallstent requires the advancement of the Wallstent over a Q,014·in or 0.018·in guldewire 
across the lesion. The distal marker band should be pOSitioned slightly beyond the distal edge of the stenosis to account 
for distal shortening of the stent during expansion. The central and proximal markers approximately define the final 
position of the stenl. The rolling membrane Is Inflated with contrast medium to 4 atmospheres prior to its gradual retraction 
to facilitate the smooth and progressive release of the self·expanding stent. 
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dissection with the Wallstent is rarely neces-
sary. TIlis compares favorably with the Gian-
turco-Roubin coil stent for which, normally, a 
9-P guiding catheter (internal diameter 0.089 
inches) is required for introduction of a 
Flexstent larger than 3.0 mm [this undesirable 
exchange of guiding catheters and sheaths 
during bailout management might be over-
come by the recent development of the Lu-
max 8-P guiding catheter (Cook), which has a 
relatively large internal lumen of 0.086 inches 
and allows delivery of the 4.0-nun Flexstent 
statl· 
An additional feature of the Wallstent is the 
\vide range of sizes available for coronary 
vessels, ranging from 2.5 to 6.0 mm in diam-
eter in the expanded state with lengths of 15 
to 30 mOl. This range of diameters is adequate 
for two reasons. First, stenting of vessels 2.5 
mIll or less in diameter appears to carry an 
unacceptable risk of subacute thrombosis, and 
a Wallstent size of 0.5 mm greater than the 
vessel size is required for optimal results to 
ensure that sufficient radial force is exerted 
on the vessel wall to prevent stent migration 
and to overcome elastic recoil. Second, few 
vessels are of greater diameter than 5.5 mm, 
even among coronary vein grafts. Wallstents 
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of greater than 6.0 mm in diameter are avail-
able, but they are usually deployed in periph-
eral vessels. The large range of lengths aYail-
able for the Wallstent may be particularly 
advantageous. It is helpful for the treatment 
of long dissections and to avoid the deploy-
ment of more than one stent for long dissec-
tions, a factor kruHvn to increase the risk for 
early thrombosis) and subsequent late reste-
nosis (particularly at the site of stent overlap 
where the metallic burden on the vessel wall 
is highest. If» Also, the large range of lengths 
permits the selection of a Wallstent of greater 
length than the lesion, thus reducing the risk 
of failing to cover the entire lesion length. 
The length of the Walls tent may shorten 
significantly upon expansion. This may result 
in a failure to cover a lesion and necessitate 
the deployment of a telescoping second Wal-
istent to cover a stenosis or dissection. To 
overcome the difficulty of unpredictable lon-
gitudinal shortening following radial expan-
sion, the design of the coronary Wallstent has 
recently been modified to produce a device 
which is less prone to shortening (the less 
shortening Wallstent). This is achieved at a 
cost of some loss of radial strength. Its tech-
nical features are depicted in Figure 3. The 
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less shortening Walls tent undergoes approxi-
mately 25% shortening upon expansion, and 
the braiding angle of its mesh is 104 degrees 
in comparison with 140 degrees for the nor-
mal shortening Wallstent. The follow-up 
phase of the first clinical study to evaluate 
this modified design has just been completed. 
All previously reported experience with the 
Walls tent has involved the earlier normal 
shortening design. 
EXPERIMENTAL STUDIES OF 
THROMBOGENICITY AND 
POLYMERIC COATING 
The primary reservation concerning clinical 
use of the Walls tent has been a relatively high 
incidence of acute thrombosis. TItis most 
likely relates to its high stent-to-vessel surface 
area. It is unlikely that the stainless steel alloy 
of Wallstents is more thrombogenic than the 
composition of other metallic stents. 
Among the stainless steel alloy stents, dif-
ferences in thrombogenicity have not been 
fOlmd, In an exteriorized arteriovenous sili-
cone shunt model in baboons, the thrombo-
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Figure 3. To overcome the problem 
of marked shortening of the Waltslent 
upon expansion, the design of the 
mesh has been modified 10 produce 
the Less Shortening Wallslent. The 
braiding angle of the mesh has been 
been reduced from 140" to 104°. This 
is assoclaled with an overall lower 
density of metal struts per unit length 
but carries a cost of lower radial sup-
port. 
genicity of the chromium-free stainless steel 
Palmaz-Schatz stent was compared with that 
of the chromium-based stainless steel Wall-
stent. The Palmaz-Schatz stent accumulated 
4.37 ± 0.68 X 10" platelets/em, wltich was 
not statistically different from the Wallstent, 
which accumulated 3.9l ± 0.42 X 109 plate-
lets/cm.!l 
Although no thrombotic occlusions were 
observed within 4 weeks in a noncomparative 
study of a tantalum stent (Wiktor) in the cor-
onary arteries of 10 pigs,2'-) evidence for lov','er 
thrombogenicity of tantalum in comparison 
with stainless steel stents has not been found 
in comparative in vitro and in vivo studies 
despite theoretical differences in ionic charge 
behveen tantalum and stainless steel. In an in 
vitro study by Hearn et a1,5 no significant dif-
ference in thrombogenicity was found be-
tween noncoated tantalum and stainless steel 
stents exposed to human blood. Further work 
from Emory University in both extracorpo-
real baboon and intracoronary porcine 
models has confirmed that stainless steel 
stents are not more thrombogenic than tan-
talum stents. 1t' 
In an effort to reduce the incidence of stent 
thrombosis, the surface of the Walls tent was 
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modified in 1989 to incorporate a polymer 
coating (BioGold). In vivo research at the 
Thoraxcenter has indicated that this poly-
meric coating may reduce the thrombogenic-
ity of the Wallstent.ll In this comparative 
study in porcine coronary arteries, thrombo-
genicity (by angiography) at I, 4, and 12 
weeks and vessel wall histology at 12 weeks 
were studied in 15 polymer-coated Wallstents 
placed with no medication and 48 uncoated 
Wallstents placed 'with the administration of 
acenocoumarol (16 stents), aspirin (16 stents), 
and no medication (16 stents). A 38% throm-
botic occlusion rate within 1 week (tmcoated 
Wallstents with no medication) was pre-
vented by polymeric coating and by aceno-
coumarol but not by aspirin. Histologic anal-
ysis showed no difference in the thickness of 
the neointimal hyperplasia between the 
groups, and the BioGold polymer did not in-
duce an inflammatory reaction. This experi-
mental histologic finding is supported by the 
retrospective angiographic comparison of 
those patients who received an uncoated Wal-
Ment before August 1989 versus those pa-
tients in whom a polymeric-coated stent was 
implanted after August 1989, in which the 
BioGold coating was found to have no signif-
icant relationship on late restenosis.](· The ef-
ficacy of this coating in the reduction of sub-
acute thrombosis, however, has yet to be 
demonstrated clinically. 
EARLY CLINICAL EXPERIENCE WITH 
THE WALLSTENT 
Valuable clinical experience "with coronary 
stenting was gained from a six-center Euro-
pean study of the vValistent which was under-
taken in the 1980s.12, H Between :1\,larch 1986 
and January 1988, 117 Wallstents were im-
planted in the native coronary arteries (94 
stents) or saphenous vein bypass grafts (23 
stents) of 105 patients, Seventy-one stents 
were implanted after dilatation of a restenotic 
lesion, 14 were placed as bai!out therapy for 
an acute occlusion following balloon angio-
plar.ty, 5 were deployed after angioplasty for 
chronic occlusion, and 27 were included as an 
adjunct procedure to primary balloon angio-
plnsty. 
It is not surprising that this early exrerience 
was fraught with the controversy 0 antico-
agulant management. Regimens ranged from 
the use of subcutaneous heparin to routine 
intracoronary urokinase, Many of the initial 
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patients in this early experience were not 
started on an oral anticoagulant regimen post-
stenling, and a few patients did not receive 
aspirin, whereas others were maintained on 
coumadin, aspirin, dipyridamole, and sulfin-
pyrazole. Even today, 8 years later, the strat-
egies proposed for anticoagulant therapy 
post-stenling continue to differ \-videly with-
out international consensus? 
The overall mortality rate for the group at 
1 year was 7.6% (eight deaths). Of these 
deaths, six were most likely the result of stent 
occlusion. Stent occlusion was angiographi-
cally confirmed at implantation in two of the 
six patients and after 24 hours in one patient, 
whereas in the other three, sudden death oc-
curred at 48 hours, 11 days, and 6 weeks, 
respectively, after stent implantation. 
Quantitative angiography (cardiovascular 
angiography analysis' system [CAAS]) re-
vealed that, overall, the minimum luminal di-
ameter improved from 1.21 ± 0,56 mm to 
1.88 ± 0.43 mm after balloon angioplasty and 
then further to 2.48 ± 0.51 mm immediately 
after stent implantation. Angiographic follow-
up was obtained in 90% of patients at a mean 
of 5.7 ± 4.4 months, At follow-up, the diam-
eter for the whole group (95 patients) had 
decreased to 1.68 ± 1.20 mm. TIle validity of 
including or excluding total occlusions from 
an angiographic follow-up analysis of reste-
nosis following balloon angioplasty is unclear 
in view of the unconfirmed mechanisms of 
total occlusion.?' 22 With coronary stenting, it 
seems more likely that total occlusions may 
represent a different phenomenon than typi-
cal restenosis in view of the frequently docu-
mented occurrence of thrombotic occlusions 
in the early period following stent implanta-
tion. "''hen the total occlusions (27 stents in 
25 patients) were removed from the angio-
graphic follow-up group, the minimal lu-
minal diameter at follow-up was 2,26 ± 0.78 
mm, Ten stents in nine patients of this group 
and one segment proximal to a stent had a 
diameter stenosis of Ilwre than 50% at folIow-
lip for a total restenosis rate of 14°/D of patients 
in whom the Wallstent was patent at follow-
up. 
LATER CLINICAL EXPERIENCE WITH 
THE WALLSTENT 
TIle previollsly described results from the 
early experience, which was pioneering not 
only for the Wallstent but also for all coronary 
stenting, were compared with the subsequent 
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results of the period from February 1988 to 
March 1990.16• 17 In addition, the cumulative 
clinical experience gained from 265 patients 
(308 lesions) from March 1986 to March 1990 
'was analyzed according to whether the Wal-
lstent was implanted in a native coronary ar-
tery or bypass vein graft (Fig. 4).1~, 17 TIle se-
lection of cases during the early and late 
periods differed significantly, with a higher 
proportion of bypass vein grafts and primary 
stenoses in the later period (1988 to 1990). 
Early occlusions following Wallstent im-
plantation 'were less frequent in later years 
(10% of stents) than in the early experience 
(18% of stents). This may relate to the adop-
tion of a more effective and standardized anti-
coagulant regimen, increased operator expe-
rience, and refined patient/lesion selection in 
the later years. In the combined early and 
later experience, early occlusions were docu-
mented in 18% of native coronary arteries 
compared with 7% of bypass vein grafts. TIle 
lower incidence of thrombotic occlusion in 
vein grafts may reflect, in part, that most of 
these vein graft stents were implanted during 
the later period when the anticoagulation pe-
riod was more aggressive and, in part, the 
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greater vessel size (recent studies indicate that 
thrombotic occlusion is less likely to occur in 
vessels larger than 3.25 mm compared with 
vessels smaller than 3.25 mm3). 
Quantitative angiographic follow-up was 
obtained in 82% of all patients. The outcomes 
for native and bypass vessels are compared in 
Table 1. It has been proposed that the higher 
late restenosis rate in vein grafts may be the 
price for lower early occlusion ratesY By di-
minishing the formation of early occlusive 
thrombus 'with more effective anticoagula-
tion, the residual nonoccluding thrombus 
could form the substrate for late restenosis.1 7 
This hypothesis is not supported by a more 
recent observation that the presence of tlU'om-
bus at the time of balloon angioplasty is not 
associated with greater luminal loss at folIow-
up if total occlusions at follow-up are ex-
cluded from the analysis.ll 
To gain a perspective of these relative re-
sults of the Walls tent in bypass vein grafts 
and native coronary arteries, it is worth, for 
comparative purposes, to consider the results 
of a prOVisional report of early ischemic 
events in bypass vein grafts and coronary ar-
teries follov\'ing implantation of the Gian-
2.21 
'+-
.-- -+ 2.03 
1.99~ 
1.59 
FU 
Bypasses 
Natives 
-~-------, 
FU 
(- early 0001.) (+ early 0001.) 
Figure 4. Minimal luminal diameter (MLD) of native coronary arteries and bypass vein grafls preprocedure, poslprocedure 
and at follow up. The mean values have been calculated wilh and without the inclusion of the early in·hospital occlusions. 
(From Strauss BH, Serruys PW, Bertrand ME, e\ al: Quanlitalive angiographic follow-up of the coronary wallslenlln native 
vessels and bypass grafts (European experience-March 1986 to March 1990). Am J Cardio169:475-481, 1992; with 
permission.) 
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Table 1, EAAlY AND LATE RESULTS FOLLOWING 
WALLSTENT IMPLANTATION' 
Vessel 
Native coronary artery 
Bypass vein graft 
Percent Early Percent 
OcclusIon Reslenosls 
19 39 
8 IS 
'Although the early occlusion rate for vein gratts was lower than 
that for native coronary arteries, tha rastenosls rata (>50% dlam· 
eler stenosis) per patient was higher In bypass vein grafts than in 
native coronary arteries_ There was no diffe~ence in the late OCelli· 
sion rate between the two vessel types (16Iesions.j" 
turco-Roubin coil stent, I~ Periprocedural «24 
hours) ischemic events occurred in 2% of vein 
grafts compared within 8% of native arteries 
(P=0.07), and the rate of later ischemic events 
at 1 to 90 days \vas at least as favorable for 
vein grafts as it was for native arteries.1H Inter-
pretation of these results, however, is con-
founded by differing clinical indications and 
lesional characteristics behveen the two vessel 
types and by the subsequent greater require-
ment for the deployment of multiple stents in 
bypass vein grafts. 
CLINICAL EVALUATION OF THE 
LESS SHORTENING WALLSTENT 
One of the factors thought to have contrib-
uted to the high rate of stent occlusion in the 
European registry of the coronary Wallstent 
in the 1980s was the frequent deployment of 
more than one stent to cover the target lesion. 
11lis factor attributed to the high degree of 
shortening of the Walls tent upon expansion. 
To overcome this limitation, the design of the 
Wallslent was modified 10 reduce the degree 
of shortening with the development Df the 
Less Shortening Wallstent. A small study was 
undertaken to determine the safety and effi-
cacy of implanting this new Walls tent for the 
management of saphenous vein coronary by-
pass graft stenoses. Between November 1991 
and lvtarch 1993, the Less Shortening Wal-
Istent was implanted in 29 patients at 6 cen-
ters in the Netherlands, Germany, and Bel-
gium.~' 
Thirty-five Wallstents were electively de-
ployed in aorto-coronary vein grafts in 29 pa-
tients. Stent deployment was sliccessful in 35 
of 36 attempts in 30 lesions. In 5 of the 30 
lesions, a second stent was required to cover 
the proximal portion of the lesion. Angio-
graphic success « 50% residual diameter ste-
nosis as determined by offline quantitative 
coronary angiography) \vas achieved in all 29 
patients. During the in-hospital phase, no ma-
jor adverse cardiac event occurred (reinter-
ventiOll, re-CABG, myocardial infarction, or 
death), and 5 patients had hemorrhagic com-
plications. Following hospital discharge, one 
patient had a subacute stent occlusion associ-
ated with symptoms and elevated cardiac en-
zymes at 11 days, another patient had symp-
toms and elevated cardiac enzymes (CK 300 
U /1) at 22 days \vith a patent stent, five pa-
tients required balloon angioplasty within the 
6 month follow-up period (four for restenosis 
and one for stenl occlusion), and one patient 
undenvent re-CAllG for a native artery ste-
nosis distal to the anastmosis of the patent 
stented vein graft. The results of this intro-
ductory study suggest that the new Less 
Shortening Wallstent may be associated with 
a reduction in the requirement for multiple 
stent deployment and a lower rate of throm-
botic occlusion in comparison to its pioneer-
ing prototype, On the basis of these results, a 
number of larger multicenter clinical trials 
have been initiated to further evaluate the 
new coronary Walls tent. 
CURRENT INDICATIONS 
Based on the data described previously the 
Wallstent is a versatile stent which, by virtue 
of its longitudinal flexibility and low profile, 
can be deployed with a high degree of success 
in complex lesions of both native coronary 
arteries and bypass vein grafts. 
Despite strict clinical indications that have 
been proved by prDspective randomized 
trials, it could be proposed that there are, as 
yet, no absolute indications for coronary 
stenting. Indeed, traditional balloon angio-
plast)' itself, the gold standard with which 
stenting frequently is compared, 17 years 
after its introduction! has yet to establish un-
equivocally its current indications in random-
ized, comparative morbidity and mortality 
trials in preference to medical therapy and 
bypass surgery.l,Y-ll 
11uts, it may be more appropriate in this 
relatively early era of coronary stent evolu-
tion to refer to clinical applications and con-
traindications. Fewer patients are required 
and randomization is not essential to detect 
contra indications to coronary stenting, 
whereas absolute indications for coronary 
stenting are more difficult to establish. Cur-
rently, these contraindications include persist-
ent intracoronary thrombus (after intracoro-
nary administration of thrombolytic therapy 
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and, when necessary, confirmation with an~ 
gioscopy) and contra indications to anticoagu-
lant therapy. Relative contraindications in-
clude a vessel size of less than 3.0 mm, 
excessive proximal tortuosity where introduc-
tion of the stent would be unlikely to succeed, 
deployment of a stent in an unprotected left 
main coronary artery, and the absence of in-
house cardiac surgical back-up. 
n is tmclear if an indication is established 
by a large randomized trial for one stent, 
whether the same results can be expected 
from a stent of similar design. In view of the 
relatively early stage of the clinical evaluation 
(8 years) of coronary stenting and the funda-
mental differences in metal surface area, strut 
composition (with or without coating), stent 
profile, delivery system, expansile mecha-
nism, longitudinal fleXibility, radial strength, 
and design among mesh stents (Walls tent, 
Palmaz-Schatz, and Strecker) and among coil 
stents (Wiktor, Gianturco-Roubin, and ACS), 
it seems that, for at least the present, each 
stent will have to prove its efficacy and safety 
for each clinical indication. Furthermore, al-
though the coating of currently available 
stents continues to necessitate systemiC anti-
coagulant therapy, the absolute indications 
for coronary stenting are likely to remain lim-
ited. 
The clinical conditions in which the coro-
nary Walls tent has been applied (usually as 
an adjunct to balloon angioplasty) during ob-
servational studies include the elective treat-
ment of primary stenoses, restenoses, and 
chronic occlusions in native coronary arteries, 
the elective treatment of primary stenoses in 
vein grafts, and the bailout managem.ent of 
acute vessel closure following coronary inter-
vention. By virtue of the high early throm-
botic rate in native vessels and the high reste~ 
nosis rate in vein grafts, it seems that, 
currently, the only condition in which im-
plantation of a coronary Wallstent can be jus-
tified outside of a randomized trial are the 
bailout management of acute ftonthrombotic 
occlusion (dissection) following interven-
tional procedures in native vessels of 2.5 mm 
or greater diameter and, possibly, the elective 
treatment of bypass vein grafts with friable 
lesions. In light of its unique mechanical 
properties, the Walls tent might be expected to 
excel over stents of different design in long 
lesions in large-diameter vessels associated 
with proximal tortuosity. 
Upcoming prospective randomized trials 
with the new less shortening Wallstent should 
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determine whether the Wallstent has been a 
victim of the pioneering era of clinical evalu-
ation during the early learning phase of coro~ 
nary stenting associated with inadequate an-
ticoagulation regimens, inappropriate patient 
selection, and multiple stent placement (on 
account of stent shortening), or whether ex-
posure of the coronary artery to the relatively 
large stent surface area of the Walls tent pre-
sents an unacceptably high early thrombo-
genic burden or, possibly, late excessive stim-
ulus to vessel wall hyperplasia in bypass vein 
grafts. 
References 
1. Beatt KJ, Bertrand M, Puel J, el al: Additional im-
provemenl in \'essellumen in Ihe first 24 hours after 
stenl implantation due 10 radial dilating force [ab-
slract]. J Am Coil CardioI13:224A, 1989 
2. de Feyter I'j, Keane 0, Deckers J, et al: Intermediate 
and long-term outcome after balloon coronilry angio-
plasly. l'rog Cardiovasc Dis 199-1, in press 
3. Doucet 5, Fajadet j, Cassagneau H, el ill: Early thwm-
botic occlusion after coronary Palmaz-Schatz stent 
implantiltion: Frequency ilnd clinical or angiographic 
predictors (abstract]. Em Heart J 13;4, 1992 
4. Gruentzig AR, Senning A, Siegenthaler WE: Non-op-
erative dilatation of coronary artery stenosis: Percu-
taneous transluminal coronary angioplasty. N Engl J 
:-.fed 301:61-68, 1979 
5. Hearn lA, Robinson KA, Roubin GS: In-vitro thTtlm-
bus formiltion of stent wires: Role of metallic compo-
sition .1nd heparin coating [abstract). J Am Coil Car-
diol17:302A, 1991 
6. Intravascular Stents: A Physician's Guide. Hawaii, 
Striltegic Business Dewlopment, 1990, pp 65-78 
6a. Keane 0, Buis B, Reifilrt N, et al: Clinic.~l ilnd angio-
graphic oulcome following implantation of the new 
Less Shortening Wailstent in ilorto-coronary vein 
grafts. J Intel"\'entional Cardiol1994i in press 
7. Keane 0, Roubin G, l\'!aro J: The Gianturco-Roubin 
Stent in Acute Closure E\'dluation (GRACE): Sub-
strate, challenges, and design of a randomi7cd trial of 
bailout therapy. J Inten'entional Cardiol 7:333-334, 
1994 
8. Krupski WC, Bass A, Kelly AB, et al: Heparin-resis-
tant thrombus formation by endovascular stents in 
baboons: Interruption by a synthetic antithrombin. 
Circulation 81:570-577, 1990 
9. Report of the ACC/ AHA Task Force on Assessment 
of Diagnostic and Therapeutic Cardiovascular Proce~ 
dures: Guidelines for percutaneous translumin,ll cor-
onary angioplasty. J 1\01 Coli Cardiol 22:2033-2054, 
1993 
10. Report of the American College of Cardiology/ Amer-
ican Heart Association Task Force on Assessment of 
Diagnostic and Therapeutic Cardiovaswlar Proce-
dures: Guidelines for percutaneous transluminal cor-
onary angioplast)'. 1 Am CoB Cardiol 12:529-5-l5, 
1988 
11. RITA Triall'articipants: Coronary angioplasty versus 
coronary arter), bypass surgery: The Randomised In-
tervention Treatment of Angina (RITA) trial. Lancet 
3·U:573-580, 1993 
DESIGN, EXPERIENCE, AND INDICATIONS OF THE CORONARY \VALLSTENT 697 
12. Serruys PW, Strauss BH, Beatt KJ, et al: Angiographic 
follow-up after placement of a self-expanding com-
nary artery stent. N EnglI Med 3J.l:13-17, 1991 
13. Shellock FG, S\\"engr05 CJ: MR imaging and biomed-
ical implants, materials and devices: An updated re-
view. Radiology 180:541-550,1991 
14. SigwMt U, Puel J, 1Hrcowitch V, et al: Intravascular 
stents to prevent occlusion and restenosis after trans-
luminal angiuplast)'. N Engl J Med 316:701-706, 1987 
14.1. Scott NA, Thomas CN, Nunes GL, ei .11: A compari-
son of the thrombogenicily of stainless steel ,md tan-
1,11um coronary stents. Am Heart J, 1994, in press 
15. Strauss BH, Rensing 81, den Boer A, et al: Do stents 
interfere with the densitometric assessment of a cor-
onar)' lesion? An in-vitro study. Cathet Cardio\'asc 
Diagn 24:259-264, 1991 
16. Strauss BH, Serm}'s PW: The coronar), walls tent. It! 
Topol EJ (ed): Textbook of Interventional Cardiology, 
ed 2. Philadelphia, WB Saunders, 1994, pp 687-701 
17. Strauss BH, Serru}'s PW, Bertrand t"lfE, et al: Quanti-
tath'e angiographic follow-up of the coronary Wal-
lstent in native vessels and bypass grafts (European 
experience-t"lfarch 1986 to March 1990). Am I Car-
diol 69:475-481, 1992 
18. Sutton 1M, Roubin GS, Williams 0, et al: Intracoro ... 
nary stenting of native arteries versus bypass vein 
grafts: Are there signific,1nt differences {abstract]? Em 
Heart J 13:4, 1992 
19. Teitelbaum GP, Bradley WG, Klein DO: ~IR imaging 
artifacts, ferromagnetism, and magnetic torque of in-
tra\'ascular filters, stents and coils. Radiology 
166:657-664, 1988 
20. Viill der Giessen WI, Serru)'s PW, van Beusekom 
H~IM, et al: Coronary stenting with a new, radi ... 
opaque, balloon-expandable endopro5thesis in pigs. 
Circulation 83:1788-1798, 1991 
21. \'an der Gicssen WI, V"ll Beusekom HM~I, \'.1n Hou-
ten CD, et al: Coronary stenling with polymer-coaled 
and wlCoated self-expanding endoprostheses in pigs. 
Coronary Artery Dis 3:631-640, 1992 
22. Violaris AG, Herrman Jr, Me1kert R, et al: Docs local 
thrombus formation incre,lse long-term luminal fen-
arro-lYing following PTCA? A qu,mtitativc angio-
gr,'phic analysis labstract]. J Am Coli Cardiol1994, in 
press 
23. Violaris AG, l1elkert R, Umans VA: Long-term lu-
minal renarrowing following coronary angioplasty of 
chronic total occlusions: A quantitative angiographic 
analysis of 3549 lesions [abstract]. Circulation 88:1-
519, 1993 
114 
Addr<'ss rcprirJl re,/uesfs fa 
Patrick W. Serrurs, MD, PhD 
Dept Inten'entional Cardiology 
Thoraxcenter, Ee 2332 
Erilsmus Unkersity 
1'0 Box 1738 
300 DR Rotterdam 
The Netherlands 
Chapter VIII 
Five year clinical and angiographic follow-up of the 
Coronary Wallstent. 
Elie '(arouny, *David Keane, Didier Carri6, Meyer Elbaz, 
* Patrick W. Serruys, and Jacques Puel. 
Service de Cardiologie, CHU de Purpan, Toulouse, France 
and 
*Catheterization Laboratory Thoraxcenter, Erasmus University Rotterdam, 
The Netherlands 
(in review) 
115 
ABSTRACT 
Objectives: This study was conducted to assess the long-term angiographic outcome of 
the first series of stents (Wallstents) implanted at our institution between March 1986 and 
December 1987. 
Background: While the short-term (six months) angiographic outcome of coronary stents 
have been extensively reported, uncertainties persist concerning the long-term tolerance 
of these metallic foreign bodies as well as the evolution of intimal hyperplasia after the 
six month period. 
Methods: Twelve patients in whom Wallstent deployment had been free of thrombotic 
complications and free of restenosis at 6-months, underwent long-term angiographic 
follow-up at five years. Absolute and percent obstruction diameters within the stented 
segments were measured by quantitative coronary angiography. 
Results: Minimal luminal diameter increased from 1.21 +/- 0.43 mm to 2.34 +/- 0.13 
mm immediately after intervention and then slightly decreased to 2.12 + /- 0.27 mm at six 
months and to 1.66 +/- 0.50 mm at five years. Percent diameter stenosis decreased from 
59.1 +/- 10% pre-stenting to 24.2 +/-10% immediately post-stenting and by 6 month 
angiographic follow-up percent diameter stenosis had increased to 32.8 + /- 10%, without 
further change at five years 134.9 + /- 12%). Only one patient had > 50% diameter 
stenosis at 5 years (53% diameter stenosis), thus indicating that from six months to five 
year follow-up, progression of the minimal luminal diameter within the stent{.46 +/- .30 
mm) was not greater than progression in the reference vessel diameter of the stented 
coronary segment (.68 +/- .62 mm). Intimal hyperplasia within the stent averaged 10.35 
+ / -0.13 mml at 5 years. 
Conclusion : The results of this limited series of patients do not lend support to the 
hypothesis that atherosclerosis within coronary stents may be accelerated or prolonged 
beyond six months. 
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INTRODUCTION 
Although the concept of implanting a tubular metallic structure in a coronary segment to 
maintain vessel patency after luminal dilatation was introduced by Dotter in 1964 (1 ). its 
clinical application in humans was not undertaken until 1986 (2). The self-expanding 
woven mesh Wallstent (Figure 1) was the first to be used in human studies for this 
purpose (2), Despite the occurrence of a high rate of acute and subacute thrombosis, this 
initial experience helped to define the clinical and ang/agraphic criteria for patient selection 
. as well as to refine their anticoagulant management. 
Whereas a 6-months angiogram is considered as a valid endpoint for assessing the result 
of bal/oon angioplasty based on long-term follow-up studies (3,4,5), it is undetermined 
whether the time course of restenosis is similar after the implantation of a metallic stent. 
Although six months angiographic follow-up of patients at the five centers evaluating the 
Wallstent has been reported (6,7), no further angiographic follow-up has been performed 
to assess whether luminal renarrowing within the Wallstent actually ceases after this 
period. 
Histological studies of synthetic arterial grafts and non-degradable stents have indicated 
that release of mediators and smooth muscle cell growth factors can continue even after 
complete endothelialization of the foreign material has occurred (8-13). Abundant 
myofibrillar cells and macrophages, the harbingers of the restenosis process, have been 
found to originate in the immediate vicinity of the individual stent struts adjacent to the 
internal elastic lamina and to fan out to fill the neointimal tissue in an evenly distributed 
fashion. On the basis of such post-endothelialization findings it has been proposed that by 
damaging the internal elastic lamina, stents render this natural barrier more permeable to 
the migration of smooth muscle cells and provide a permanent stimulus to smooth muscle 
proliferation and thus both accelerate and prolong the restenosis process (14). 
To assess whether the continued exposure to the metallic surface and sustained pressure 
(barotrauma) associated with coronary stents provide a permanent stimulus for neointimal 
proliferation, we addressed the 5-years angiographic outcome of patients in whom a 
Wallstent was implanted at our institution and in whom a subacute occlusion or restenosis 
at 6 months had not occurred. Our study population included the first patient ever to have 
received a stent (Figure 2). 
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Figure 1. 
Coronary Walls tent 
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METHODS 
Study population. Between March 1986 and December 1987, 27 stents were implanted 
after dilatation of a restenotic lesion in native coronary arteries in 27 patients at our 
institution (6). Of this pioneering experience, eight patients developed thrombotic occlusion 
within 2 weeks and four patients developed restenosis at 6 month follow-up (> 50% 
diameter stenosis), Thus fifteen patients were free of acute complications and late 
restenosis at 6 months and represented our population study. Baseline characteristics and 
lipid profile are shown in Table 1. 
Stent design. The design of the stent and its method of implantation have been previously 
described (2,6,15). Briefly, it is a self-expanding, stainless steel, woven mesh endovascular 
prosthesis which can be positioned in the coronary artery according to the standard over-
the-wire technique through an 8 or 9 French guiding catheter. It is constructed of 16 wire 
filaments, each 0.08 mm wide, constrained in an elongated configuration on a 1.57 mm 
delivery catheter, the distal and being covered by a removable rolling membrane. The 
prosthesis returns to its unconstrained original diameter as the rolling membrane is 
withdrawn. The unconstrained stent diameter was selected to be 0.5 mm larger than the 
visual estimate of the coronary artery diameter. 
Quantitative coronary angiography. The initial procedure as well as the six-months' follow-
up angiograms were recorded on 35 mm cinefilm and the five year follow-up angiograms 
were recorded on analogue videotape (16). All angiograms were analysed at a core 
laboratory (Cardialysis, Rotterdam) by means of a computer-assisted cardiovascular 
angiography analysis system (CAAS) as described elsewhere (17). Briefly, a selected frame 
area encompassing the coronary segment of interest is optically magnified and digitized. 
A computer-assisted automated edge detection technique is applied to determine the 
vessel contour based on the weighted sum of the first and second derivative functions 
applied to the digitized brightness information after correction for pincushion distortion. A 
calibration factor based on a computer analysis of the non-tapering part of the contrast-
empty catheter is calculated, and absolute MLD as well as the interpolated reference 
diameter based on a computed estimation of the original diameter of the artery at the level 
of obstruction are measured accordingly. Percent diameter stenosis is then derived from 
the observed and reference diameter values. 
In addition to the above off-line quantitative analyses at the core laboratory, the five years 
follow-up angiograms were studied on-line using the Automated Coronary Analysis (ACA) 
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Flgur. 2. 
First coronary stent implantation in a human in March .1986: 
1) Upper left panel: Restenotic lesion in the proximal left anterior descending artery 
2) Upper right panel: Immediate result post implantation of a Wallstent 
3) Lower left panel: Six month angiographic follow-up. 
4) Lower right panel: Five year angiographic follow-up. 
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software package of the Philips Digital Cardiac Imaging (DCII system, as described 
elsewhere (18). These latter on-line assessments were preferred for manual tracing on the 
metallic stents which were more reliably detected on the original digital radiographic 
images. This enabled the following analyses to be made: 
- Observed stent diameter: computed after manual drawing of the stent contour along the 
vessel wall. 
- Stent expansion: calculated as the (ratio of observed diameter/nominal unconstrained 
stent size * 100). 
- Mean intimal thickness : calculated as half the difference between observed stent 
diameter and mean luminal diameter within the stent. This last measurement is computed 
as the reference luminal diameter when the start-point and the end-point are selected at 
the proximal and distal extremity of the stent lumen. 
Other stent parameters assessed were: contour aspect, qualified as parallel or divergent, 
lumen regularity, radiopacity, presence of calcification in proximity to the stent and the fate 
of side branches originating at the site of the stent. 
Statistical analysis. All continuous variables are expressed as mean values ± standard 
deviation. Individual comparisons of MLD, percent stenosis and reference segment 
diameter between phases of follow-up were made' by two-tailed t-tests for paired data. A 
correlation coefficient was calculated to assess possible relations between quantitative 
variables. A p value less than 0.05 was considered significant. 
RESULTS 
Clinical data. Among 15 patients eligible for long-term angiographic restudy, twelve (10 
males, 2 females) underwent coronary angiography at a mean of 60.9 + /- 7.0 months 
after stent implantation (48 - 75 months). The 3 remaining patients refused catheterization 
and were asymptomatic and had a negative treadmill exercise test. Of the 1 2 patients who 
underwent long-term angiographic follow-up, 10 were asymptomatic and 2 had class I 
angina pectoris according to the Canadian Cari:.fiovascular Society. One patient had 
experienced recurrent angina 3 months after stenting and had been found to have 
significant left main-stem disease for which he had undergone bypass surgery. 
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Table 1. 
Baseline Characteristics of The Study Population 
No of patients 15 
Mean age (yr) 66.6 + /- 9.4 
Gender (M/F) 13/2 
Smokers 11 
Serum cholesterol baseline 270 +/- 32 
Serum cholesterol follow-up 238 +/- 28 
No of stents 15 
Stent size 
- 3.0 mm 2 
- 3.5 mm 11 
- 4.0 mm 2 
Implanted site 
- LAD: 10 
- LCxA : 2 
- RCA: 3 
Indication for stent 
- Restenosis : 15 
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Qualitative angiographic data. The vessel lumen within the stent was regular in 5 patients 
and irregular in 7. The luminal irregularities in the 7 patients were due to the presence of 
narrowing at the distal portion of the stent in 4 patients, at the mid portion of the stent in 
2 others and throughout the stent in the remaining patient. 
Side branches originating from the stented segment were patent in 8/8 patients without 
a reduction in blood flow. The stent itself remained radiopaque in all cases, and no 
calcification was seen in proximity to the stents. No disruption of the metallic structure of 
the stent was seen. By the time of the control angiogram, two patients who were in class 
I angina had developed new lesion involving small vessels. 
Quantitative angiographic data. Mean MLD increased from 1.21 +1- 0.43 mm before 
dilatation to 2.34 +/·0.13 mm immediately after stent placement (p < .01) and 
subsequently decreased slightly (n.s.) to 2.12 + /- 0.27 mm at 6 months. At 5 years the 
mean MLD had decreased to 1.66 + /- 0.50 mm indicating a progression of atherosclerosis 
from 6 months to 5 years of .46 + /- .30 mm within the stent (p = .01) (Figure 3) *. 
Mean reference segment diameter was 2.92 + 1- 0.47 mm before dilatation, 3.12 + /-
0.33 mm immediately post stenting (n.s.) and 3.18 + /- 0.36 mm at six months (n.s.). At 
5 years the mean reference segment diameter had decreased to 2.50 + /- 0.37 mm 
indicating a progression of atherosclerosis from 6 months to 5 years of .68 +/- .62 mm 
in the coronary segment containing the stent {p < .01', 
The percent diameter stenosis decreased significantly from 59.1 + /- 9.8% before to 24.2 
+/- 10.0% immediately post-stenting (p < .01), and was 32.8 +/- 9.9% at 6 months (p 
< 0.5) and 34.9 +/- 11.5% at 5 years (n.s.). Thus no significant deterioration (2.1 %) 
occurred in diameter stenosis after 6 months (Figure 4). While one patient had > 50% 
stenosis within the stent at long term follow-up, the absolute change in percent diameter 
stenosis from 6 months to 5 years in this patient was only 4.6%. 
Percent stent expansion at 5 years was 89.6 + /- 4% (82.5 - 95.4). Mean intimal thickness 
within the stent was 0.35 + /- 0.13 mm (0.18 - 0.55). Negative correlation (-.79) was 
found between the initial stent/artery size ratio and 5-years percent diameter stenosis, but 
no significant correlation with ultimate MLD, stent expansion or intimal thickness was 
found. 
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DISCUSSION 
Time course of restenosis and comparison with balloon angioplasty. This study clearly 
shows that the restenotic process after stent implantation is time-limited and does not 
appear to progress after the period of six months follow-up, Questions had always raised 
concerning the long-term tolerance of a stent and its interaction with the vessel wall 
constituents (19,20). Six-month angiographic follow-up was always considered in the 
literature as describing the ultimate outcome of any stent (6,21-26)), This was proven to 
be true with balloon angioplasty, so that restenosis rate is almost always based on 6-
months' angiogram (3,27). A part from one angiographic study addressing the one year 
outcome of Palmaz-Schatz stents (28), clinical but not angiographic issues of implanted 
stents after 6 months have been reported (29). Clinical follow-up, however, does not 
accurately reflect the restenosis process, as we know from balloon angioplasty, that silent 
restenosis may be present even in the presence of negative treadmill exercise testing and 
that silent restenosis may effect long-term prognosis (30-34). 
The intentional oversizing in our first series of coronary stents may have resulted in more 
severe acute injury to the vessel wall, a more profound denuding effect and more extensive 
disruption of the internal elastic lamina, all factors associated in experimental studies with 
a more severe hyperplastic reaction (35-37). The time course of this response, however, 
which is greater than that induced by a conventional balloon (26), seems to follow the 
same pattern as PTeA. Whereas most series addressing the late outcome after dilatation 
emphasize the long-term benelits provided by the balloon (38-40) and some show that 
percent stenosis may event tend to decrease after six months (27), few cases of late 
rest enos is have been reported (27,41). 
Experimental studies of different animal models show that, shortly after stent implantation, 
a thin layer of platelets and fibrin becomes adherent to the deendothelialized surface and 
neointima which covers the stent struts progressively thickens to reach its maximum after 
about 8 weeks (35,42). Medial atrophy and inflammatory infiltrates are the other prominent 
features described in short follow-up experimental studies (35). Although smooth muscle 
cell proliferation under denuded areas may continue at rates up to 50 times the control one 
for periods longer than 12 months (43), the neointima have been shown to undergo rapid 
growth during the first two months before progressively thinning over the ensuing 6 to 9 
months (42). 
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Determinants of intimal hyperplasia. The magnitude of the hyperplastic response to injury 
varies and depends on, among other factors, the stent to artery ratio, stent design and 
animal models (44). The constituent metal type does not appear to exert different effects 
on smooth muscle cell proliferation (37). Some animal studies suggested that a thinner 
metallic structure, like that of the Palmaz-Schatz stent, may induce only limited 
proliferative reaction (45,46). However, in human studies using the same device, maximal 
intimal hyperplasia averaged 400 - 450 u in thickness and reached more than 650 u event 
within those stents free of restenosis (47,48). Previously published data on the Wallstent" 
revealed similar degrees of intimal thickness (200 - 500u) (2,10). Factors associated with 
abnormally excessive progression of intimal hyperplasia include multiple stents per lesion, 
saphenous bypass graft site and excessive over-sizing of the stent (49). In our patients, 
one single stent was implanted at one site, in a native coronary segment. Intentional stent 
oversizing was correlated neither with ultimate intimal thickness nor with MLD changes 
between 6 months and 5 years, indicating that the factors able to modulate cellular 
response cease to operate after the first few months. 
Qualitative angiographic features of the Wallstent at 5 years. Radiological characteristics 
of the Wallstent were unchanged by time, side branches were still patent at ultimate 
control, as has been described with other stents (50) and no angiographic calcifications 
were seen around it, which suggests its long-term tolerance by the human body. 
Study limitations. By examining the luminal renarrowing process beyond the 6 month 
period in a limited number of patients who did not develop a thrombotic occlusion or 
undergo reintervention at the stent site, we have inherently studied a selected population 
of patients. It is conceivable that patients who develop a significant renarrowing within 6 
months of stent implantation, might be more predisposed to a prolonged restenosis 
process, however, in order to study such a population it would be necessary to withhold 
reintervention for five years - a stance difficult to justify in patients with recurrent 
symptoms. 
127 
CONCLUSION 
Contrary to previous concerns over the long-term effect of a metallic foreign body exerting 
prolonged barotrauma in the coronary arterial wall, 5 year angiographic follow-up after 
Walls tent implantation in patients without restenosis at 6 months suggests that 
progression of atherosclerosis within the stent may not be accelerated. Such angiographic 
evidence provides hope that the short-term benefits which have been recently 
demonstrated in randomized trials of metallic stents may be maintained in the long - term. 
Over the next few years, similar long-term angiographic studies should be undertaken with 
other stent designs to determine whether the implications of our study can be generalized 
Of only limited to the self-expanding stainless steel mesh stent. 
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Chapter IX 
Clinical and angiographic outcome following implantation of the new 
Less Shortening Wallstent in aorto-coronary vein grafts : 
Introduction of a second generation stent in the clinical arena. 
D Keane, B Buis, ~, Reitart, TH Plokker, J Ernst, E Mast, J Renkin, G Heyndrickx, 
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Clinical and Angiographic Outcome Following Implantation of the New 
Less Shortening Wallstent in Aortocoronary Vein Grafts: Introduction of a 
Second Generation Stent in the Clinical Arena 
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mphy) 11'1/5 IIchil'l'CIl ill all 29 patients. Durillg Ihl' ill-IImpital phase, llO major ai/I'N.IC j"(m/iac I'I'I'I/t occllrn'l[ 
(reillfen'l'lIIion, rl'-CAJJG, myocardial infarctioll, or dCalh) alld fire patifnts had hemorrhagic complicatiolls. 
Following hospital disclwrge, 0111' patient hlld II ,<'lIhacllll' stl'nt oCc/llsiol/ a,\'lociated wilh .'.ymptoms and c/t'Wl1t'd 
cardiac clIlymcs aI/I days, at,ml'l'r patiellf had ,\Ylllptolll,\' a/ld dl'\'llied mrdiac eIlZYIII.,s (CK 3UO VI/) at 22 
Ifays with a patent stelll, fil'e pl/timls required balloo!/ allgioplmty lI'ithill the 6 /I/OlIIh fol/oll"IIP period (four 
jiJr restl'lIosis al/d /JII/' for sll'lII OCc/U,\iOIl), 0111' jilltiellt ulldenl'ent re-CARe jilr a IIlltire artel)' stCI/(!,liI' dis/al 
to tlte {I/!i/.~Iom{)\'is of lite pall'lIl stell/eli I'ein graft, Tlte rc.I/IIIJ of this ill/roill/flory ,lllIdy suggesl thai the 111'\\' 
Lt'sS Shortening Wallslellt mlly he aU(lciatt'd lI'ith II redllCtioll ill the re111lirement for mulliple .\tclIl deployml'lII 
(//1(1 (j IOll'er raIl' afthrombotic occ/uyioll ill cOlllpuriHlII til its pioneering protolype. Ollfhl' basis of tlle,l(' "'.Hllts, 
a !IIlmber of larger IIIlIltiet'llta diniml trials lul\'t' been illilialcli til Jimher I'mllUl/e tlte 1/('\1' CO/'OI/ary II/al/sunl, 
(J Inlcrvcn Cardiol 199--1-:7:557-564) 
Introduction 
To date, revascularization procedures for diseased 
aortocoronary bypass vein grafts have been associated 
with poor clinical and angiographic outcome.1.2 Re-
peat coronary artery bypass graft surgery (CABO) is 
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technically more difl1cuIt, is associated with a higher 
morbidity and mortality, and has inferior long-term 
clinkal results when compared with a firsl bypass op-
eration,J-5 While the immediate results of balloon an-
gioplasty has been shown 10 be favorable in patients 
with discrete lesions in venous bypass grafts,6,7 results 
have been unfavorable in diffusely diseased, ulcerated, 
or thrombosed venous grafts. Furthermore, it appears 
that the rate of restenosis is high, varying from 40% 
to 7070 depending on the site of the lesions lind ovcrall 
extent of disease in thc graft.8- t4 
In our previous study of vein graft revilscularization 
with the 1'ledinvent Wallstent (Lausanne, Switzerland) 
in 26 patients and the polymer-coated Biogold 
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Wallstent in 43 patients between 19118 und 1990,2 we 
reported a procedural success mte of 100% (postproce-
dural diameter stenosis of < 50%). Despite this initial 
technical advantage and despite the implementation 
of a comprehensive antithrombotic regimen (pre- and 
intraprucedural intravenous heparin and dextmn, im-
mediate postprucedural intracoronary urokinase and 
post procedural intravenuus heparin [3-5 days], aceno-
coumarul13-6 months], aspirin [300 mg/daYl, and di-
pyridamole [300-450 mgldayl) the rate of in-hospital 
thrombotic occlusion was 10%. Of 53 patients whu 
had no major in-hospital complications and underwent 
follow-up angiography at 4.9 months, restenosis (as 
defined by > 50% diameter .~Ienosis) was present in 
25 (47%), three of whom had stellt occlusions. The 
primary reason for this excessively high mte of stent 
occlusion was felt to reflect the patient selection. The 
patients had not been recmited within the rigorous in-
clusion/exclusion criteria of a pruspective trial but 
rather had been .~e1cctcd outside the connnes of a pro-
tocol for compassionate use often in patients with un-
stable angina and end-stage disease who had been 
turned down from surgery. 
Furthermore, the IvIedinvent Wallstent was charac-
terized by a high metallic surface area, a high level of 
radial force and marked shortening upun deployment. 
The high degree of shortening resulted in uifi1culty in 
predicting the final location and extent orthe deployed 
stent and thus necessitated the deployment of multiple 
stenls in a large proportion of patients as exemplified 
in the ubove series where, 136 stents were implanted 
in fi9 patients (30 single stents in single lesions, 90 
multiple stents in single icsions, and 16 multiple stents 
in multiple lesions). The resultant augmented lleeUIllU-
lalh'e metallic surface area of multiple s1ents is felt to 
have also have cuntributed to the higher rate of sub-
acute thrombo.'>is in the above series.1 For this reason, 
the design of the Wallstent was modit1ed to redu,:e the 
degree of shortening associated with stellt expansion. 
TIle braiding angle of the stainless .~teel mesh was re-
duced from approximately 140'" to approximately 1040 
with a reduction in shortening to approximately 25170 
of the stent's length; the degree uf shortening and final 
braiding angle of this new Less Shortening Wallstent 
varies according to the degree of expansion of the de-
ployed stent and the stent:vessel size ratio. An inherent 
advantage of this mudHication is a reduction in the 
metallic surface area of the expanded stent albeit at a 
cost of a concomitant reduction in radiil! force. IS ,17 
In view of the previous history of a prohihitive risk 
(10%) of ,~tenllhrolllbosis with its predecessor, it was 
felt that a feasibility and safety trial of the new Less 
Shortening Wallstent should be undertaken in a con-
trolled context including monitoring by a safety com-
mittee that was independent from both the investiga-
tors as well as industry and had the mandate to tenni-
nate the trial at any stage of recmitment. 
Methods 
Study Design, The study was a noncomparative ob-
servational series in 29 patients undergoing implanta-
tion of the less shortening coronary \Vallstent between 
November 1991 and i\'Iarch 1993 in six investigating 
centers. Patients with recurrent angina who had under-
gone saphenous vein coronary ,mery bypass graft sur-
gery (SV-CABG) at least 60 days prior to the current 
admission were considered for inclusion. The key fea-
tures of the study population were as f'ol1ows: Patients 
had to be suitable candidates for a .~econd surgical 
bypass procedure. The patient's history, signs, and in-
vestigations had to indicate that the current clinical 
symptoms were attributable to myocardial ischemia, 
fur which the graft stenosis was principally suspected 
as being the culprillesioll. Patients had to give signed 
informed consent that emphasized the critical impor-
tance of fi-month angiographic follow-up. The inclu-
sion ,II1U exdLlsion criteria ,Ire listed in Table 1. 
Technical Considerations. The new less shorten-
ing coronary Wallstent (Schneider-USA, Minneapolis, 
MN, USA) has an uncoated stainless steel tubular 
Indu'iion Criteria 
(I) a nul\' {fIIll-ofO in th~ 
target ve"c1 of at lI'3.q 
'l'ltllI grude 2 
{2) a ~teflll.\b length lOf 
< 20 mm, with the 
unc(ln'itwined dimel1'iiol1 
uf tlie ~tent pnll'iUing a 
mo.rgin of at lealt 4 mm 
nil either ~ide of the 
leliun 
{3) a w"c1 ~ize nf 3.5-5.5 
mm in dbmeter 
Ewiu'iion Criteria 
{I) a le,ion II hkh 
cncnmp3."'cd the dhtJI 
~na5tomo,i~ (eitl1Cr end-
t<,·end ur ~ide-to-.\it1e 
{2) a target \'C"d whkh 
doe, not regionally 
supply a majur vascutar 
bed 
{3J a target ve"et with 
significant dbtal disease 
(4) more than nne pre\'iou.\ 
angiopla'ily at the 
pwpo,ed ~tent 
implantation site 
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mesh design. Eighteen to twenty 0.07-0.10 IlllB thick 
monofilaments are used to fabri<.:ate each coronary 
Wallstent resulting in a metallic surface area in the 
expanded state of approximately 20%18 and a metallic 
cross-sectional area 0.062mm2•19 The intersections of 
the filaments of the mesh structure are not fixed or 
soldered together, thereby providing greater longitudi~ 
nal flexibility. The outer diameter of the coronary 
stent-Illounted delivery catheter of the Wallstent is 
1.57 mm, which compares favorably tu uther stents. 17 
The low profile of the Wallstent permits its introduc-
tion through an 8Fr guiding catheter (0.077 inch inter-
nal diameter). 
The Wallstent is self-expanding and, therefore, does 
nut require a balloon for deployment. This may be 
particularly advantageous in friable, diffusely diseased 
bypass grafts at high risk of embolization with balloon 
angioplasty. Instead, the Wallstent is mounted on 11 
low profile catheter and is Illaintained in a collapsed 
state until it is progressively released by the retraction 
of its rolling melllbrane. 17 111e doubled-over restrain-
ing membrane and delivery mechanism prevent acci~ 
dental release of the sten!. 
An additional feature of the Wallstent is its wide 
range of available sizes for coronary vessels of up to 
6.0 mm diameter in the expanded state with lengths 
of up to 40 mm. Wallstent.~ of > 6.0 mm diameter arc 
available but they are usually deployed in peripheral 
vessels and the biliary tree ami have a reduced longitu-
dinal flexibility. The large range of lengths available 
for the Wallstent may be particularly advantageous: 
first for the treatment of long lesions in diffusely dis-
eased vein grafts; second to avoid the t1eployment of 
more than one stent-a factor known to increase the 
risk of early thrombosis2u and subsequent late resteno-
sis (particularly at the site of stellt overlap where the 
metallic burden on the vessel wall is higheslll ); and 
third it permits the selection of a Wallstent of greater 
length than the lesion thus retlucing the risk of failing 
to cover the entire lesional length. 
Definitions. 
-Allgiographh' slI('ce.l'S was defined as it postproce~ 
dural (Wallstent implantation) residual diameter 
stenosis of < 50% as determined by quantitative 
coronary angiography at the core laboratory llsing 
the average of multiple matched views. 
-Procedllral SIlCceSS was defined as an angiograp!Jic 
success in the absence of any of the following in-
hospital major adverse cardiac events; re-PTCA, rc-
CABO, myocardial infarction, or death. 
-Restello.l'is was defined as a diameter stcnosis of > 
5090 in the treated lesion as detennined by quantita-
tive coronary angiography at the core laboratory 
lIsing the average of multiple matched views. 
-Study elld poillts: The primary clinical end point of 
the trial was the occurrence of any of the following 
four major adverse cardiac events; re-PTCA, re-
CABO, myocardial infarction (cardiac cnzymes 
more than twice the upper limit of normal) or death. 
The primary angiographic end point was the rcste-
nosis rate at angiographic follow-up. The secondary 
clinical end point was anginal symptoms at 6 month 
follow-up. 
Anticoagulant Therapy. Investigators were cn-
couraged to commence the patient on anticoagulant 
therapy I or 2 days before the planned procedure. 
However, when the investigator proceeded directly to 
intervention after diagnostic angiography, anticoagu-
lant therapy was started on the day of the procedure 
itself. The pharmacological protocol was as follows: 
~Aspirin (not enteric coated) 325-500 mg daily be-
fore the procedure and 80-100 I11g daily perma-
nently after the procedure. 
-Dipyridamole beginning I or 2 days prior to stent 
implantation and continuing for 6 months there-
after. 
-Warfarin 5 mg daily beginning I or 2 days prior to 
implantation lind adjusted to maintain tin interna-
tional normalized ratio (INR) of 2.2-4.1 (at an in-
temational sensitivity index of 2.4). 
-Nifedipine 30-60 mg (slow release) once daily be-
ginning the day of the procedure. 
-Heparin intravenously. A bolus of 10,000-20,000 
IU was given at the beginning of the intervention 
and subsequently monitored every 30 minutes to 
maintain the activated clotting time (ACT) greater 
than 300 seconds until the procedure was com-
plctcd. The sheath was removcd when the ACT fell 
below 150 seconds. One hour after sheath removal, 
heparin was rc~larted to maintain the parliallhrom-
boplastin time (PIT) at 1.5-2.0 times normal. The 
heparin was continucd for 5 days or until the INR 
was greater than 2.2. 
-Dextran intravenously. Following a preceding test 
dose of dextran I (Promit) 20 IllL over 2-15 min-
utes, low molecular weight dextran (dextran 40) 
was administercd for 2 hours before the procedure 
at a rate of 100 mLlhr. At the start of the procedure, 
the dose of dextran was reduced to 75 mLlhr. Dex-
Vol. 7, No.6. 19\1-1 Jlllllllaiof Intawntinoa] CurJiotngy 
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tran was discontinued 3 hours after sheath removal 
or after a maximum of I L had been administered. 
Quantitative Coronary Angiography. Angio-
grams were obtained immediately pre- and postproce-
dure (WaUstent implantation) and at 6-month follow-
up. At least three projections (of> 300 apart) of the 
coronary segment scheduled for stent implantation 
were recorded on cinefilm before intervention. The 
same projections were repeated after the intervention 
and at follow-up angiography. The angiograms were 
recorded in such a way that they were suitable for 
quantitative coronary angiography (QCA).22.n 
The quantitative analysis of the aortocoronary vein 
graft stenoses pre- and postprocedure and at 6-month 
follow-up was performed by an off-line semiauto-
mated edge-detection system (Cardiovascular Angiog-
raphy Analysis System, CAAS-Pie Medical, Maas~ 
tricbt, TIle Netherlands) at a core angiographic labora-
tory (Cardialysis, Rotterdam, The Netherlands) after 
digitization of the cineangiograms.24,25 The average of 
multiple matched views with orthogonal projections is 
reported whenever possible. Correction for pincushion 
distortion was enabled by the prerecording on cinefilm 
of a centimeter grid in all participating catheterization 
laboratories. All measurements were calibrated by the 
use of the angiographic guiding catheter in the con-
trast-empty state. The accuracy and precision of this 
QCA system has been found to be - 0.09 mill and ± 
0.23 mm during measurements of in vivo phantom 
steno.~es using catheter calibration26 and the reproduc-
ibility of measurements of serial clinical angiograms 
with this QCA system27.28 at this core angiographic 
laboratory27 has been found to be ± 0.20 mm.27,28 
Statistics. Descriptive statistical methods have been 
used to report the results. As one patient had two le-
sions treated within the one graft, the results of quanti-
tative coronary angiography of this patient are taken 
as the mean value for the two lesions. 
Results 
Fourofthc 29 patients broke the inclusion/exclusion 
criteria for the following four reasons: 
(1) Two .~eparate segments in the same graft were 
treated by the implantation of Wallstents (one 
Wallstent at each lesion)-one patient. 
(2) Another segment in a native coronary artery un-
denvent concomitant intervention-one patient. 
(3) Previous implantation of stents in coronary ar-
teries-one patient. 
(4) One patient was 78 years old. 
The mean age of the patients was 62.5 years (27 
male, 2 femalc). Four patients had unstablc angina. 
The mean age of the grafts was 9.5 years and 19 of 
the grafts had multipic distal anastomoses. Four of the 
lesions had calcification and four of the stenoses were 
recurrent following a previous intervention at the same 
site. TIle clinical features of the patients and vein graft 
characteristics are given in Table 2. 
Stellt Deployment. Stent deployment was success-
ful in 35 of 36 attempts in the 29 patients. More than 
one stent was used in seven patients; in five patients 
the stent was placed too distally and only partially 
covered the lesion and subsequent implantation of an 
overlapping second sten! covered the lesioQ entirely 
in all four patients. In one patient, two stcnts were 
implanted in two separate lesions within the same vein 
graft, and in another patient the sten! delivery system 
was inserted and removed without implantation due 
to inability to release the stent. The mean nominal stent 
diameter and nominal implanted stent length were 4.50 
± 0.61 mm and 26.86 ± 4.03 mm, respectively. 
Table 2. Clinical Charncteri,tics of Study Population 
Total Number of Patient, 
MalefFemale 
Ago 
Smokers 
Hypertension 
Hypercholesterolemia 
Diabetes 
Angina stable/unstable 
Prior myocardial infarction 
Prior PTCA (to same or other segment) 
Prior PTCA at target site 
Age of bypass grafts 
Distribution of grafts: 
left anterior descending 
Left circumfle.o; 
Right coronary artery 
Multiple distal anastomoses ("jump" 
grafts) 
Number of lesions stented 
Portion of graft stented 
Ostia! 
Body 
Distal 
Calcified lesions 
BaUoon dilatation within stent 
29 
27/2 
625 (40-78 years) 
10 
7 
15 
25/4 
18 
11 
4 
9.5 (2-18 years) 
10 
9 
10 
19 
30 
14 
12 
4 
4 
25 
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Procedural Success. Procedural success ;:IS defined 
by < 50% residual diameter stenosis in the absence 
of any in-hospital major adverse cardiac event (re-
PTCA, re-CABO, myocardial infarction, or death) was 
achieved in all 29 patients. 
In-Hospital Complications and Events. The fol-
lowing in-hospital complications occurred: femoral 
hemorrhage-three patien~s (of these three patients, 
two required transfusions and one required surgical 
removal of the femoral sheath); hematuria-two pa-
tients (one of these patients had nephrolithiasis and 
the other had benign prostatic hyperplasia); acute oc-
clusion of the native right coronary artery after con-
comitant balloon angioplasty at this arterial segment 
(protocol violation), which was successfully managed 
during the primary interventional procedure by bailout 
stent (palmaz-Schatz) placement. 
Complicalions and Events Following Discharge. 
Eight major adverse cardiac events occurred in seven 
patients within 6 months of stent implantation. These 
consisted of repeat balloon angioplasty to the origi-
nally stented site in five patients; Q wave myocardial 
infarction in one patient (the peak creatine phosphoki-
% OS 
100 
60 
50%f---~~ 
40 
20 
o 
Pre 
nase (CK) was 885 UlL and was associated with stent 
occlusion 11 days postslenting, which was managed 
by balloon angioplasty); non-Q wave myocardial in-
farction in one patient (the peak CK was 300 UfL at 
22 days poststenting and was associated with a patent 
stent-minimalluminal diameter of 2.66 mm); and 
repeat coronary artery bypass graft surgery due to a 
stenosis in the native coronary artery distal to the graft 
anastomosis in the presence of a patent stented site in 
the vein graft in one patient. In addition to the a'bove 
events within the 6~month study period, an additional 
patient presented with increased symptoms at 8 
months, which wa." managed by balloon angioplasty 
to the stented segment. While no patient had residual 
angina at the time of hospital discharge, seven patients 
had angina at 1- and 6-month follow-up visits. 
Quantitative Coronary Angiography. Coronary 
angiograms suitable for quantitative analysis were ob-
tained in all 29 patients pre- and poststent implanta-
tion. Follow-up angiography was obtained at 6 months 
or sooner if clinically necessitated in 25 patients. Four 
patients refused follow-up angiography. 
Off-line quantitative analysis of the 29 patients gave 
Post F-up 
Figure 1. Change, in percent diameter stenosis ('>fDS) fwm pre,tenting through post,tenting to follow· 
up for the 25 patients with angiographic follow-up. Procedural success « 50% diameter steno~i<; 
pOSt'itcnting) was achieved in all patients. Restcnnsis (> 50% diameter stenosis at fnllow-up) occurred 
in eight of the 25 patient, yielding a re.ltenosis rate RR of 32%, In four patients a significant improycment 
in minimal luminal diameter wa, obscrwd at follow-up (see text), 
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on overage vessel size of the saphenous vein grafts 
prcstenting of 3.66 ± 0.89 mm. Tllis indicated a ratio 
of the nominal stent diameter to vessel diameter of 
1.27 and a nominal stent diameter to vessel diameter 
difference of 0.84 ± 0.64 mm. Tn the 29 potients, 
minimal luminal diameter (MLD) prestenting was 1.32 
± 0.68 mm, which increosed to 2.98 ± 0.71 mm 
poststenting. Angiographic success os defined by < 
50% residual diameter stenosis postprocedure by 
quantitative coronary angiography at the core lobora-
tory was achieYCd in all 29 patients. 
Restenosis as defined by > 50% diameter stenosis 
at follow-up by quontitative coronary angiography ot 
the core laboratory occurred in 8 of the 25 patients with 
angiographic follow-up providing a restenosis rate of 
32%. Of the eight patients, three had total occlusions 
(one total occlusion was associated with a myocardial 
infarction at 11 days and the other two total occlusions 
were observed at 6-month follow-up). The meon loss 
in luminal diameter over follow-up of the 25 patients 
was 0.64 ± 1.11 mm resulting in a MLD at folIow-
up of2.31 ± 1.13 mm. The net gain index for the 25 
patients was 0.25 ± 0.35, whereby net gain index = 
(gain in MLD at intervention-loss in MLD at follow-
up)/vessel size. The individual chonges in percent di-
ameter stenosis from prestenting through postslenling 
to follow-up for the 25 patients is displayed in Figure 
1 where it can be seen that while eight of the patients 
had greater thon 50% diameter stenosis at follow-up, 
further improvement in stent diameter stenosis oc-
curred in other patients over the follow-up period. At 
follow-up, the absolute ~'fLD had increased from the 
poststenting value in seven patients. In four of these 
patients the obsolute increase in MLD was :2: 2 stan-
dard deviations of the clinical reproducibility of the 
QCA system in serioi angiographic studies (Le., :2: 
DAD mm). 
Discussion 
In this ,~eries, deployment of the new Less Shorten-
ing Wall.~tent wos successful in 35 of 36 attempts. 
Historically the procedural success for deployment of 
the Wallstent has always been high, retlecting its tech-
nicol performance.29- 31 The unique trackability of-
fered by the Wallstent results from three features:(I) 
low profile (1.57111111); (2) longitudinal flexibility; and 
3) the smooth rolling membrane (covering sheath), 
which protects the struts until the stent is across the 
lesion to be ,~tented. 17 
Because the Wallstent is not 0 balloon expondable 
stent, precise positioning can be technically exacting 
as evidenced by the use of multiple slents. This is 
particularly critical for ostial lesions. Deployment of 
a second Less Shortening WaUstent was required (to 
cover the proximal portion of the lesion) in five of the 
30 lesions stented (16.6%), which compares favorably 
to the previously described vein graft experience with 
the original Wallstent design (136 stents deployed in 
74 lesions).2 This problem was primarily encountered 
by those operators on the learning curve of Wallstent 
deployment ond wos not seen with the more experi-
enced opemtors. 
The 304% (by patient) incidence of subacute stent 
occlusion (one subacute occlusion at II days post 
stenting) in our current ,~tudy ogoin compares well with 
the previously reported incidence of early (acute ond 
subacute) occlusions \vith the original Wallstent de-
sign (8% by patient in vein grafts and 19% by patient 
in native arteries),2.30,31 Although, the reasons for ,~ub­
acute occlusions poststenting are multifactorial, it is 
likely thot the lower requirement for multiple stent 
deployment in addition to a slight reduction in metallic 
surface area per stent associated with the less shorten-
ing design of the new Wollstent may have contributed 
to the low incidence of subacute stent occlusion. 
The incidence of bleeding events in our series was 
high. This may relate to the aggressive anticoagulation 
policy adopted in our study protocol, which was ad-
vised by the manufacturer of the device (Schneider, 
Bulach, Switzerland) and by the independent safety 
committee of the trial. This was felt to be necessary in 
view of the previously high rate of subacute occlusion 
observed with the previous Wallstent design as de-
scribed above. 
The mean residual percent diameter stenosis 
poststeliling ill our 29 patients was 20.6 ± 9,8%, with 
a percent diameter stenosis of > 30% in five of the 
29 patients. This is lower than our current stent prac-
tice and recently we have defined angiographic suc-
cess as < 20% diameter stenosis for upcoming inter-
ventional trials.23.32,33 The increasing use of intracofO-
nary ultrasound to guide stellt deployment and ensure 
maximal ond uniform stent expansion and apposition 
to the vessel wall should further reduce the incidence 
of subacute thrombosis and improve long-term angio-
graphic outcome. 
Because of the low profile of the Walblent, o large 
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amount of predilitation is not required. 11lis reduced 
the risk of disruption of friable degenerating tissue 
within the grafts. This was reflected by the low inci-
dence of patients in whom an acute elevation of car-
diac enzymes. occurred poststent implantation; no pa-
tient had a significant elevation of CK during the in-
hospital phase while two patients (8.3%) had an eleva-
tion at 11 and 22 days post stenting as described ear-
lier. This incidence compares favorably with the CA-
VEAT II experience of CK elevation following direc-
tional coronary atherectomy in venous bypass grafts.J-l 
In addition to the relatively low rate of restenosis 
(32%) ill this series of vein graft lesions,8-14 it is of 
interest to note the occurrence of a negative loss in 
luminal diameter (Le., further expansion of the lumen) 
over a 6-month follow-up in seven patients. In four of 
these patients the negative loss was 2': two standard 
deviations of the clinical reproducibility of QCA mea-
surements at the core laboratory (Le., 2': DAD 010127 ,28) 
and thus is highly likely to represent a significant ex-
pansion in luminal diameter in these patients. This 
most likely reflects the self-expanding nature of the 
Wallstent, which may continue to expand after deploy-
ment.J5 
The results of this introductory study suggest that 
the new Less Shortening Wallstent may be associated 
with an improvement in requirement for multiple stent 
deploymcnt ami a lower rate of thrombotic occlusion 
in comparison to its pioneering prototype. On the basis 
of these rewits, a numbcr of larger multicenter clinical 
trials have been initiated to further evaluate the new 
coronary Walistent. 
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Chapter X 
Clinical and angiographic outcome following implantation of the 
Palmaz-Schatz stent in small coronary arteries. 
Implications for vessel selection and stent sizing. 
David Keane, Aida J Azar, Carlos Macaya; Wolfgang Rutsch, Ulrich Sigwart, Antonio 
Colombo, Jean Marco, Sylvia Klugmann, Peter Crean, Marie-Angele Morel, 
and Patrick W Serruys, on behalf of the BENESTENT Investigators'. 
(in review) 
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ABSTRACT 
Background: While recently completed trials indicate that stent implantation may improve 
both clinical and angiographic outcome following coronary intervention, it is unknown if 
such advantages are conveyed in coronary vessels of < 3.0mm diameter. 
Methods: To determine whether small vessel size subtends an increased risk of adverse 
cardiac events during and following elective stent placement, we performed both a 
categorical and continuous analysis of vessel size using an intention-to-treat approach in 
the patients who were randomized to receive a Palmaz-Schatz stent (n = 259) or to 
undergo balloon angioplasty alone In ~ 257 ) in the BENESTENT trial. 
Results: Using a categorical approach we divided the stent population into two groups 
according to vessel size >3.00mm In ~ 118) and <3.00mm (n ~ 132).ln small vessels 
the stent to vessel diameter ratio was significantly higher (1.23) than in large vessels 
(1.07) with subsequent significantly greater relative gain (Rei Gain = procedural 
improvement in minimal luminal normalized for vessel size), however, the loss index (late 
loss at follow-up I acute procedural gain) was signfficantly greater in small vessels 
(p < .001). Small vessel size conveyed a significantly higher (p < .05) risk of adverse cardiac 
events including procedural failure (procedural failure = procedural cross-over, > 50% 
residual diameter stenosis, or occurrence of in-hospital event), subacute thrombosis (SAT)' 
and myocardial infarction (M!), need for revascularization (rePTCA & CABG), and 
occurrence of any cardiac event during 6 month follow-up. 
For those patients randomized to balloon angioplasty, a similar pattern between vessel size 
and need for revascularization was seen, however, small vessel size was not associated 
with a higher rate of bailout stent, post-procedural abrupt vessel closure or subsequent MI 
during follow-up in the balloon angioplasty population. 
Logistic regression indioated that decreasing vessel size (as a continuous variable) was 
associated with an increasing risk of cardiac events for both the stent and balloon 
angioplasty populations. 
Conclusion: While recent studies have indicated a favourable clinical outcome following 
elective coronary stent placement, the relative merits of coronary stenting may be reduced 
in vessels of < 3.00mm diameter. 
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INTRODUCTION 
Two recently completed randomized trials, BENESTENT (1 J and STRESS (2]. comparing 
elective coronary stent implantation with balloon angioplasty, have indicated that stent 
implantation may improve both clinical and angiographic outcome following coronary 
intervention. Analyses of previous non-randomized data of coronary stenting have provided 
conflicting evidence on the outcome of stenting in small coronary vessels. The results of 
previous analyses have· been obscured by a number of confounding variables in their study 
populations including diverse indications for coronary stent implantation (bailout, 
suboptimal result, and elective), diverse lesion characteristics (restenotic lesions and 
primary lesions in native arteries and vein grafts), and diverse clinical status (unstable and 
stable angina). 
The per protocol inclusion criteria of the BENESTENT trial required that the size of the 
target coronary vessel be more than 3.0mm as determined by the investigator and the 
STRESS trial required a vessel size of greater than or equal to 3 .Omm. Despite such per 
protocol inclusion cri~eria, quantitative coronary angiographic analysis (OCA) at the trial 
core laboratories indic,lted a mean vessel size of 3.00 and 3.01 mm in the BENESTENT and 
STRESS trials respect I rely. It is unknown whether the relative advantages conferred by 
coronary stent implantation are limited to large vessels and specifically if the rate of 
subacute stent thrombosis and the degree of lumen renarrowing is different in small 
vessels following stent implantation. 
To determine whether small vessel size conveys an increased risk of adverse cardiac 
events during and following elective stent placement and following balloon angiopiasty, we 
performed both a categorical and continuous analysis of vessel size using an intention-to-
treat approach in the patients who were randomized to receive a Palmaz-Schatz stent or 
to undergo balloon angioplasty alone in the BENESTENT trial. 
METHODS 
Details of the methodology and primary outcome of the BENESTENT trial have been 
previously published [1}. For inclusion patients wete required to have stable angina due to 
a single de novo lesion in a native coronary artery. The target lesion needed to be < 15mm 
long and to be located in a vessel of more than 3.0mm in diameter (as determined by the 
investigator) which supplied a. normal functioning myocardium. Patients with an ostial 
lesion, a lesion at a bifurcation, or a lesion in a previously grafted vessel were excluded 
from the study, as were patients in whom an intracoronary thrombus was suspected. 
Balloon angioplasty was performed according to the routine practice of the investigators. 
Deployment of the Palmaz-Schatz stent was performed with either the premounted 
sheathed Stent Delivery System or with a bare stent which was crimped by the operator 
on a standard angioplasty balloon. Following stent implantation, additional intrastent 
balloon inflations were often performed. Post intervention all patients who received a stent 
were managed with intravenous heparin, warfarin, and acetylsalicyliC acid. 
QUantitative coronary angiography. Ouantitative coronary angiography at the core 
angiographic laboratory (Cardialysis, Rotterdam, The Netherlands) was performed on the 
Cardiovascular Angiography Analysis System (CAAS - PIE Medical, Maastricht, The 
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Table 1 
Clinical Characteristics of Patients with Small and Large Coronary Vessels 
Stent & Balloon Populations Combined 
Female Gender 
Diabetes Mellitus 
Smoker 
Previous Myocardial Infarction 
Left Anterior Descending Artery 
Vessel Size 
>3.00mm 
n = 236 
15% 
6% 
25% 
22% 
53% 
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Vessel Size 
<3.00mm 
n = 266 
23% 
7% 
23% 
17% 
72% 
p-value 
Chi Sq. 
.02 
n.s. 
n.s. 
n.s. 
<.001 
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Netherlands} [3-13). Calibration of the quantitative analyses was achieved by the use of 
the guiding catheter as a scaling device [14-20]. Vessel size was measured at each study 
phase after the administration of intracoronary nitrates. Standardization of angiographic 
procedures was adhered to during acquisition by the investigator and during analysis at the 
core laboratory in order to reduce the variability of serial quantitative angiographic 
measurements [21,211. Rather than using an operator selected reference point, CAAS 
determines the size at the target coronary segment using a computer derived interpolated 
reference diameter [4, 1 0,21 J. The interpolated reference diameter is derived from the edge-
detected diameter function of the non-stenotic proximal and distal subsegments. The 
reference vessel diameter values are estimated by fitting a straight line to the diameter 
function proximal and distal to the obstruction followed by a shift such that 80% of the 
diameter values are below the adjusted straight line. This line then represents the 
reconstructed reference diameter function and gives an estimate of the arterial size at each 
point along the analysed coronary segment. The interpolated reference vessel diameter is 
taken as the value of the reconstructed diameter function at the position of the minimal 
luminal diameter. The advantages of this approach is that it is essentially user independent 
and thus highly rejlroducible and that every measurement is based on multiple 
measurements (every scan line) proximal and distal to the lesion. The limitation of this 
technique is in ostial lesions where a proximal segment is unavailable, however, in 
BENESTENT ostial lesions were excluded per protocol. All measurements of both vessel 
size as well as minimal luminal diameter were the mean values of multiple matched 
projections. 
Angiographic Indices. In order to make valid comparisons between coronary vessels of 
different size the following angiographic indices were examined: 
Vessel Size = Interpolated reference diameter pre intervention 
MLD = minimal luminal diameter of the angiographic segment analysed 
Acute Gain = MLD post intervention - MLD pre intervention 
Late Loss = MLD at 6 month follow-up - MLD post intervention 
Relative Gain = Acute gain normalised for (divided by) vessel size 
Relative Loss = Late Loss normalised for (divided by) vessel size 
Net Gain Index = Relative Gain - Relative Loss 
Loss Index = Late loss normalised for (divided by) Acute Gain 
Clinical events. Procedural failure was defined as procedural cross-over, > 50% residual 
diameter stenosis, or occurrence of in-hospital event. Clinical events analyzed for both the 
in-hospital phase and subsequent follow-up to 7 and 12 months included: 1) cardiac death 
(one patient in the balloon group committed suicide and this was therefore not included 
under cardiac death), 2) myocardial infarction, 3) coronary artery bypass surgery, 41 
reinter venti on, 5) abrupt vessel closure. Abrupt vessel closure following balloon angioplasty 
typically occurs during the interventional procedure or within 6 hours of the procedure l23-
321, while following coronary stent placement abrupt vessel closure due to stent 
thrombosis is delayed up to 14 days with a median of 4-5 days and therefore may not 
occur until the patient has been discharged from hospital [33-41). Following stent 
placement in the BENESTENT trial subacute sten't thrombosis (within 14 days of stent 
implantation! was diagnosed in 10 patients. In eight patients, occlusion of the vessel was 
demonstrated angiographically, while in two cases the diagnosis was clinical. Of these 
latter two patients, one sustained an acute myocardial infarction which was successfully 
treated by systemic thrombolytic therapy with electrocardiographic evidence of 
reperfusion. In the second case the patient presented to his local hospital with chest pain 
and ST elevation on ECG and died before angiography could be performed. 
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Statistical analysis. From the total intention-to-treat population of BENESTENT [1]. 502 
patients (252 assigned to balloon angioplasty and 250 assigned stent implantation) in 
whom vessel size was quantified were included in our 'analysis. Using a categorical 
approach We divided the stent and balloon angioplasty populations into two groups each 
according to vessel size >3.00mm and <3.00mm. Odds ratio with 95% confidence 
intervals were calculated for the development of a clinical event for both small vessels 
«3.00mm) and large vessels (>3.00mm). The influence of vessel size on clinical and 
angiographic outcome was examined using the technique of multivariate logistic 
regression, allowing for the influence of minimal lumen diameter pre (MLD-pre), minimal 
luminal diameter (post), as well as the clinical variables diabetes mellitus, gender, and 
previous myocardial infarction. A p value of < .05 was taken as an indicator of statistical 
significance. 
RESULTS 
In the stent group 118 patients had a vessel size of > 3.00mm and 132 patients a vessel 
size of < 3.00mm. In the balloon angioplasty group 118 patients had a vessel size of 
> 3.00mm while 134 patients had a vessel size of < 3.00mm. The clinical characteristics 
of the patients with small « 3.0mm) and large (> 3.0mm) coronary vessels are compared 
in table 1. Patients with small vessels were more likely to be female (23% versus 15% for 
patients with small and large coronary vessels respectively, p < .05). Small coronary 
segments were more commonly located in the left anterior descending artery (72% versus 
53% for small and large vessels respectively, p<.001). 
The angiographic outcome and clinical outcome of patients with small or large coronary 
vessel size in the stent and balloon angioplasty groups are compared in tables 2 and 3 
respectively. The individual vessel size of the patients who developed abrupt vessel closure 
in the both the stent and balloon angioplasty populations are displayed in figure 1. 
Stent population. In small vessels the stent (nominal) to vessel diameter ratio was higher 
(p < .01) with consequent greater relative gain compared to large vessels (p < .05). At 6 
month angiographic follow-up, however, the relative loss and loss index were greater in 
small vessels (p<.001 and p<.01 respectively). 
In patients randomized to stent'implantation, small vessel size conveyed a significantly 
higher (p < .05) risk of advers'e cardiac events including procedural failure, subacute 
thrombosis (SAT), myocardial infarction (MI)' need forrevascularization (rePTCA & CABG), 
and occurrence of any cardiac event during follow-up to 7 or 12 months. 
In the stent population, logistic regression indicated that decreasing vessel size (as a 
continuous variable) was associated with an increasing risk of cardiac events for the stent 
population. The relationship of vessel size and probability of a clinical event post stent 
implantation is displayed in the logistic regression curve in figure 2. 
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Table 2 
Angiographic Outcome for Small and Large Vessels 
Stent 
Stent : Vessel Ratio 
Acute Gain 
Relative Gain 
Late Loss 
Relative Loss 
Loss Index 
Net Gain 
Balloon 
Balloon: Vessel Ratio 
Acute Gain 
Relative Gain 
Late Loss 
Relative Loss 
Loss Index 
Net Gain 
Vessel Size 
>3.00mm 
n = 118 
1.07 ± .11 
1.49 ±.44mm 
0.44 ±.13 
0.59 ±.52mm 
0.17 ±.15 
0.40 ±.41 
1.32 ±.44mm 
Vessel Size 
>3.00mm 
n = 118 
1.02 ±.11 
1.01 ± .39mm 
0.30 ± .12 
0.24 ± .49mm 
0.07 ±.14 
0.31 ±.70 
0.93 ±.43mm 
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Vessel Size 
<3.00mm 
n = 132 
1.23 ±.17 
1.28 ±.38mm 
0.49 ±.15 
0.71 ±.60mm 
0.27 ±.24 
0.59 ± .57 
1.01 ±.41mm 
Vessel Size 
<3.00mm 
n = 134 
1.18 ±.12 
0.90 ±.31mm 
0.34 ± .11 
0.37 ± .45mm 
0.14 ±.17 
0.42 ±.76 
0.77 ±.32mm 
p-value 
<.01 
<.001 
.02 
.10 
<.001 
<.01 
<.001 
p-value 
<.01 
.02 
.01 
.04 
.03 
.25 
.001 
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Table 3 
Clinical Outcome for Small and Large Vessels 
Stent 
Subacute Stent Thrombosis 
Cardiac Death 
Myocardial Infarction 
CABG 
Re-intervention 
CABG or Re-intervention 
CerebroVascular Accident 
Any Clinical Event - 7 Months 
Balloon 
Bailout Stent during procedure 
Abrupt Vessel Closure post procedure 
Cardiac Death 
Myocardial Infarction 
CABG 
Re-intervention 
CABG or Re-intervention 
CerebroVascular Accident 
Any Clinical Event - 7 Months 
Vessel Size 
>3.00mm 
n ~ 118 
0 
4 
11 
14 
0 
15 
Vessel Size 
>3.00mm 
n ~ 118 
4 
3 
0 
6 
4 
17 
21 
26 
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Vessel Size 
<3.00mm 
n ~ 132 
9 
2 
9 
11 
23 
31 
0 
36 
Vessel Size 
<3.00mm 
n ~ 134 
9 
4 
0 
5 
6 
41 
46 
54 
p-value 
Chi Sq. 
.02 
.18 
.02 
.10 
.06 
.02 
n.8. 
.004 
p-value 
Chi Sq. 
n.8. 
n.s. 
n.s, 
n,s. 
n,s . 
. 002 
.003 
n,s, 
.002 
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Balloon angioplasty population. The balloon (nominal) to vessel ratio was significantly 
greater in small vessels (p < .01) with consequent greater relative gain in small vessels. As 
in the stent group, small vessel size was associated with greater subsequent relative loss 
and a higher loss index at 6 month angiographic follow-up. 
For those patients randomized to balloon angioplasty, small vessel size was associated 
with a greater requirement for subsequent revascularization. Unlike the stent group, small 
vessel size in the balloon angioplasty group was not associated with a higher rate of 
procedural crossover (bailout stent), post procedural abrupt vessel closure or subsequent 
myocardial infarction during follow-up to 7 or 1 2 months. 
As for the stent population, logistic regression indicated that decreasing vessel size (as a 
continuous variable) was associated with an increasing risk of cardiac events for the 
balloon angioplasty population. 
DISCUSSION 
The key findings of this study are ; 1) during both stent implantation as well as balloon 
angiopJasty, smaller coronary vessels are treated with relatively larger devices (higher 
device: vessel ratio) with consequent greater acute relative gain in lumen diameter; 2) 
smaller vessels subsequently sustain greater relative loss and a higher loss index (luminal 
renarrowing over 6 months normalized for vessel size and gain respectively); 3) In both the 
stent and balloon groups this greater relative loss in lumen diameter is associated with a 
greater requirement for revascularization procedures during follow-up; 4) While in those 
patients undergoing stent implantation smaller vessel size is associated with a greater risk 
of procedural failure, subacute stent thrombosis, and myocardial infarction during follow-
up, in patients undergoing balloon angioplasty smaller vessel size is not associated with 
a significantly higher risk of bailout stent, procedural failure, abrupt vessel closure or 
myocardial infarction during follow-up. 
Previous studies. Sutton et a!. on behalf of the Gianturco-Roubin Intracoronary Stent 
Investigator Group undertook an analysis of predictors of adverse events after acute and 
elective coronary stenting on a pooled registry database [36]. They found vessel size of 
patients who experienced an adverse clinical event post stenting to be 3.16 ±0.59mm 
compared to a vessel size of 3.06 ±0.62mm in those patients without an event (p = .14 
on univariate analysis and p = .0001 on multivariate analysis). In a stepwise logistic 
regression model, they found larger vessel size was associated with an increased odds 
ratio for a clinical event of 2.87 (95% C.1. 1.74 - 4.711. These findings are at variance to 
expectations and to the results of our current study. The potential confounding variables 
which may have contributed to the findings of the study by Sutton et al include; the 
absence of a single standardized core angiographic laboratory; vessel size was determined 
by calliper measurement in an adjacent coronary segment in the single worst view ; the 
pooling of native artery with bypass graft results; and the spectrum of indications for stent 
implantation (predominantly for the acute management of dissections and the elective 
management of restenotic lesions). 
Schomig et aI., in a report of their experience with the Palmaz-Schatz stent in bailout 
therapy; found the difference in vessel size between patients who developed a subacute 
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Figure 1 
Vessel Size in Patients with Abrupt Vessel Closure following Balloon 
Angloplasty and following Stent Implantation 
7/ 
4 
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.. .. .. Balloon (7 patients) 
---S/en/ (10 patients) 
Polar plot of the individual vessel size of each of the patients who developed an abrupt vessel 
closure following balloon angioplasty (7 patients) and following stent implal1tation (10 patients). 
While small vessel size was associated with a higher risk of subacute thrombosis~ vessel size 
was not predictive of abrupt vessel closure following balloon ang;oplasty. 
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Influence of Vessel Size on Clinical Outcome following 
Coronary Stent Implantation 
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Figure 2 
By logistic regression, decreasing coronary vessel size (as a continuous variable) was associated 
with an increasing probability of a clinical event over 7 months post stent implantation, 
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stent occlusion (n = 21) and those without a subacute occlusion (n = 280) was not 
statistically significant (3.1 ± OAmm and 3.3 ±O.6mm, p ~ .16) [43]. 
In a previous univariate relative risk analysis from our group of restenosis following 
implantation of the coronary Wallstent, vessel size was not found to be predictive of 
restenosis. In a more recent analysis from our group of the influence of vessel size on the 
rest enos is process following successful (per protocol) balloon angioplasty, vessel size was 
found after normalization for confounding variables to exert an independent negative effect 
on luminal loss and a positive effect on minimal lumen diameter at 6 month angiographic 
follow· up [43]. These findings are consistent with those of our present study of a greater 
relative loss and loss index in vessels < 3.0mm in patients undergoing balloon angioplasty 
in the BENESTENT trial and might be predicted from geometrical or mechanical 
considerations. 
Clinical implications. The precise reasons as to why operators select a higher device to 
vessel ratio in smaller vessels is not clear and may possibly relate in part to the common 
practice of visual guidance of interventional procedures rather than the more reliable 
guidance of on-line quantitative coronary angiography to provide absolute measures of both 
vessel size as well as minimal lumen diameter [20J. 
Our study has shown that while the relative influence of vessel size on acute and 6 month 
angiographic outcome is similar for stent implantation and balloon angioplasty, the 
influence of small vessel size on adverse clinical events is different for stent implantation 
and balloon angioplasty. Specifically, while small vessel size is not associated with an· 
increased risk of abrupt vessel closure or myocardial infarction following balloon 
angioplasty, small vessel size is associated with an increased risk of abrupt vessel closure 
and myocardial infarction post stanting. Current ap·proaches to reduce the risk of subacute 
stent thrombosis by the development of stent coatings [44-46] and the introduction of 
improved antiplatelet regimens [47-50] may be expected to improve the outcome of 
stenting in smaller coronary vessels. Until such expectations are confirmed by prospective 
studies in vessels of < 3.0mm, balloon angioplasty may continue to be the elective 
procedure of choice in smaller vessels. 
Conclusion: While recent studies have indicated a favourable clinical and angiographic 
outcome following elective coronary stent placement, the relative merits of coronary 
stenting over balloon angioplasty may be reduced in vessels of < 3.0mm diameter. 
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APPENDIX 
BENESTENT Study Group 
The fol/owing institutions and investigators participated in the BENESTENT study. The 
number of patients enrolled at each center are given in parenthesis: 
1) University Hospital San Carlos, Madrid, Spain (76): C Macaya, F Alfonso, J 
Goicolea, R Hernandez, A Iniguez, 
2) University Hospital Rotterdam ~ Dijkzigt, Thoraxcenter, Rotterdam, The Netherlands 
(57): PW Serruys, P de Jaegere, MA Morel, PJ de Feyter, M van den Brand, 
3) Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands (50): F Kiemeneij, GJ 
Laarman, R vander Wieken, 
4) Universitatsklinikum Rudolf Virchow/Charlottenburg, Berlin, Germany (39): W 
Rutsch, 
5) Onze Lieve Vrouwe Ziekenhuis, Aalst, Belgium (38): G Heyndrickx, B de Bruyne, 
6) Sahlgrenska Hospital, Goteborg, Sweden (36): H Emanuelsson, P Albertsson, 
7) Clinique Pasteur, Toulouse, France (32): J Marco, J Fajadet, S Doucet, 0 Bar, 
8) Sart-Tilman, Centre Hospitalier Universitaire, Liege, Belgium (32): V Legrand, 
9) Hopital de la Citadelle, Liege, Belgium (19): P Materne, J Boland, 
10) Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina (19): J Belardi, 
J Berrocal, R Piraino 
11) Royal Brompton, National Heart and Lung Hospital, London, United Kingdom (12): 
U Sigwart, N Buller, K Priestley 
12) Centro Cuore, Milano, Italy (11): A Colombo, L Maiello, 
13) CHUV, Lausanne, Switzerland (11): JJ Goy, E Eeckhout, 
14) Middelheim Ziekenhuis, Antwerpen, Belgium (10): P van den Heuvel, F van den 
Brande, 
15) Gregorio Maranon, Madrid, Spain (10): J Delcan, E Garcia, 
16) Ziekenhuis de Weezenlanden, Zwolle, The Netherlands (8): H Suryapranata, J 
Hoorntje, 
17) St Antonius Ziekenhuis, Nieuwegein, The Netherlands (8): Th Plokker, G Mast, 
18) Hospital Maggiore, Trieste, italy (8): S Klugmann, E Della Grazia, A Salvi, 
19) H6pital Cantonal Universitaire, Geneve, Switzerland (7): P Urban, E Camenzind 
20) Academisch Ziekenhuis Groningen, The Netherlands (6): P den Heijer, R van Dijk, 
21) Academisch Medisch Centrum, Amsterdam, The Netherlands (6): J Piek, K Koch, 
22) Christian Albrechts University, Kiel, Germany (6): R Simon, F Herrmann, 
23) Centre Cardiologique du Nord, Paris, France (5): MC Morice, TRoyer, 
24) James Hospital, Dublin, Ireland (5): P Crean, 
25) Catharina Ziekenhuis, Eindhoven, The Netherlands (3): H Bonnier, J Koolen, F 
Bracke, 
26) Cliniques Universitaires St Luc, Universite Catholique de Louvain, Bruxelles, Belgium 
(2): W Wijns, 
27) CHUR, Nancy, France (2): N Danchin, Y Juilliere, 
28) Polyclinique Volney, Rennes, France (2): C Bourdonnec, 
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A quantitative angiographic study of inflation and recoil of the 
Gianturco-Roubin stent in native coronary arteries : 
Results of a learning phase with implications for stent sizing and deployment. 
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ABSTRACT 
Background: The Gianturco-Roubin stent is composed of a balloon-expandable stainless-
steel incomplete coil with a clamshell configuration. Its low metallic surface area is 
achieved by a relatively large distance between its transversely parallel struts. To 
determine the acute expansile and elastic properties of the stent in-vivo, we studied the 
behaviour of the stent during deployment in native coronary lesions by detailed quantitative 
coronary angiographic analysis. 
Methods: Thirty-nine Gianturco-Roubin stents were implanted in the native coronary 
arteries of 35 patients between October 1992 and October 1994 for the management of 
primary lesions, restenotic lesions, and acute or threatened closure after primary balloon 
angioplasty. All lesions were predilated by primary coronary angioplasty prior to stent 
deployment. A nominal (manufacturer's) stent size of on average .61 ± .61 mm greater 
than the reference vessel diameter was selected. This report includes our early learning 
experience with this stent design and the performance of an additional high pressure 
intrastent inflation of a non-compliant balloon was only performed latterly in eight of our 
patients. Computerised quantitative coronary angiography was performed on the inflated 
balloon and inflated stent as well as pre and post balloon and stent dilatations. 
Results: Neither the mean nor the minimal luminal diameter achieved post stenting matched 
the nominal diameter of the Gianturco-Roubin stent. Acute procedural changes in minimal 
luminal diameter were from 1.10 ± .53mm pre-intervention through 2.87 ± .51mm during 
balloon inflation to 1.56 ±. 78mm post primary balloon angioplasty. Minimal luminal 
diameter subsequently increased significantly during stent inflation to 2.97 ± ,42mm but 
fell to a final result of 2.56 ± .39mm post stent deployment. Performance of an additional 
high pressure intrastent inflation with a non-compliant balloon resulted in a significant 
improvement in final angiographic outcome (2.68 ± .34mm, p < .05). Analysis of the 
standard deviation of the diameter and analysis of the difference between the minimal and 
mean diameter (as indices of lumen irregularity) of the inflated balloons and stented 
segments indicated a non-uniform stent expansion and recoil. Recoil post stenting of the 
minimal luminal diameter was 15.7 ± 11.6% (0.34 ± .68mm), while elastic recoil post 
stenting of the mean diameter was 8.9 ± 9.3% (0.30 ± .33mm). 
Conclusions: Inflation and recoil of the Gianturco-Roubin stent is not uniform which may 
relate to the large interstrut distance (with protrusion of intima or plaque between the 
struts) and use of a highly compliant premounted balloon. Even with a policy of stent 
oversizing (stent vessel ratio = 1.23 ± .25mm), a "residual diameter stenosis of 20% may 
persist. This study supports the recent change in interventional practice from matching the 
size of the Gianturco-Roubin stent to the vessel diameter to the new policy of stent 
oversizing, and the performance of post delivery high pressure intrastent inflations with a 
non-compliant balloon under the guidance of on-line OCA. 
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INTRODUCTION : 
Seven different metallic coronary stents, each of unique design, are currently available for 
clinical implantation. These can be loosely grouped into different design categories, the 
mesh stents (The Less-Shortening Wallstent 11,2], Palmaz-Schatz 13,4]'), the intermediate 
design of the AVE Micro (zig-zag axial struts), and the coil design (Gianturco-Roubin 15,6), 
Wiktor 17), Cordis, Multilink). While the mesh stents generally offer strong radial support 
(particularly the AVE Micro and Palmaz-Schatz stents) and have more longitudinal or 
oblique orientation of their struts, they do have a large metallic (particularly the Wallstent 
and Palmaz-Schatz) and therefore potentially thrombogenic surface area. In contrast, the 
coil stents offer a relatively low metallic burden and a greater degree of longitudinal 
flexibility and a lower propensity to shorten upon expansion. These potential advantages 
of coil stents, however, come at a price of potentially providing lower circumferential 
support. Furthermore, the call stents have a more transverse orientation of their struts and 
thus provide less longitudinal continuity in their scaffolding of the vessel wall. In an 
attempt to reduce this limitation of coil stents, the struts of the Wiktor, Cordis and ACS 
stants have been crenulated to increase the longitudinal scaffolding provided to the vessel 
wall. In the case of the Gianturco-Roubin coil stent, however, the stainless steel wire is 
straight and not crenulated. Instead, the Gianturco-Roubin stent is composed of .006 inch 
wire wrapped in a serpentine manner so that every 3600 the wire makes a 1800 turn. The 
resultant series of parallel U and inverted U-shaped loops allows the coil to expand in a 
clam-shell manner. The transversely parallel struts of the Gianturco-Roubin stent, however, 
are spaced at a distance of 1 mm to each other (figure 1) . To determine the acute expansile 
and elastic properties of the Gianturco-Roubin stent and the effect such large interspacing 
of the transversely oriented straight struts may have on the behaviour of the Gianturco-
Roubin stents in-vivo, we performed detailed quantitative angiographic analysis before, 
during and following deployment of the Gianturco-Roubin stent in the native coronary 
arteries of 35 patients. 
METHODS: 
Patient population. Thirty nine Gianturco-Roubin stents were successfully implanted in the 
native coronary arteries of 35 patients for the management of primary lesions, restenotic 
lesions, and acute or threatened closure after primary balloon angiopJasty. The average age 
of the patients was 57 ± 10 years and 30 of the 35 patients were male. Eleven of the 
patients had a previous balloon angioplasty at the site of the target lesion. Three of the 
patients had peviously undergone coronary artery bypass surgery. Nine of the patients had 
a history of myocardial infarction. No patient had left ventricular ejection fraction below 
40% and no patient had diabetes mellitus. Oualitative angiographic assessment of the 
target lesions pre-intervention revealed that 8 of the lesions were ACC I AHA fS] type A, 
21 lesions were type 8, 6 of the lesions were type C. The clinical characteristics and 
qualitative angiographic profile of the coronary lesions are given in Table 1. 
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Figure 1. The Gianturco-Roubin coronary flexible stent is composed of a mono filamentous, surgical 
stainless steel wire, 0.006 inch in diameter, wrapped in a serpentine manner around a compliant 
polyethylene balloon catheter so that every 3600 the wire makes a 1800 tum [6}. This results in a 
series of interdigitating V and inverted V-shaped loops and allows the coil to expand in a clam-shell 
manner as the balloon is inflated. 
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Table 1 
Clinical Characteristics and Procedural Details 
Age 
Gender 
Hypertension 
Hypercholesterolaeima 
Smoking history 
Never 
Previous 
Current 
Number of diseased coronary vessels 
1 vessel disease 
2 vessel disease 
3 vessel disease 
Coronary vessel 
left anterior descending artery 
right coronary artery 
left circumflex 
57 ± 10 years 
30 male I 5 female 
8 patients 
12 patients 
12 patients 
10 patients 
13 patie.nts 
22 patients 
9 patients 
4 patients 
19 patients 
11 patients 
5 patients 
Pre-balloon angioplasty ACC I AHA Lesion Type 
A 8 lesions 
8 21 lesions 
C 6 lesions 
Indication for stenting post balloon angioplasty 
elective management of restenosis ; 7 patients 
unplanned management of a suboptimal result; 4 patients 
bailout of dissection with threatened closure (TIMI [11 J flow 2 or 3); 17 patients 
bailout of acute vessel closure (TIMI flow 0 or I); 7 patients 
Interventional procedure. During the primary balloon angioplasty procedure the maximal 
inflation pressure was 11.3 ±3 atm,'s with an average of 3.8 ± 1.8 inflations performed. 
The indication for stenting was elective management of restenosis {7] following previous 
balloon angioplasty in 7 patients, unplanned management of a suboptimal result of balloon 
angioplasty in 4 patients, bailout management 19] of a dissection with threatened [9,1 OJ 
closure (TIMI [111 flow 2 or 3) in 17 patients, and bailout management of an acute closure 
(TIMI flow 0 or I) in 7 patients. An attempt to cover the full extent of the lesion or 
dissection was made in each patient. In four of the lesions, a second stent was required 
to cover the length of the dissection, Three of the stents had a length of 12mm while the 
other 36 stents were 20mm long. A policy of selecting a nominal stent diameter greater 
than the vessel size was practised throughout the study. The nominal (manufacturer's) 
diameter of the stents deployed were 3.64 ± .45mm [range 3.0 to 4.0mmJ. The maximal 
inflation pressure with the premounted balloon to deploy the stent was 6.6 ± 2.0 atm.'s 
with a total number of 3.8 ± 1.8 inflations of the premounted balloon being performed. 
This report includes our early learning experience with this stent design (commencing in 
October 1992) and during our two year period of evaluation of the Gianturco-Roubin stent 
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Figure 2a-e. Quantitative coronary angiographlc analysis was performed pre-balloon inflation fA), 
during balloon Inflaaon (B), post-balloon Inflation (e), during stent Inflation (0), and post-stent 
deployment tE). 
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information became available from studies at the University of Alabama to indicate that the 
performance of an additional high pressure intrastent inflation of a non-compliant balloon 
should be performed routinely in nearly all patients undergoing implantation of a Gianturco-
Roubin stent. Accordingly following delivery of the stent on the premounted balloon, 
additional high pressure (13.3 ± 3. 7atm. 's) intrastent inflations of a non-compliant balloon 
was performed latterly in eight of our patients. 
Contrast coronary angiography was performed after the administration of intracoronary 
nitrates pre-intervention, post-balloon angioplasty, post stent deployment, and post 
additional inflation of a non-compliant intrastent balloon. Angiograms were also recorded 
without luminal contrast at peak inflation pressure after waisting of the angioplasty balloon 
and waisting of the stent balloons were deemed by the operator to have disappeared. 
Quantitative angiographic analysis. Subsequent computerised quantitative coronary 
angiographic measurements on the cineangiograms were conducted on the inflated balloon. 
and inflated stent as well as pre and post balloon and stent dilatations, thus providing a 
total of five consecutive procedural phases of quantitative analysis 1) pre balloon 
angioplasty; 2) during balloon inflation; 3) post balloon angioplasty; 4) during stent 
inflation; and 5) post stent deployment (figure 20·e). During analysis of the body of the 
inflated angioplasty balloons and intrastent deployment balloons, the 1 mm tapered balloon 
terminals beyond the limits of the stent were not included. The quantitative angiographic 
parameters of the analyzed segment which were studied at each procedural phase were 
the minimal luminal diameter [12,13], the mean luminal diameter [12,131, the standard 
deviation of the luminal diameter (as an indicator of the irregularity of the luminal borders), 
and the interpolated reference vessel diameter of 'the coronary segment. 
The computerized quantitative coronary angiographic analysis of the cineangiograms was 
performed with the Coronary Angiography Analysis System (CAAS II) 114J. After the 
selection of views which were most suitable for quantitative angiography (e.g. absence of 
overlapping side branches and foreshortening {15,16H, a 6.9 x 6.9mm region of interest 
within the 18 x 24mm cineframe is digitized into a 512 x 51 2 pixel matrix using a CCD-
camera (8 bits = 256 density levels) resulting in a final resolution of 1329 x 1772 pixels. 
A correction for pincushion distortion was applied for all analyses by the recording of a 
centimeter grid at each image intensifier setting at each interventional suite in our cardiac 
catheterisation laboratory prior to the study [14]. To initiate the analysis the operator 
defines a number of centerline points within the arterial segment which are subsequently 
connected by straight lines, serving as a first approximation of the vessel centerline. The 
edge detection algorithm is carried out in two iterations. First, the model is the initially 
defined centerline and second, the model is a recomputed centerline, determined 
automaticallY as the midline of the contour positions which were detected in the first 
iteration. 
Calibration of all angiographic measurements was achieved by the use of the coronary 
guiding catheter as a scaling device I 17]. The non-tapering part of the tip of each guiding 
catheter was measured with a precision-micrometer (No. 293-501, Mitutoyo, Tokyo, 
Japan; tolerance 0.001 mm). The calibration procedure using automated edge detection 
was applied to the images obtained, yielding the corresponding scaling factor (mm/pixel). 
Statistical analysis. Recoil post stent deployment was calculated for both the minimal and 
mean diameters from quantitative analysis of the intrastent deployment balloon recorded 
at peak inflation pressure and the luminal diameter post stent deployment as follows: 
(minimal diameter of the inflated stent - minimal luminal diameter post stenting) * 100 
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minimal diameter of the inflated stent 
and 
(mean diameter of the inflated stent - mean luminal diameter post stenting) * 100 
mean diameter of the inflated stent 
Student's t-test for paired data was used to compare quantitative angiographic parameters 
of the same patients at different procedural phases. A p value of < .05 was taken as an 
indication of statistical significance. . 
RESULTS: 
The average vessel size was found to be 3.04 ± .52mm pre-intervention which was .61 
± .61 mm smaller than the nominal stent size thus indicating a stent : vessel size ratio of 
1.23 ± .25. While vessel size did not change during primary balloon angioplasty, the 
vessel diameter increased significantly to 3.28 ± .36mm following stent deployment 
(p< .05). The final residual percent diameter stenosis post stenting was 22 ± 8%. Neither 
the mean nor the minimal luminal diameter finally achieved post stenting matched the 
selected nominal diameter of the Gianturco-Roubin stent. 
The dynamic changes in minimal (and mean) luminal diameters at each procedural phase 
are displayed in figure 3 and changes in all angiographic measurements are given in table 
2. The minimal luminal diameter Was found to increase from 1.10 ± .53mm pre-balloon to 
2.87 ±.51mm during balloon inflation and subsequently to decrease to 1.56 ±.78mm 
post primary balloon angioplasty. Minimal luminal diameter subsequently increased during 
stent inflation to 2.97 ± ,42mm but fell to a final result of 2.56 ± .39mm post stent 
deployment. In the eight patients in whom an additional high pressure inflation was 
performed with a non-compliant balloon, the minimal luminal diameter was found to further 
improve significantly changing from 2.28 ± .42mm following stent delivery to 3.39 
± .48mm during high pressure inflation (Swiss Kis's) to a final angiographic result of 2.68 
±.34mm (p < .051. 
Uniformity of stent inflation. Although the inflated primary angioplasty balloons and 
intrastent deployment balloons were filmed at peak pressure when waisting of the balloons 
were felt to have disappeared by the operator, marked differences were observed between 
the minimal diameter and the mean diameter and large standard deviations of the diameter 
of the maximally inflated balloons and stents were observed (figure 3). The minimal 
diameter of the primary angioplasty balloon during peak inflation pressure was .29 
± .23mm smaller than the mean diameter of the inflated balloon and the standard deviation 
of the diameter of the inflated balloon was .17 ± .11 mm (table 2). During peak inflation 
of the pre-mounted intrastent deployment balloon, the minimal diameter of the inflated 
stent was .37 ± .20mm smaller than the mean diameter of the inflated stent and the 
standard deviation of the diameter of the inflated stent was .19 ± .07mmm. In those 
patients in whom an additional inflation of a non-compliant intrastent balloon was 
performed the minimal diameter of the inflated stent at peak pressure was .20 ± .06mm 
smaller than the mean diameter of the inflated stent and the standard deviation of the 
diameter of the inflated stent was .13 ± .03mmm 
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Figure 3. Serial intraprocedural changes in minimal and mean luminal diameter measurements for 
all patients studied. The minima/luminal diameter of the treated lesion can be seen to decrease 
(recoil) following deflation of the primary angioplasty bal/oon and following deflation of the stent 
deployment balloon. 
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Table 2 
Results of quantitative angiographic analysis at each of five intraprocedural phases 
Minlum Diam 
(MlD) 
Mean lum Diam 
(MeanLD) 
MeanlD-MinLD 
Standard Dev of 
lum Diam (SDD) 
Interpolated Ref 
Vessel Diam UVD) 
% Diam Stenosis 
(%05) 
Pre-
balloon 
1.10 
±.53mm 
2.52 
±.46mm 
1.35 
±.51mm 
0.66 
±.16mm 
3.04 
±.52mm 
62% 
±16% 
Balloon 
inflation 
2.87 
±,51mm 
3.16 
±.46mm 
0.29 
±.23mm 
0.17 
±.11mm 
Post~ 
balloon 
1.66 
±.77mm 
2.62 
±.67mm 
1.00 
±.35mm 
0.59 
±.22mm 
3.05 
±.63mm 
49% 
±22% 
Stent 
inflation 
2.97 
±.42mm 
3.34 
±.37mm 
0.37 
±.20mm 
0.19 
±.07mm 
Post-
stent 
2.56 
±.39mm 
3.09 
±.37mm 
0.63 
±.17mm 
0.34 
±.llmm 
3.28 
±.36mm 
22% 
±8% 
Following stent deployment acute recoil of the minimal luminal diameter of the stented segment was 
15.7% ± 11.6%, which was significantly larger than recoil of the mean luminal diameter of the 
stented segment, 8.9 ± 9.3% (p <.001). The interpolated reference vessel diameter (IVDl [14/ was 
seen to increase following stent deployment. With an interventlonal policy of stent oversizing, 
neither the mean nor the minimal luminal diameter reached the nominal size of the stents deployed 
(3.64 ± .4SmmJ. 
Stent recoil of the minimal and mean diameter. Diameter measurements of the intrastent 
deployment balloon during peak inflation pressure were compared with the diameter 
measurements of the resulting stented lumen after removal of the deployment balloon. 
Recoil of the minimal luminal diameter was significantly greater than recoil of the mean 
luminal diameter of the stented segment. Recoil post stenting of the minimal luminal 
diameter was 15.7 ± 11.6% (0.48 ± .35mm), while elastic recoil post stenting of the 
mean diameter was 8.9 ± 9.3% (0.30 ± .33mml (p < .0011. In those patients in whom 
an additional inflation of a non-compliant intrastent balloon was performed recoil of the 
minimal luminal diameter was 20.6 ±6.3% (0.71 ±.27mm) and recoil of the mean 
diameter was 11.65 ±8.0% (0.44 ±.33mml (p < .001). 
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DISCUSSION: 
The key findings of our study are; firstly, that despite a policy of overslzlng by 0.61 
± .61 mm of the Gianturco·Roubin stent, a final residual diameter stenosis of 22 ± 8 % was 
found to persist; secondly, that elastic recoil post deployment of the Gianturco-Roubin 
stent is significant and inhomogeneously distributed and will vary considerably in value 
according to whether recoil of the minimal diameter or mean diameter is considered; and 
thirdly, quantitative angiographic analysis of the lumen diameter throughout the stented 
segment indicates that the longitudinal scaffolding of the vessel wall may not be uniform 
over the length of the Gianturco-Roubin coil stent. 
Stent sizing. We have demonstrated that when the Gianturco-Roubin stent is deployed in-
vivo, the stent rarely achieves its nominal diameter (as determined by the manufacturer's 
in-vitro testing). Even when an additional post-deployment high pressure intrastent inflation 
of a non-compliant balloon is performed, neither the minimal nor the mean diameter of the 
stented segment reaches the nominal diameter of the stent. Potential contributing factors 
to these findings might include a) an additional high pressure intrastent inflation of a non-
compliant balloon was only performed latterly in eight of our patients when the 
angiographic result was deemed by the operator to be suboptimal rather than being 
routinely performed in all patients, b) use of the pre-mounted highly compliant 
polyethylene delivery balloon to deploy the stent, which by protruding through the 1 mm 
interstrut intervals may not exert an adequate and uniform expansile force directly on the 
stainless steel coils, c) inability of this coil stent when deployed as a single unit (i.e. 
without telescoping or overlapping multiple stents) to eliminate recoil throughout the 
stented segment, d) a policy of selecting a stent of greater nominal diameter than the size 
of the target vessel will make it more difficult to fully expand the stent to reach its nominal 
diameter than if a stent of equal size to the vessel diameter is selected, and e) a 
systematic tendency of QCA measurements to underestimate large lumen diameters has 
been recently recognised [18,19], although this would primarily limit the reliability of the 
absolute values of measurement more than limit the reliability of relative measurements of 
changes in luminal diameter throughout the procedural phases. 
Quantitative angiographic analysis of coronary stenting. The QCA system employed in our 
study provides an interpolated reference diameter measurement [14] rather than a less 
reproducible and less objective manual selection of a proximal or distal diameter point by 
the aCA analyst. It can be seen from Table 2, that while the reference vessel diameter did 
not change from 3.04 ± .52mm pre-intervention to post primary balloon angioplasty (3.05 
± .63mm), the reference vessel diameter did increase significantly after stent deployment 
to 3.28 ± .36mm (p < .05). This increase in vessel size post stenting may result from 
improved flow and dilatation of the segment distal to the stent, or may relate to the 
contribution of maximally dilated intrastent subsegments to the assimilation of the 
interpolated reference vessel diameter. As a result of the increase in interpolated vessel 
diameter post stenting, the reported final residual diameter stenosis is 22%, rather than 
a residual diameter stenosis of 16% if the pre-intervention vessel size was considered. Of 
interest in the BENESTENT trial [20]' where the same OCA system was used to measure 
luminal diameters, the reference vessel increased significantly from 2.99 ± .45mm pre-
intervention to 3,16 ± .43mm post implantation of a Palmaz-Schatz stent, as a result of 
which the post stent residual diameter stenosis was reported as 22% rather than a value 
of 17% if the pre-intervention vessel size was considered. In contrast, however, in the 
STRESS trial [21] where vessel size was taken as an average of manually selected proximal 
and distal diameter points, vessel size was reported as not to have increased from pre~ 
intervention (3.03 ± .42mm) to post Palmaz-Schatz stent deployment (3.05 ± .40mm) 
with a reported residual diameter stenosis of 19%. Thus for the evaluation of an 
173 
Gianturco·Roubin slenllnfialion & recoil 
interventional device which results in an increase in the interpolated reference vessel 
diameter, assessment of acute angiagraphic outcome should not be limited to the residual 
% diameter stenosis, but also consider the absolute improvement in minimal luminal 
diameter. Furthermore, guidance of stenting procedures by visual assessment rather than 
the performance of on-line OCA may fail to appreciate the absolute gain in luminal diameter 
in addition to failing to appreciate non-uniform and inadequate balloon inflation and 
subsequent stent expansion {16]. 
Previous studies. Our findings are consistent with those recently reported by the group at 
the University of Alabama at Birmingham in a study of sizing of the Gianturco-Roubin stent 
[22] and lend support to their recommendation of a change in interventional practice from 
matching the stent size to the vessel size to a policy of stent oversizing. While, they 
recommended a stent oversizing by 0.0 to OAmm [22], we feel that when the Gianturco-
Roubin is deployed as a single unit without overlapping multiple stents, oversizing by 
~.5mm may be required to improve the final angiographic outcome. While the highly 
compliant pre-mounted polyethylene balloon provides the unsheathed Gianturco-Roubin 
stent with a more firm grip on the delivery system and thereby reduces the risk of 
premature stent dislodgement, the subsequent performance of a high pressure intrastent 
inflation of a non-compliant balloon may be required to obtain an optimal result. Given that 
the nominal diameter of the pre-mounted polyethylene balloon is 0.5mm greater than the 
nominal size of the Gianturco-Roubin stent, it is important that when adopting a policy of 
stent oversizing that initial delivery inflation pressures with this balloon should not exceed 
the recommended delivery inflation pressure of 4-6 atm. 's in order to avoid the risk of 
distal dissection by the unrestricted expansion of the compliant balloon beyond the distal 
limits of the stent [23,24]. 
Following the adoption of the current strategy of routine additional high pressure intrastent 
inflations of a non-compliant balloon, the primary function of the pre-mounted compliant 
balloon is now more limited to safely deliver and position the stent in the target lesion, 
rather than to optimize stent deployment and it could therefore now be proposed that the 
balloon diameters achieved during the initial inflation of the pre-mounted compliant balloon 
should not be used by the operator to estimate the final angiographic potential of the stent. 
Furthermore, if a 3.5mm Gianturco-Roubin stent is placed in 3.0mm vessel then a non-
compliant balloon of 3.5mm should be used for high pressure inflations. Further studies will 
be required to determine the effect of oversizing by ;;:O.5mm on restenosis over six months 
[23 -25]. It is likely that the degree of oversizing of different stents should be related to 
the distribution of radial force exerted by each individual stent design and that a general 
guideline for sizing of all stent designs would be inappropriate. 
Elastic recoil. A difference of .37mm between the minimal diameter and the mean diameter 
of the inflated intrastent balloon and a difference of .56mm between the minimal luminal 
diameter and the mean luminal diameter post stent deployment was observed [12,13J. 
Explanations for the variability in stretch and recoil throughout the stented lesion may 
include that atherosclerotic lesions in native coronary arteries may have a non-uniform 
distribution of elastic and non-distensible tissue and secondly that the design of the 
Gianturco-Roubin stent may be inherently predisposed to the protrusion through its 1 mm 
interstrut spacing of the compliant polyethylene balloon during inflation and subsequent 
encroachment of the vessel wall into the lumen after stent deployment. Determination of 
elastic recoil by assessment of the mean diameter of the stented segment alone will 
underestimate the residual functional significance of recoil which is primarily determined 
by recoil of the minimal luminal diameter. This finding is of relevance for the gUidance of 
stent deployment by on-line OCA in clinical practice as well as for the design of future 
studies on the acute angiographic outcome following stent deployment. 
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Figure 4a-c_ The large interstrut distance of fmm of the Gianturco-Roubin stent allows the 
performance of interventional procedures in a sidebranch of the stented coronary segment through 
the strut intervfJls, Fig 48; an occlusive dissection in the bifurcation of the left anterior descending 
(LAD) fJnd diagonal (Of) arteries occurred following primary balloon angioplasty. Fig 4b; a 20mm 
Gainturco-Roubin stent is placed in the LAD covering the segments proximal and distal to the 
diagonal artery, Fig 4c; the second guide wire in the diagonal artery is withdrawn and then 
readvanced inside the Gianturco-Roubin stent and through the strut intervals back into the diagonal 
artery. An A VE Micro stent is then advanced over the guide wire through the strut intervals into the 
diagonal artery where it is successfully deployed. Such a procedure would not be possible through 
a stent without large interstrut intervals, 
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In a previous study from our group of acute recoil following implantation of the Wiktor 
stent (a crenulated tantalum coil stent) in restenotic lesions in native coronary arteries 
following previously successful balloon angioplasty using the same automated edge-
detection DCA system, recoil of the mean diameter was found to be 8.2% {O.25 
± .32mml, while recoil of the minimal luminal diameter was not reported [26]. In a study 
by Haude et al. on acute recoil following implantation of the Palmaz-Schatz stent in 
restenotic lesions in native coronary arteries, a manual (eye-hand) edge detection 
methodology was used and recoil was defined as the difference between the maximal 
balloon size assuming uniformity along the entire length of the inflated balloon and the 
subsequent residual minimal lumen diameter [27]. With this methodology recoil following 
implantation of the Palmaz-Schatz stent was reported to be 3.5% 10.10 ± .07mml [27]. 
In a different study by Schomig et al of patients treated by implantation of the Palmaz-
Schatz for the management of dissection complicating balloon angiopiasty, elastic recoil 
was defined as the difference between the maximally inflated intrastent balloon diameter 
and the resulting final minimal lumen diameter, however, it was not stated as to whether 
the mean or minimal intrastent balloon diameter was analysed [28}. In this latter report, 
elastic recoil following Palmaz-Schatz implantation was found to be 16% (.51 ±34mm) 
[28). The discrepancy (3.5% versus 16%) between the two reports (27,28] of elastic 
recoil following implantation of the Palmaz-Schatz stent, highlight the importance of 
defining whether the minimal or the mean diameter of the intrastent balloon is taken for 
determination of recoil and that uniformity of balloon inflation should not be assumed 
[12, 13}. Until a standardized quantitative angiographic analytical approach is adopted by 
independent studies attempting to examine recoil post stenting, direct comparisons of the 
compliance of different stent designs in vivo cannot be drawn. Furthermore, direct 
inters tent comparisons should await the execution of stent studies in equivalent patient 
popUlation groups (e.g. in patients undergoing elective stent placement for restenosis or 
patients undergoing bailout stenting of dissected primary stenoses). 
Stent design. While our quantitative angiographic analysis of the Gianturco-Roubin stent 
would indicate that the lumen of the stented segment may not be uniformly expanded, it 
should be acknowledged that the acute and long-term clinical results associated with 
implantation of the Gianturco-Roubin coronary stent have been extensively reported 
particularly in the bailout management of acute and threatened closure following balloon 
angioplasty and have been found to be at least comparable to those of other stents 
[5,6,10,9,29-32], The reported favorable clinical results may in part result from some of 
the positive aspects of the structural design of the Gianturco-Roubin stent. Potential 
advantages of the large 1 mm intervals between the parallel struts of the Gianturco-Roubin 
stent include the following: Firstly, the metallic (and thus the thrombogenic) surface area 
of the stent is thereby reduced (10% surface area in the expanded state). Secondly, the 
large interstrut intervals allows the stent following optimal deployment to be embedded 
more deeply into the the intimal layer of the vessel wall thereby further reducing the 
metallic surface area exposed to the lumen [6]. Thirdly, the free proximal and distal 
terminals of the stent are felt to embed into the vessel wall which may provide the stent 
with longitudinal grip and stability to prevent recoil caused by spiralling of the coil stent 
and to prevent migration of the stent during or after deployment. Fourthly, the larger 
interstrut distances reduce the amount of "jailing" of side branches, whereby the ostia of 
side branches remain unobstructed with minimal risk of occluding side branches and 
rendering it possible to perform an interventional procedure in a side branch through the 
strut intervals (see figure 4). Fifthly, the longitudinal flexibility of the stent is enhanced. 
Sixthly the parallel transverse orientation of the non-crenulated struts results in the 
Gianturco-Roubin stent being the only stent which does not shorten longitudinally upon 
radial expansion. Seventhly the parallel strut orientation offers a transverse mechanical 
advantage over oblique and axially orientated strut designs for the resistance of radial 
compression. 
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Top panel: Coronary angiogram of a right coronary artery in which 
a Gianturco-Roubin stent (arrows) was placed for the management 
of a long dissection. The radiopaque markers (inset linage) of the 
premounted stent-delivery balloon are located 1-2mm beyond the 
/linils of the stent. 
Second panel from top.' Intracoronary ultrasound cross-sectional 
linage within the stented coronary segment revealing a soft plaque 
of low echogenicity between 4 - 11 0 'clock and a highlyechogenic 
strut of the coil stent which is seen to be symmetrically deployed 
and in apposition to t{'le vessel wall throughout the visualised 
transverse arc. 
Third panel from top: A longitudinal reconstruction of the sequential 
intracoronary ultrasound data sets which were acquired using an 
automated pull-back device showing a widely patent lumen and well 
deployed stent 
Bottom panel: A blood-speckle identification program (Echo vision, 
CVIS, Sunnyvale, CA, USA) which distinguishes between the 
varying backscatter pattern of flowing blood cells in the vessel 
lumen and the more stable pattern of the vessel wall, has been used 
for three-dimensionsal reconstruction of the ICUS data sets which 
are displayed here in a "clam-shell" view [34J. In order to obtain a 
three-dimensional image the voxels (image volumetric elements) 
identified as part of the'blood pool by th,~ automated detection are 
removed. Note the slight artefact in the proximal left side behind the 
stent where part of the low echogenic plaque has been 
misinterpreted as part of the blood pool. 
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Study Limitations. A prospective policy of inflation of a non-compliant balloon following 
delivery of the Gianturco-Roubin stent in all patients might have produced additional 
improvement in the acute ang/ographic results in our patients. We have now adopted this 
policy for stents of all design. While we use on-line QCA for guidance of all stent 
procedures, intracoronary ultrasound guidance of stent deployment was only performed 
in a minority of our patients undergoing Gianturco-Roubin stent deployment (see figure 5). 
The additional and independent value of intracoronary ultrasound for the guidance of stent 
deployment has, however, yet to be firmly established as most studies reporting the value 
of intracoronary ultrasound have not used on-line QCA to first optimize the angiographic 
result prior to ultrasonic evaluation [33,34,35]. It is likely that intracoronary ultrasound 
may be of greater value for the deployment of poorly radiopaque stents such as the 
Gianturco-Roubin stent compared to radiopaque stents such has the AVE Micro stent, 
where expansion of the individual struts can clearly be seen in orthogonal radiographic 
projections. The imminent introduction of on-line ECG-gated three-dimensional 
reconstruction [36] of intracoronary ultrasound images may present a significant advance 
in the acute evaluation of stent deployment and of the mechanical behaviour in-vivo of 
different stent designs. 
CONCLUSIONS: 
Detailed quantitative angiagraphic analysis reveals that inflation and recoil of the Gianturco-
Roubin stent are not uniform which may relate to the large interstrut distance and use of 
a highly compliant pre-mounted balloon. Even with a policy of oversizing (stent size 0.61 
± .61 mm > vessel diameter), a residual diameter stenosis of 22% may persist when the 
Gianturco-Roubin stent is used as single unit without overlapping of multiple stents. 
Following delivery of the Gianturco-Roubin stent on the pre-mounted balloon to the target 
stenosis, performance of a high pressure intrastent inflation with a non-compliant balloon 
may improve the angiographic result. This study supports the recent change in 
interventional practice from matching the size of the Gianturco-Roubin stent to the vessel 
diameter to the new policy of stent oversizing, and the performance of post delivery high 
pressure intrastent inflations with a non-compliant balloon under the guidance of on-line 
QCA. 
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The Substrate-Abrupt and 
Threatened Vessel Closure 
Coronary interventional techniques carry a signifi-
cant risk of abrupt vessel closure either during or soon 
after the procedure. Abrupt closure can be defined as 
a sudden obstruction in a coronary artery resulting in 
either, a complete or critical reduction in blood flOW,I,2 
Typically acute closure is accompanied by chest pain 
and or electrocardiographical evidence of myocardial 
ischemia. Although most reported series of abrupt ves-
sel closure have been devoted to those complicating 
the most common percutaneous transluminal coronary 
technique, namely balloon angioplasty, 1-10 abrupt ves-
sel closure may result from all coronary interventional 
techniques"-18-even though many of the newer de-
vices may have been partly designed to improve the 
procedural success rates for coronary lesions with high 
risk features. 19 
The timing of periprocedural coronary artery occlu-
sion following balloon angiopiasty varies among re-
ports. In the NHLBI report of the experience at 15 
centers from the period of 1985-1986, 72% of occlu-
sions occurred inside and 28% occurred outside the 
catheterization laboratory, 2 In a series of abrupt vessel 
closure in 109 patients, Lincoff et aI.7 reported a me-
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dian time from first balloon inflation to vessel closure 
of 27 minutes with a range of 0 minutes to 5 days. 
The determination of the true incidence of acute 
occlusion has been hampered not only by the use of 
different criteria to define acute occlusion, but also 
in the selection of the study population in which the 
incidence was reported. The principle reports have ex-
cluded either none, some, or all of the following pa-
tient groups: acute myocardial infarction; out-of-Iabo-
ratory events; unsuccessful balloon angioplasty; and 
balloon angioplasty in saphenous vein grafts. Conse-
quently, the reported acute closure rates have varied 
from 2% in a study adopting all of the above exclu-
sion criteria6 to 8.3% in a study with none of the 
above exclusion criteria.7 Of eight series with different 
exclusion criteria, each involving> 1,000 patients, 
reflecting an accumulative experience from 1979-
1991,1-3,6-10 the weighted and crude averages of 
their reported incidence of abrupt closure following 
balloon angioplasty were both 5.3%. Nonetheless, 
these data often do not include cases where vessel clo-
sure is either silent or accompanied by mild or atypical 
symptoms. Nor do they necessarily include patients 
who die, show ECG or enzyme evidence ofmyocardiaI 
infarction, or for a variety of reasons are referred for 
coronary artery bypass surgery. Accordingly, abrupt 
closure after balloon angioplasty has probably been 
underestimated in most previous studies. 
The clinical consequences of abrupt vessel closure 
are significant. The NHLBI Registry reported that 
20% of ail deaths, 40% of myocardial infarctions, and 
25% of coronary artery bypass operations recorded at 
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1 year follow-up occurred in the 6.8% of patients who 
had peciprocedural coronary occlusion.7•2o 
Mechanism of Abrupt Vessel Closure 
Once arterial spasm has been excluded by the intra-
coronary administration of nitroglycerine, abrupt ves-
sel closure is found to be predominantly caused by 
either dissection, thrombus, or a combination of both. 
Although contrast angiography has detected intralumi-
nal thrombus in up to 44% of patients with coronary 
occlusion, often superimposed upon medial dissec-
tion,1·8.19.21 angiography appears to be a suboptimal 
imaging mOdality for the study of the mechanism of 
acute vessel occlusion.19.22 In an angiographic study 
of 109 patients with abrupt vessel closure, Lincoff et 
ai,1 diagnosed dissection in 28% of patients, thrombus 
in 20% of patients, an additional combination of 
thrombus and dissection in 7% of patients, and were 
unable to detennine the mechanism of acute closure 
in 45% of patients. 
The sensitivity of the above contrast angiographic 
studies (particularly with respect to thrombus recogni-
tion) would appear to be low in the light of recent 
studies using intravascular imaging modalities. Tn an 
angioscopic study by Jain et tl1.23 of ten patients with 
an acute occlusion following balloon angioplasty, in-
travascular thrombi were observed at the site of the 
acute occlusion in nine of the ten patients and were 
occlusive in two patients; fragmentcd plaque and tis-
sue flaps secondary to dissection of the arlerial wall 
was seen in all ten patients and were occlusive in eight 
patients; seven of the occlusive dissections were asso-
ciated with nonocclusive mural thrombi, and the two 
occlusive thrombi were associated with superficial 
(nonocclusive) dissections; only one patient had evi-
dence of an occlusive dissection without thrombus 
present.23 Thus, although the primary cause of acute 
closure was most often an occlusive dissection, nonoc-
clusive intracoronary thrombi were associated with 
these dissections in all but one of ten cases.23 It is 
likely that the mechanism of acute occlusion during 
and following the use of the newer interventional de-
vices differs from that of balloon angioplasty (e.g., 
following stent implantation, spasm and dissection ap-
pear less frequently than acute and subacute thrombus 
formation). 
These angioscopic findings throw into question the 
principle that thrombus present~ a relative/absolute 
contraindication to stenting. Indeed many issues con-
cerning the interaction betwcen intracoronary throm-
bus (which has been previously underestimated by 
contrast angiography) and coronary stents have yet to 
be addressed. Is angioscopically detected thrombus 
different from angiographically detectable throm-
bus-is it purely a matter of volume? Should intracor-
onary thrombolytic therapy be routinely administered 
prior to, following, or instead of coronary stent implan-
tation? What precisely happens to thrombus when 
compressed by a balloon or stent? Ts such compressed 
(? dispelled) thrombus less likely to propagate within 
a stent than uncompressed thrombus by reduction in 
surface area of the thrombus? It seems likely that the 
higher rate of thrombotic occlusion seen after bailout 
stenting compared to elective stenting of primary le-
sions, relates at least in part to the higher preexisting 
burden of thrombus in threatened and acute occlu-
sions. The extent of vessel wall damage and release 
of "tissue factors" responsible for platelet activation 
and thrombus fonnation almost certainly also playa 
role, 
Little is known of the incidence of medial hematoma 
in the absence of disscction and while intravascular 
ultrasound may be our only tool for diagnosing Ilondis-
sected hemorrhage in the media, we will remain unable 
to determine the true incidence of such a diagnosis in 
total occlusions until the advent of forward scanning 
intravascular ultrasound technology. Perhaps this 
mechanism in addition to acute recoil may contribute 
to those lesions that are currently referred to as a sub-
optimal result. 
Therapeutic Strategies for Abrupt 
Vessel Closure 
Although the reported therapeutic strategies for 
acute occlusion include standard balloon,24-25 perfu-
sion balloon,26-29 and laser baUoon angioplasty,30 in-
tracoronary stenling,31 directional coronary atherec-
lomy,32 thrombolytic therapy,33,:\-t ultrasonic dissolu-
tion, catheter reperfusion,35.36 and intraaortic balloon 
counterpulsation,37 currently, the two most frequently 
practiced approaches are baUoon angioplasty and 
stcnting. These lattcr two management strategies are 
undcr comparison in the GRACE trial (Gianturco-
Roubin stent Acute Closure Evaluation) (Gianturco-
Roubin stent, Cook Inc. Bloomington, TN, USA), The 
loumai of Illtervelliionai Canlioiog), Vol. 1, No.4, 199-1 
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GRACE trial will address the immediate and long-
tenn efficacy and safety of urgent stent implantation 
in the setting of failed balloon angiop!asty or other 
interventional devices. TIle control limb will be ran-
domized to prolonged andlor repeated balloon dilata-
tion with a minimal accumulative postrandomization 
inflation time of 15 minutes. 
It may be tempting to believe that stenting offers a 
more definitive and, therefore, more effective solution 
than balloon angiopiasty for aCllte and threatened ves-
sel closure. Before this stance should be adopted uni-
versally, however, scientific evidence that can only be 
provided by a randomized trial is required to confirm 
whether this preconception is indeed true. It is also 
critical that we leam to identify which categories of 
threatened closure are most and least suitable for bail-
out coronary stenting or prolonged and/or repeated 
balloon angioplasty. Much of our confidence in stent-
ing has evolved from experience gained in elective 
stenting. The favorable clinical and angiographic re-
sults of coronary stenting (with the Palmaz-Schatz 
mesh stent (Johnson & Johnson Interventional Sys-
tems, Warren, NJ, USA}) obtained in the recent Bene-
stenes and STRESS (STent in REStenosis Study)39 
studies apply only to elective stenting of single proxi-
mal primary lesions ideally suited to stenting in native 
coronary vessels of > 3.0-mm diameter in patients 
with stable angina. The lesions that are most likely to 
develop ahmpt closure following intervention are 
those lesions that are known to increase the risk of 
subacute thrombosis following coronary stenting i.e., 
long lesions, type C lesions containing intracoronary 
thrombus or dissection4D--42 and thus our confidence 
in stenting should be checked until we learn of the 
results of prospective randomized trials using standard 
definitions of comparative treatment of angio-
graphically unattractive vessels with threatened and 
total occlusions (e.g., what is the best management 
strategy for a threatened closure of a complex distal 
lesion of 15-mm length in a small vessel of 2.5-mm 
diameter with proximal tortuosity and possible 
thrombus?). 
Our current preconceptiuns of the results for the 
bailout management of acute or threatened closure by 
stenting or prolonged and repeated balloon angioplasly 
may be distorted by several confounding variables. 
Results to dale have been based on noncomparative 
observational series that have been plagued by (often 
retrospective) detinitions of threatened vessel clo-
sure.40 In addition, different case selection, end point 
definitions and stages of device development bet\\'een 
previously reported observational series make conclu-
sions difficult. For this reason a prospective randolll-
ized trial of bailout management has become necessary 
in order to make a valid scientific judgement on the 
optimal bailout strategy. The GRACE inclusion crite-
ria pennits a range of vessel closure criteria with indi-
vidual subanalyses planned for totally occlusive dis-
sections, and, at the opposite end of the spectmm of 
entry criteria, "the suboptimal result" with> 50% 
diameter stenosis. 
TIle Gianturco-Roubin stenl is a stainless steel coil 
stent that is premounted on a highly compliant balloon. 
While its longitudinal flexibility is excellent, the pri-
mary limitation of the current prototype is its relatively 
high profile, which Illay limit its deployment in distal 
lesions. Proximally tortuous vessels, especially if 
calcified, necessitate the exchange of the guiding cath-
eter or guidewire during the bailout procedure. The 
emcaey of the Gianturco-Roubin stent in the manage-
ment of acute and threatened vessel closure has been 
documented in several observational series.43-4fi In 
one such series reported by Roubin et al.,43 deploy-
ment of the sten! was attempted in the bailout manage-
ment of 115 patients with acute (10% of vessels) or 
threatened closure at a single center between 1989 and 
1991 by operators experienced at stent deployment. 
Angiographic success « 50% residual diameter ste-
nosis) was obtained in 93% of vessels. In three pa-
tients, it was not possible to track a .~tent into the lesion 
on account of diffusely diseased, calcified andlor tor-
tuous proximal segments. In two other vessels, stents 
had been sllccessfully deployed in the right coronary 
artery proximally and attempts at deployment of a sec-
ond stent through the proximal stent failed. In all nve 
cases the nondeployed Gianturco-Roubin stent was re-
moved froIll the patient. Overall in-hospital mortality 
was 1.7% and coronary artery bypass surgery was re-
quired in 4.2%; Q wave myocardial infarction oc-
curred in 7% and non-Q wave myocardial infarction 
in 9%. Stent thrombosis occurred in 7.6%. A major 
hemorrhagic event occurred in 10% of patients; these 
consisted of four gastrointestinal bleeds, two retroperi-
toneal hemorrhages, and six local groin hematomas. 
Additional complications relating to anticoagulation 
therapy post stenting included pericardial tamponade 
in one patient (who had also received intracoronary 
urokinase). Another 13 patients required a transfusion 
of one or more units. Six percent of patients required 
vascular surgical repairs, fOllr for expanding pseu-
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doaneurysms, and one for failure to control femoral 
arterial bleeding. Four other patients developed local 
femoral arterial complications; three pseudoaneu-
rysms and one arteriovenous fistula, none of which 
required surgical intervention. Thus it can be seen that 
while coronary stenting may achieve an acceptable im-
mediate angiographic result in a high percentage of 
patients, the cost in temlS of clinical events is signifi-
cant. These events relate primarily to the delicate bal-
ance between the thrombogenicity of the stented vessel 
and the induced hemorrhagic consequences of antico-
agulation. 
What can we expect from repeated andlor prolonged 
balloon dilatation? Most of the large series of abrupt 
vessel closure treated by balloon angioplasty were re-
ported before the widespread availability of the auto-
perfusion catheter and the coronary stent. Thus, the ef-
fect of technical advances and evolving patient selec-
tion should be taken into consideration when compar-
ing noncontemporaneous series of balloon angioplasty 
with more recent stent series. In a single center experi-
ence reported by de Peyter et aLl of bailout manage-
ment of acute vessel closure of 104 patients between 
1986 and 1988, repeat redilatation with a standard bal-
loon was attempted in 95 patients. Of these 95 patients, 
angiographic success was obtained in only 33 patients 
(3 of whom subsequently reoccluded). The overall 
mortality for the 104 patients treated in this prestent 
era was 6% and the myocardial infarction rate (com-
bined non-Q wave and Q wave) was 36%. Clearly 
these results are less favorable than those reported 
more recently for bailout stenting. Perhaps the most 
significant difference in the above two series of bailout 
management by repeat balloon dilatation reported by 
de Peyter et al. l and by stenting reported by Roubin 
et al.43 is the very different inclusion criteria. In the 
~eries reporting outcome for repeat balloon dilatation 
all patients had either a complete (TIM! flow 0) or 
critical reduction in flow (TIMI flow I or 2), while in 
the series reporting outcome for bailout stenting only 
10% had TIMT flow 0 or 1 and only another 16% 
had TIMI flow 2. This major difference in inclusion 
criteria again serves to emphasize the scientific inval-
idity of drawing hard conclusions on the comparative 
efficacy of two devices on the basis of nonrandomized 
observational series. Despite the apparent limitations 
of stenting, the need to pursue carefully perfomled 
clinical studies is compelling. Tn a recent rcport44 of 
the multicenter experience of the Gianturco-Roubin 
stent, 156 patients with established acute closure 
(TIMI 0 or I flow) were identified. In this cohort, stent-
ing resulted in a relatively favorable outcome with a 
2.69 mortality (7.7% emergency coronary artery by-
pass surgery and 7.6% incidence of myocardial infarc-
tion (3.8% Q wave). 
With the advent of the perfusion balloon, results of 
small series would indicate that the prolongation of 
the inflation time (to approximately J8 minutes) per-
mitted by the perfusion balloon conveys a therapeutic 
advantage over the shorter inflation times (approxi-
mately I J minutes) of conventional repeated balloon 
dilatation.47 Further prolongation of inflation time of 
a perfusion balloon to several hours, however, appears 
to convey no further advantage.48 
Accepting the above caveats, it might be cautiously 
expected that those patients in the GRACE trial who 
are randomized to prolonged andlor repeated balloon 
inflation would be unlikely to have such a high angio-
graphic success rate compared to those randomized to 
stenting. However, for those patients who do respond 
to repeat balloon dilalation without crossing over to 
stenting, the subsequent clinical event rates are likely 
to compare very favorably with those patients assigned 
to stenting. 
A key feature of the GRACE trial (possibly of more 
benefit to the balloon limb) is a minimal period of 
waiting 15 minutes after obtaining angiographic suc-
cess by bailout management to ensure that the vessel 
patency is maintained. In a report by Satler et al.49 of 
1,000 consecutive cases, who underwent repeat angi-
ography 10 minutes after the last balloon inflation of 
elective balloon angioplasty. partial or total loss of 
the initial gain was observed in 7% of cases requiring 
further balloon dilatation, A second period of 10 min-
utes was allowed before the final angiographic study. 
In this series, the incidence of abrupt vessel closure 
after patients left the catheterization laboratory was 
< 1 %, suggesting that repeat dilatation may prevent 
subsequent abrupt vessel closure in patients with early 
loss of the initial improvement after balloon angio-
plasty. 
Lessons Learned from Prestudy and 
the Concept of the Evolving Protocol 
One important aspect of the trial design is the inclu-
sion of a prestudy phase of over 200 patients during 
which investigators must exhibit proficiency at im-
Journal of Interventional Cardiology Vol. 7, No.4, 199-1 
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plantation of the Gianturco-Roubin stent. Before com-
mencing the fonnal GRACE trial, the investigator 
must have a less than 5% rate of subacute closure or 
thrombosis and < 10% rate of hemorrhagic complica-
tions during the prestudy. Furthermore, investigators 
should have enough potential patients to meet the min-
imum cases per institution criterion. This design con-
cept represents a new direction in interventional trials 
with emphasis on optimal performance by all investi-
gators at the upper plateau of the learning curve. 
Significant procedural experience has been gained 
during the GRACE prestudy at the 21 participating 
centers. Over 300 stents have been implanted in over 
250 patients. While investigators with less previous 
stent experience were encouraged to begin the 
prestudy with elective stenling of primary lesions, over 
two thirds of the stents of the prestudy have been im-
planted for the nonrandomized bailout management 
of acute or threatened closure. Thus the procedural 
experience gained during the prestudy should serve 
well the randomized phase. 
Given the rapid evolution of coronary slenting and 
the enthusiastic embracement of new developments in 
this field, the results of any clinical trial of coronary 
stenting are almost redundant before the completion 
of the randomization and follow-up. A trial of bailout 
therapy such as the GRACE trial would be particularly 
prone to rapid developments in coronary stenting, 
given that even at centers with a high volume of inter-
ventional procedures the incidence of abrupt vessel 
closure remains low and thus recruitment of 250 pa-
tients is likely to require 12 months. To overcome this 
risk, the GRACE trial has attempted to adopt evolving 
clinical strategies learned during the conduction of its 
prestudy. When the first draft of the protocol was writ-
ten in 1992, anticoagulation poststenting by the admin-
istration of intravenous heparin for several days t"ol-
lowed by the administration of warfarin fur 3 months 
was practiced almost universally and this standard reg-
imen was, therefore, incorporated in the original study 
protocol. During the GRACE prestudy, alternative ap-
proaches to reduce the incidence of thrombotic occlu-
sion were developed in Europe by investigators partic-
ipating in GRACE. A survey of the preferred anticoag-
ulation practice of the GRACE participants revealed 
that .~ome of the centers no longer prescribed warfarin 
routinely post elective or bailout stenting. TIle use of 
ticlopidine had been adopted in many of the French 
centers as an alternative to warfarin5()-52 and the use 
of intravascular ultrasound to confirm optimal and 
symmetrical stent expansion was introduced in an Ital-
ian center 10 reduce the incidence of subacute throm-
bosis.53 To ensure that the results of the randomized 
phase of the GRACE trial would have implications for 
current practice, those investigators who had estab-
lished these alternative anticoagulation strategies in 
their routine practice were pennitted to do so in the 
trial by a revision of the GRACE protocol. 
TIle issues of stent sizing and postdeployment dila-
tation have also continued to evolve. During the writ-
ing of the original GRACE protocol in 1992, most 
investigators matched the nominal (labelled) stent size 
to the vessel size (i.e., to the diameter of the "normal" 
proximal and distal segments) and postdeployment dil-
atation with another balloon was not routinely per-
formed. Quantitative coronary angiographic studies at 
the University of Alabama and at the Thoraxcenter 
of patients in the prestudy of GRACE54 revealed a 
significant degree of under expansion that follows low 
pressure deployment of the Gianturco-Roubin coil 
stent by the premounted highly complianl polyethyl-
ene balloon. As a result, the GRACE protocol on stent 
sizing was revised to advise a policy of stcnt oversiz-
ing (by 0.5-mm) and when necessary to perform fur-
ther dilatations with a noncompliant balloon or to im-
plant additional Gianturco-Roubin stcnts to increase 
the total radial force. Preliminary quantitative coro-
nary angiographic analysis of the baseline data of those 
patients that have recently entered the randomized 
phase of GRACE has confinned that the policy of stent 
oversizing has indeed been adopted. 
Conclusion 
The need for a multicenter randomized trial to study 
the clinical success of stenting versus prolonged atHV 
or repealed balloon inflation for the treatment of acute 
closure is apparent. The rapid dcvelopments in the 
clinical practice of stenting have presented exciting 
challcnges for the design and execution of such a trial. 
TIIC experiences from II prestudy and a flexibility of 
the protocol to accommodate evolving strategies of 
stent practice, should ensure that the results of the ran-
domized phase of GRACE will have clinical relevance 
for the practice of coronary stenting by operators who 
arc advanced along the plateau oflhe procedural Ie am-
ing curve. 
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Editorial 
The Bailout Stent 
Is a Friend in Need Always a Friend Indeed? 
Patrick \Y. Serruys, MD, PhD; David Keane, MB, MRCPI 
When im'ited to write an editorial on bailout ~ stenting, many titles came to mind-"The Double-Edged Sword," "Friend or Foe," 
and "Jekyll and Hyde" - to convey the current balance 
of the efficacy and the risk associated with bailout stelll 
therapy. Rather than consolidating the role of stenting 
in the emergency management of abrupt or threatened 
occlusion following coronary interventional procedures, 
the observational study reported by Hearn and col-
leagues in this issue of Circulation! raises further ques-
tions over the benefit-Io-risk ratio of bailout sirnling. 
See" 2086 
Abrupt vessel closure occurs during coronary balloon 
angioplasty in 5.6% of patients, whereas an additional 
1.7% of patients develop an occlusion during the fol-
lowing 24-hour period.2 The mechanisms of abrupt 
coronary occlusion include a combination of dissection, 
subintimal hemorrhage, thrombus formation, vasocon-
striction, and elastic recoil,3 When acute coronary oc-
clusion persists, it leads to myocardial infarction in 
about 40% of cases and death in about 4%. 
In the early experience of balloon angioplasty, abrupt 
occlusion was managed by emergency coronary artery 
bypass surgery. In contrast to elective surgery, however, 
emergency surgery was found to convey a high morbid-
ity and mortality risk. As experience with balloon 
angioplnsty grew, the practice of immediate redilatation 
was developed. While prolonged balloon inflation with 
or without a perfusion balloon or laser balloon angio-
plasty offered an alternative to emergency surgical 
management, they rarely achieved definitive success. 
Thrombolytic therapy (either intravenous or intnlcoro-
nary) has been anecdotally successful. However, the 
overall experience has been disappointing. Moreover, if 
the patient proceeds to emergency surgery, prior throm-
bolytic therapy may complicate the operation. Despite 
these strategics, abrupt closure after coronary interven-
tion continues to result in unacceptable morbidity and 
mortality. With such room for imprm'ement, stenting 
with its scaffolding propertics opencd a new avenue, 
and while initially viewed by some as a bridge to surgery, 
it is now heralded by many as the path to avoid surgery. 
The opinions expressed in this editorial ronunent are not neces-
sarily those of the editllN or of the American Heart Association. 
From the Department of Interwntional Cardiology, Thora.x- , 
center, Erasmus University, Rotterdam, The Netherlands. 
Correspondence to Dr Patrick W. Serruys, Department of 
inter\"entional Cardiolugy, Thoraxcenter, Erasmus University, Ec 
2332, PO Dox 1738, DR 30lln, Rotterdam. The Netherlands. 
The Paradox 
Considerable overlap exists behveen the lesional 
characteristics predisposing to abrupt closure following 
coronary intcrventional procedures and the relative 
contraindications to electivc stenting (and thus it could 
be thought that thc bailout stent gives coronary stenting 
a bad reputation): Univariate and multivariate analyses 
of qualitative and quantitative eriteria have shown that 
severe, long, complex lesions, at a branch or bend point, 
of ACC/AHA type B, C, containing intracoronary 
thrombus or dissection and unstable angina lead to an 
increased likelihood of acute closure following balloon 
angioplasty. While factors found to predict subacute 
thrombosis after stent implantation have included bail· 
out indication (odds ratio, 5.4), lesion length, type C 
lesion, stent size <3.25 mm, residual thrombus, and 
unstable angina.4~ 
Unfortunately, in the setting of an abrupt vessel 
closure attended by acute ischemic consequences, an 
operator is unable to electively select only those vessels 
and lesion characteristics that are ideally suited to stent 
implantation. Thus, vessels containing characteristics 
that might normally be regarded as relative contraindi-
cations to stenting frequently impose themselves on the 
interventionist who is left with a choice of either 
stenling under unfavorable conditions or adopting an 
alternative, less-eJlective strategy known to carry a 
higher risk, Stenting in bailout management could be 
considered the best of a bad 101. In large vessels, 
subtending a substantial amount of myocardium, which 
develop a totally occ\usiye dissection, the case for 
bailout stenting appears clear (white), whereas for small 
vessels <2 mm developing a subocc\usive thrombosis 
following intervention, the preferencc for stenting over 
alternative nonsurgical strategies is weak (black). Un-
fortunately, like many aspects of medicine, most cases 
fall into a "gray" intermediate category. 
Empty Tlneats? 
Studies of emergency therapy are inherently con-
founded by terminology and the quality of data acqui-
sition. In the case of bailout stenting, although the term 
"acute closure" of a vessel appears steadfast and clear, 
the term "threatened closure" appcars soft and open to 
interpretation by the operator. Indeed, a threatened 
event such as an "impending myocardial infarction" is a 
diagnosis that in reality can only be confirmed after the 
event if intervention is withheld. In the observational 
study reported by Hearn et ai, the definition of threat-
ened occlusion included either static or dynamic ele-
ments. 1 A static component such as a large dissection 
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will remain subjective, whereas the incorporation of an 
evolving process such as a recorded decrease in luminal 
diameter or ch,mge in TIMI grade flow over time offers 
a more rigorous approach. In most reports on bailout 
stenting, outcome for threatened occlusion has been 
grouped to include a wide spectrum of angiographic, 
ECG, or clinical criteria, thus rendering the results 
difiicult to interprct and limiting their direct applicabil-
ity to clinical practice. 
The Learning Cun'c and the Legacy 
The historical series of bailout coronary stenting 
reported by Hearn et al' reflects the early experience of 
coronary stenting. Behveen September 1987 and De-
cember 1990, Gianturco Roubin stents were implanted 
in 103 patients. In view of the approximately 3- to 6-year 
time span from stcnt implantation to publication of the 
resuits, the report is to some extent of limited relevance 
to the current practice of coronary slenting. The design 
of the pioneering series necessitated the referral to 
bypass surgery of all nine patients in the first phase of 
the study and an additional nine patients in phase II in 
whom potential closure "muld have incurred a signifi-
cant risk of mortality. Their rate of emergency coronary 
artery bypass surgery for ongoing ischemia after stenl 
implantation was 11 of 98 patients (11%) in whom 
stenting was attempted and in whom surgery was not 
mandated by the study protocol. Their ratcs of in-
hospital q wave myocardial infarction and mortality 
after stenting were 4.9% and 4.0%, respectively. It is not 
possible to decipher whether their results with bailout 
stenting improved over the 3-year study period as the 
sequential breakdown of their results is presented in 
only two phases, with the first phase containing only the 
first nine patients as above. 
In a second single-center observational series of 
bailout therapy with Gianturco Roubin stents in 115 
patients between October 1989 and June 1991 involving 
an operator previously experienced with Gianturco 
Roubin stent implantation, the in-hospital rates for 
emergency bypass surgery, q-wave myocardial infarc-
tion, and mortality were 4.2%, 7%, and 1.7%, respec-
tively.6 A comparable outcome was subsequently re-
ported in a multicenter study of similar design.7 These 
results were favorable considering that in a meta-
analysis of nine series of bailout stent therapy incorpo-
rating an accumulative experience of five different stent 
prototypes in 464 patients from 1986 through 1991, 
mean rates of in-hospital emergency bypass surgery, 
myocardial infarction, and mortality were 8.4%, 10.6%, 
and 4.1%, respectively.s 
The Pl'Ospects 
Clearly, the results of the above bailout studies com-
pare poorly with those reported for elective stenting 
from the same era. It would also be envisaged that over 
recent years the outlook for all stenting has improved 
due to advances in procedural and post procedural man-
agement. Following the observations that subacute 
thrombosis and restenosis occur more frequently in 
stents of smaller size and the quantitative angiographic 
observations that even during maximal stent inflation 
the nominal manufacturer's size of a stent is rarely 
achieved and that recoil immediately after stenl implan-
tation is the order of 20%,9 policies have changed from 
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matching stent size in the reference vessel diameter to a 
policy of choosing a stent of slightly larger nominal size 
than the reference vessel size to compensate for the 
above limitations. On the basis of a large databank at 
the Thoraxcenter of balloon angioplasty procedures, 
only approximately 20% of the population would be 
able to receive a stent of more than 3.0 mill under a 
policy of strict matching for vessel size. In the series 
reported by Hearn et aP a stent size of >3.0 mm was 
chosen in only 16% of patients which compares with the 
series of Roubin et al where 17% of stents deployed 
were >3.0 nlln.6 The stent sizing chosen by Hearn et al 
may, however, have been influenced by their process of 
patient selection whereby patients were selected if they 
had "lesions that, if closed after stent placement, would 
not result in massive myocardial ischemia or hemody-
namic instability." It is noteworthy that the recent 
Benestent I and STRESS trials on electivc stenting 
excluded vessels of <3.0 mm. 
A second change in policy is the criterion of proce-
dural success, In the reporl of Hearn et al,1 procedural 
success was defined as <50% residual diameter steno-
sis. As with other interventional techniques the current 
aim in coronary stenting is now changing to achieve a 
"zero" percent residual diameter stenosis. This latter 
change in policy is likely to have a major effect in both 
short- and long-term outcome after coronary stcnting 
particularly in patients receiving a stent of small size. 
Accurate implementation of both the new stcnt-sizing 
policy and the policy of greater luminal gain (the bigger 
the better) has recently been made possible by the 
almost ubiquitous presence of on-line computerized 
quantitative coronary angiography in the interventional 
suitc. 
The advent of intracoronary imaging has further 
improved procedural management. Intracoronary ultra-
sound can be used to detect asymmetrical stent expan-
sion or residual dissection behind a stent, whereas 
angioscopy can provide valuable information on stent 
deployment with the detection of luminal encroachment 
at sites of articulation in a mesh stent or protrusion of 
intima between struts in a coil stent, both of which may 
be ameliorated by the placement of a second stent or 
prolonged or high-pressure inflation of a noncompliant 
balloon within the sten!. Furthermore, angioscopy can 
detect the development of thrombus within a stent that 
can be treated with intracoronary urokinase or t-PA. As 
a reflection of its practical value, angioscopy altered 
management in 18 cases in a recent series of 50 stenl 
implantations (unpublished data from the Scripps Clinic 
and Research Foundation and the Arizona Heart 
Institute). 
The postprocedural hazard of subacute thrombosis 
continues to curb enthusiasm for coronary stenting. 
Once solved, the inherent complications of our current 
approach to its prevention will be obviated, ie, internal 
hemorrhage and local femoral arterial ,complications. 
While the development of material that is less throm-
bogenic than stainless steel and tantalum has so far 
been disappointing, local coating of struts with heparin 
may offer some hopelO and will be addressed by the 
ongoing pilot phase of the Benestent II trial. In the 
meantime, the optimization of anticoagulant control by 
the use of the coagulant markers. TAT and FHl have 
helped to drastically reduce the incidence of subacute 
thrombosis.s.1l Furthermore, improved mechanisms of 
achieving local hemostasis by Vasoseal-$i and collagen 
plugs in addition to the use of mechanical devices such 
as Femostop® and clamping devices, have facilitated 
uninterrupted anticoagulant therapy following stent im-
plantation. Recently, some investigators have opted to 
not anticoagulate patients receiving large-diameter 
stents after optimal deployment has been confirmed by 
intracoronary imaging.12 However, the safety of this 
approach has not been determined, 
The Selection 
All series of bailout stenting have reported a high 
implantation success rate, which is remarkable taking 
into account the technical difficulties that may be en-
countered in a bailout situation. Disappearance of 
angiographic landmarks and spasm of the vessel seg-
ment may render stent delivery and correct positioning 
difficult.-The selection of the diameter, length and type 
of stent, and selection of the guide wire and guiding 
catheter may all influence deployment success. In the 
case of acute takeoff and tortuosity, longitudinal flexi-
bility of the stent is desirable. 
Sten! selection may also be guided by mural tomo-
graphic information provided by intracoronary ultra-
sound. Lesions characterized by excessive clastic recoil 
may require a "hard" stent with strong circumferential 
support such a mesh sten! with sturdy metallic struts, 
whereas lesions that have been extensively disrupted 
may require only a "soft" stenl with a lighter architec-
ture and minimal metallic surface area. The precise 
effect of lesional characteristics and the role of intra-
coronary ultrasound in the determination of stent re-
quirements are an area of future research. 
fIn Doubt - Let's Randomize' 
Are randomized trials of bailout coronary stenting 
ethical? A fractured radius is currently managed by 
fixation in a plaster of Paris. Yet the need for a 
randomized controlled trial of fixation of limb fractures 
has been deemed to be unnecessary. As we feel confi-
dent from observational studies that bailout stenting 
can be effective in the prevention of myocardial infarc-
tion and the preemption of emergency bypass surgery, 
how can randomized trials of bailout stenting be war-
ranted? Until such time as thc thrombotic and hemor-
rhagic sequelae of coronary stenting can be overcome, 
randomization of patients to the nonstenting limb of a 
controlled trial seems ethical. The policy proposed by 
Andreas Gruntzig and echoed by Spencer King-"in 
doubt - Let's randomize" - still appears reasonable. 
The Gianturco Roubin Stent Acute Closure Evalua-
tion (GRACE) trial will address the immediate and 
long-term efficacy and safety of urgent stent implanta-
tion in the setting of failed balloon angioplasty or other 
interventional device. The control limb will be random-
ized to prolonged and/or repeated balloon dilatation. 
One important aspect of the trial design is the inclusion 
of a pre study phase on 200 patients during which 
investigators must exhibit proficiency at implantation of 
the Gianturco Roubin sten!. Before commencing the 
formal GRACE trial, the investigator must have a less 
than 5% rate of subacute closure or thrombosis and less 
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than 10% rate of hemorrhagic complications during the 
prestudy. Furthermore, investigators should have 
enough potential patients to meet the minimum cases 
per institution criterion. This design concept represents 
a new direction in interventional trials in keeping with 
the upcoming directional atherectomy trials EURO-
CARE «20% residual stenosis required) and OARS 
and BOAT, with emphasis on optimal performance by 
all investigators at the upper plateau of the learning 
curve. 
The Showdonn 
To convincingly evaluate the relative merits and de-
merits of bailout slcnting, large, multicenter random-
ized trials need to be conducted exclusively by experi-
enced operators at high-volume centers over a short 
period of time and reported expeditiously to have an 
impact on current practice. 
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Chapter XIV 
The new AVE Micro coronary stent as a single stent or 
as a complementary device for multiple stenting. 
David Keane, Yukio Ozaki, Peter Ruygrok, Pim de Feyter, Simon Stertzer!! 
and Patrick W. Serruys. 
Catheterization Laboratory, Thoraxcenter, Erasmus University, Rotterdam 
& 
"* Division of Cardiovascular Medicine, Stanford University Medical Center 
Part of this chapter will be published in Am J Cardlol 1995;in press, 
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ABSTRACT: 
Background. The range of short lengths (4 to 16mm), the radiopacity of the stent struts, and the 
premo un ted balloon-expandable user-friendly delivery system, render the new AVE Micro stent 
suitable for either the treatment of short focal dissections as a single device or for the treatment of 
long complex dissections as a complementary device in combination with longer stents of different 
design. In particular, the short design of the Micro stent render it ideal for improving the inflow and 
outflow of longer stents and for bridging the gap between both proximally and distally deployed 
stents. 
Methods. We report our experience with this novel stent as a versatile component of a multiple stent 
strategy for the treatment of complex coronary dissections. Deployment of 36 AVE micro stents was 
attempted in 28 coronary lesions in 25 patients who developed acute or threatened closure after 
balloon angioplasty. Fourteen stents Were deployed in the left anterior descending artery, 12 in the 
circumflex, and 10 in the right coronary artery. Twelve of the 28 lesions were at ostial or bifurcation 
sites. All patients were managed with intravenous and oral anticoagulant therapy post intervention. 
Luminal dimensions at the site of the Micro stent deployment were measured using a computer-
based quantitative coronary angiography system (CAAS 11). The acute angiographic results as well 
as the thirty day clinical event rate are reported. 
Procedural outcome. Stent deployment was successful in 35 of 36 attempts (98%). In one patient 
the attempted stent deployment was unsuccessful and the patient was managed by emergency 
coronary artery bypass surgery while in twenty-four patients stent deployment was successful. In 
five of the twenty-four patients Micro stents were deployed as a single device to treat short 
dissections while in nineteen patients Micro stents were deployed as part of a multiple stent strategy 
for long dissections. In four of the nineteen patients who received multiple stents, all of the stents 
were Micro. In fifteen of the patients the Micro stent was deployed in combination with longer stents 
of different design. In ten patients Micro stents were advanced through proximally deployed stents 
and in four patients stents of different design were advanced through proximally deployed Micro 
stents. In no patient did stents become caught in other stents during stent delivery, however, in one 
patient following successful delivery of the Micro stent to the target site proximal migration of the 
stent occurred during the deployment process. 
Clinical events. The patient who underwent emergency coronary artery bypass surgery made an 
otherwise uneventful post-operative recovery. The clinical course of the 24 patients in whom stent 
deployment was successful was free of coronary re-intervention, bypass surgery and death. A 
myocardial infarction was observed in 2 patients (8%), in one of whom the stent was implanted 
within 24 hours after the onset of acute myocardial infarction and in the other acute vessel occlusion 
was present for 58 minutes prior to stent implantation. A femoral haemorrhage and haematuria 
requiring blood transfusion was observed in one patient (4%). No subacute occlusion was observed. 
Event-free survival at 30 days following stent implantation was 88% (22 of 25 patients), 
Angiographlc outcome : Minimal luminal diameter (MLD) was 0.79 ± O.56mm pre BA, 2,67 
±0.40mm during balloon inflation, 1.21 ±0.62mm post BA, 3.26 ± O.47mm during stenting, 2.70 
±0.48mm post stent, 3.42 ±0.46mm during balloon inflation post stenting (Swiss Kiss), and 2.85 
±0.44mm post Swiss Kiss. Average percent diameter stenosis was reduced from 70% pre BA 
through 55% post SA to 16% post stenting. During the initial stent implantation, stent recoil was 
0,56±0.31mm (17±9% of MLD during stent inflation). A Swiss Kiss was performed in 14 Micro 
stents with an average pressure of 14 ± 3 atmosphere and residual stenosis was reduced from 
2.54mm (20% diameter stenosis) to 2.85mm (15% diameter stenosis) in these lesions. Angiographic 
success « 30% residual diameter stenosis) was achieved in all stented lesions. 
Conclusion. The results of this early experience would indicate that the new AVE micro stent may 
be deployed as either a stand-alone stent or as complementary device for multiple stenting with a 
high procedural success rate and a minimal learning curve. Specifically the Micro stent can be 
successfully passed through other proximal stents which have been optimally deployed. While 
primary deployment of this new balloon-expandable stent significantly reduced residual diameter 
stenosis and restored coronary flow after failed SA, performance of additional high-pressure intra-
stent balloon inflations (Swiss Kiss) may optimize the angiographic outcome. 
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INTRODUCTION: 
One of the major risks associated with balloon angioplasty (8A) is acute or threatened 
closure of the coronary artery. When acute coronary occlusion persists following balloon 
dilatation, 27 to 40% of the patients sustain a myocardial infarction and 4 to 5% of the 
patients die [1-BJ. Several non-randomized studies have suggested that deployment of the 
Wallstent [9,1 OJ, Gianturco-Roubin stent [11-15), or Palmaz-Schatz stent [16,17,18) may 
be of value in the bailout management [20,21] of acute or threatened closure following BA. 
Given the spectrum of structural design and metallic composition of currently available 
stents it cannot be presumed that clinical results obtained with one stent will be 
necessarily matched by stents of alternative design and each stent will thus have to 
undergo individual clinical evaluation. A number of second generation stents have recently 
been developed and are currently entering the clinical arena. One of the most recently 
developed stents is the AVE micro stent. This short stent represents a new direction in 
coronary stent design characterized by a simple balloon expandable deployment technique, 
0.008" stainless steel struts with moderate radiopacity, a zig-zag structure, and is 
composed of 4mm welded and unconnected segments providing a range of lengths from 
4 to 16 mm Isee Figure 1). 
This study reports our early experience with the AVE micro stent in the clinical arena. 
Clinical events up to thirty days (to cover both the period of in-hospital events and period 
of risk of subacute thrombosis) are reported as well as the acute angiographic results. 
Quantitative angiographic measurements at the site of the Micro stent deployment were 
made at 7 intraprocedural phases; pre primary balloon angioplasty, during primary balloon 
inflation, post balloon angioplasty at the time of acute or threatened vessel closure, during 
stent inflation, post stent deployment, during high pressure intra-stent balloon inflation 
(Swiss Kiss), and final post Swiss Kiss, using a quantitative coronary angiographic analysis 
system ICAAS II). 
METHODS: 
Patients : To determine the feasibility and safety of deployment of this new stent, we 
deployed 36 AVE micro stents in 28 native coronary artery lesions in 25 patients who 
developed acute or threatened closure after balloon angioplasty (BA). Clinical 
characteristics of the study population are provided in Table 1. Average age was 55 ± 7 
ranging from 45 to 68 years old and 21 patients were male. Sixteen patients had stable 
angina and the remaining 9 patients had unstable angina [21]. Of the 9 patients with 
unstable angina 4 patients had Braunwald type II and 5 had type III (21). 
Criteria of acute and threatened vessel closure: Post BA lesion morphology was 
categorized according to the dissection criteria proposed by Huber et al [22] and coronary 
flow distal to the lesion was classified according to the TIMI criteria [23]. Acute occlusion 
was defined as TlMI 0 flow. Threatened closure was defined as TlMI 1,2 or 3 flow with 
visible dissection type C, 0, E or F, or as dissection type A or 8 and TIMI 1,2 or 3 flow 
with a residual diameter stenosis of greater than 50% [22,23}. 
Stent Design: This short stent is characterized by a simple balloon expandable deployment 
technique, 0.008" stainless steel struts with moderate radiopacity and a zig-zag structure. 
Metallic surface area in the expanded state has been found in vitro to be 8.4% for the 
stent of 3.5mm diameter. This stent is composed of 4mm welded and unconnected 
segments providing a range of lengths from 4 to 16 mm (Figure 1). 
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Figure 1. A 8 mm A VE Micro stent. The A VE micro stent is a pre-mounted balloon-expandable stainless steel 
stent composed of 4mm welded or unconnected segments. 
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Table 1. Clinical characteristics of 25 patients 
Gender, male 
Angina pectoris type-l' 
Stable 
Unstable 
Prior MI 
Prior SA 
Prior CABG 
Coronary risk factors; 
Hypercholesterolemia 
Systemic hypertension 
Cigarette smoking 
Diabetes 
AVE Nicro stent as a single or complementary device 
Number of Patients 
(25) 
21 
16 
9 
10 
11 
2 
12 
10 
9 
3 
MI; myocardial infarction, BA; balloon angioplasty, CABG; coronary artery bypass grafts, * Angina 
pectoris classification /21 J. 
Balloon Angioplasty and Stent Implantation : Balloon angioplasty and stent deployment 
were performed according to standard clinical practice by the femoral approach at the 
Thoraxcenter (Rotterdam, The Netherlands). The coronary stents were delivered on a pre~ 
mounted balloon catheter. The size of the balloon is .25mm larger than the stent diameter 
to allow for stent recoil. Selection of the nominal stent size was determined to match the 
vessel reference diameter obtained from on-line quantitative angiographic measurement. 
Of the 36 stents used in 28 lesions, 13 were of 3mm diameter, 19 were 3.5mm and 4 
were 4mm in diameter. Of the 36 stents 9 were 4mm in length, 22 were Bmm, 2 were 
12mm, and 3 were 16mm in length. 
During the primary balloon angioplasty, the nominal balloon diameter was 3.04 ±0,41 mm 
and the maximum inflation pressure given was 9.6 ±3.1 atmospheres. Following initial 
deployment of the stent high pressure inflations (14.6 ±3.1 atmospheres) to optimise 
stent expansion (Swiss Kiss) were made with balloons of 3.58 ±O.52mm nominal 
diameter. 
The coronary position of the Micro stent relative to the other multiple stents and the order 
of deployment of the multiple stents is provided in Table 3. 
Anticoagulant therapy : At the beginning of the procedure, patients were given an 
intravenous bolus dose of 10,000 i.u. of heparin, and subsequently 5,000 Lu. as required 
to maintain the ACT (activated clotting time) > 300s throughout the procedure. The post 
intervention anticoagulant regimen was conventional {24] : One hour following removal of 
the femoral sheath, a heparin intravenous infusion was commenced to maintain the APTT 
(activated partial thromboplastin time) between 70 to 90s until oral anticoagulant therapy 
(Coumadin) had achieved a PT INR (prothrombin time international normalised ratio) of 2.5 
to 3.5. Coumadin was prescribed for three months post stent implantation and aspirin 
indefinitely [241. 
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Figure 2. Reconstruction of a right coronary artery by multiple stenting following successful recannalization 
of a chronic total occlusion fAJ. Following successful advancement of a guide wire through the proximal 
occlusion, balloon angioplasty was performed throughout the epicardial course of the vessel. Two Wallstents 
(nominal diameters 6. a and 5. 5 mm, nominal length 45 and 45 mm when maximally expanded) were placed 
in AHA segments 1 and 2 (proximal and mid right coronary artery) fBJ. Two manually crimped Palmaz-Schatz 
stents (15mm nominal length) were placed in AHA segment 3 (distal right coronary artery) leaving a short 
unstented gap between the distal end of the Walls tent and the proximal end of the Palmaz-Schatz stent. A 
single AVE Micro stent Idiameter 4.0mm, length 4,Omm) was deployed to bridge the unstented gap using 
the radiopacity of the short thick struts to aid the precise posWoning and to avoid overlap with the other 
stents fC)' Contrast angiography of the resultant vessel reveals a continuity of vessel calibre throughout the 
reconstituted artery with an appropriate degree of tapering [OJ. 
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Quantitative coronary angiographic analysis: The new version of the computer-based 
Coronary Angiography Analysis System (CAAS 1I)(25,26J was used to perform the 
quantitative analysis. In the CAAS analysis which has previously been described elsewhere 
[26-29J, the entire cineframe of 18 x 24 mm is digitized at a resolution of 1329 x 1772 
pixels. Correction for pincushion distortion is performed before analysis. Boundaries of a 
selected coronary segment are detected automatically. The absolute diameter (mm) of the 
stenosis is determined using the guiding catheter as a scaling device. To standardize the 
method of angiographic analysis, the following measures were taken ; all study frames 
selected for analysis were end-diastolic to minimize motion artifact, and arterial segments 
were measured between the same identifiable branch points after the administration of 
isosorbide dinitrate [30,31] at each stage of the procedure. 
Study endpoints and definition : The primary clinical endpoint of the study was the 
occurrence of any of the following adverse cardiac events ; acute or subacute stent 
thrombosis, repeat intervention, coronary artery bypass surgery, myocardial infarction or 
death. Procedural success was defined as technically successful deployment of the stent 
in the absence of an adverse cardiac event. Angiographic success was defined as a less 
than 30% residual diameter stenosis following final deployment of the stent. Subacute 
thrombosis was defined as a stent thrombosis within 14 days of deployment. Acute clinical 
outcome included all cardiovascular events occurring within 1 month of stent deployment. 
Statistical analysis: Paired Student's t-test was used to compare sequential changes at 
the same segment in the same patients. A p value of less than 0.05 was considered 
significant. 
RESULTS: 
lesion characteristics: The angiographic characteristics of the treated lesions are given in 
table 2. Of 28 lesions, 10 lesions were the left anterior descending coronary arteries, 8 
were the right coronary arteries and the remaining 10 lesions were the circumflex coronary 
arteries. Five of the lesions were ostial and seven were at sites of major bifurcation. Pre 
balloon angioplasty, the lesions were categorized according to the AHA/ACC Task Force 
criteria [32]. Of the 28 lesions, 3 lesions were type A, 17 were type B, and the remaining 
8 lesions were type C. Post primary balloon angioplasty, at the time of acute or threatened 
vessel closure 3 lesions had a type A dissection (with> 50% diameter stenosis), 1 a type 
B dissection (with > 50% diameter stenosis), 14 a type C dissection, 1 a type D 
dissection, 8 a type E dissection and 1 a type F dissection [22]. At this pre-stent phase, 
TlMI flow [23] was grade 0 in 1 lesion, grade 2 in 9 lesions and grade 3 in 18 lesions and 
the angiographic appearance of intra coronary thrombus (intraluminal filling defect) was 
present in 8 lesions [33]. 
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Table 2, Angiographic lesion characteristics of 28" lesions 
Number 
location of lesions 
LAD 10 
RCA 8 
LCX 10 
Portion of artery stented 
ostial or major bifurcation site 12 
middle segment 16 
Modified AHA/ACC classification lf 
type A 3 
type B1 6 
type 82 11 
type C 8 
Type of dissection before stent If If 
type A 3 
type B 1 
type C 14 
type D 1 
type E 8 
type F 1 
TIMI flow before stent If If If 
TIMIO 1 
TIM I 1 0 
TIM I 2 9 
TIMI3 18 
Thrombus before stent If If If If 8 
Indication for stanting 
Threatened closure 27 
Acute complete occlusion 1 
BA; balloon angioplasty, CABG; coronary artery bypass grafts, LAD; left anterior coronary artery, 
RCA; right coronary artery, LCX; left circumflex coronary artery. *AHAIACC task force {32}, 
* *Dissection classification {22}, * * lfTlMI flow {23}, * *:. *Presence of thrombus/33}. 
Procedural outcome: Stent delivery was possible in 35 of 36 stents (97%). In one patient 
the stent could not be advanced beyond a curved branch point to the target stenosis in the 
mid-left anterior descending artery. The unexpanded stent was withdrawn through the 
guiding catheter without difficulty and the patient was managed by emergency bypass 
surgery after which the patient had no further event. In a second patient, a 12 mm stent 
was deployed at the origin of the left anterior descending artery, During the process of 
stent inflation the proximal un welded 4mm unit of the 12mm stent migrated proximally 
into the mainstem of the left coronary artery. This 4mm unit was then expanded fully in 
the left mainstem and the patient had an uneventful clinical course. 
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In five of the twenty-four patients Micro stents were deployed as a single device to treat 
short dissections while in nineteen patients Micro stents were deployed as part of a 
multiple stent strategy for long dissections. The Micro stent was used to both improve the 
inflow and outflow of longer stents of different design as well as to bridge the gap 
between longer proximal and distal stents. In table 3, the relative position and order of 
deployment of each of the Micro stents are listed individually. In four of the nineteen 
patients who received multiple stents, all of the stents were Micro. In fifteen of the 
patients the Micro stent was deployed in combination with longer stents of different 
design. In ten patients Micro stents were advanced through proximally deployed stents and 
in four patients stents of different design were advanced through proximally deployed 
Micro stents. In no patient did stents become caught in other stents during stent delivery. 
An example of the stent implantation to the lesion of dissection after BA can be seen in 
Figure 2. 
In-hospital events : One patient in whom stent delivery was unsuccessful underwent 
emergency bypass surgery and made an uneventful post operative recovery. The clinical 
course of the other 24 patients in whom stent deployment was successful was free of 
coronary re-intervention, bypass surgery and death. A myocardial infarction was observed 
in 2 patients (8%). in one of whom the stent was implanted within 24 hours after the 
onset of acute myocardial infarction and in the other patient acute vessel occlusion was 
present for 58 minutes prior to stent implantation. A femoral haemorrhage and haematuria 
requiring blood transfusion was observed in one patient (4%). All patients remained event 
free post hospital discharge and thus the event-free survival at 30 days follow-up was 
88% (22 of 25 patients). 
Quantitative angiographic analysis : Quantitative angiographic analysis provided 
measurements of luminal diameter at each procedural phase. Minimal luminal diameter 
(MLD) was seen to change from 0.79 ±0.56mm pre primary balloon angioplasty to 1.21 
± O.62mm post balloon angioplasty at the time of dissection. Implantation of the AVE 
micro stent increased the MLD to 2.70 ±0.48mm (p<.001). The changes in MLD from 
pre primary balloon angioplasty through stent implantation to post Swiss Kiss are displayed 
in Figure 3. In 16 lesions which required post stent balloon dilatation (Swiss Kiss) MLD 
increased significantly from 2.54 ±0.46mm (pre Swiss Kiss) to 2.85 ±0.44mm (post 
Swiss Kiss, p < 0.01). Absolute value of the acute stent recoil in the initial implantation 
(MLD during stent inflation - MLD post stent) was 0.56 ±0.31mm and acute recoil ratio 
of this stent (MLD during stent inflation - MLD post stent I MLD during stent inflation) was 
17 ± 9%. 
Angiographic success was achieved in all lesions with successful deployment of the stent. 
Thus, the angiographic success rate of all lesions attempted was 96% (27 of 28 lesions). 
Average percent diameter stenosis decreased significantly from 70% pre intervention to 
a final residual value of 16% post stent deployment. Figure 4 shows the sequential 
changes in percent diameter stenosis. Performance of a Swiss Kiss in 14 lesions achieved 
a further reduction in residual percent diameter stenosis from 20% pre Swiss Kiss to 15% 
post Swiss Kiss (p < .05). 
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Table 3 
Patient Vessel 
AHA segment 
RCA~1 &3 
2 RCA-2 
3 CX-ll 
4 LAD-6 
5 LAD-6 
6 CX~13 
7 LAD-9 
8 CX-13 
9 RCA-I 
10 RCA-3 
11 LAD-6 
12 RCA-' 
13 LAD-6viaSVG 
14 LAD-6 
15 CX-13 
16 RCA-I 
17 LAD-7 
18 RCA-2 
19 CX-11 
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Combination of 
Multiple Stents 
Micro! Micro 
Micro I Micro 
Micro I Micro 
Micro I Micro I Micro 
PS I Micro 
GR I Micro 
GR I Micro 
sPS I Micro 
Micro I WS 
WS I Micro 
PS I Micro 
Micro I PS 
WS I Micro 
sPS I sPS ! Micro 
PS I Micro I Micro 
Micro I Micro I PS 
Micro I Micro I Micro I PS 
WS IWS I Micro! PS I PS 
PS I PS ! Micro I Micro I Micro I PS 
Order of Deployment 
of Micro Stent 
distal then proximal 
distal then proximal 
distal then proximal 
middle then proximal then distal 
Micro before PS 
Micro after GR 
Micro after GR 
Micro after sPS 
Micro after WS 
Micro after WS 
Micro after PS 
Micro before PS 
Micro after WS 
Micro after sPS 
2 Micros after PS 
2 Micros before PS 
3 Micros before PS 
Micro after WS and PS 
3 Micros after 2 prox & before dist PS 
MultIple stenting with AVE Micro stent in combination with other AVE Micro stents (patients 1 ~ 4) and in combination with longer stents 
of different deSign (patients 5 - 19). 
RCA = right coronary artery I LCX = left circumflex artery I left anterior descending artery I AHA segment No. 1-16 = coding system 
of the American Heart Association for coronary segment !ocadon I viaSVG = native coronary artery with proximal occlusion stented 
through saphenous vein graft I Micro = AVE Micro stent I WS = Walls tent I sPS = sheathed Palmaz-Schatz stent on premounted 
delivery system I PS = bare Palmaz-Schatz stent crimped by operator on a standard angioplasty balloon I GR = Gianturco-Roubin stent 
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DISCUSSION: 
The key findings of this early experience were as follows: 1) Delivery to the target lesion of the 
radiopaque premounted AVE Micro stent as a stand-alone stent or as a complementary device for 
multiple stenting can be achieved in a high proportion of cases (27 of 28 lesions) ; 2) Following 
delivery of the stent (27 lesions), angiographic success as defined by < 30% residual diameter 
stenosis can be achieved in a high proportion of cases (27 of 27) ; 3) Acute recoil following 
dilatation of the micro stent in vivo compares favourably with other stents [34,35]; 4) Despite the 
bailout indication for stenting, deployment of this low metallic surface area stent (8.4%) resulted 
in a low risk of acute or subacute stent thrombosis (O of 27 stented lesions). 
Successful delivery of the micro stent may be attributed to two characteristics of the stent design. 
Firstly the 1.65mm profile of the micro stent in its unexpanded balloon-mounted state compares 
favourably with that of other stents and thus an intraprocedural exchange of the guiding catheter 
or guidewire should rarely be necessary. Secondly, the unconnected junctions of the modules and 
the 4mm and 8mm length of the individual modules provide the stent with hinge joints and very 
limited rigid segments to aid the negotiation of tortuous vessels. The monorail delivery system and 
the ease of identifying the individual. 203mm thick struts further enhance the deployment of the 
Micro stent. The oblique longitudinal orientation of the Micro stent struts reduce the chance during 
multiple stenting of the struts catching in other stents despite the absence of a protective sheath. 
Conventionally mUltiple stenting is performed by the deployment of the most distal stent first. This 
conventional order of deployment avoids the potential risks associated with passage of stents 
through other stents whereby the struts of the stents may catch. Recently, the importance of 
optimal stent deployment for the reduction of risk of subsequent subacute stent thrombosis has 
been increasingly recognized. Optimal deployment entails maximal stent and vessel expansionl 
apposition of the stent struts against (or embedded into) the vessel wall at all points, and the 
obtainment of a symmetrical lumen. Such optimal deployment has the additional benefit of 
facilitating and reducing the risks associated with the advancement of additional low profile stents 
through stents which have already been deployed proximally - see Table 3. 
The proximal migration during inflation of a 4mm segment of an unconnected 12mm stent into the 
left mainstem in one of our patients, indicates that only connected (welded) units of the AVE Micro 
stent should be placed in ostial lesions to prevent such an occurrence. 
Although 24 of 28 lesions had dissection type C, 0, E, and F after primary balloon angioplasty, 
stenting was effective in tacking back the dissection flap and restoring TIMI 3 flow in all 27 lesions 
stented. While 8 of the lesions with threatened closure had angiographic evidence of intracoronary 
thrombus prior to stenting, deployment of the micro stent without the administration of 
intracoronary thrombolytic therapy resulted in neither acute nor subacute thrombosis during follow~ 
up. The absence of stent thrombosis may relate to the low metallic surface area of the micro stent 
(8.4% for the 3.5mm stent in the expanded state) and the optimal expansion of the stent « 30% 
residual diameter stenosis in all stented lesions) with the additional performance when necessary 
of a Swiss Kiss [36,371. 
Two of our patients (8%) had significantly elevated creatine phosphokinase (CPK) levels and ECG 
changes of myocardial infarction. In one of these two patients stent implantation was performed 
within 24 hours of the onset of an acute Q-wave myocardial infarction and the patient became 
asymptomatic post stenting and CPK levels continued to decline post stenting without a further 
rise. In the other patient acute vessel closure had been present for 58 minutes prior to stent 
deployment. This patient had no further chest pain post stent implantation and the peak CPK level 
in this patient was 720 ju/l. Lincoff et al. indicated that peak CPK levels directly related to the time 
to stent placement after the onset of vessel closure and significant CPK elevation was commonly 
observed when vessel closure persisted for more than 49 minutes [13]. Thus, the elevated CPK 
205 
4-
MLD 
(mm) 
3 
2-
13.26 13.42 ..... ]2.86·· .1 2.85 
l2.54 
1.21 
1 -
0.79 
o ~-~~~ ---"-------'--
PRE SA POST 
SA 
AVE 
STENT 
POST 
AVE 
SA 
POST-
AVE 
POST 
SWISS-
KISS 
Figure 3. Changes of minimal luminal diameter (MLD) in 28 lesions from pre-procedure through stent 
implantation. Swiss Kiss (see text) was carried out in 16/esions. MLD improved significantly after AVE stent 
implantation and after the performance of a Swiss Kiss (14.6 ± 3.1 atmospheres). 
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levels in our two patients were felt to reflect their clinical events prior to stent deployment rather 
than the occurrence of an acute or subacute thrombosis post stenting. 
Both single center and multicenter observational series of bailout stenting have been reported for 
the Wallstent [1 0], Palmaz Schatz stent [11-15], Gianturco Roubin stent [16-181. These have been 
associated with a deployment success rate of 89 to 98%, a myocardial infarction rate of 4 to 
43%, a CABG rate 1 to 60%, a subacute thrombosis rate 7 to 16%, and a mortality rate of 1 to 
7%. More recently a number of new stents have become available for clinical evaluation, these 
include the Cordis and Multilink (A.C.S. - Advanced Cardiovascular Systems) stents. While the 
structural design of the above stents can be grouped into two categories of mesh stents and coil 
stents, the AVE micro stent represents a new design concept. Given their fundamental differences 
in structural design (profile in the unexpanded state, longitudinal flexibility, mechanism of 
deployment, metallic surface area in the expanded state, interstrut distance, strut orientation, and 
radial strength) each stent will have to prove its own safety and efficacy for each clinical indication 
in prospective trials. It is likely that stents with a low metallic surface may be more suited to the 
more thrombogenic substrate of bailout stenting, while the more rigid mesh stents with higher 
metallic surface area stents may be more suited to the elective treatment of primary or recurrent 
stenoses with strong elastic recoil in non-tortuous vessels. 
This study revealed sequential changes of luminal diameter from pre primary intervention, through 
stent implantation, to the performance of a Swiss kiss. Percent diameter stenosis decreased from 
70% (pre balloon angioplasty) through 55% (post balloon angioplasty) to 15% (post Swiss kiss). 
While previous in-vitro testing of this stent has found recoil to be 8.7 % for the 3.5mm diameter 
stent, in this quantitative angiographic study of the stent in diseased coronary arteries in-vivo we 
found recoil to be 17 ±9% (O.56mmJ with an average stent diameter of 3.37mm. Furthermore, the 
post stent MLD achieved matched or was greater than the nominal stent size in only 4 of 27 
stented lesions. The performance of a high pressure (14 atmospheres) Swiss kiss may result in an 
increase in MLD by 0.31 mm, and may be a useful complementary technique when on-line 
quantitative angiographic analysis is available to guide the optimization of stent deployment. 
Conclusion. Early experience with the new AVE micro stent would indicate that delivery of the 
stent to the target lesion and the subsequent achievement of optimal angiographic results can be 
expected in a high proportion of cases with the use of additional high pressure intrastent balloon 
inflations when necessary. The Micro stent may effectively serve as a stand-alone stent or as a 
complementary device for multiple stenting where it can be used to improve the inflow and outflow 
of longer stents of different design or to bridge the gap between proximal and distal stents. The 
proximal migration during inflation of a 4mm segment of an unconnected 12mm stent into the left 
mainstem in one of our patients, indicates that only connected (welded) units of the AVE Micro 
stent should be placed in ostial lesions to prevent such an occurrence. The safety of deploying the 
AVE micro stent for the management of threatened or acute vessel closure as indicated by the low 
rate of clinical events in this early series indicate that further clinical evaluation of the stent is 
warranted. 
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Does the method of transluminal coronary revascularization influence 
restenosis ?: Balloon angioplasty, directional coronary atherectomy, 
Wiktor stent, and Wallstent compared. 
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DOES THE METHOD OF TRANSLUMINAL CORONARY 
REVASCULARISATION INFLUENCE RE-STENOSIS? BALLOON 
ANGIOPLASTY, ATHERECTOMY AND STENTS COMPARED 
DP FOLEl: ,liB, MRCPI, D KEANE, JIB,MRCPI, PI\' SERRUYS, MD. FESC, Depal'/mel/t ojllllelTl'lIliollal Cardiology, The 
Thorax(,l'lIlrl', Erasmlls University, ROlleldam, The Netherlands 
SUMMARY Luminal renarrowing after successful coronary angioplasly is now recognised as a 
continuously distributed process which is determined largely by the extent of luminal increase 
achieved at angioplasty. In this study an alternative analytical approach is applied to determine 
whether luminal renarrowing following coronary intervention is related to the mechanism of 
luminal increase (ie by balloon, by atherectomy, by a self-expanding stainless steel mesh stent, or 
by a balloon-expandable tantalum coil stent). The resulls confirm the known proportional 
relationship between luminal renarrowing during follow-up and luminal improvement at 
intervention, regardless of the device used. However, significant differences were observed 
between the devices, which may reflect device-specific characteristics of the hyperplastic 
response to vessel injury and may have clinical implications. 
Since its inception, balloon angioplasty has been plagued by what has now become known as the 'Achilles heel' of re-stenosis l whkh, according to 
current (albeit incomplete) understanding, appears to con-
sist of the healing response of the vessel wall to the injury 
imparted during treatment.2 AltempL~ to prevent oreontral 
this phenomcnon have taken the foml of clinical trials of 
a plethora ofphaml<lCoiogical agenls,) and have in addition 
led to technological advances culmill<!ting in the develop~ 
ment of a succession of alternative devices for primary 
tmnsluminal revascularisation.~ No phamlUcologicaltrial 
has yet provided the antidote to re-stenosis·1 and, despite 
optimism over alternative percutaneous revascularisation 
devices, none of the new strategies has tllUs far fulfilled its 
expeetations in preventing luminal renarrowing.H 
Clinicnl trials comparing directional athercctomy with 
conventional balloon angioplasty have reported no signifi-
cant reduction in the categorically defincd angiogmphic 
re-stenosis rate by atherectomy and no significant acute or 
long-tenn clinical benefit of this device. Trials evaluating 
the Palmaz-Schatz stCllt have reported improved clinical 
and angiographic outcome, but this reduction (mthcr than 
prevention) in luminal renarrowing came at the price of an 
increased rate of haemorrhagic complications; full reports 
and comprehensive analyses of l1ndings of these trials arc 
awaited. 
Observational studies comparing stent implantation 
with directional atllerectom)' and balloon angioplaslY have 
concluded that the device is essentially irrelevant: it is, 
rather, thc acute angiographic re~ult that is the most impor-
tant predictor of long-tenn results. Our group has pre-
viously perfonned comparative studies on patient groups 
treated by different devices by 'matching' each patient for 
lesion location, scvcrity and vessel size with a comparablc 
patient treated by balloon angiop[asty.HI-H In these studies, 
differences in expected relative luminal loss were detected 
between directional atherectomy- and balloon 
angioplasty-treated patients, as well as between patients 
treated by the Wallstent or balloon angiopla.<ity and those 
treated by excimer laser or balloon nngioplasty. 
This clinical study was intended to compare the effect 
on late re-stenosis of ha11ool1 angioplasty, directional 
atherectomy and implantation of a Wallstent (self-expand-
ing stainless steel mesh stent 15) or Wiktor stent (balloon-
expandable ranralum coil .'ilent), by using previously de-
scribed quantitative angiographic parameters of relative 
luminal gain and loss as angiographic correlates of vessel 
wall injury and hyperplastic response (re-stenosis). 
METHODS 
For the purposes of this study, clinical and quantitative 
angiographic data were obtained from already completed 
prospective I11ulticentre e1inical tria\sI~2" and ongoing 
clinical expericnce at our centre,Y,I-I.lI.21 The study popula-
tion consisted of 1234 patients (1452 lesions) who had 
been treated by balloon angioplasty, 120 patient.<i (123 
lesions) who had undergone directional coronary atherec-
tomy, 104 patients (110 lesions) in whom an endoluminal 
self-expanding stainless steel mesh stent was implanted, 
and 100 paticnts (101 lesions) treated by balloon-expand-
able tantalum coil stent implantation for native coronary 
artery disease. Pertinent baseline demographic data are 
given in Table 1. 
The balloon angiopl:lsty patients had been enrolled in 
two ~eparate European multiccntre placebo-controlled re-
stenosis preventiolltriais, the details of which have already 
been published,110.11 In each of these triais the p!Jan11a-
cological agent under investigation was found to have no 
signil1c;lIlt effect on the process of luminal renarrowing, 
so all the paticnts were pooled for the purposes of the 
present study. Entry criteria for these two studies were 
similar, all patients scheduled for angioplasty with angio-
graphically proven native primary coronary artery disease 
affecting single or Illultiple vessels and with clinical symp-
ADDRESS CORRESPONDENCE TO: Proressor Patrick W Sertuys, MD. PW, FEse. FAce, Department of InteNentionat Cardiology, 
Erasmus University Ee 2332, Thoraxcenler, PO Box 1738, 3000 DR Rotterdam, The Netherlands 
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Table 1. DemographIc data for the four pallent groups. Male/female ratios, age, treated vessel and frequency of 
diabetes are similarly distributed. The dIrectional atherectomy and balloon-expandable stent groups have a 
greater frequency of class III and IV and unstable angina, and no chronic tolal occlusions were trealed by either 
of these devices. Lesion type varies widely between groups 
Balloon angloplasty Olrecltonal alherectomy Balloon·expandable stent Self·expandlng stent 
Patients 1234 120 
Lesions 1435 123 
Maleffemale ("!o) 987/247 (80/20) 97123 (81119) 
Age (years) 56.4 ±9 57.6±10.8 
Lesion type 
primary 100% 70% 
reslenosls 0 25"/" 
bail·out 0 5% 
Vessel 
lAD 47% 65% 
RCA 30% 22% 
LCX 23% 13% 
Total occlusion 4% 0 
Diabetes 7% 6% 
Classes III or IV angina 52% 73% 
Unstable angina 12% 51% 
toms of stable or unstable angina pectoris being considered 
for inclusion, Spccific exclusion criteria and procedural 
details can be found in the original publications, 16.l7 Only 
those having a successful dilatation, defincd by lhe opera-
tor as a reduction in lesion severity to <50% diameter 
stenosis, were actually included in the trials for the ultimate 
assessmcnt ofangiogrnphic outcome. Eventuaily a total of 
1234 patients with 1452 lesions had full angiographic 
follow-up. 
Paticnts undergoing implantation of the Wailstent wcre 
recmited at six centres involved in a non-randomised trial: 
for the treatment of acute coronary artery occlusion during 
balloon angioplasty (14%), as an adjunct to suboptimal 
angioplasty (19%), re-stcnosis aller angioplasty (49%), 
and primal)' coronary artery disease (18%, of which 4% 
were for chronic total occiusion)Y·18 The \viktor stents 
were implantcd for symptomatic angiographically docu-
mented re-stenosis aftcr balloon angioplasty in a Illulticen-
tre .triaL21J T~le resp:ctive implantation met~lOdo~~§); and 
anllcoagulallon regimens have been described. . Pa-
tients expericncing in-hospital stent occlusion (<14 days 
after implantation) were excluded, as this iS~l conscqucnce 
of a thrombotic event, not intimal hypcrplasia, and is not 
of interest in this study. 
Directional athcrectomy, using the Simpson atherec-
tomy catheter, was perfonncd at Iwo specialised institu-
tions: as a primary procedure in 70% patients, as a bailout 
after complkaled balloon angioplasty in 5%, and for rc-
stenosis after previous intervention in 25%. TIle atherec-
tomy procedure has bcen described in detail elsewhere.")1 
Quantitative coronar~' angiography 
. Coronary angiography was perfonned bcfore and immedi-
ately after intervention and at 6 month follow-up. 'I1Je 
angiograms were recorded using a fixed table system and 
35 111m cinefilm at a minimum speed of 25 frames/sec 
according to the guidelines of the core angiogf<lphic labo-
ratory, whereby a ,~eries of previously reported measures 
were taken to reduce variability in radiographic acquisi-
tion.2~,l.\ All cineangiograms were analyscd using the 
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100 104 
101 110 
85115 (85/15) 87117 (84/16) 
56.6±11.7 57 ±11 
0 14% 
100% 49% 
0 33% 
52% 55% 
34% 35% 
14% 10% 
0 4% 
12% 5% 
68% 50% 
?% 26% 
computer-assisted cardiovascular angiographic analysis 
system (CAAS, validated and described in detail else-
where2f>..11) (Figurc I). 
Angiographic val'iables 
In this study we exmnined the relationship between luminal 
improvement at intervcntion and luminal renarrowing during 
follow-up for lesions treated by balloon angioplasty, direc-
tional atherectomy or stent implantation; to that end, 
per-lesion analysis (to include the potential intluence of all 
treated lesions, where I1ll1ltilesion intervention was per-
fonned) was done using the following parameters:9•n .. 1$ 
Figure 1. Depicts the difference In % diameter 
stenosis ('%DS) measurement by conventional 
'user-defined' reference diameter (RefD) proximal 
andlor distal to the lesion and the automated 
interpolated reference diameter (IRD), provided by 
the Cardiovascular Anglographlc AnalysIs System 
(CAAS). The computer algorithm automatically 
measures the diameter along each scanllne {every 
0.1 mm} of the detected contours of the segment, 
proximal and distal to the lesion {excluding the 
lesion Itself}. Then a polynomial function 
reconstructs the contours over the diseased 
segment (shown as smooth, thIck, slightly tapering 
lines). The IRD is the diameter of the reconstructed 
contours at the mInImal luminal diameter (MLD), 
giving a %DS of 66% 
;:'7= 
Rel;'.."- 2':~ r~ ReID 3.2mm 3.4mm /: ~ 
~5~DS ~Slng 6S%DS 77%DS using 
user·defined usln9 IRD user·defined 
proximal AelD proximal Aero 
76%DS using mean of 
proximal and distal 
user-defined ReID 
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Table 2. Relevant quantitative anglographlc measurements, given as means +slandard deviation (95% CI) 
Balloon angloplasty Dlrecllonal atherectomy Balloon-expandable Self-expanding stent 
n=1435 (95%CI) n=123 (95%CI) stent n=100 {95%CI} n=110 (95%CI) 
MLD preinlervenlion 
(inmm) 1.02 ±0.31' (1.0-1.04) 1.17 to.39 (1.13~1.21) 1.11 iO.31 (1.04-1.18) 1.21 to.54 (1.11-1.31) 
MLO poslinlervention 
(inmm) 1.78 ±0.36' (1.76-1.80) 2.46 ±O.42 (2.37~2.55) 2.43 ±0.33 t (2.36-2.50) 2.60 ±0.51 (2.50-2.70) 
MLO at follow-up (in mm) 1.50 iO.57' (1.47-1.53) 1.78 ±0.63 (1.65-1.91) 1.71 ±D.66 (1.57-1.85) 1.89 ±0.90 (1.72-2.06) 
Vessel size (lAO 
preintervenlion) (in mm) 2.63 iO.54' (2.60-2.66) 3.25 ±O.64 (3.12-3.38) 2.86 ±0.49 f (2.76-2.96) 3.10 ±D.61 (2.99-3.21) 
Gain in MLO al 
intervention (in mm) 0.76 .i0.40' (0.74-0.78) 1.29 ±D.49 (1.19-1.39) 1.32 ±O.32 (1.25-1.39) 1.39 ±D.63 (1.27-1.51) 
Loss in MLO during 
follow-up (in mm) 0.28 .i0.51 , (0.25-0.31) 0.67 ±a.67 (0.53-0.71) 0.71 ±0.60 (0.58-0.84) 0.71 ±a.92 (0.54-0.88) 
Relative gain (in MLD at 
intervention) (in mm) 0.29 ±D.16' (0.28-0.30) 0.42 ±O.20 (0.38-0.46) 0.47 .i0.13 (0.44-0.50) 0.46 ±D.t9 (0.43·0.49) 
Relative loss (in MLD at 
intervention) (in mm) 0.1 ±D.21 , (O.10·0.12) 0.26±O.24 (0.21-0.31) 0.23 ±D.28 (0.18-0.28) 0.23 ±0.25 (0.18-0.28) 
Net gain index at 
follow-up (in mm) 0.18 ±a.21·{0.17-0.19) 0.19 ±O.20 (0.15-0.23) 0.21 ±0.23 (0.16-0.26) 0.23 ±O.31 (0.17-0.29) 
'Signiflcant d'fference between PTCA and each of the other three groups. P<O.OS fOI each compali50n (Student's Host). 
t Signitcant difference between the balloon-expandab:e slent group and each of tho other threB groups (P<O,OS). 
* Marginatiy significant difference between the bal!oon-Bxpandab!e and self-expand,ng stent groups (P;Q,048). 
IRD = interpolated reference d-ameler; MLD = min'mal luminal d'ameter; PTCA = percutaneous trans1uminal coronary ang:op!asty 
• Gain = a."ILD postintervention -l\'fLD preintervention) 
• Loss:= (MLD postintervention - MLD at follow-up) 
• Relative gain:;:; gain/vessel size 
• Relative loss:;:; loss/ve,ssel size 
• Net gain index = (1ILD al follow-up - r ... iLD 
preintef\rention)/vessei size. 
where MLD is the minimal luminal diameter, and the 
vessel size is represented by the interpolated reference 
diameter preintervention (Figure I); 'gain' and 'loss' re-
spectively represent the ahsolute improvement in t\'iLD 
achieved at intervention and Ihe absolute change during 
follow-up, measured in mm; 'relative gain' and 'relative 
loss' depict these absolute changes in luminal diameter, 
normalised for the vessel size in each individual case; 'net 
gain index' is a measure of the ultimate net effect of the 
intervention in question, in tenus of the change in minimal 
luminal diameter from pre-procedure to follow-up, nor-
malised for the vessel size. 
As the main focus of interest was the relationship be-
tween luminal improvement at intervention and deteriora-
tion during follow-up, only those lesions having an identi-
fiable increase in r-,'ILO, defined as a rdative gain greater 
than 0, 'were included. Consequently, of 1452 lesions 
treated by balloon angiophL~ty with satisl~lclory angiographic 
follow-up, 1435 were indudcd, as well as 122 of 123 treated 
by atherectomy and all lesions in both ~tent groups. 
Slatisticalmcthods 
Statistical analy.~es were carried out using a standard com-
mercially available statistical package (BlvIDP statistical 
software, University of Califomia, Berkeley, CA).' 
The data obtained by qU'lIltitative angiographit: analysis 
are given as means ±SD and SE~t Patient groups were 
compared by analysis of variance: for differences regard-
ing minimal luminal diameter pre- and postintervention 
and at follow-up, for vessel size (interpolated reference 
diameter pre intervention), for abwlute gain and lo~s in 
minimal luminal diameter, relative gain and relative loss 
in minimal hnninal dinmeter, and net gain index. IfsigniH-
cant differences were found by analysis of variance, the 
Student t-test was applied to all possible intergroup com-
parisons to pinpoint sources of difference. 
Pearson's correlation coefficient is used to assess the 
association between relative gain and relative loss for each 
patient group. A least-squares linear regression analysis of 
relative loss on relative gain was perfomled in each group 
and resultant regression equations compared by analysis 
of variance. To e.-.;amine .for possible hidden differences 
between the patient groups trented by the different devices, 
with regard to the relative gain/relative loss relationship at 
various levels of relative gnin, the patient groups were 
.~ubdivided into 'small', 'moderate' and 'large' relative 
gain increments by obtaining the lower and upperquartiles 
for relative gain for each group, and then taking the means 
of these as the cut-off points. 
RESULTS 
lvlean quantitatively derived values, with standard devia-
tions and 95% cont1dence intervals are given in Table 2, 
for minimal luminal diameter pre- and postintervention 
and at follow-up, for vessel size (interpolated reference 
diameter pre intervention), for absolute gain and lo~s in 
IloiLO, relative gain and relative loss in MLD, and net gain 
index, with respect to each patient group. TIle mean values 
for the absolute measurements of ~\'ILD pre- nnd postinter-
vel1tion and at follow-up, for vessel size (interpolateu 
reference diameter pre intervention), and for absolute gain 
and loss in ivlLD are .~ignit1cnntly less for the balloon 
angioplasty group than for each of the other three groups. 
TIlerI.' are no signif1cant differences between the directional 
atherect01ny, self-expanding stainle~s ~teel ~tellt and batloon-
expandable tantalum coil stent groups for any of these 
variables, except that the mean vessel size in the 
balloon-expandable ~tent group is ~ignificantly smaller than 
in the atherectomy and self-expanding stent groups ,Uld the 
mean r.,'ILO pmtintervention in the balloon-expandable sterll 
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Figure 2. a,b,c,d: Scallerplots of relative loss on relative gain for lesions trealed by balloon angloplasty 
(a, 11=1435), directional coronary atherectomy (b, n=123), balloon·expandable tantalum call stent Implantation 
(c, n=101) and self-expanding stainless steel mesh slenllmplantat!on (d, 11=110), with regression lines and their 
95% confidence limits superimposed. Although there Is considerable data scatter In each graph) which is 
reflected by the relatively weak coefficients of correia lion, the association between lhese variables Is slrlklngly 
statistically significant; more notably, least·squares regression reveals a definite linear dependency of rei alive 
loss on relative gain) for each treatment group, as described by their respective regression lines and P values 
Table 3. Regression and correlation coefficients for the relalive gain/relative loss relationship for each group 
Balloon angloplasly Directional atherectomy Balloon-expandable slent Self·expandlng stent 
Line slope 0.43 0.78 
Intercept -0.02 -0.10 
Pearson's product moment 
correlation coefficient r 0.34 0.68 
Significance value Pof both 
correlation and regression <0.00005 <0.00005 
group is less than in the self.--expanding stent group. 
The mean relative gain achieved by balloon angioplasty 
and the mean relative loss are both significantly less IIHlIl 
for any of the three other treatment modalities, which do 
not themselves differ significantly with respect to these 
parmneters. The me<lI1net gain index does not vary signifi-
cantly between the four patient groups. 
Examination of the balloon angioplasty group with 
regard to the relationship between relative gain and 
relative loss produces a correlation coeft1cient 1'=0.34 
(P<O.00005). Linear regression analysis yields a regres-
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0.75 0.33 
- 0.09 0.07 
0.39 0.21 
0.0002 0.03 
sionequation (y=hr+a) of: relative loss =0,43 relative gain 
-0.02 (P<O.OO005) (Figure 2). Regressionequations for the 
other three groups arc shown in Table 3 and illustrated in 
Figure 2. Analysis of variance reveals a signit1cant diner-
ence between the regression lines (P=O,Q0002), Results of 
intergroup comparisons are shown in Table 4 and the four 
regression lines plutted in Figure 3, Direct comparisons 
between all possible group combinations, also by analysis 
of variance, are shown in Table 4 and the four regression 
lines plotted in figure 3. Significant differences are ob-
served between the balloon angioplasty group and both the 
BJCP, JANUARYIFEBRUARY 1995, VOL 49 NO 1 
directional atherectomy and balluon-expandable tantalum 
coil stent groups, and also bctwccn the directionnl athcrec-
tomy and self-expanding stent groups. A trend towards a 
significant difference is observed between the balloon 
angioplasty and self-expamling stent groups. 
Subdivision of the patient groups (to further analyse 
overall differences and to examine for possible hidden 
differences between the groups, with regard to the relative 
gain/relative loss relationship) according to the method 
previously described, produces cut-off points of 0.3 and 
0.5 for 'small', 'moderate' and 'Iargc' relative gain. Where 
relative gain was 'small' «0.3) there wcre 845 Icsions in 
the PTCA group, 41 in the directional atherectomy group, 
13 in the balloon-expandable stent group, and 16 in the 
self-expanding stent group; for 'moderate' relative gain 
(0.3-0.5) the corresponding group sizes were 443, 47,46, 
and 51; where relative gain was 'large' (2':0.5) there were 
147 in the PTCA group, 34 in the directional atherectomy 
group, 42 in the balloon-expandable stent group, and 43 in 
the self-expanding stent group. Analysis of variance of 
regression between the subgroups is shown in Table 4. 
Overall differences observed between the balloon 
0.8 
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Figure 3. Linear regression plots for all four patient 
groups (A = directional atherectomYi B = 
balloon-expandable stent; C = self-expanding stenl; 
D = balloon angioplasty) superimposed. Analysis of 
variance reveals significant differences between the 
respective regression lines, as explained In Ihe text 
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angioplasty and both the directional atherectomy and bal-
loon-expandable tantalum coil stent groups as well as the 
difference between the directional atherectomy and the 
self-expanding stent group appear to be explained by dif-
ferences encountered where RG 2':0.5 (p",O.OO I, P",O.06 
and P=0.08 respectively). The balloon angioplasty and 
self-expanding stent groups differ significantly where RG 
<0.3 (P=O.OI). 
Intergroup comparisons at the various levels of relative 
gain to detect the actual, as opposed to predicted, differ-
ences in relative loss between the patient groups are shown 
in Table 5 and Figure 4. A pattern of increasing mean 
relative loss is apparent, from small, to modcrate, to large 
relative gain. In fact the incremental increase in relative 
gain is associated with significant increases in relative loss 
for the balluon angiopiast)' group (P<O.OI for each 'step 
up' in relative gain). Whcre RG is large (0.5), a ~tatistically 
significant difference is detected for relative loss between 
the balloon angioplasty and directional atherectomy 
groups, and a trend towards a difference is apparent be-
tween balloon angioplasty and Wiktor stent groups. 
DISCUSSION 
Our group and othcrs havc shown that luminal renarrowing 
over 6 months is related to the extent of luminal gain 
(injury) achicvcd at coronary intervention:12,l-I,lJ-H While 
others have reported no influence of the nature of the 
device used for interventiun on the degree of late luminal 
renarrowing, our findings suggest otherwise. Definite 
differences have been shown here between balloon 
angiopla.~ty, directional coronary atherectomy and stent 
implantatiun with respect to the degree of renarrowing 
(rcJative loss), which may be anticipated as progressively 
greater degrees of luminal increase (relative gain) 
achieved with these different dcvices. TIle use of relative 
gain, relative loss and net gain index (rather than absolute 
changes) in luminal diameter adjust for the known con-
founding influence of significant differences in vessel size 
between the patient groups treated by thediftcrent dcvices, 
which render the subsequent differences observed for 
absolute luminal gain at intervention and loss during fol-
low-up difficult to interpret. 
Although balloon nngiopla~ty docs not generally achieve 
as great a mean relative gain ,L~ the other three devices, which 
do not difl'cr significantly, balloon angioplasty is also not 
attended by the same degree of relative loss, .~o thaI the 
Table 4. Outcome of analysis of variance of the relative gaIn/relative [ass relallonshlp between the pallent 
groups, given as Pva[ues, The overall differences between the regression lines are shown In the first column; 
the next three describe the differences between the patient groups at various levels of relative gain. Small, 
moderate and large relative gain levels were defined by first obtaining the [ower and upper qua rilles for relative 
gain In each group, and taking the means of these values as the respeclive lower and upper cut-off points 
Overall 'Small' «0.3) 'Moderate' (0.3·0.5) 'large' (>0.5) 
differences relative gain relative gain relative gain 
PICA vs DCA 0.00007 0,52 0.45 0.001 
PICA vs balloon·expandable stent 0.0009 0.74 0,24 O.ost 
PICA V$ se!f·expanding stent O.OSf 0.01 0,35 0.44 
DCA V$ balfoon'expandable stent 0.98 0.51 0.37 0.58 
DCA vs self-expanding stent 0.04 0.15 0.91 Q,08t 
Balloon-expandable vs self-expanding stent 0,20 0.48 0.76 0.60 
'Stat'stica!ly sigoif,cant d,Herence. 
tC!ear, a!ihou9h not statis\ica!fy s'gM,can\ d,t/ereoce, 
DCA ~ d,rectiooat coronary atherectomy: PTCA" perculaneous trans!umioat coronary ang'op'asty 
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ultimate net benefit (net gain index) was found (0 be similar 
for each treatment modality in this study. 
Linear relationship of relative gain and relative loss 
Despite the relatively weak correlation there is an undoubt-
edly linear relationship between relative gain at interven-
tion and relative loss during follow-up for each (rculmenl 
device, as illustrated by the regression lines (Figure 3), 
with the dear message that the greater the improvement in 
minimal luminal diameter achieved by intervention -
regardless orlhe device used - the greater the subsequent 
magnitude of luminal renarrowing. 11tis maxim is essen-
tially in agreement with the pathological infonnatioll pro-
vided by the pordne model employed by Schwartz el al;'(' 
and has now been reported by many investigators .. n~3 
Differences between groups treated b~' different devices 
With regard to comparison of the devices assessed in this 
study (Figure 2), a therapeutic procedure where the regres-
sion line describing the relative gain/relative loss relation-
ship has a gentle slope (bisecting the origin) might be 
considered in general preferable to one that is attended by 
0.5 08alloon angioplasty 
DSelf-expandlng 
0.4-
~ 
.20.3 
,~ (iiO.2 
a: 
O~LF ~. 
EJ Balloon-expandable 
~Atherectomy 
<0.3 0.3-0.5 
Relative gain 
>0.5 
Figure 4. Intergroup comparisons are shown at the 
various levels of relative gain (RG) to detect the 
actual, as opposed to predicted, differences In 
relative loss between patient groups. A patlern of 
Increasing mean relative loss is apparent, from small 
to moderate to large RG. The Incremenlallncrease In 
RG Is associated with significant Increases in relative 
loss for the balloon angloplasty group (P<0.01 for 
each 'step up' in RG). Where RG Is large (0.5), a 
statisllcally significant difference Is detected for 
relative loss between balloon angloplasty and 
dIrectional atherectomy groups, and a trend towards 
a difference Is apparent between balloon angloplasty 
and Wiklor stent groups 
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a steep slope. By this scheme, directional athercctomy and 
balloon-expandable stent implantation are assodated with 
less favourable profiles than balloon angioplasty or self-
expanding stent implantation. Analysis of variance of the 
regression lines reveals a highly significant diJJerence 
(P;;;O.00002), which is intcrpreted as demonstrating that 
the relationship between relative gain in minimal luminal 
diameter at intervention anu relative loss during follow-up 
for the respective patient populations, of which the four 
groups in this study are samples, cannot be described by 
the same regression line. 
Comparisons between the patient groups to characterise 
this overall difference with regard to the relative gain/rela-
tive loss relationship (Table 3) reveal that the atherectomy 
anu balloon-expandable sten! groups are similar (P=O.97), 
and that both groups differ significantly from the balloon 
angioplasty group (P=O.00007 and P=O.0009 respec-
tively). In addition, the directional athercctomy group (but 
not the balloon-expandable stent group) differs signiti-
cantly from the self-expanding stent group (P=O.Q4). There 
is also a clear, although not actually 'significant', differ-
ence between the balloon angioplasty and self-expanding 
stent groups (P=O.06), which is apparently explained by 
the difference between the groups at the lower levels of 
relative gain (1"=0_01). 'Illis may be due to the fact that in 
all cases of self-expanding stent implantation in this study 
a relative gain grcater than 0.13 was achievcd, whereas 
15% (11=238) of lesions treated by balloon angioplasty that 
had been considered sllccessfully dilated (diameter 
stenosis <50% as assessed by the interventionalist) were 
associated with a relativc gain of less thanlhis.lllC overall 
differences observed between the balloon angioplaslY 
group and the directional atherectomy and baltoon~ 
expandable stent groups are, conversely, explained by 
differences at the upper end of the relalive gain spectrum 
(~O.5). These observations may relate to the inherent meth-
odological properties of the devices for the mechanical 
achievement of increase in luminal dimensions whereby 
there may be differing degrees of occult trauma imparted 
to the vessel wall by the different devices, to attain a given 
proportional luminal improvement, that become most ap-
parent at higher levels of relative gain. 
i\lechanistic cOllsidel'ations 
Diret'tiollal al!tcrectomy. It could be hypothesised that the 
type and extent of injury imparted by the traumatic re-
moval of Ihsue during directional coronary atherectomy, 
with exposure to Ihe circulation of extensive arca~ of 
denuded intimal, medial or even adventitiallayers,41.4.1 create 
Table 5. Mean relative loss values ±slandard deviation and 95'% CI of the mean for each patient group with 
regard to 'small', 'moderate' and 'large' Increments of relative gain, as derived from the mean of the lower and 
upper relative gain (A G) quartlles for each group 
Mean relative loss at 
'smajj' «0.3) RG 
Mean relative loss at 
'moderate' (O.3-0.5) RG 
Mean relative loss at 
'Iarge' (>0.5) RG 
Balloon angloplasly 
(95%CI) 
0,06 ±O.1 i (0.05-0.07) 
0.16±O.20· (0.14-0.18) 
0.25 ±O.29-n (0.19-0.29) 
Dlrecllonal athereclomy Balloon·expandable 
(95%CI) stent (95%CI) 
0.11 ±O.17t (0.05-0.17) 0,04 ±O,23 (-0.13-0.40) 
0.18 ±O. I 7t (0.13-0.23) 0.23±0.17 (0.18·0.28) 
0.43 ±O.30H (0.32-0,54) 0.34 ±0.28~ (0.25-0.43) 
'S!gn'ficant d·f!erence In relative loss with incrementat increase in relative ga:n in the ba!!oon ang'op'asty group (P<O.OI). 
tSign,ficant dJference in relative loss with incremental increase in relative ga'n in the d'rectional alhereclamy group (P<O.OS). 
lS;gnificant d·fference between lile bal'aon ang:op'asty and d·rectional alherectomy groups (P<O.003). 
IJTrend towards a 5;gniflcan\ difference between the balloon ang'op!asty and baPoon-expandab!e stent groups (P=O.056) 
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Self·expandlng stent 
(95"/"CI) 
0.15 ±O.25 (0.02·0.27) 
0.19 ±O.25 (0.11 -0.25) 
0.30 ±O.33 (0.20-0.44) 
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a large .'.ubstrate for an aggressive healing response to 
re-endothelialise the resultant 'wound' surfnce. 2 Also, the 
potential local turbulence and shear-force altering elJects 
of an irregular, scalloped luminal cont1guration (as often 
persists after sllccessful directional atherectomy·u.A1), may 
delay re-endothelialisation and thus promote excessive 
neointimal fomlation,~' The extent of the ensuing intimal 
thickening may thus be more directly dependent on the depth 
ilnd nHlgnitude of injury~~ than is the Cilse for the other 
devices. 
Ballooll (llIgiop/asty. It is not difficult to imagine that the 
extent and depth of vessel wall dbruption caused by lesion 
,~tretching amI tearing during balloon angioplast/1 de-
pends, to a greater or lesser extent, on a large number of 
individual factors such as lesion length and symmetry, 
plaque composition (proportion of loose connective and 
dense t1brous or calcified tissue) and volume, vcssel cur-
vature amI elasticity, presence of thrombus or intimal 
dissection.5J.55 1l1C allgiographic relative gain in minimal 
luminal diameter may not therefore rellect the degree of 
intimal injury so accurately, and thus is not quite so clearly 
associated with subscquent relative loss (luminal renar-
rowing) <L~ is observed with athereetomy. FUlthemlOre, 
although (as previollsly mentioned) we have found relative 
£ain to be the greatest single detemlinant ofluminal renar-
rowing in stepwise multivariate regression analysis, a 
number of other clinical, lesion and proceuur.ll factors 
have bcen reported to be predictive of or associated with a 
greater risk of re-stenosis: unstahle angina, shorter dur.l-
tion of angina, angina class (III or IV), lesion length> 10 
mm, eccentricity, pre-procedural lesion .~everity, location 
in a bend, ~maller arterial size, calcitlcation, residual trans-
stenotic gradient >20 mmHg, angiographically visible 
thrombus atler angiopl<l~,ty etc. JL'~·5'I-rl1e in fiuence ofthese 
factors attenuates the relationship between relative gain 
and relative loss, to variable degrees, in these patients. In 
addition, the luminal contour immediately after successful 
balloon angioplasty often adopts an irregular non-circular 
configuration and is much more often disrupted by intimal 
dissection than is appreciated by angiography.-".l-'''''''~·M 
lvteasurement of the minimal luminal diameter, and thus 
relative gain and relative loss values, are therefore subject 
to potential imprecision after balloon angioplasty, particu-
larly when compared with stent implantation, where the 
IUlllen postintervention tends to lIssume a smoother and 
more circular conl1guration,47,".l and also perhaps when 
compared with directional atherectomy, after which lumi-
nal disruption and dissection is less often observed by 
intravascular ultrasound.""'\.~" 
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adopt an indented, undulating appearance (with potential 
turbulence effects), depending on the helical .~tructure. 
111ese and other ,L~ yet unknown considerations dilute the 
,L~sociation of vessel wall injury and tissue response in 
stented patient groups with a consequently relatively weak 
correlation between luminal improvement after stent im-
plantation and remurowing during follow-up. 
Despite the apparent graphic difference between the 
regression lines of the Iwo stent groups, analysis of vari-
ance reveals no statistically signitlcant difference (P=O.2). 
This is due to the wide 95% contldence intervals of the 
regression line for each group, which might constrict 
somewhat with the addition of further patients or in fact he 
a leature of the multifarious nature of the vessel wall injury 
and subsequent response provoked by implantation of 
appropriately sized endoluminal prostheses. The group 
treated by self .. expamling stainless steel mesh stent im-
plantation in this study is non-homogeneous, with a mix-
ture of emergency implantations (for acute or threatened 
vessel closure during balloon angioplasty), re-stenotic and 
primary lesions, and the balloon-expanding stent group 
consists exclusively of re-stenotic lesions. These lesion 
categories are reported to be associated with differing 
long-teon ,mgiographic outcome, 6')-12 which might contrib-
ute to the differences observed between the two groups. 
However, a previously publbhed relative risk analysis for 
re-stenosis in the patient group treated by implantation of 
self-expanding stainless mesh stent demonstrated no signifi-
cant differences in Ie-stenosis rates (by two commonly used 
re-stenosis criteria) between the three lesion categories. 
It must also be recognised that the inclusion of re-steno-
tic lesions only, in our group treated by impltmtiltion of this 
stent, may contribute to the observed differences between 
the tantalum coil stent and balloon angioplasty groups, 
even though the evidence indicating a signil1cantly differ-
ent respon~e ~o repeat waH injury in such patient.s is ;g~~~l 
what confllctlllg and thus far not wholly conclUSIve. -
Where relative gain is in the moderate range (0.3-0.5), 
there is no obvious long-teon advantage of any device, as 
evidenced by the similar predicted and actual relative los~ 
for all four groups in that range. 
!.imitations. The coronary angiogrmn is a two-dimensional 
luminal silhouette, providing only indirect evidence oflhe 
milieu in a coronary vessel, which may undergo profound 
disruption after intervention, in the absence of angio-
gmphic abnonnality,W,n This is a limitation of all angio-
gruphically based studies, which we have attempted to 
minimise by the use of an automated contour detcction 
system for (]ltantitative angiographic analysis, to provide 
StCllt implalltation. The use of an implantable endolull1inal objective, reproducible and absolute measurements of lu-
prosthesis, whether a hallooll-C>.\])III1l/a!Jlc tanta/1I111 coil or minal dimensions. Accepting Ihis inherent limitation ofcoro-
sdFe.\]1Ulldillg .llIIillll'.I.I" ,Ital II/csh, introduces ndditional nary angiogwphy we believe that relative gain and relative 
compounding factors such as the scaffolding effect of the loss repre~ent the best available angiogwphic correlates of 
device, the embedding eHect of the wires, the long-tenn arterial wall injUl)' and intimal hyperpla~ia respectively. 
presence of a foreign hody (with its inherent thrombogenic The effect of other clinical, procedural llnd lesion-
effect and inability to mount an appropriate physiological related characteristics Oll the relative gain/relative loss 
response), the potential molecular effect of the electrical relationship was not considered. It is conceivable that the 
charge of the stent molecules, as well as the unquantifiable app<lfently greater frequency of unstable angina in each of 
persisting barotraumatiL' injury orthe self-expanding stent on the patient groups treated by directional atherectomy and 
the vessel wall.I·1f<'"h? As a further entangling issue, the hallooll-expandable tantalum coil stent implantation con-
smoothing effect orthe stent in reducing turhulence and shear tributes to the differences observcd between these groups 
stressl~(" may facilitate rapid endothelial recovery and there- and the balloon angioplasty group. Also, the balloon 
fore retard smooth muscle cell proliferation,~' although thc angioplasty group comprises exclusively primary lesions, 
luminal contour several weeks after ~teJlt implantation may whereas the llthercctomy and self-expanding stent groups 
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include a mixture of primary. 'bailout' and fe-stenotic 
lesions, and the balloon-expandable sten! group comprises 
fe-stenotic lesions only, which may contribute to the be-
tweell-group differences observed. However, in reply to 
these points, a number of recent studies from our group 
(including stepwise regression analysis uf multiple clini-
cal, angiographic and procedural factors) have found lu-
minal improvement at intervention or 'relative gain' to be 
t~lC slronBe~\~7~lerminant of lurnin~1 renarr0v.:ing or r~la­
live loss.- J --. We were thus most mterested III cxplonng 
a dynamic relationship between these isolated variables as 
a clinical evaluation of the injurylhyperplasia hypothesis. 
The imbalance in patient numbers between the balloon 
rmgioplasty group and the other three might be considered 
to contribute to the observed intergroup differences in the 
relative gain/relative loss relationship. Furthermore, some 
of the atherectomy and self-expanding stent data represent 
the initial clinical experience with these devices, whereas 
the angioplasty data are obtained from recent European 
clinical trials, which may also have some bearing on inter-
group diiJerences. On the other hand, additional differ-
ences might become apparent between the two stent groups 
or between the directional atherectomy and self-expanding 
stent groups with larger patient numbers, as the wide 95% 
conHdence intervals for mean values and line slopes in the 
stent groups would most likely be reduced if these groups 
were larger. Perhaps amalgamation of similarly acquired 
quantitative angiographic data from other institutions 
would solve this shortcoming. 
We accept that the correlation coeftlcients describing 
the relative gain/relative loss association are weak. This 
demonstrates the limitation of applying simple geometric 
principles to describe a compound, multifactorial phe-
nomenon. However, tests of the significance of Ihe asso-
ciation between relative gain and relative loss arc strik-
ingly significant for balloon angioplasty, directional 
atherectomy and balloon-expandable stent groups and 
mildly significant for the self-expanding stent group, dem-
onstrating that thesc variables are clearly related beyond 
chance. Similarly, the regression equationsdest:ribing their 
interrelationship clearly illustrate a linear dependcncy of 
relative loss on relative gain. Wc recommend application 
of this approach to homogeneous patient groups treated by 
different devices to ascertain more ret1ned infonnation 
with respect to various clinical syndromes. 
CONCLUSION 
Differences in the relative gain/relative loss relationship 
between the devices studied may renect Ihe inherently 
disparate intensity of wall injury characteristic of each, in 
the achievement of their benet1cial effects, which become 
particularly evident at it higher scale of luminal improve-
ment. Despite these diffeTCnces, none of the devices evalu-
ated demonstrates the qualities of an ideal device, which 
would not provokc any untoward luminal renarrowing in 
response 10 maximisation of luminal increase during 
angioplasty. The ultimate roules tu the prevention of rc-
stenosis, therefore, cannot lie solely ill devices to achieve 
increasing luminal improvements, but must be via an ap-
proach integrating pharmacologists, histupathologists, 
molecular biologists, geneticists as well as intcrvcntional-
isis in the development of an 'agellt'1.<.7~ for the control or 
prevention of the tissue response to the apparently un-
avoidable injury imparted to the vessel wall during the 
revascularisatiol1 process. 
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Coronary lumen quantification at 6 month follow-up of the new 
radiopaque Cordis stent : An experimental and clinical study with 
quantitative coronary angiography and intracoronary ultrasound. 
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ABSTRACT: 
Background. While the radiopacity of tantalum stents may facilitate their deployment in coronary 
arteries, the outline of the radiopaque stent struts embedded in the vessel wall may interfere with 
the reliability of automated quantitative angiographic analysis of the stented lumen in the 
presence of intimal hyperplasia at 6 month angiographic follow-up. 
Methods. To determine the reliability of geometric (edge-detection) quantitative angiographic 
analysis (OCA) of restenosis within the new Cordis tantalum stent, OCA and intracoronary 
ultrasound (lCUS) measurements were compared in both an experimental restenosis model and 
in the clinical follow-up of patients. In the experimental series, plexiglass phantom vessels with 
concentric stenosis channels ranging from 0.75 to 3.0 mm in diameter and with a reference 
diameter of 3.0mm were imaged both prior to and following their insertion in tantalum stents. 
For the experimental series, measured values of minimal luminal diameter (MLD) and of the 
reference diameter obtained from OCA and ICUS were compared with the true diameters of the 
plexiglass vessel to determine the accuracy and precision of measurements. In the clinical series 
the agreement of QCA and ICUS measurements were studied in twenty-three patients who had 
undergone coronary implantation of the Cordis stent and twenty-three patients who had 
undergone balloon angioplasty 6 months previously. Measurements of the reference vessel 
diameter by QCA were based on a computer derived interpolated diameter which assimilates the 
diameter of the entire length of the analysed segment, while measurement of the reference 
vessel diameter by ICUS was based on measurement at one point. 
Results. Experimental results for minimal luminal diameter. The reliability of OCA measurements 
deteriorated in the presence of the radiopaque stent (accuracy of OCA fell from -.07mm to -
.12mm), while the reliability of lumen measurements by ICUS was independent of the presence 
of the radiopaque stent (-.12mm and -.13mm prior to and following introduction of the stent 
respectively). 
Experimental results for reference vessel diameter and % diameter stenosis. Without the stent, 
the average MLD obtained from OCA of the 1.00mm plexiglass vessel was 1.00 ± .01 mm and 
the 3.00mm reference vessel diameter was 2.81 ± .05mm providing a 64 ± 1 % diameter 
stenosis. Following introduction of the stent, the average MLD was 0.99 ± .06mm and the 
average reference vessel diameter was 3.36 ± 0.17mm providing a diameter stenosis of 71 
± 2 %. ICUS measurements (2.77mm) of the reference vessel diameter (3.00mm) were 
unaffected by the presence of the stent. 
Clinical series. The agreement of ICUS and OCA measurements (lCUS - OCA) was poorer in the 
balloon angioplasty patients (.68mm ± ,42mm) compared to the stented patients (-.05mm 
± ,42mml. Similarly, the correlation of ICUS and QCA measurements was ,40 in the balloon 
angioplasty population and .60 in the stented patients. 
Conclusion. In the 6 month follow-up of patients who have undergone implantation of the highly 
radiopaque Cordis tantalum stent, assessment of restenosis can be reliably quantified by OCA 
by the use of the minimal luminal diameter rather than the percent diameter stenosis. 
Assessment by QCA of the reference diameter of the stented coronary segment at follow-up 
should not be performed in the interpolated mode but may in the case of this highly radiopaque 
stent be more accurately performed by the selection of reference points outside the stent. 
Alternatively for the conduction of multicenter studies the pre-intervention interpolated reference 
vessel diameter may be utilized for the determination of the relative loss and net gain index. 
While ICUS measurements are unaffected by the radiopaque stent, the poorer accuracy of ICUS 
measurements, the mechanical problem of ICUS catheter wedging in stenoses of < 1.00mm, and 
the substantial cost of ICUS catheters will restrict the widespread application of ICUS for the 
assessment of intrastent restenosis. 
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INTRODUCTION : 
The increasing use of coronary stents for the elective prevention of restenosis and the bailout 
management of acute or threatened vessel closure following coronary angioplasty has resulted 
in a greater need for reliable quantitative measurement of angiographic outcome. While most of 
the currently available stents are of moderate radiopacity, the new tantalum Cordis stent is highly 
radiopaque. Although during the interventional procedure itself, the strong radiopacity of the 
tantalum stent facilitates the exquisite positioning of the stent in the target lesion and the 
subsequent precise placement of additional non-compliant balloons for high pressure intrastent 
inflations, the radiopaque stent struts may interfere with the assessment of restenosis within the 
stent at angiographic follow-up. 
In a previous in-vitro study by our group comparing the effect on videodensitometric quantitative 
angiographic measurements of a stainless steel stent (Palmaz-Schatz, Johnson & Johnson, NJ), 
a cobalt alloy stent (Walls tent, Schneider, Bulach, Switzerland), and a tantalum stent (Wiktor, 
Medtronic, MN), it was found that the radiopaque tantalum stent (Wiktor) resulted in a consistent 
overestimation of the minimal luminal cross-sectional area by 9-56% compared to the control 
values (varying with the contrast concentration and size of the phantom vessel) [1]. Furthermore, 
in the quantitative angiographic analysis of the multicenter Wiktor restenosis study, it was found 
that automated edge detection was unreliable in 8% of patients at angiographic follow-up 
requiring operator interaction 12,3J, The new Cordis tantalum stent has a greater impact on the 
radiopacity of the contrast-filled lumen than the Wiktor tantalum stent on account of its more 
dense and highly crenulated strut configuration. 
To evaluate the potential application and reliability of computer-based quantitative coronary 
angiographic analysis (OCA) of restenosis within the new radiopaque stent, we compared 
automated QCA and manuallv traced intracoronarv ultrasound measurements of the vessel lumen 
with and without the radiopaque stent in both an in-vitro plexiglass restenosis model as well in 
the 6 month follow-up of patients who had undergone implantation of the Cordis stent and 
patients who had undergone balloon angioplasty 6 months previously. 
METHODS: 
PART I EXPERIMENTAL SERIES 
Experimental image acquisition of plexiglass restenosis model with and without stent. 
For the in-vitro assessment of rest enos is measurements within a new radiopaque stent, phantom 
vessels were filmed prior to and following their insertion in balloon-expanded Cordis stents of 3.5 
mm nominal diameter. The phantom vessels were composed of radiolucent plexiglass cylinders 
(45 mm length, 3.6 mm in outer diameter) with precision-drilled concentric circular lumens of 
0.75, 1.0, 1.25, 1.5, 2.0, 2.5 and 3.0 mm in diameter [4-8). The length of each phantom 
stenosis channel was 5 mm and the adjacent "normal reference" channel length of the proximal 
and distal segments was 20 mm. The plexiglass channel including the artificial stenosis was filled 
with contrast medium [iopamidol 370; 370 mg iodinelml IBracco, Milano, Italvll. Cine film 
acquisition was performed with additional plexiglass blocks (50 mm anteriorly and 50 mm 
posteriorly). These plexiglass blocks provide a more appropriate kV -level and a scatter medium 
which more closely approximates the radiological scatter of the human thorax during 
angiography. Angiograms were performed using a 5" field of the image intensifier, with separate 
recordings using two different focal spots (O.4mm and O. 7mm). The radiographic system settings 
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were kept constant (kV I mAl x-ray pulse width) for each radiographic acquisition. All phantoms 
were imaged at the radiographic isocenter of the X-ray gantry [9] and acquired on 35-mm 
cinefilm (Kodak CFE Type 2711, Paris, Francel. For each of the seven phantom vessels, 10 
cineframes were selected both prior to and following their insertion in the Cordis stents providing 
a total of 140 cineframes for quantitative analysis. 
PART II CLINICAL SERIES 
Coronary balloon angioplasty. Balloon angioplasty was performed using 8 French polyurethane 
catheters in 23 lesions of 23 patients at the Thoraxcenter l Erasmus UniversitYI Rotterdam. The 
size of balloon was selected to match the reference vessel diameter obtained from on-line 
quantitative angiographic analysis after the intra coronary administration of isosorbide dinitrate. 
Of the·23 lesions treated;" a 2.5mm diameter balloon was used in 6 lesions, a 3.0mm in 10 
lesions, a 3.5mm in 6 lesions and a 4.0mm balloon in 1 lesion. Of the 23 lesions, 11 were in the 
left anterior descending coronary artery (LAD), 5 in the left circumflex coronary artery (LCX), and 
7 in the right coronary artery (RCA). The follow-up angiogram and intracoronary ultrasound 
(lCUS) examination were performed at 6 ± 2 months after balloon angioplasty. 
Coronary stent implantation. Following predilatation, implantation of a new radiopaque coronary 
stent (Cordis, Miami, U.S.A) was performed using 8 French polyurethane catheters in 23 lesions 
of 23 patients at Kokura Memorial Hospital, Kitakyushu, Japan. Twenty-one stents were 
implanted in 21 lesions of 21 patients and four stents were deployed in two lesions of two 
patients (two stents in each lesion). Of the 25 stents used in 23 lesions, 14 stents were 3.0mm 
in diameter and 11 stents were 3.5mm in diameter. Of the 23 lesions, 11 were in the LAD, 5 in 
the LCX, and 7 in the RCA. The follow-up angiographic and ICUS examination Were performed 
at 6 ± 1 months after stent implantation. The number and location of lesions were identical in 
the balloon angioplasty and stent implantation groups. 
Clinical angiographic image acquisition at 6 month follow~up. Six month follow-up coronary 
angiography was performed after the administration of intra coronary isosorbide dinitrate [10-12] 
prior to manual injection of contrast medium (iopamidol 370; 370 mg iodine/mil at 37°C. The 
5" field of the image intensifier was selected and the radiographic settings were kept constant 
(kV, mA, x-ray pulse width) in each projection. All clinical images were acquired on 35-mm 
cinefilm at a frame rate of 25 images per second. An average of 2.6 cineframes per patient were 
selected for quantitative angiographic analysis. Minimal luminal diameter (MLD), reference vessel 
diameter (Ro) and luminal dimension at the proximal and distal extremities of the radiopaque 
stent Were measured. 
Quantitative angiographic analysis. Cinefilms from both the experimental and clinical series were 
quantitatively analyzed using the computer-based Cardiovascular Angiographic Analysis System 
(CAAS II; Pie Medical, Maastricht, The Netherlandsl [4-8,13-17). Prior to the performance of the 
calibration and analyses of the stenoses, computerized correction for pincushion distortion was 
applied by the recording and subsequent off-line digitization of a centimeter grid placed in front 
of the image intensifier in each cardiac catheterization laboratory. For both the experimental and 
clinical angiograms, quantitative measurements were calibrated by the use of the recorded 
contrast~free catheter tip as a scaling device [18]. The nontapering catheter tip was measured 
with a precision-micrometer (Mitutoyo No.293-501, Tokyo, Japan; accuracy 0.001 mm). In the 
experimental study a sufficiently long segment of the plexiglass cylinders including the phantom 
stenosis with or without the stent was selected for analysis. In the clinical study frames without 
foreshortening nor overlapping side branches were selected {19,20]. Arterial dimensions of 
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clinical frames were measured at specific distances from identifiable branch points in end-
diastolic frames. 
In the CAAS II system, the entire cineframe of size 18 x 24 mm is digitized at a resolution of 
1329 x 1772 pixels. In the CAAS system, the edge detection algorithm is based on the first and 
second derivative functions applied to the digitized brightness profile along scanlines 
perpendicular to a model using minimal cost criteria [17J. The contour definition is carried out in 
two iterations. First, the user defines a number of centerline points within the arterial segment 
which are interconnected by, a straight line, serving as the first model. Subsequently, the program 
recomputes the centerline, determined automatically as the midline of the contour positions 
which were detected in the first iteration. A computer derived estimation of the original 
dimensions of the vessel at the site of the obstruction was used to determine the interpohited 
reference vessel diameter. 
If the automatically detected contour did not faithfully track the border of the lumen, the level 
was changed of the light emitting diode (LED) which regulated the image brightness during 
digitization of the cineframe. Manual correction of the automatically detected contours was not 
performed in either the experimental phantom nor the clinical studies. Minimal luminal diameter 
(MLO) and reference diameter (AD) were quantified in multiple matched views. 
Image Acquisition of Intracoronary Ultrasound (lCUS). Following selective coronary angiography, 
a mechanical intra coronary ultrasound imaging catheter (3D-MHz, 4.3Fr or 2.9Fr, CardioVascular 
Imaging Systems, Sunnyvale, CAl was introduced over a 0.014 inch guidewire. In the 
experimental series, a slow manual pull-back was performed to assess the luminal dimension at 
the site of stenosis. In the clinical series after the imaging catheter was passed into and beyond 
the lesion, a motorized pull-back (CardioVascular Imaging Systems, Sunnyvale, CAl with a 
constant speed of 0.5 mm/second was started to obtain an initial assessment of the target 
lesion. A simultaneous fluoroscopic image of the position of the ICUS catheter-tip was 
continuously displayed. Side branches and stent struts visible on both the ultrasound and 
angiographic images served as reference points to ensure that the coronary sites of ultrasound 
and quantitative angiographic analysis were identical. ICUS images were stored on super VHS 
videotape for subsequent analysis. 
Quantitative assessment of Intracoronary ultrasound IICUS). Luminal area was defined as the 
integrated area central to the intimal leading edge echo. Images with minimal cross sectional area 
(MCSA) in the stent were selected from the pull-back sequence by reviewing the position of the 
ICUS catheter on the angiographic image. Contrary to the QCA measurements, calculation of the 
reference vessel diameter by ICUS is based on a point measurement and is not interpolated. 
Minimal luminal diameter and reference vessel diameter was calculated from MCSA (rcr2). To 
determine the interobserver variability of ICUS measurements, 3D lesions were independently 
measured by two observers. The mean signed difference and correlation of the measurements 
of cross sectional area was 0.02 ±0.37mm2 and 0.97 respectively. 
Statistical analysis. In the experimental study, the individual measurements of MLD were 
compared with the true phantom diameter using the paired Student's t-test and linear regression. 
The mean of the signed differences between the true phantom diameters and the individual MLD 
values derived from measurements of QCA and ICUS was considered an index of accuracy and 
the standard deviation of the differences an index of precision. 
In the clinical study, the mean and standard deviation of the signed differences between 
measurements of MLD derived from QCA and from ICUS were used as an index of agreement 
between measurements. This statistical approach to the comparison of two measurement 
systems has been previously recommended by Bland and Altman [21 J. 
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Figure 1. QCA measurements obtained from 70 cineframes of tile p/exiglass restenosis model 
without (figure 1a) and subsequently with (figure 1b) insertion of the vessel in the tantalum stent. The 
measurement values have been plotted against the true diameter of the contrast-filled lumen of the 
pfexigiass vessel (linear regression). 
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RESULTS: 
PART I EXPERIMENTAL SERIES 
Experimental results for minimal luminal diameter. The results for measurements of the minimal 
luminal diameter within the plexigiass vessel with and without the stent are presented in table 
1 and in figure 1 a & b (OCAI and figure 2 a & b IICUS). Prior to positioning the plexiglass 
vessels in the stents, measurements of the phantom vessel lumen by OCA were more accurate 
than ICUS. The reliability of QCA measurements, however, deteriorated in the presence of the 
radiopaque stent (accuracy of OCA fell from -.07mm to -.12mml, while the reliability of lumen 
measurements by ICUS was independent of the presence of the radiopaque stent (-.12mm and 
-.13mm prior to and following introduction of the stent, respectively). 
Measurement Accuracv Precision Significance Correlation 
QGA without stent -0.07 ±0.08 p<.OOI 0.997 
QGA with stent -0.12 ±0.10 p<.OOI 0.992 
IGUS without stent -0.12 ±0.09 p<.OOI 0.989 
IGUS with stent -0.13 ±0.11 p<.OOI 0.986 
Table 1. aCA and ICUS measurements values of the minima/luminal diameter were compared to the true 
luminal diameter of the plexiglass vessel (1.00mm). 
Experimental results for reference vessel diameter and % diameter stenosis. Results of reference 
vessel measurements by QCA and IGUS are displayed in figure 3 a & b. Measurement by QGA 
of the reference vessel diameter within the stent was significantly larger than without the stent 
(p < .001) and the percent diameter stenosis was consequently significantly more severe with the 
stent than without the stent (p < .001). Without the stent, the average MLD obtained from OCA 
of the 1.00mm plexiglass vessel was 1.00 ± 0.01 mm and the reference vessel diameter was 
2.81 ±0.05 mm providing a 64 ± 1 % diameter stenosis. Following introduction of the plexiglass 
vessel in the stent, the average MLD was 0.99 ± 0.06mm and the average reference vessel 
diameter was 3.44 ± 0.1 Omm providing a diameter stenosis of 71 ± 2%. IGUS measurements 
(2.77mm) of the reference vessel diameter (3.00mm) were unaffected by the presence of the 
stent. 
An example of automated quantitative angiographic analysis of the contrast-filled plexiglass 
vessel without and with the tantalum stent is provided in figure 4. 
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Figure 3. Comparison of reference diameter obtained from QCA (3a) and tGUS (3b) without and 
with the radiopaque stent. While measurement obtained by QCA of the reference vessel diameter within 
thesten! was significantly larger than without the stent (p<O.001), {GUS measurements were unaffected 
by the radiopaque stent (n-s). 
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Figure 4. The contrast-filled lumen of the plexiglass vessel is shown without the stent in the left 
panel and following insertion of the vessel within the radiopaque stent in the right panel. Automated 
quantitative angiographic analysis was found to faithfufly track the contour of the stenotic segment (true 
value = 1.00mm) in both the absence and subsequent presence of the stent (minimal luminal diameter 
= 0.99mm and 0.98mm, respectively). Automated quantitative angiographic analysis of the normal 
reference vessel diameter (true value = 3.00mm), however, was significantly effected by the presence 
of the radiopaque stent, with undulations and evident tracking out to include the contour of the stent 
struts rather than tracking the true edge of the contrast filled lumen. The maxima! diameter was fOllncj 
to be 3. 77mm following introduction of the stent. The overestimation of the reference vessel diameter 
in the presence of the stent resulted in an exaggeration of the severity of the percent diameter stenosis. 
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PART II CLINICAL SERIES 
The results of measurements of MLD from ICUS are plotted against those from QCA for the 
balloon angioplasty and coronary stent patients in figure 5 a and figure 5 b respectively. Of the 
23 stented lesions, 3 showed signs of catheter wedging of the ICUS catheter and in the 
remaining 20 lesions minimal cross sectional area and MLD was measured. Of the 23 balloon 
angioplasty lesions, 8 showed a signs of catheter wedging. The agreement of ICUS and QCA 
measurements (ICUS M QCA) was poorer in the balloon angioplasty patients (.68mm ± .42mm) 
compared to the stented patients (-.05mm ± ,42mm). Similarly, the correlation of ICUS and QCA 
measurements was .40 in the balloon angioplasty population and .60 in the stented patients. 
To ensure that the differences between QCA and ICUS measurements of the minimal fumen 
diameter were not related to analysis at different locations in the stented coronary segment by 
ICUS and QCA, measurements were also compared at the proximal and distal extremities of the 
stent which were clearly identifiable during both QCA and ICUS analysis. The results of 
measurements of the luminal dimension at the proximal and distal extremity of the each 
radiopaque stent (46 measurements) from ICUS are plotted against those from QCA in figure 6. 
The agreement between the two sets of measurements at the extremity of the stent was M 
0.06mm ± 0.42mm (mean and standard deviation of the signed differences) associated with a 
correlation coefficient of 0.63. 
An example of angiographic measurement of the MLD of a patient with a new radiopaque stent 
can be seen in figure 7. The difference between ICUS and OCA measurements was small both 
at the site of the MLD and at the stent extremity. 
DISCUSSION: 
The principle findings of our study were: a) in the plexiglass restenosis model, QCA provided 
more accurate measurements of minimal luminal diameter than ICUS; b) following introduction 
of the plexiglass vessel in the radiopaque stent, the accuracy of QCA measurements deteriorated 
while the accuracy of ICUS measurements of both the minimal luminal diameter as well as the 
reference vessel diameter was unaffected by the radiopaque stent; c) measurements by QCA of 
the interpolated reference vessel diameter of the plexiglass vessel were rendered inaccurate by 
the presence of the radiopaque stent and resulted in the overestimation of the severity of the % 
diameter stenosis; d) in the 6 month follow-up of patients post coronary intervention, agreement 
of ICUS and QCA measurements was higher in patients who were stented compared to those 
who underwent balloon angioplasty alone. 
Comparison between ICUS and edge-detection OCA measurement. Previous studies which 
examined the relationship of the ICUS and OCA measurements in normal coronary segments 
reported a favourable correlation between the two quantitative imaging modalities (22(23), while 
those studies which included lesions post balloon angioplasty reported a poor correlation of the 
two measurement techniques [24-261. Complex morphological changes caused by balloon 
angioplasty may result in a deterioration of agreement between the two measurement systems 
post balloon angioplasty. As it is assumed that coronary lumen may be more circular and smooth 
post stent implantation than those post balloon angloplasty, the better agreement obtained 
between ICUS and QCA measurements may be conveyed by the lumen symmetry enforced by 
stent implantation. 
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Figure 5. The figures display the agreement between measurements obtained from geometric 
QCA and IGUS according to the statistical approach proposed by Bland and Affman (21) at 6 month 
follow-up of patients who had undergone balfoon angioplasfy (5a) and of patients who had undergone 
implantation of fhe radiopaque stent (5b). In 5a the difference in values between the IGUS and QCA 
measurements has been plotted against their mean value in 15 lesions without wedging of the !CUS 
catheter at follow-up in the baffoon angioplasfy group. In 5b the difference in values between the ICUS 
and QCA measurements has been plotted against their mean value in 20 lesions without wedging of 
the ,CUS catheter at follow-up of the stented patients. 
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Figure G. The figure displays the agreement between measurements obtained from QCA and 
/CUS at the 46 proximal and distal extremities of the 23 stents at 6 month foJ/ow-up according /0 the 
statistical approach proposed by Bland and Altman {21J. The differences between /CUS and QCA 
measurement values have been plotted against their mean value. 
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Figure 7. At six month fof/ow-up angiography, the radiopacity of the tantalum stent can be traced 
by automated edge detection without contrast media (left panel). In this patient, automated edge 
detecfion of the minimal luminal diameter appeared to function reliably following contrast injection (right 
panelj. 
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Limitation of aCA. During aCA measurement of the minimal luminal diameter within a stented 
vessel segment, the automated edge detection algorithm will trace the true diameter of the 
contrast-filled lumen at the point of most severe stenosis in between the radiopaque stent struts 
i.e. in the interstrut intervals. QCA measurements of the minimal luminal diameter will thus 
remain reliable for two reasons; firstly at 6 month follow-up in the presence of significant intimal 
hyperplasia, the outer edge of the radiopaque stent struts will be deeply embedded in the vessel 
wall at an adequate distance from the border of the contrast-filled true lumen and will thus not 
interfere with the automated edge detection process; and secondly the measurement is based 
on a very limited segment of the coronary lumen (according to the degree of smoothing or 
minimal cost criteria) which is shorter in length than the gap between successive radiopaque 
stent struts. 
However, during measurement of the interpolated reference vessel diameter OCA measurements 
by automated edge detection may be unreliable for two reasons; firstly, beyond the subsegment 
of maximal restenosis the outer contour of the radiopaque stent struts lie in close proximity to 
the border of the true lumen and may therefore interfere with the automated edge detection 
which may be unable to differentiate the outer contours of the lumen and stent struts; and 
secondly the interpolated reference vessel diameter is based on multiple scanlines over a large 
extent of the analysed segment which will incorporate both scan lines which do and scanlines 
which do not include the outer contour of the radiop~que stent struts. 
Rather than using a subjective operator-selected reference point, the default mode of the CAAS 
system determines the size at the target coronary segment using an objective computer derived 
interpolated reference diameter [4-8,13-171, The interpolated reference diameter is derived from 
the edge-detected diameter function of the non-stenotic proximal and distal subsegments. The 
reference vessel diameter values are estimated by fitting a straight line to the diameter function 
proximal and distal to the obstruction followed by a shift such that 80% of the diameter values 
are below the adjusted straight line. This line then represents the reconstructed reference 
diameter function and gives an estimate of the arterial size at each point along the analysed 
coronary segment. The interpolated reference vessel diameter is taken as the value of the 
reconstructed diameter function at the position of the minimal luminal diameter. The advantages 
of this approach is that it is essentially user-independent and thus highly reproducible and that 
every measurement is based on multiple measurements (every scan line) proximal and distal to 
the lesion. The limitation of this technique is in ostial lesions where a proximal segment is 
unavailable and in the case of this new highly radiopaque tantalum stent where selection of a 
reference point either proximal or distal to the Cordis stent (or an average of both) may prevent 
the overestimation of vessel size associated with use of the default interpolated reference vessel 
diameter mode. 
limitation of Intracoronary ultrasound. ICUS can provide clinically useful information on lesion 
and vessel characterization as well as for the guidance of optimal stent deployment [27-30J. 
However, the 2.9 French size of the ultrasound catheter restricts the application of ICUS for 
lumen quantification to lesions of > 1.0mm in diameter on account of mechanical wedging of the 
catheter. In our study 3 of 23 stented lesions and 8 of the 23 lesions previously treated by 
balloon angiopiasty showed signs of catheter wedging and these measurements were therefore 
excluded from analysis {these proportions (3/23 and 8123) would be consistent with expectations 
of the different long-term angiographic outcome conveyed by the two interventlonal techniques). 
Thus while ICUS may be useful immediately post intervention for assessment of stent 
deployment, by the time of 6 month follow-up those lesions with significant restenosis may be 
unsuitable for ICUS evaluation. Furthermore, as the price of ultrasound catheters remain 
expensive (approximately $1,600), it is difficult to justify the use of Ie US for the follow-up of 
all stented patients. 
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Implications. For patients undergoing 6 month ang/ographic follow-up of this new radiopaque 
stent, measurements by QCA of the minimal luminal diameter may be performed reliably. When 
a QCA system is used which offers a default interpolated reference vessel diameter mode, the 
reference vessel diameter of the stented segment may be overestimated and thus the severity 
of the percent diameter stenosis overestimated unless a manually selected reference point(s) 
proximal and/or distal to the tantalum stent is used. Alternatively for the determination of relative 
loss (absolute loss in minimal luminal diameter normalised for vessel size) the interpolated 
reference vessel diameter measured pre intervention may be used. 
At the time of stent implantation and thus prior to the development of intimal hyperplasia, the 
stent struts will be in apposition to the vessel wall and thus the outer contour of the radiopaque 
stent struts should be coincident with the outer contour of the contrast filled lumen. At this 
procedural phase, we do not find in clinical practice that the radiopacity of the stent struts 
interfere with on-line QCA measurements during stent deployment. Thus determination of the 
absolute (MLD post - MLD pre) and relative (MLD post - MLD pre normalised for reference vessel 
diameter pre) gain achieved at stent implantation, the absolute (MLD post - MLD follow-up) and 
relative (MLD post - MLD follow-up normalised for reference vessel diameter pre) loss in minimal 
luminal diameter over 6 months, and the loss index (loss / gain) (restenosis process) as well as 
measurement of the absolute minimal luminal diameter at follow-up (final outcome) should be 
feasible with OCA in patients undergoing implantation of this tantalum stent. 
Conclusion. In the 6 month follow-up of patients who have undergone implantation of the highly 
radiopaque Cordis tantalum stent, assessment of restenosis can be reliably quantified by QCA 
by the use of the minimal luminal diameter rather than the percent diameter stenosis. 
Assessment by QCA of the reference diameter of the stented coronary segment at follow-up 
should not be performed in the interpolated mode but may in the case of this highly radiopaque 
stent be more accurately performed by the selection of reference points outside the stent. 
Alternatively for the conduction of multicenter studies the pre-intervention interpolated reference 
vessel diameter may be utilized for the determination of the relative loss and net gain index. 
While ICUS measurements are unaffected by the radiopaque stent, the poorer accuracy of ICUS 
measurements, the mechanical problem of ICUS catheter wedging in stenoses of < 1.00mm, and 
the substantial cost of ICUS catheters will restrict the widespread application of ICUS for the 
assessment of intrastent restenosis. 
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Abstract 
Background. Although all coronary stents currently undergoing clinical evaluation are 
metallic, each stent is unique in design with resultant variable radial compliance and 
different degrees of radiopacity. In the selection process of an individual stent for an 
individual patient, the clinician should be familiar with the technical characteristics of 
each stent. The mechanical characteristics of stents are important to gain insight into 
the altered vessel wall compliance and the force exerted by the stent wires on the 
vessel wall post stent implantation while the radiographic characteristics are of clinical 
importance for the facilitation of the deployment procedure and the analysis of the 
angiographic outcome. 
Methods. To enable the comparison of the relative advantages and disadvantages and 
potential clinical niche of each stent design, we performed a comparative analysis of all 
the stents which are currently available for clinical evaluation. We performed our study 
in three parts: In part I, to gain insight into the range of radial compressibility proffered 
by each of the currently available coronary stents we investigated 8 self- and balloon-
expandable stents by measuring the Pressure-Diameter ratio relation in vitro in a 
customized measurement system. In part II, we determined the relative radiopacity of 
each stent by comparing the video signal of a Iineplot through the radiographic profile 
of each stent successively. In part III, we determined the influence of each metallic 
stent on the reliability of automated quantitative angiographic measurements by both 
the geometric (edge detection) and densitometric techniques of the contrast-filled 
vessel lumen. 
Results. Our study revealed marked variability among the currently available stents in 
terms of their radial compliance, their radiopacity, and their interference with the 
reliability of automated quantitative angiographic measurements by both geometric 
(edge detection) as well as videodensitometric techniques. The findings of our studies 
were consistent with the expectations from the strut thickness and configuration and 
the metallic composition of each stent design. The comparative results may be of 
relevance for the selection of different stents for different coronary indications and the 
analysis of subsequent angiographic outcome. 
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INTRODUCTION 
Coronary stents are intended to scaffold the coronary vessel wall, tacking back intimal 
dissections post balloon angioplasty and preventing acute and chronic recoil with 
consequent reduction in restenosis over 6 months. Although all coronary stents 
currently undergoing clinical evaluation are metallic, each stent is unique in design with 
resultant variable radial compliance and different degrees of radiopacity. In the selection 
process of an individual stent for an individual patient, the clinician should be familiar 
with the technical characteristics of each stent. While the range of diameters, lengths 
and profile of each stent are readily available and easily compared among the different 
stent designs there is yet no standardized information on the relative mechanical 
behaviour or the comparative radiographic features of each stent design. 
To enable the comparison of the relative advantages and disadvantages and potential 
clinical niche of each stent design, we undertook a comparative analysis of the 
mechanical behaviour and radiographic features of the all the stents which are currently 
available for clinical evaluation. We performed our study in three parts: 
In part I, to gain insight into the range of radial compressibility proffered by each of the 
currently available coronary stents we investigated 8 self- and balloon-expandable 
stents by measuring the Pressure-Diameter ratio relation 3 in vitro in a customized 
measurement system. 
In part II, we determined the relative radiopacity of each stent by comparing the video 
signal of a linep/ot through the radiographic profile of each stent successively. 
In part III, we determined the influence of each metallic stent on the reliability of 
automated quantitative angiographic measurements by both the geometric (edge 
detection) and densitometric techniques of the contrast-filled vessel lumen. 
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Figure 1 
Paper collar used to exert a radial pressure (Plan tile stent with an outer diameter 0 by pulling 
with an calibrated force (Fl. The resulting displacement M is measured with a micrometer. 
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-Figure 2 
Measurement apparatus. The bar with the collar assembly is pushed against the micrometer by 2 
springs. Vertical translation of the bar is achieved by rotation of the micrometer. 
251 
Comparative quantitative anafyses of 8 stent designs 
METHODS 
PART I 
RADIAL COMPLIANCE 
Measurement apparatus. The basic method used to deform the stents was described by 
Fallone et al. and consisted of a wrap-a-round collar of the nonelastic paper backing of 
Scotchal' film [1,2]. We used nonelastic coated low-friction paper [3M, St.Paul, MNI 
collar with a 30mm width IFigure 11. We fixed the upper end of the paper collar to a 
bar which was pushed up by springs against a micrometer (Mitutoyo 0-25 mm, 
resolution 0.01 mm). The micrometer was mounted on a frame and vertical translation 
of the bar was achieved by rotation of the micrometer spindle. The lower end of the 
collar was fixed onto a weight of 300 gr which was positioned on a balance (Sartorius 
1409 MP, resolution 0.01 gllFigure 21. 
Measurement procedure. First the micrometer reading was calibrated using a glass tube 
with a reference diameter IDrel) of 7.3 mm while a force of 0.05 Newton INI was 
applied to the collar. When measuring stents with diameters different from the glass 
tube, the relation between the micrometer reading and the stent diameter was defined 
by: 
(1) 
where 0 is the actual stent diameter and M the corresponding micrometer reading, and 
Dref and Mref represent the diameter of the glass tube and the corresponding 
micrometer displacement reading respectively. 
Stiffness of the system itself was determined by repeated (n:;;;;: 4) measurement of the 
force-displacement curve using a stainless steel tube with an outer diameter of 4.1 mm, 
a wall thickness of 0.6 mm and a length of 47 mm. After inserting the tube in the 
collar, a force [0.1 to 1 NI, was applied to the collar with 0.1 N increments by 
adjustment of the micrometer. 
Stents. The force-displacement curve of a self-expandable cobalt-based alloy Wallstent 
(Schneider, Bulach, Switzerland) and 7 balloon-expanded stents, the original single-
articulation stainless steel Palmaz-Schatz design and the new multiple helicoid 
articulation stainless steel Palmaz-Schatz design (Johnson & Johnson Interventional 
Systems NJ), the stainless steel Gianturco-Roubin (Cook, IN - stainless stee!), the 
tantalum Wiktor (Medtronic, MN - tantalum), the stainless steel Micro (Applied Vascular 
Engineering CAl, the tantalum Cordis (Cordis FL - tantalum), and the stainless steel 
Multilink (Advanced Cardiovascular Systems CAl was measured. After inserting the 
expanded stent in the coliar, a lightsource was used to illuminate the inner side (lumen) 
of the collar in order to visualize the collar wall approaching the stent struts. After the 
micrometer was adjusted until the stent struts were in apposition with the collar, the 
balance was tared. The micrometer reading reflected the initial expanded outer diameter 
of the stent according to equation 1. A force from 0.1 to 1 N in 0.1 N increments 
indicated by the balance, was applied to the collar by micrometer adjustment. The 
corresponding displacement was measured by the micrometer reading. All stent 
diameter measurements were corrected for the elasticity of the system by subtracting 
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Figure 3 
Elasticity of the system l'lIustrated by the force~displacement curve of a stainless steel tube with 
a diameter of 4. 1 mm. Note the nonlinear region caused by shape-adaptation of the callar. 
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measurement of the force-displacement curve is plotted against the global radial pressure (P) 
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the lengthening of the collar as measured on the stainless steel tube at the 
corresponding forces. The length of the stents was measured at zero force and at 
maximal force (1 N) applied to the collar using a calliper. 
Pressure calculation: To allow for comparison of different types of stents, we 
normalized for the length of each stent by introducing the global radial pressure. At the 
intermediate steps the length of the stents used in the radial pressure calculations was 
achieved by linear interpolation. If we neglect the thickness of the collar and stent, the 
applied force F on the collar results in a wall tension T in the stent of: 
F T~-
L 
where F is the applied force on the collar and L the length of the stent. 
Laplace's law the relation between tension T and pressure Pis: 
p~2T 
D 
(2) 
According to 
13} 
where P is the global radial pressure, T is the wall tension and D the stent diameter. 
Substitution of 12} in 13} gives: 
14} 
In order to express the pressure P in mmHg, the applied force F in N and the length L 
and diameter D in mm, (4) results in: 
F P~--CDOT 
B8LD (mmHg) 15} 
To account for the varying initial stent diameters,. the global radial pressure was related 
to the relative stent diameter Dr : 
D Dr~-
Do 16} 
with Do being the stent diameter at the initial force of 0.1 Nand D the actual stent 
diameter. 
Analysis of the linear force-displacement curve of the stainless steel tube resulted in a 
stiffness (F/L) of 4 N/mm, for the measurement setup (Figure 3). The mean variability 
of the displacement measurement on the stainless steel tube fn =4) over a force range 
of 0.1 to 1 N expressed as the standard deviation was ± 27J1m. 
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The variability of the method was evaluated by repeated measurement (n = 5) of the 
force-displacement curve of the Wallstent over a 0-200 mmHg pressure range. 
Repeated measurement showed a very low variability with a mean relative error of < 
1.4% (SDI of the measured mean diameter (Figure 41, 
The nonlinear region in the force-displacement curve of the stainless steel tube results 
from adaptation of the paper strip to the shape of the tube and deformation of the 
paper strip especially at the positions where it is fixed. The stiffness (F/L) of the system 
in the linear region was 4 N/mm. Correcting the measurements for the relative low 
stiffness of the paper collar assembly introduces an additional error which will be small, 
because of the very low variability in the system stiffness measurement using a 
stainless steel tube (27J1mJ. The estimated increase in variability of the diameter 
measurements introduced by this correction is 8.6 pm ( 27 I n). As repeated 
measurements of the force-displacement curve of the Wal/stent demonstrated a low 
variability in the measured diameter, we expect the measurement error introduced by 
the limited stiffness of the system, and the variability in the stent diameter 
measurements are small. 
Due to construction restraints and the limited flexibility of the paper collar some force 
is needed to adapt the collar to a circular shape. The mean force to deform the collar in 
the measured diameter range was .075 ± .0125 N. For stent diameters smaller than 
2.5 mm the force to deform the paper collar steeply rises, however, all coronary stents 
are;:::: 2.5mm and this should therefore not limit the application of the method to 
coronary stent analysis. 
The relative diameter (0100) of 8 different self- and balloon-expandable stents were 
plotted against the global radial pressure (PI (figure 5). 
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PART II 
COMPARATIVE RADIOPACITY 
The eight stents under comparison were aligned on plexiglass blocks to provide a 
kHovoltage of 70kV and recorded on fluoroscopy on a Coroskop T.O.P. X-ray unit 
which incorporated a Polydoros ISIC generator and a Megalix 30/82 X-ray tube with a 
focal spot size of O.4mm (Siemens A.G., Munich Germany). Using the HONIE software 
function of the HICOR system (Siemens), the videosignal of each stent was analyzed 
and compared. With this system, a moveable (joystick) plotline was drawn to pass 
through the struts of each metallic stent in the transverse axis of the stent and thus the 
oblique or longitudinal axis of the struts. The displayed videosignal for each stent was 
compared and the order of alignment of the eight 'stents was switched until a 
consecutive descending order of radiopacity was achieved from left to right (figure 6). 
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Figure 6 a & b 
Relative radiopacity of eight coronary stents were compared using a line plot of their video 
signal. In order of decreasing radiopacity from left to right the stents were 1) Cordis, 2) Wiktor, 
3) A VE Micro stent, 4) Gianturco-Roubin, 5) Wallstent, 6) new Palmaz-Schatz design, 7) old 
Palmaz-Schatz design (thinner strut diameter than new Palmaz-Schatz), 8) Multilink. 
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PART III 
COMPARATIVE GEOMETRIC AND DENSITOMETRIC QUANTITATIVE ANGIOGRAPHY 
For the in-vitro assessment of the effect of each metallic stent on the reliability of 
automated quantitative angiographic measurements by both videodensitometry as well 
as by edge detection (geometric) techniques we compared measurements of a contrast 
filled plexiglass vessel which was inserted in each stent consecutively. The radiolucent 
plexiglass vessel had normal reference vessel diameter segment (3.00mm in diameter 
and 20mm in length) as well as a stenosis segment (1 .00mm in diameter and 5mm in 
length). The total length of the plexiglass vessel was 45mm and the outer diameter was 
3.6mm (figure 7). The plexiglass channel including the artificial stenosis was filled with 
contrast medium (iopamidol 370; 370 mg jodine/ml (Bracco, Milano, Italy)). Cinefilm 
acquisition was performed with additional plexiglass blocks (50 mm anteriorly and 50 
mm posteriorly). These plexiglass blocks provide a more appropriate kV-level and a 
scatter medium which more closely approximates the radiological scatter of the human 
thorax during angiography. Angiograms were performed using a 5" field of the image 
intensifier, with separate recordings using two different focal spots (O.4mm and 
0.7mm). Each stent was imaged at the radiographic isocenter of the X-ray gantry (17) 
and the radiographic system settings were kept constant (kVp, rnA, ms) for each stent. 
The images were acquired on 35-mm cinefilm (Kodak CFE Type 2711, Paris, France) 
using an Arritechno 90 cine camera (Arnold & Richter, Munich, Germany) with an 100 
mm optical lens (over framing). The cinefilms were processed by a Refinal developer 
(Agfa-Gevaert, Leverkusen, Germany) for 4 minutes at 2SoC. The film gradient was 
measured in all cases to ensure that the optical densities of interest were on the linear 
portion of the sensitometric curve. For each of the eight stents and for the plexiglass 
vessel without a stent, 10 cineframes were selected providing a total of 90 cineframes 
for quantitative analysis. 
Quantitative angiagraphic analysis. Cinefilms were quantitatively analyzed using the 
computer-based Cardiovascular Angiographic Analysis System (CAAS II; Pie Medical, 
Maastricht, The Netherlands) [5-14J. Prior to the performance of the calibration and 
analyses of the stenoses, computerized correction for pincushion distortion was applied 
by the recording and subsequent off-line digitization of a centimeter grid placed in front 
of the image intensifier. Quantitative measurements were calibrated by the use of an 
isocentrically-recorded contrast-free catheter tip as a scaling device [16-21]. The 
nontapering catheter tip was measured with a precision-micrometer (Mitutoyo No.293-
501, Tokyo, Japan; accuracy 0.001 mm). A sufficiently long segment of the plexiglass 
cylinders including the phantom stenosis with or without the stent was selected for 
analysis. 
Geometric (edge detection) QCA. In the CAAS II system, the entire 18 x 24 mm 
cineframe is digitized at a resolution of 1329 x 1772 pixels. In the CAAS system, the 
edge detection algorithm is based on the first and second derivative functions applied to 
the digitized brightness profile along scanlines perpendicular to a model using minimal 
cost criteria. The contour definition is carried out in two iterations. First, the user 
defines a number of centerline points within the vessel which are interconnected by a 
straight line, serving as the first model. Subsequently, the program recomputes the 
centerline, determined automatically as the midline of the contour positions which were 
detected in the first iteration. If the automatically detected contour did not faithfully 
track the border of the lumen, the level was changed of the light emitting diode (LED) 
which regulated the image brightness during digitization of the cineframe. Manual 
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Figure 7. The phantom plexiglass vessel served as an in-vitro model for intfastent restenosis by 
the insertion of the model into each expanded stent. Quantitative angiographic measurements 
were made of the contrast-filled lumen without the stent (control measurements) and 
subsequently within each stent. 
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correction of the automatically detected contours was not performed in either the 
experimental phantom nor the clinical studies. 
Videodensitometric QCA. Videodensitometric measurement is based on the relationship 
between the attenuating power of the lumen filled with contrast medium and the X~ray 
image intensity [11-141. Using this relationship, a videodensitometric profile which is 
proportional to the cross-sectional area of the lumen was obtained. Subtraction of 
patient structure noise was applied after computing the linear regression line through 
the background pixels located on both sides of the detected luminal contours. 
Consecutive densitometric profiles of the analyzed segment were acquired in all scan 
lines perpendicular to the vessel including lesion, reference and non-diseased area. 
Conversion of the individual videodensitometric profiles to absolute values was 
performed after a transformation of the videodensitometric profile found in a cross-
sectional area of non-diseased segment, assuming a cross-sectional area at any point is 
proportional to the densitometric profiles at the point. Minimal luminal diameter was 
calculated from the minimal luminal cross sectional area. 
The individual measurements of the minimal luminal diameter, the mean luminal 
diameter I and the maximal luminal diameter were compared with the true phantom 
diameter using the paired Student's t-test and linear regression. The mean of the signed 
differences between the true phantom diameters and the individual MLD values derived 
from measurements of QCA was considered an index of accuracy and the standard 
deviation of the differences an index of precision. The percent deviation of QCA 
measurements for each stent was calculated from the measurement of the plexiglass 
vessel when analyzed in the absence of any stent (control DCA measurement). 
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RESULTS 
PART' 
In part I the radial compressibility of 8 different metal balloon-expandable and self-
expandable stents were measured (figure 5). The results of the measurements indicated 
that Wallstent was the most compliant stent while the AVE Micro stent proffered the 
greatest resistance to compression. The radial compliance of the new Palmaz-Schatz 
design and the Wiktor stent were equivalent and second to the AVE Micro stent, while 
the compliance of the Gianturco-Roubin, ACS, old Palmaz-Schatz, and Cordis stent 
were similar and in an intermediate third category as displayed in figure 5. 
PART 1/ 
The relative radiopacity of each stent design can be visualized in figure 6. The two 
tantalum stents were found to be the most radiopaque while the thin strutted stainless 
steel Multilink (ACS) stent was found to be the least radiopaque. In order of decreasing 
radiopacity the stents were 1) Cordis, 2) Wiktor, 3) AVE Micro stent, 4) Gianturco-
Roubin, 5} Wallstent, 6} new Palmaz-Schatz design, 7} old Palmaz-Schatz design 
(thinner strut diameter than new Palmaz-Schatzl, 8) Multilink. 
PART 1/, 
The results of the computer-based quantitative angiographic (OCA) measurements of 
the contrast-filled plexiglass vessel without any stent and subsequently within each of 
the eight stents are presented in table 1 a&b and table 2a&b. 
In measurement of the minimal luminal diameter in the contrast-filled 1.00mm stenosis 
(table 1 a), it was found that the superimposition of the struts of the AVE Micro and the 
new Palmaz-Schatz design occasionally drew the automated edge detection algorithm 
inside the outer border of the contrast-filled lumen due to a further increase in the 
brightness profile of the digitized image. On videodensitometric analysis (table 1b), the 
additional increase in brightness caused by the highly radiopaque tantalum Cordis stent 
had a marked effect on measurement of the lumen resulting in a significant increase in 
the measured value (in the presence of the Cordis stent the 1.00mm lumen was 
measured to be 1.32mm instead of the O.99mm measurement value when the stenosis 
of the plexiglass vessel was analyzed in the absence of any stent. 
In measurement of the mean and maximal value of the 3.00mm segment of the 
plexiglass vessel, it was found that the two tantalum stents (Cordis and Wiktor) 
resulted in an increase in the measurement value. The effect was much greater by both 
the geometric and densitometric techniques for the Cordis stent, compared to the 
Wiktor stent. For the edge detection technique this was seen to be due to the tracking 
by the algorithm of the outer edge of the tantalum stents which lay in close proximity 
to but external to the contrast filled lumen. Given the previously described [20] 
tendency of automated quantitative angiographic techniques to underestimate large 
diameters (-0.26mm in this study for the 3.00mm segment) , the absolute numerical 
effect in mm's of the increase in measurement value associated with the tantalum 
stents was limited. 
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Table 1 a. Comparison of the minimal luminal diameter of the plexiglass vessel with 1.00 mm stenosis without 
and subsequently with each of the 8 stents 
Edge-detection Videodensitometry 
Accuracy Deviation Precision Accuracy Deviation Precision 
Plexiglass 
vessel -.01 ±.01 -.01 ±.01 
without stent 
Cordis -.02 (-1 %) ±.03 .33 (34%) ±.08 
Wiktor -.05 (-3%) ±.04 .03 (4%) ±.06 
AVE -.11 (-10%) ±.03 -.07 (-6%) ±.06 
GR -.06 (-4%) ±.05 -.04 (-3%) ±.04 
Wallstent -.06 (-5%) ±.04 -.06 (-5%) ±.04 
PS (new) -.10 (-9%) ±.04 -.10 (-9%) ±.04 
PS (old) -.02 (-1 %) ±.02 -.01 (O%) ±.03 
ACS -.01 (0%) ±.03 -.01 (0%) ±.03 
(%) % difference between the stented vessel and vessel without stent 
Table 1 b. Comparison of minimal luminal diameter in pfexiglass vessel of 3 mm diameter without and 
subsequently with each of the 8 stents 
Edge-detection Videodensitometry 
Accuracy Deviation Precision Accuracy Deviation Precision 
Plexiglass 
vessel -.26 ±.03 -.26 ±.03 
without stent 
Cordis -.20 (3%) ±.05 .27 (19%) ± .12 
Wiktor -.27 (0%) ±.04 -.23 (1%) ±.03 
AVE -.30 (-1 %1 ±.09 -.25 (0%) ±.03 
GR -.31 (-1 %1 ±.05 -.27 (0%) ±.04 
Wallstent -.26 (0%) ±.01 -.31 (-2%) ±.04 
PS (new) -.28 (0%) ±.07 -.25 (O%) ±.03 
PS (old) -.30 {-1 %1 ±.O5 -.29 (-1 %1 ±.02 
ACS -.27 (0%) ±.04 -.26 (0%) ±.02 
1%) % difference between the stented vessel and vessel without stent 
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Table 2a. Comparison of mean vessel diameter in plexiglass vessel of 3 mm diameter without and subsequently 
with each of the 8 stents 
Edge-detection Videodensitometry 
Accuracy Deviation Precision Accuracy Deviation Precision 
Plexiglass 
vessel -.26 ±.04 -.25 ±.03 
without stent 
Cordis .20 (17%1 ±.22 .42 (24%1 ± .12 
Wiktor -.22 (2%1 ±.03 -.15 (4%) ±.03 
AVE -.25 (0%1 ±.07 -.21 (1%) ±.O3 
GR -.27 (0%1 ±.05 -.24 (0%) ±.O3 
Wallstent -.26 (0%1 ±.01 -.28 (-1%1 ±.O3 
PS (newl -.24 (1%1 ±.06 -.23 (1%1 ±.O3 
PS (oldl -.28 (-1 %) ±.05 -.27 (-1 %) ±.02 
ACS -.24 (1%1 ±.O4 -.24 (0%1 ±.02 
(%) % difference between the stented vessel and vessel without stent 
Table 2b. Comparison of maximal vessel diameter in plexiglass vessel of 3 mm diameter without and 
subsequently with each of the 8 stents. 
Edge-detection Videodensitometry 
Accuracy Deviation Precision Accuracy Deviation precision 
Plexiglass 
vessel -.24 ±.Ol -.23 ±.O3 
without stent 
Cordis .64 (32%1 ±.09 .59 (30%1 ±.O8 
Wiktor -.16 (3%1 ±.O2 -.07 {6%1 ±.02 
AVE -.19 (2%1 ±.09 -.17 (2%1 ±.06 
GR -.26 (-1%1 ± .05 -.21 (1%) ±.O4 
Wallstent -.25 (0%) ±.01 -.25 (-1 %) ±.O2 
PS (new) -.22 (1 %1 ±.06 -.21 (1%1 ±.O3 
PS (oldl -.23 (0%1 ±.O6 -.25 (O%) ±.01 
ACS -.21 (1%) ±.04 -.23 10%) ±.03 
(%) - % difference between the stented vessel and vessel without stent 
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DISCUSSION 
Our studies have clearly demonstrated that the mechanical behaviour, radiographic 
profile, and effect on computer"based quantitative angiographic analysis vary markedly 
among currently available coronary stent designs. 
Radial compliance. 
The mechanical characteristics of stents are important to gain insight into the altered 
vessel wall compliance and the force exerted by the stent wires on the vessel wall post 
stent implantation. Intracoronary ultrasound studies have demonstrated compliance of 
healthy coronary vessels with marked diastolic to systolic differences in lumen 
dimensions. Implantation of a stent would be expected to restrict the compliance of the 
stented coronary segment. The degree of radial compliance of a stent will be dependent 
upon the strength of the metal alloy, the thickness of the stent struts, the proximity of 
successive struts {i.e. the interstrut interval}, the angle of orientation of the struts 
against the vessel wall, and the presence of either welded or free interstrut junctions. 
The compliance mismatch between the coronary vessel and the metallic stent might be 
expected to result in focally accentuated shear stress or barotrauma in the vessel wall 
especially at the proximal and distal extremities of the stent. This may be more marked 
recently following the introduction of the interventional policy of "bigger is better", the 
selection of oversized stents, and the optimization of stent deployment by ultrasound~ 
guided high pressure intrastent inflations of non-compliant balloons. While it may 
therefore be felt that a degree of compliance might be desirable in a stent, it should 
also be considered that the exertion of sustained radial force by the stent on the vessel 
wall may be required to withstand elastic recoil and vascular spasm and to prevent 
stent migration following deployment. Results of detailed quantitative angiographic 
studies of patients undergoing stent implantation suggest that stents do demonstrate a 
degree recoil upon deflation of the stent deployment balloon. 
In our study, except for the Wallstent and AVE stents the relation between the radial 
pressure and diameter ratio appears to be nonlinear (figure 5). This nonlinear behaviour 
results in part from adaptation of the stent to the cylindrical shape of the collar during 
the pressure build"up. Such a deviation of the stent surface from a cylindrical shape, 
may result in a nonuniform distribution of the applied radial pressure on the stent wires. 
This can be appreciated in figure 6, where the axial photograph of the lumen of all the 
stents reveals that both the Wallstent and AVE Micro stent were symmetrically 
expanded and thus the radial force exerted by each strut would have been recruited 
simultaneously by the cylindrical collar. The inhomogenous expansion of stents may 
result in non-uniform distribution of radial force throughout the stented coronary 
segment. 
The comparative results of our in-vitro measurement are not necessarily directly 
applicable to the dynamics of deployed stents in"vivo. In particular it should be noted 
that our low friction model allows the longitudinal extension of stents upon 
compression. While stents with primarily transverse orientation of their struts (e.g the 
Gianturco"Roubin stent) do not undergo significant changes in length upon radial 
expansion or compression, other stent designs such as the Wallstent undergo 
significant lengthening upon radial compression. Once deployed in the vessel wall, the 
Wallstent struts would be expected to become embedded in the intima of the vessel 
wall and the coronary vessel itself would thereby be expected to resist longitudinal 
extension. This supposition may be indirectly assessed by the use of quantitative ECG-
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Figure 8. Quantitative ultrasonic analysis of compliance within a stented coronary artery, 
Left panel; 
Upper right panel; 
Lower right panel; 
ECG-gaited three-dimensional reconstruction of an intracoronary 
ultrasound recording within a Wellstent in a native coronary artery. 
Images were acquired using a motorized pull-back device reVIS). 
Filtering of the ultrasonic data sets has been applied during off-line post-
processing of the image to enhance the back scatter from the metallic 
struts of the stent. 
Automated measurements of luminal and medial area in end-diastole 
analyzed over 200 frames at an interval of 0.1 mm / frame indicating a 
diastolic luminal volume of 46. 79 mm3 
Automated measurements of luminal and medial area in end-systole 
analyzed over 200 frames at an interval of O. 1 mm / frame indicating a 
systolic luminal volume of 47.16 mm3 
This data adds support to the concept that the Wal/stent demonstrates low compliance in-vivo 
when significant elongation of the stent is restricted by the atherosclerotic wall of the coronary 
artery in which the stent is embedded 
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gaited three dimensional [22,231 intracoronary ultrasound analysis of stented segments 
(figure 8). By comparing the systolic and diastolic intrastent diameters and volumes in a 
native coronary artery immediately following Wallstent implantation it can be seen that 
no significant cyclical changes can be seen within the stented segment thus supporting 
the concept that the compliance of the Wallstent following deployment in a coronary 
vessel wall behaves differently than in our low~frjction in-vitro measurement system [4J. 
Despite the limited direct applicability of the reported absolute in-vitro results to in-vivo 
expectations for stents which undergo elongation upon radial compression, the system 
described does offer a simple and standardized approach to compare the radial 
compressibility of stents. Refinement of the apparatus may be achieved by the 
incorporation of a corrugated collar which might offer longitudinal friction or resistance 
to stent elongation or alternatively the testing of each stent in an excised coronary 
vessel from an autopsy specimen or animal model. 
It should be noted that the interaction of the radial compliance of a stent and the 
prevention of vessel recoil and subsequent restenosis in-vivo has yet to be 
demonstrated. Furthermore additional studies are required to address the influence of 
the distribution of radial force (a coil stent with large interstrut intervals e.g. Gianturco-
Roubin stent versus a dense mesh e.g. Walistent) exerted by stents on angiographic 
outcome. 
Relative radiopacity. 
While the radiopacity of tantalum stents may facilitate their deployment in coronary 
arteries, the outline of the radiopaque stent struts embedded in the vessel wall may 
interfere with the reliability of automated quantitative angiographic analysis of the 
stented lumen in the presence of intimal hyperplasia at 6 month angiographic follow-up. 
While most of the currently available stents are of moderate radiopacity, the new 
tantalum Cordis stent is highly radiopaque. Although during the interventional procedure 
itself, the strong radiopacity of the tantalum stent facilitates the exquisite positioning of 
the stent in the target lesion and the subsequent precise placement of additional non-
compliant balloons for high pressure intrastent inflations, the radiopaque stent struts 
may interfere with the assessment of restenosis within the stent at angiographic follow~ 
up. 
Effect of metallic stents on automated quantitative angiography 
The new Cordis tantalum stent was found to exert a greater impact on the radiopacity 
of the contrast-filled lumen than the Wiktor tantalum stent on account of its more 
dense and highly crenulated strut configuration. In a previous in-vitro study by our 
group comparing the effect on videodensitometric quantitative ang/ographic 
measurements of a stainless steel stent (Palmaz~Schatz, Johnson & Johnson, NJ), a 
cobalt alloy stent (Wallstent, Schneider, Bulach, Switzerland), and a tantalum stent 
(Wiktor, Medtronic, MNL it was found that the radiopaque tantalum stent (Wiktor) 
resulted in a consistent overestimation of the minimal luminal cross-sectional area by 9-
56% compared to the control values (varying with the contrast concentration and size 
of the phantom vessel) [23]. Furthermore, in the quantitative angiographic analysis of 
the multicenter Wiktor restenosis study, it was found that automated edge detection 
was unreliable in 8 % of patients at angiographic follow-up requiring operator interaction 
[24,25]. Our results would indicate that videodensitometry is unlikely to offer a more 
reliable alternative to geometric QCA measurements in the presence of tantalum stents. 
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CONCLUSIONS 
We have demonstrated that marked variability exists among the currently available 
stents in terms of their radial compliance, their radiopacity, and their interference with 
the reliability of automated quantitative angiographic measurements by both geometric 
(edge detection) as well as videodensitometric techniques. The comparative results may 
be of relevance for the selection of different stents for different coronary indications 
and the analysis of subsequent angiographic outcome. 
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INTRODUCTION 
Coronary stents were developed to overcome the two primary limitations of balloon 
angioplasty, namely, abrupt vessel closure and late restenosis. Coronary stents achieve the 
acute maintenance of vessel patency following failed balloon angioplasty by the provision 
of a scaffolding lattice to tack back intimal flaps and seal the dissected vessel wall. 
Following procedurally successful balloon angioplasty, coronary stents prevent late recoil 
and consequent restenosis by mechanically enforced remodelling and resetting of the 
vessel size of the stented segment. 
Although coronary stent implantation commenced in 1986, only one indication (elective 
treatment of primary lesions in native coronary arteries) for one stent (Palmaz-Schatz) has 
to date been evaluated by the rigorous process of the randomized trial [1,2]. BENESTENT 
[1 J and STRESS [2J have indicated that coronary stenting may indeed be effective in the 
reduction of the restenosis rate at six months compared to balloon angioplasty. This 
reduction in restenosis rate is achieved despite the accommodation of a greater absolute 
loss in lumen diameter over six months in stented patients. Such an achievement is made 
possible by the even greater gain in lUmen diameter achieved at the time of stent 
implantation compared to the procedure of balloon angioplasty alone in addition to the 
prevention of late recoil of the stented vessel wall. 
While following balloon angioplasty abrupt vessel closure due to dissection and thrombus 
formation typically occurs while the patient is still in the cardiac catheterization laboratory 
or within the first 4 - 6 hours [3-13}, stent implantation may delay the onset of abrupt 
vessel closure due to thrombotic stent occlusion which typically occurs at a median time 
of 3 - 5 days post stenting [1 ,2J. This delayed risk of thrombotic occlusion on the metallic 
coronary stent has necessitated the administration of systemic anticoagulant therapy with 
an associated increased risk of haemorrhagic events [1,2]. Approaches to address these 
limitations of stenting include the substitution of anticoagulant therapy (heparin and 
coumadin) by effective antiplatelet therapy (ticlopidine and aspirin) [14-16J and the current 
drive towards optimal stent deployment guided by on-line quantitative coronary 
angiography [17, 18J in multiple projections and I or intracoronary ultrasound [19-23J 
(figure 1), and at some centers guided by angioscopy [24,25J (figure 2). Additional 
measures include the use of improved femoral haemostatic devices [26-29] and the 
application of stent coatings [30] which were initiallY introduced for clinical evaluation on 
the Walls tent (polymer coating, {BioGold, PlasmaCarb Inc., Bedford, NH, U.S.A.)) from 
1989 through 1991 [31,32, 49], and more recently on the Palmaz-Schatz stent (heparin 
coating {Carmeda AB, Stockholm, Sweden)) [33]. 
Apart from BENESTENT and STRESS the available data on all other stents and all other 
indications for coronary stenting arises from non-comparative studies and registry data. 
Results of ongoing randomized trials on elective stenting in native coronary arteries of 
primary lesions (START[34]), total occlusions (SICCO), and restenotic lesions (REST [35]), 
and in vein graft lesions (SAVED), and randomized trials on bailout stenting of acute and 
threatened vessel closure (GRACE[36], TASC II [37]), should become available in 1996. 
With enthusiasm unabated by the current paucity of prospective controlled randomized 
data, the clinical practice of coronary stenting has marched on in accordance with 
interpretation of non-comparative series of clinical applications with strikingly different 
inclusion I exclusion criteria, only occasionally presented with historically-matched case 
controls [38}, and in accordance with the level of restrictions exerted by national or federal 
regulatory bodies. Accordingly the current indications for coronary stenting include 1) 
bailout therapy of acute and threatened vessel closure [39-45], 2) non-elective 
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Figure 1 
Intracoronary ultrasound (/CUS) images of a Wallstent in an aortocoronary bypass graft. A blood-speckle 
identification program (Echo vision, CVIS, Sunnyvale, CA, USA) which is able to distinguish between the 
varying backscatter pattern of flowing blood cells in the vessel lumen and the more stable pattern of the 
vessel wall, has been used for three-dimensionsal reconstruction of the ICUS data sets. In addition to the 
transverse and longitudinal views a true three dimensional view is displayed (right side), presenting the data 
in a cylindrical format which has been opened longitudinally ("clam-shell" view) /85/. Stent deployment can 
be checked and offer guidance for addiaonal high pressure intrastent inflations of a non-compliant balloon 
when necessary. In this patient the Wallstent was found to be symmetrically expanded. 
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improvement of the suboptimal angiographic result of primary balloon angioplasty [45], and 
3) elective stenting of primary lesions in native coronary arteries [1,2] and saphenous vein 
grafts [32, 49,46-53], restenotic lesions [54, 56], and total occlusions [551. 
Given the spectrum of clinical indications and coronary lesions amenable to stent therapy, 
there is clearly a need for more than one stent design. Following the recent introduction 
of the Less Shortening Wallstent, Multilink lACS), AVE Micro, and Cordis stents and the 
recent withdrawal of the Strecker stent, there are now seven different coronary stents 
available for clinical evaluation. The scaffolding lattice of each stent differs markedly in 
configuration (figure 3) varying in the balance between the presentation of as minimal a 
metallic surface area as possible to lower the thrombogenic burden and the provision of 
strong radial force. The stents can be categorized into the mesh stents characterized by 
strong and extensive scaffolding of the vessel wall (Wal/stent, Palmaz-Schatz, AVE Micro, 
(Strecker)) and the coil stents characterized by a low metallic surface area and 
predominantly transverse strut orientation (Gianturco-Roubin, Wiktor, Multilink, Cordis). 
The AVE Micro and ACS Multilink stents only loosely belong to such simplistic categories 
and the detailed structural design of each stent will be individually discussed later in this 
chapter while the key features of each stent are presented in tables 1-3, Within each 
category each stent offers a unique structural profile and consequently conveys its own 
clinical advantages and disadvantages. When selecting a stent for an individual patient 
with an individual indication and lesion the operator needs to take a number of patient and 
procedural related factors into consideration as well as to consider the structural properties 
and delivery system of each available stent. This chapter aims to rationalize coronary stent 
selection and to focus on the clinical and technical guidelines to help the operator select 
the most appropriate stent for each patient. In the first section, the requirements of each 
of the current indications for stenting are considered in relation to the clinical setting, the 
vessel and lesion characteristics, and procedural details. In the second section of this 
chapter the suitability of each of the currently available stents to meet the requirements 
of each indication and lesion is critically reviewed. 
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Figure 2 
Angioscopic examination following opamal deployment of a Walls tent demonstraang the mesh lattice of the 
stent struts (left sidel which has been well opposed to the vessel wall and a symmetrical/umen. No 
protrusion of intimal flaps or thrombus are seen. The guide wire can be seen to run axially in the center of 
the lumen. 
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SECTION I 
Indication. 
For bailout stenting the threatened or acute vessel closure typically results from a 
subocclusive or occlusive intimal flap accompanied by a varying degree of intracoronary 
thrombus [57]. Extensive dissections are more likely to be induced by aggressive 
angioplasty performed in accordance with the "bigger is better" policy. Thus at the time 
of stent implantation the tough primary lesion has already been "cracked" and the 
immediate "bailout" function of the stent becomes one of tacking back the dissected flap 
rather than overcoming recoil. Therefore in the bailout setting, the selection of a coil stent 
should be adequate without the necessity of a mesh stent with strong radial force and high 
metallic surface area. It is of interest to note that the incidence of subacute stent 
thrombosis following emergent stent placement in multicenter experience over the same 
period of 1988 - 1991 was 16% for the Palmaz-Schatz mesh stent [45J compared to 8.7% 
for the lower metallic surface area Gianturco-Roubin coil stent [42}. 
In the case of the suboptimal result (acute recoil with or without medial haemorrhage) after 
coronary angioplasty which may previously have been taken as > 50 % residual diameter 
stenosis but is now more commonly taken as > 25% residual diameter stenosis, a stent 
proffering strong radial support will be required, Similarly a strong radial force will be 
required for elective stent placement where the primary objective is to reset the vessel size 
at the point of the lesion and to enforce mechanical remodelling thereby improving the 
accommodation of intimal hyperplasia and to preve'nt late recoil over the ensuing 6 months 
[58,59]. The selection of a mesh stent with extensive scaffolding (sieve) will prevent 
encroachment on the lumen by intimal protrusion acutely and may contribute to the 
reduction in lumen renarrowing due to intimal hyperplasia over 6 months through the 
interstrut intervals [1,2,54, 56]. In both the case of "touching-up" the suboptimal 
angiographic result of primary angioplasty as well as in the case of elective primary stent 
placement, selection of a stent with a relatively high metallic surface area should not be 
of major concern and the obtainment of a large lumen with laminar flow should be the 
primary aim. 
Clinical setting. 
The thrombogenic state of the coronary artery is felt to progressively increase when going 
from the setting of stable angina, through unstable angina, to acute myocardial infarction. 
In a study comparing the outcome of stenting in patients with unstable angina and patients 
with stable angina [60J, instability of symptoms was not found to convey a negative 
outcome. This finding, which was in contradistinction to previous findings with balloon 
angioplasty, was felt to possibly relate to the sealing of dissections or to the use of full 
conventional anticoagulation in all patients in this series [60]. In an analysis of the 
multicenter registry data on the Gianturco-Roubin stent [43], angiographic evidence of 
intra coronary thrombus was found to be predictive of subsequent adverse clinical events 
following elective stent placement but not after baiJout stenting. Herrmann et ai, however, 
in an analysis of a multicenter experience of emergent placement of the Palmaz-Schatz 
stent, found angiographic evidence of intracoronary thrombus to be associated with a 
significantly higher risk of subsequent subacute thrombosis {45]. The very limited number 
of reported patients who have been stented in the setting of myocardial infarction render 
conclusions on this last frontier for stenting premature 161-64]. Thus the impact of the 
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Walls tent Multilink 
Figure 3 
The seven coronary stents which are currently available for clinical evaluation. 
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thrombogenic state or stability of symptoms on outcome following coronary stent 
implantation remains to be clearly defined by prospective studies. While it might appear 
advantageous to select a stent with a low metallic surface area in patients with a profile 
of increased risk for acute / subacute thrombotic occlusion, it is likely that the procurement 
of an optimal angiographic result with high laminar flow is of greater importance than the 
metallic (thrombogenic) burden of the stent used to achieve such a result. 
Vessel size. 
Further to our increased understanding of the importance of vessel size as well as the 
minimal diameter of the lesion on acute and long term outcome, on-line quantitative 
coronary a"ngiography (OCA) has become an integral component of optimal stent 
deployment [17J. On·line QCA data is used to guide both the prestenting or priming balloon 
inflations as well as for appropriate stent sizing. Depending on the structural design of the 
individual stent selected, a nominal (manufacturer's stated) stent size of 0.1 to 0.5mm 
larger than the vessel size is selected. In a patient with a vessel size of > 4.0mm only two 
of the currently available stent designs have an adequate range of stent sizes to cover such 
a vessel, namely the Wallstent and the Palmaz (unarticulated) "biliary" stent. Stenting of 
larger vessels is associated with a higher procedural success rate and improved clinical 
outcome compared to stenting of smaller vessels. Furthermore the reported lower 
complication rate for elective stenting in the right coronary artery [65} may in part relate 
to the large size of the right coronary artery. 
In addition to vessel size considerations, the coronary flow of the target vessel is also of 
prognostic importance post stenting. Stenting in a vessel with poor distal run-off supplying 
an infarcted myocardial region or stenting in the presence of poor left ventricular function 
is associated with a higher risk of subsequent subacute stent thrombosis [56}. 
Vein graft versus native coronary artery. 
When stenting a venous bypass graft, the scaffolding properties of the stent as well as the 
stent size should be taken into consideration. Old bypass grafts frequently contain 
extensive friable tissue prone to embolization in the subtended coronary arterial bed. It is 
unlikely that a coil stent with a large interstrut distance such as the Wiktor or Gianturco-
Roubin stent would provide sufficient scaffolding of the vein graft wall to prevent such 
embolization of friable tissue. In contrast the cross-hatched mesh design [32] of the 
Wallstent [491 and to some extent the Palmaz-Schatz stent [50-53] offers greater 
protection against the risk of embolization by virtue of their shorter interstrut distance and 
higher metalllc surface area. The absence of side branches in the shaft of vein grafts 
obviates any concern of jailing of vessels by the stent mesh. Although long lesions located 
in the body (shaft) of coronary vein grafts are particularly well treated by the Wallstent, 
lesions located at the ostium of vein grafts are unsuited to Wallstent implantation on 
account of movement of the stent and proximal shortening which normally occur during 
retraction of the rolling membrane and expansion of the Wallstent. Thus for ostial lesions 
where exquisite positioning is required to avoid protrusion of the proximal terminal of the 
stent into the aorta! a balloon expandable and preferably radiopaque stent may produce 
more predictable results particularly for those operators without extensive experience in 
Wallstent deployment. For lesions located in the distal segment of "jump" (sequential) vein 
grafts, it is important that a stent with a sufficiently long delivery system be selected. 
Chronic total occlusions. 
To date published results for stenting of chronically occluded vessels have been limited to 
non-comparative series [55]. Following successful recanalization of vessels with chronic 
total occlusions! it is often found that the entire vessel is extensively diseased in either a 
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Figure 4 
A Focal lesion In the left anterior descending artery prior to directional coronary atherectomy 
B A Less Shortening Walls tent was delivered to treat a dissection Induced by atherectomy 
C Final angiographic outcome reveals a smooth-contoured stented segment with no loss of slde-
branches and absence of vessel splinting which may be seen following deployment of more rigid 
stents 
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diffuse or segmental manner. Recently we have adopted a policy of resetting the size [67] 
of the entire vessel, whereby we select a long Wallstent (35mm nominal length when fully 
expanded) with a nominal diameter of 1.5mm larger than the maximal diameter of the 
vessel (MVD) obtained from the diameter functibn of the on-line OCA. When grossly 
oversized, the axial shortening of the Wallstent is further reduced resulting in a final 
deployed length of up to 40mm. When necessary a second (and rarely a third) Wallstent 
is deployed to ensure that the entire length of the reconstructed vessel is expanded. The 
flexibility and continuity of large diameter of the resultant stented vessel results in an entire 
reconstruction of the epicardial vessel. Whether such enforced mechanical remodelling of 
the vessel results in an improved accommodation of intimal hyperplasia in patients so 
treated remains to be determined by long-term angiographic follow-up. 
Lesion length and location. 
Given the limited range of lengths available for most of the currently available stents, long 
coronary lesions and spiral dissections are normally managed by the tandem implantation 
of multiple stents. In the case of the Palmaz-Schatz stent overlapping or telescoping of 
sequential stents should be avoided while for coil stents with low metallic surface area 
such as the Gianturco-Roubin stent, overlapping of multiple stents may occasionally be 
advantageous to provide additional radial support. 
For short lesions located immediately proximal or distal to a vessel curve, attention must 
be paid to ensure an adequate inflow or outflow of the stented segment. For this reason 
it mayan occasion be necessary to deploy a stent of significantly longer nominal length 
than the apparent lesion length to avoid the extremity of the stent being directed at the 
outer wall of the vessel curvature. This is particularly the case for more rigid stents such 
as the Palmaz-Schatz stent, where splinting by the stent of the previously curved vessel 
segment is angiographically evident. For lesions located in tortuous segments, the 
preference for a flexible stent is clear. Similarly for distal lesions located in vessels with 
proximal tortuosity, flexibility and low profile of the stent delivery device will be required. 
Concerns have previously been expressed over the outcome of side branches located in the 
stented segment. Two recent papers reporting the outcome of side branches arising from 
Palmaz-Schatz stented coronary segments have provided reassuring data over this concern 
[68,69]. From these reports it appears that side branch occlusion following stent 
placement occurs infrequently « 10%), the occluded side branches usually have preceding 
ostial disease, their occlusion typically does not result in myocardial infarction, and the 
occluded side branches are usually found to have recanalised at 6 month angiographic 
follow-up {6S,69]. "Jailing" the ostium of major side branches by stent struts whereby 
intervention in the affected side branch is precluded arises in stents with a fine lattice such 
as the Wallstent, Palmaz-Schatz, Multilink, and Cordis stents, while the Gianturco-Roubin 
and Wiktor stents have sufficiently large interstrut intervals to make interventional 
procedures in major side branches possible. 
As in vein grafts, lesions located in the ostium of native coronary arteries require exquisite 
stent delivery to avoid the risk of proximal mig~ation and protrusion. Thus a balloon-
expandable radiopaque stent should be selected for such lesions. 
Multiple stenting. 
In general, when it is felt that more than one stent [18, 70] will be required to treat a long 
lesion or spiral dissection, it is advisable to begin with the placement of the most distal 
stent. Occasionally , however, placement of a single proximal stent will eliminate the distal 
extension of the false lumen and obviate the necessity for multiple stenting. When a 
284 
Figure 5 
A Dissection following balloon angioplasty in the proximal left anterior descending artery 
8 Following delivery of a Gianturca-Roubin Flexstent through a Superflow SF Judkins guiding catheter 
to the target vessel, the radiopaque markers (located 1mm proximal and distal to the stent 
extermities) facilitate the final positioning of the stent prior to inffation of the delivery balloon 
C Contrast angiography post stent deployment demonstrates preservaion of the vessel curvature in 
the slented segment 
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second distal stent is to be passed through a proximally deployed stent, the profile and 
trackability of the second stent becomes of paramount importance. A stent with a low 
profile which is preferably sheathed to avoid catching of struts in the proximally deployed 
stent should be selected. Flexibility of the second stent will also reduce the risk of the 
second stent failing to pass through the proximally deployed stent. 
Guiding catheter and guidewire. 
In the case of non-elective stenting, the guiding catheter and guidewire in-situ which have 
been used during the primary coronary angiopiasty procedure may have a bearing on the 
stent to be selected. If a regular lumen 8 French guiding catheter has been used, selection 
of a stent with a high profile (e.g. 3.5 or 4.0 mm Gianturco-Roubin stentl will not be 
possible without necessitating the exchange of the guiding catheter. Similarly, exchange 
to an extra support .018" guidewire may be required for the advancement of the 
Gianturco-Roubin delivery system (premounted balloon) through a proximally tortuous 
vessel. Such technical limitations of the Gianturco-Roubin stent will soon be overcome by 
the introduction of a lower profile 2nd generation device. 
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TABLE 1 
Coronary Stent Design Deployment Premounted Sheathed Delivery First Clinical Implantation 
Wallstent Wire mesh Self-expanding balloon not sheathed over-the wire 1986 [39J 
required 1991 (Less Shortening 
Wallstent) [32, 49] 
Pa[maz--$chatz Sioned tube 8aJloon-expandable pre-mounted sheathed over-the-wire 1988 [76A5J 
0-2 articulations & & 1994 (Heparin coated 
helicoid connection) [33] 
free unsheathed over-the-wire 
or monorail 
Gianturco-Roubin Incomplete coil 8<JlJoon-expandable premounted unsheathed ovor-the-wire 1989 [411 
clam shell loop 
Wlktor Sinusoidal Balioon-expand<lble premounted unsheathed over-the-wire 1991 [54] 
helical coil or monorail 
Multilink Multiple rings with Balloon-expandable premounted sheathed over-the-wire 1993 [831 
multiple [inks 
Cordis Sinusoidal BalJoon-expandable premounted unsheathed over-the-wire 1994 
helical coil 
AVE Micro Zig-Zag axial struts Balloon-expandable premounted unsheathed monoraH 1994 
4mm units 
WaJlstent - Schneider Bulach, Switzerland I Palmaz-Schatz - Johnson & Johnson, Warren, New Jersey, USA I Gianturco-Roubin - Cook, Bloomington, Indiana, USA I 
Wiktor - Medtronic, Minneapolis, Minnesota, USA lACS - Advanced Cardiovascular Systems, London, U.K. I Cordis, Cordis, Miami, Florida, USA I 
AVE Micro, Advanced Vascular Engineering, Santa Rosa, California, USA. 
Different stents for different lesions 
TABLE 2 
Profile (mm) Diameters (mm) Lengths (mm) Shortening (%) Metallic SA (%) 
Wallstent 1.57 3.5 - 6.0 12 - 35 25% 
Palmaz-Schatz. 1.65 3.0, 3.5, 4.0 8,9,14,15,18 2.5-25% <20% 
(pre-mounted) 
3.0, 3.5, 4.0, 5.0, 6.0 
(unmounted) 
Gianturco-Roubin 1.78 I 2.13 2.0, 2.5, 3.0, 3.5, 4.0 12,20 0% 10% 
'" 
(2.0-3.0 I 3.5 & 4.0) Q:) 
'" 
Wiktor 1.75 3.0, 3.5, 4.0 16 8.8% 
Multilink 1.37 3.0, 3.25, 3.5 15 3% 7% 
Cordis 1.27 - 1.52 3.0, 3.5, 4.0 15 10% 15% 
(3.0- 4.0) 
AVE Micro 1.65 3.0, 3.5, 4.0 4,8,12,16 2% 8.4% 
Profile - profile of stent delivery system I Metallic SA - metallic suriace area of stented coronary segment when the stent is expanded to its nominal diameter 
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TABLE 3 
Coronary Stent Metal Strut Thickness Relative Position of 
composition Radiopacity'" radiopaque markers 
(1-7) 
Wallstent Cobalt based alloy .07-.10 mm 5 Distal & proximal & intermediate for 
expected final length 
Palmaz-Schatt 316 L Stainless Steel .102 mm 6 Distal & proximal 
(premounted) 
Gianturca.oRoubin 316 L Stainless Steel .152mm 4 Distal & proximal 
Wiktor Tantalum .127 mm 2 Central 
Multilink 316 L Stainless Steel .056 mm 7 Distal & proximal 
Cordis Tantalum .127 mm Central 
AVE Micro 316 L Stainless Steel .203 mm 3 Distal & proximal 
"Relative radiopacity score (1-7) - based on ongoing comparative densitometry studies by Keane et al. at the Thoraxcenter. 
A relative score of 1 = most radiopaque, while a relative score of 7 = least radiopaque. 
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SECTION II 
Currently Available stents 
The currently available stents, a description of their design, and the year of their clinical 
introduction are listed in table 1. For comparative purposes the key structural features and 
technical details of the different stents are provided in tables 2 & 3. In the absence of 
prospective randomized interstent comparative trials, it is difficult to draw conclusions on 
the relative merits and demerits of each stent design, however, individual experience and 
registry data from each stent allow preliminary impressions to be made on the advantages 
and limitations of each stent. 
Wallstent 
The Wallstent was the pioneer of stents [39, 83] through which we learnt the risk profile 
and indications for coronary stenting and the necessity and adverse effects of 
antithrombotic measures. In a European cooperative registry in the late eighties [46,4 71, 
both a quantitative angiographic as well as clinical Wallstent database was built up from 
which predictors of subacute thrombotic occlusion and restenosis were identified in both 
vein grafts as well as native arteries [71]. In 1991, the new Less Shortening Wallstent was 
developed through a change in the braiding angle [32, 49] and results of the first clinical 
implantation of this second generation stent in coronary vein grafts have been promising 
149]. The unique advantages of the Wallstent include the extensive range of diameters and 
lengths available, thereby allowing the Wallstent to be used for the management of long 
spiral dissections, and for vessel reconstruction. The sheathed "balloon-less I! delivery 
system in combination with the free unconnected wire mesh design, render the Wallstent 
one of the most trackable, pushable and flexible stents (figure 4) for negotiating vessel 
tortuosity and passing through proximally deployed stents. Its fine cross-hatched mesh 
(figures 2 & 3) design provides excellent scaffolding properties which is particularly well 
suited to entrap friable material in diffusely diseased vein grafts (figure 1), however, the 
fine mesh also raises questions over the "jailing" of major side branches. Its primary 
limitations are the longitudinal shortening of the stent upon radial expansion and motion 
of the stent during retraction of the rolling membrane rendering the stent less suitable for 
ostial lesions. 
Palmaz-Schatz Stent 
The Palmaz-Schatz stent has been extensively investigated in a broad range of coronary 
lesions [19-22,45,50-53,55,62,68,69,72-78]. It is the only stent to date to have 
completed prospective randomized trials comparing the clinical and angiographic outcome 
with that of balloon angioplasty [1 ,2}. The angiographic results following Palmaz-Schatz 
stent implantation are predictable and the slotted tube design (figure 3) allows the 
performance of high pressure intrastent balloon inflations without risk of structural 
deformation. The low radiopacity of the Palmaz-Schatz stent, however, can render the 
positioning of a non-compliant balloon for post deployment high pressure intrastent 
inflations difficult. The availability of a free unmounted Palmaz~Schatz stent which can be 
crimped by the operator on any balloon provides more procedural versatility and results in 
a lower profile during stent delivery. It does, however, increase the risk of losing the stent 
during deployment and in general the unmounted Palmaz-Schatz stent should not be 
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Figure 6 
A Short dissection in the origen of the left circumflex coronary artery following balloon angioplasty 
B An A VE Micro stent is delivered to the target vessel through an SF Amplatz guiding catheter, the 
two radiopaque markers at the extremities of the are clearly seen 
C Following delivery of the stent, the thick radiopaque stainless steel struts facilitate the precise 
positioning of a short non-compliant balloon (single marker) within the stent for subsequent high 
pressure inflations and optimization of stent deployment 
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selected when attempting to pass through another stent which has been deployed 
proximally on a bend. This limitation arises partly as a result of the rigidity of the Palmaz-
Schatz stent, which is only partially compensated by the newer helicoid connections. The 
connected tubular segments of the Palmaz-Schatz stent negotiate vessel bends like the 
carriages of a train rather than the continuity of flexibility proffered by the Wallstent and 
coil stent designs. When multiple Palmaz-Schatz stents are implanted in tandem, overlap 
of the stents should be avoided. The Palmaz-Schatz stent is particularly suited for focal 
lesions in nontortuous coronary segments. 
Gianturco-Roubin Stent 
Prior to obtaining FDA approval for non-investigational clinical use, most of the clinical data 
on the Gianturco-Roubin stent was gathered in single and multicenter registries in the 
U.S.A. [38,8, 41-44]. The indication for the Gianturco-Roubin stent for which most data 
has been gathered is for the bailout of subocclusive and occlusive dissections following 
balloon angioplasty in native coronary arteries. The data gathered compares well with 
historical controls treated by repeated and prolonged balloon angioplasty alone and results 
of the first randomized trial of the Gianturco-Roubin in bailout therapy (GRACE) are awaited 
with interest [36]. The principle advantages of the Gianturco-Roubin stent include its range 
of lengths and longitudinal flexibility. While the relatively large interstrut intervals of 1 mm 
(figure 3) raise questions over the suitability of this stent for the management of friable 
vein graft lesions, the advantages of the Gianturco-Roubin stent design include minimal risk 
of "jailing" side branches and the potential to perform coronary interventional procedures 
in side branches through the interstrut spaces. While this stent excels in long dissections 
in curved coronary segments (figure 5), its more generalised use is hindered by the high 
profile of the current prototype. 
Wiktor Stent 
The available clinical data on the Wiktor stent arises from observational studies and registry 
data [54,56,79-821, the principle registry of which has been in the management of 
restenotic lesions. Like the Gianturco-Roubin stent, the Wiktor stent is a coil stent (figure 
3) which offers marked flexibility and thus conform ability with the vessel curvature, 
however, also like the Gianturco-Roubin stent, the Wiktor stent is unlikely to excel in the 
treatment of friable vein grafts on account of the large interstrut interval of the Wiktor 
stent and subsequently reduced scaffolding properties. The radiopacity of the Wiktor stent 
allows exquisite pOSitioning of the stent in ostial and focal lesions, while the flexibility of 
the stent makes it suitable for short dissections on curved coronary segments. The recent 
introduction of the option of a monorail delivery system improves the user-friendliness of 
the device. The limitations of the current prototype of the Wiktor stent include the 
availability of only one length, the limited scaffolding properties with the potential for the 
protrusion of intimal flaps through the interstrut intervals, and occasionally the radiopacity 
of this tantalum stent can interfere with on-line quantitative angiographic analysis of the 
stented segment. 
Multilink Stent 
The ACS stent [39, 83] currently has the least clinical experience of the currently available 
stents and is undergoing its first 100 patient registry which is being conducted at five 
European centers. The advantages of this new stent include the flexibility and low profile 
ITable 11 of the sheathed stent and delivery system. Although the Multilink stent design 
manages to provide remarkable scaffolding propert.ies (Figure 3), the metallic burden to the 
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Figure 7 
A Complex lesion of the mid-segment of the right coronary artery 
B Positioning of the Cordis stent was facilitated by the radiopacity of the tantalum struts which are 
clearly seen during inflation of the contrast-filled intrastent balloon to 12 atmospheres 
C Angiography post stent deployment reveals the stent struts to be embedded in the vessel wall 
external to the contour of the contrast-filled lumen 
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stented vessel remains very low by virtue of the small diameter of the corrugated struts. 
The limitations of the stent include its radiolucency (Table 3) rendering the positioning of 
non-compliant balloons for post-delivery high pressure intrastent inflations very difficult. 
The current availability of only one length of 15mm, means that the 1 st prototype can only 
be used for very focal lesions. Following some minor modifications this stent may offer 
some significant advantages over the earlier generation of stent designs. The attachment 
of radiopaque tips on the stent would present a significant enhancement. 
AVE Micro Stent 
The AVE Micro stent is now undergoing clinical evaluation in a large number of countries 
[84J. The high degree of radiopacity ITable 31 and balloon expandable deployment should 
render the stent ideal for exquisite positioning in highly focal and ostial lesions (Figure 6), 
however, by virtue of the longitudinal (axial) orientation of its eight struts, the 4mm AVE 
Micro stent units may be prone to proximal migration and protrusion and therefore 
preferably longer welded AVE Micro stents should be deployed in ostial locations. The 
customized range of short lengths make the AVE Micro stent ideal as an adjunctive 
complementary device for multiple stenting, filling in the gaps between longer stents and 
improving the inflow or outflow of longer stents. Despite the absence of a protective 
sheath, the low profile and longitudinal strut orientation, make the AVE micro stent one 
of the easiest stent to pass through other proximally deployed stents. The monorail delivery 
system increases the user-friendliness of the device which has a short learning curve. The 
strong radial support proffered by the thick struts should make the stent suitable for the 
prevention of recoil and restenosis. Care should be taken, however, to avoid the 
positioning of junctions between the unconnected 4mm units at the site of the minimal 
lumen diameter of lesions in order to prevent intimal protrusion. 
Cordis Stent 
The Cordis stent continues to undergo early evaluation in the clinical arena. The principle 
investigator of this stent has been Masakio Nobuyoshi and colleagues in Kyoto, Japan 
where over 80 Cordis stents have now been deployed. Like the A.C.S. stent, the Cordis 
stent offers some advantages over the first generation stents by virtue of its low profile, 
flexibility, and comprehensive scaffolding properties. The absence of a protective sheath 
on the delivery system, however, increases the possibility of stent dislodgement or 
disruption during delivery. The operator should be aware of the protrusion of the delivery 
balloon beyond the limits of the Cordis stent if inflations of higher pressure are considered. 
While the strongly radiopaque tantalum struts (Table 3) allow exquisite positioning (Figure 
7) of the stent in short dissections in curved coronary segments, the radiopacity may pose 
problems for on-line quantitative angiographic assessment, particularly during assessment 
of luminal renarrowing at 6 month angiographic follow-up. 
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CONCLUSIONS 
Clearly none of the currently available stents is ideal or free from limitations. Moreover, no 
stent should be expected to serve all indications and all coronary lesions. It is probably 
appropriate for each interventional center to adopt two or three different stent types. Use 
of all seven currently available stents at one center may result in unfamiliarity of each 
operator with all stents and prolonged learning curves. Rationalization of the selection of 
stents at each center should be based upon the case mix of the interventional practice. 
Tertiary referral centers with a high volume of complex lesions including chronic total 
occlusions, long lesions in diffusely diseased vessels, and vein graft reconstructions may 
wish to have the Wallstent (which requires extensive experience for optimal deployment) 
in their stent armamentarium, while secondary referral centers with a standard 
interventional case mix and smaller patient volume might be adequately served by more 
user friendly stents with a shorter learning curve. Each center will require 1) at least one 
standard mesh stent with strong radial support such as the Palmaz-Schatz stent or AVE 
Micro stent primarily for recoil and restenosis prevention and lesions in straight coronary 
segments, and 2) at least one flexible coil stent primarily for dissections and lesions located 
in tortuous vessels. 
Given the increasing demands for accountability of cost:benefit efficacy in interventional 
cardiology, it might be proposed that centers not participating in research studies should 
include one low budget economical stent in their selection for "straight forward lesions" 
in routine practice. If each stent will be expected to prove its own clinical indications and 
niche by randomized trials comparing them to either conventional balloon angioplasty or 
with previously established stent prototypes, the ultimate cost of each stent design will 
continue to represent a significant consideration in stent selection. The three most 
important considerations in the stent selection process for the individual patient, however, 
should continue to be 1) will the stent have an appropriate profile and trackability to be 
safely and successfully delivered to the individual coronary segment ? 2) is the structure 
of the stent appropriate for the indication? , and,3) will the dimensions of the selected 
stent allow the achievement of an optimal angiographic resul ? 
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Key points for clinical practice 
• The aim of obtaining < 50% residual diameter stenosis post intervention has 
changed to one of < 25% residual diameter stenosis for baUoon angioplasty and 
to one of 0% residual diameter stenosis for coronary stenting 
• The achievement of optimal angiographic results obtained at the time of coronary 
stent implantation confers a reduced risk of subsequent adverse clinical events 
• Optimal stent deployment can be obtained by the guidance of on-line quantitative 
coronary angiography in multiple projections aiming for < 0% diameter stenosis in 
all views using the interpolated reference vessel diameter 
• Any additional benefit conferred by the routine use of intracoronary ultrasound over 
the optimal use of on-line quantitative coronary angiography in multiple projections 
alone for the guidance of stent deployment has yet to be demonstrated. 
• The specific role of coronary stenting in vessels of < 3.0mm diameter has yet to 
be addressed by prospective studies. It is hoped that the development of 
thromboresistant (e.g. heparin-coated, heparin-eluting) stents may have a significant 
impact in this domain. 
• The results of early studies by highly experienced investigators on the feasibility of 
coronary stenting without post-procedural anticoagulant therapy by the combination 
of optimal stent deployment in vessels of > 3.0mm and effective antiplatelet 
therapy (ticlopidine and aspirin) are promising but await confirmation by large 
international multicenter studies to determine if this can be safely achieved routinely 
at less experienced centers. 
• A stent size of at least equal to or greater than the reference vessel diameter as 
measured by on-line quantitative coronary angiography, should be selected. The 
degree of stent oversizing, however, should vary according to the structural design 
of the stent 
• Caution should be exerted over the inflation to high pressures of premounted 
compliant balloons which extend beyond the extremities of the stent 
• Exchange of the premounted delivery balloon for a non-compliant balloon (of shorter 
length and occasionally of larger diameter) for the performance of post-delivery high 
pressure intrastent inflations may be required to achieve an optimal angiographic 
result 
• Particular attention should be paid to ensure an optimal inflow and outflow of (rigid) 
coronary stents especially when placed in proximity to a vessel curvature 
• Axial shortening of stents upon radial expansion varies from 25% for the mesh 
design of the Wallstent to 0% for the coil design of the Gianturco-Roubin stent 
• The length of the selected stent should be longer than the lesion to be covered in 
order to provide a proximal and distal margin of more than 2mm after allowance for 
axial shortening of the stent upon radial expansion. 
• For vein grafts, a stent with an adequate range of diameters and adequate 
scaffolding lattice such as the Wallstent or Palmaz biliary stent should be selected. 
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SAMENVATTING 
Na implantatia van de eerste coronaire stent door Jacques Puel in Toulouse in 1986, heeft 
de stent zieh, via pionierswerk in de tBchtiger jaren en via gerandomizeerde trials in de 
negentiger jaren, een prominente plaats verworven in de huidige praktijk van de interventie 
cardiologie. De conventionele stent vertegenwQordigt de mechanische benadering van aen 
bi%gisch probleem. De corona ire stent kan een dissectie aanleggen en de normale 
bloedstroom in vaten met sen dreigende of acute afsluiting herstellen, en het voorziet in 
aen methode om angioplastiek van primaire vernauwingen en restenotische lesies in zowel 
natieve kransslagaders als in aorto-coronaire bypass-grafts te optimaliseren. 
Gns onderzoek heeft zich primair gericht op het vastleggen van harde klinische eindpunten 
(re'(nterventies, bypass-chirurgie, hartinfarcten en doden), en op kwantitatieve coronalr 
angiografie IOCA). OCA tijdens de interventie procedure is een leidraad naar optima Ie stent 
ontplooiing, en biedt de mogelijkheid de winst aan diameter en de recoil na stentimplantatie 
te kwantificeren. Bij angiografische follow-up geeft QCA een maat voor het 
restenoseringsproces in de stent en veranderingen in dimensies van het proximaal en 
distaal van de stent gelegen vat. 
Deel I van dit proelschrift beschrijlt de betrouwbaarheid van QCA, en deel II beschrijft de 
resultaten van kwantitatief angiografische en klinische evaluatie van de korte en lange 
termijn uitkomst bij electieve en bail-out stent implantaties in natleve kransslagaders, en 
van primaire stent implantatie in veneuze aorto-coronaire bypass-grafts. 
In hoofdstuk II worden de resultaten van 3 studies weergegeven (de relatie tussen klinische 
eindpunten en QCA, catheter calibratie voor QCA metingen, en de toepassing van signal-
averaging voor analoge videotape analyse). Hoofdstuk III geeft een vergelijking weer van 
10 QCA system en die gebruikt worden in leidende core-labs in de Verenigde Staten, 
Canada en Europa. De tendens om grote diameters te onderschatten en kleine diameters 
te overschatten werd bij aile systemen gezien. In hoofdstuk IV beschrijven we de resultaten 
van een methode om de averse hatting van kleine diameters teniet te doen door de 
introduetie van een dynamisch edge detection algoritme. In hoofdstuk V rapporteren we 
een nieuwe techniek om een corona Ire "stent-stenose" te plaatsen om QCA-meting van 
grote diameters in varkens te mogelijk te maken. In hoofdstuk VI vergelijken we de 
uitkomsten van videodensitometrische en geometrische QCA techniek, met de uitkomsten 
van intracoronair ultrageluid in patienten tijdens een coronaire interventie. 
Deel II van dit proefschrift evalueert de stents die momenteel klinisch worden toegepast 
Ihoofdstukken VII - IX: Wallstent, hoofdstuk X: Palmaz-Schatz stent, hoofdstuk XI en XII: 
Gianturco Roubin stent, hoofdstuk XIII: de bail-out stent, hoofdstuk XIV: de AVE Micro 
stent, hoofdstuk XV: de Wiktor stent en de Wall stent, en in hoofdstuk XVI: de 6 maands 
resultaten van de Cordis stent gebaseerd op zowel QCA als intracoronair ultra-geluid. In 
hoofdstuk XVII worden de mechanische en radiografische eigenschappen van aile zeven 
momenteel beschikbare stents, inclusief de ACS en Cordis stent vergeleken, en op basis 
hiervan wordt in hoofdstuk XVIII vaor elke type stent een potentiele plaats binnen het 
klinisch toepassingsgebied voorgesteld. 
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